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ABSTRACT  
 
Influenza A viruses (IAVs) are common infections of certain avian reservoir species, and 
they periodically transfer to mammalian hosts. These cross-species jumps are usually associated 
with sporadic outbreaks, and on rare occasions lead to the establishment of a lineage in the 
new host species. The immune pressure exerted by the new host on the emergent virus forces 
it to evolve and adopt strategies to evade immunity in order to survive in nature. Understanding 
the biological mechanisms that allow successful inter-species transmission and adaptation to 
mammals is crucial to develop the theoretical tools required to predict and/or control 
emergence of new viruses in humans and animals. H3N8 equine influenza virus (EIV) represents 
an interesting model to study the dynamic of within-host variation of an avian-origin IAV. 
Indeed, this virus has emerged from birds in 1963 and has circulated in horse populations for 
more than fifty years despite the availability of vaccines. Evidence of evolution of EIV virulence 
factor non-structural protein 1 (NS1) also exists. NS1 is the main viral antagonist of the host 
interferon (IFN) response, and it relies on different strategies for overcoming these responses, 
which varies depending on the viral strain. While some NS1 proteins effectively block the 
induction of IFN and IFN stimulated genes (ISGs), others block general gene expression at a 
post-transcriptional level, and therefore reduce the synthesis of IFN and ISGs indirectly. 
Importantly, little is known about the contribution of these NS1 functions to EIV infection 
phenotype and adaptation to horses.  
In this work, we characterised NS1 proteins spanning the entire EIV lineage and showed that 
NS1s from different time periods after EIV emergence counteract the IFN response using 
different and mutually exclusive mechanisms. While EIVs circulating in the early 1960s blocked 
general gene expression by a NS1-mediated blockade of the cleavage and polyadenylation 
specificity factor 30 (CPSF30), NS1s from contemporary EIVs specifically inhibit the induction 
of ISGs by interfering with the JAK/STAT pathway. These contrasting anti-IFN strategies are 
associated with two mutations that appeared sequentially during EIV evolution, E186K 
substitution and C-terminal truncation. These changes in NS1 allowed contemporary EIVs to 
replicate in the presence of high levels of IFN. The results shown here with EIV indicate that 
the interplay between virus evolution and immune evasion plays a key role in IAV mammalian 
adaptation. 
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1. General introduction 
 
Influenza viruses cause an acute febrile respiratory disease in various host species, 
including horses. They are responsible for seasonal infections or explosive outbreaks with 
high morbidity or mortality in susceptible populations.  
 
 
1.1. Equine Influenza 
 
Equine influenza is a highly contagious disease in horses and other equids, which 
most commonly affects two- and three-year-old individuals and may be the most common 
cause of respiratory illness in racehorses (Arthur and Suann, 2011). Some tracks may even 
experience several influenza outbreaks within a racing season, which lead to significant 
economic losses for the equine industry (Myers C, 2006, Crawford et al., 2005, Smyth et al., 
2011, Park et al., 2004). Indeed, even if EIV infection is generally self-limiting and the 
majority of horses recover uneventfully, it strongly affects a horse’s performance, and 
requires time out of work for recovery (several weeks to months). Infected horses may also 
suffer life-threatening complications, such as bacterial pneumonia, particularly when not 
provided with an adequate period of rest.  
 
 
1.1.1. Aetiology  
 
The etiologic agent of equine influenza is an Influenza A virus (IAV), which belongs 
to the family Orthomyxoviridae. This family comprises six genera: Influenzavirus A, B, C, 
and D, Thogotovirus and Isavirus. The classification system places influenza viruses into 
genera and species (A, B, C or D), then into 18 hemagglutinin (HA) and 11 neuraminidase 
(NA) subtypes (Center for Disease Control and Prevention, Types of Influenza Viruses [2017 
December 12] cited http://www.cdc.gov/flu/about/viruses/types.htm). Two subtypes 
have been identified in horses: H7N7 and H3N8 (see section 1.1.5). Viruses are further 
categorized by host, geographical origin, strain, number and year of isolation. Of note, 
Influenza A viruses can infect horses as well as other host species, such as humans, donkeys, 
dogs, pigs, birds, mink, seals, camels, cats, and whales (Parrish and Kawaoka, 2005). In 
contrast, Influenza B viruses are only pathogens of humans, Influenza C viruses can infect 
pigs and humans, although they rarely cause disease, and Influenza D viruses were recently 
discovered and are thought to primarily infects cattle (Center for Disease Control and 
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Prevention, Types of Influenza Viruses [2017 December 12] cited 
http://www.cdc.gov/flu/about/viruses/types.htm). 
 
 
1.1.2. Clinical signs 
 
EIVs are highly contagious pathogens spread by infectious secretions and aerosols 
generated by frequent sneezing and coughing. Close contact between individuals seems to 
be necessary for rapid transmission of the disease, however, fomites may also contribute to 
virus distribution (Myers C, 2006). In horses, the course of infection usually lasts between 
two and ten days in uncomplicated cases, and signs of disease appear three to five days 
following exposure to the virus. Virions are excreted during the incubation period, and 
individuals remain infectious for at least five days after the onset of clinical disease. In 
addition, an immunologically naïve horse will shed larger amounts of virus for a longer 
period of time than a horse previously exposed to viral antigens through vaccination or 
natural infection (Myers C, 2006). 
Infected horses exhibit a sudden fever, which may be biphasic ranging from 39.1oC to 41.7oC, 
accompanied by serous nasal discharge, anorexia, depression, and in most cases a repetitive 
harsh, dry, explosive and non-productive cough. Submandibular lymphadenopathy, and 
pharyngitis, tracheitis, as well as mild bronchitis can be found during endoscopic 
examination of the respiratory tract, associated with minimal changes in lung sounds (Myers 
C, 2006, Elton and Bryant, 2011). Some horses exhibit myalgia, myositis, and limb oedema, 
and are thus reluctant to move. In some cases, a mild form of azoturia (myoglobinuria) may 
occur. In young foals, influenza is severe and produces signs of viral pneumonia, which may 
lead to death within 48 hours (Elton and Bryant, 2011, Daly et al., 2011). Similarly to 
humans, cases of EIV associated with neurological signs have been described and are 
associated with high levels of pro-inflammatory cytokines (i.e. IL-6 and TNF-a) (Daly et al., 
2011). 
 
 
1.1.3. Diagnosis 
 
As EIV spreads rapidly among susceptible horse populations, an early diagnosis is 
crucial to prevent an outbreak from occurring. Historically, paired serology samples 
collected during the acute and convalescent phases of the disease has been the diagnostic 
technique of choice. Antibody titres can be measured either by hemagglutination inhibition 
(HI), virus neutralization test, or single radial hemolysis. Serological assays have also been 
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developed to detect antibodies against the non-structural protein 1 (NS1), which are not 
produced following classic vaccination regimes (see section 1.3.1 for more information 
about NS1). This test is particularly useful for differentiating vaccinated from non-
vaccinated horses (Myers C, 2006). 
Several diagnostic tests are also available, such as an ELISA assay (DirectigenTM Flu ELISA, 
Becton Dickison, Microbiology Systems, Mississauga, Ontario, Canada), or a Polymerase 
Chain Reaction (PCR), both based on the detection of the viral nucleoprotein (NP) gene 
(Bryant et al., 2010). Furthermore, immuno-PCR techniques combining ELISA and PCR to 
detect HA and NS1 are under investigations at present.  
Finally, virus isolation can be performed when grown from a nasopharyngeal swab in 
embryonated chicken eggs or passaged through Madin-Darby canine kidney (MDCK) cells, 
and detected by HI tests using specific antisera to H3N8 and H7N7 viruses. Results usually 
take several days to weeks; however, it is the only diagnostic procedure that yields a virus 
isolate that can be characterized antigenically and genetically. EIV characterization is vital 
for surveillance, and provides virus for the manufacture or update of vaccines (Myers C, 
2006, Damiani et al., 2008) 
 
 
1.1.4. Prevention and treatment 
 
The increased international movement of horses for breeding and competition 
purposes has complicated the task of veterinarians and is recognized as an important factor 
in the spread of EIV throughout the world. A better understanding of the host immune 
response to natural infection and vaccines, as well as the strategies employed by the virus 
to escape this response is crucial to elaborate better control measures and more efficient 
vaccines in the future (Myers C, 2006). 
 
To date, disease prevention remains the best way to protect horses, as the treatment 
against EIV is mainly symptomatic and vaccines have often failed to provide adequate 
protection. Individuals demonstrating clinical signs of disease or that have been in contact 
with affected horses should be placed in quarantine and diagnostic techniques should be 
conducted. Furthermore, contaminated stables, equipment and vehicles should be 
disinfected.  
 
The treatment of equine influenza consists in supportive therapies with strict stall 
rest, good nursing care, access to clean water, electrolyte solutions and palatable food. 
Antitussives are contraindicated as the cough reflex enhances clearance of the virus, and 
Chapter 1 - Introduction 
	 21	
bronchodilators are of limited value as the pathophysiology of the disease does not include 
significant bronchoconstriction in uncomplicated cases. (Myers C, 2006) Antiviral agents, 
such as Amantadine and Rimantadine, are expensive and of little benefit to an already 
infected horse but could be valuable to protect horses during an outbreak. Amantadine has 
been shown to prevent disease in 90% of experimentally infected horses, however, it has 
also been reported to induce seizures that can be fatal. Rimantadine is a safer and more 
effective derivative of amantadine (Myers C, 2006). Nonsteroidal anti-inflammatory drugs 
(NSAIDs) may be administered to counteract fever and subsequent inappetence, but they 
must be used with caution in dehydrated horses. In addition, antimicrobials (Penicillin G or 
Trimethoprim/Sulfonamide) may be indicated if the horse is at risk of secondary bacterial 
infection. Furthermore, to allow a complete recovery and avoid complications, a horse 
should have one week of rest for each day of fever, thus approximately thirty to sixty days. 
Returning to work earlier may favour secondary bacterial infections and long-term 
complications, such as myocarditis and recurrent airway obstruction (Myers C, 2006).  
 
An effective vaccination regime is also critical to protect equine populations, and 
vaccination became mandatory for racing Thoroughbreds in 1981. EIV vaccines currently 
licensed for use in the horse are either inert vaccines (i.e. sub-unit vaccines, immune-
stimulating complex, DNA vaccines), or live vaccines (live-attenuated virus vaccine and 
canarypox-based vaccine). A current list of commercialised EIV vaccines can be found at: 
(Animal Health Trust, equiflunet) http://www.equiflunet.org.uk/. 
The United Kingdom (UK) and other countries conduct ongoing surveillance of equine 
influenza virus, and an Expert Surveillance Panel (ESP) reviews annually all information 
provided and decide when vaccine strains need to be updated (Daly et al., 2011, Elton and 
Bryant, 2011). Within the UK, this work is funded by the Horserace Betting Levy Board and 
carried out by the Animal Health Trust, a World Organisation for Animal Health (OIE) 
reference laboratory for EIV. Unfortunately, vaccines are rarely updated in accordance with 
the ESP recommendations, and many current vaccines still contain outdated strains 
(Gonzalez et al., 2014, Yamazaki and Ichinohe, 2014, Olguin Perglione et al., 2016). EIV 
vaccines should contain both FC1 and FC2 viruses (see section 1.1.5 and 1.1.6 for more 
details), such as A/equine/South Africa/04/2003-like or A/equine/Ohio/2003-like viruses 
for the former, and A/equine/Richmond/1/2007-like viruses for the latter (World 
organisation for animal health, Equine influenza, [cited 2017 December 12] 
http://www.oie.int/en/our-scientific-expertise/specific-information-and-
recommendations/equine-influenza/). 
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1.1.5. Epidemiology 
 
Throughout history several introductions of avian IAVs in horses have occurred (Guo 
et al., 1992), and work done by Kawaoka and colleagues revealed that several genomic 
segments (PB2, M and NS) were introduced more recently than others (PB1, PA and NP) into 
equines (Kawaoka et al., 1998) (cf. section 1.1.7.1 for more details about the composition 
of the Influenza genome). EIVs are evolutionary distinct from other IAVs, and are thought 
to have been maintained in the equine population for a long time (Webster et al., 1992). 
Accordingly, Absyrtus, a Greek veterinarian, recorded a disease outbreak in 433 AD 
resembling influenza in horses, and more recently “The Great Epizootic of 1872” (World 
organisation for animal health, Equine influenza, [cited 2017 December 12] 
http://www.oie.int/fileadmin/Home/eng/Media_Center/docs/pdf/Disease_cards/EQUINE
S-EN.pdf), which spread throughout North America and affected many horses, was likely an 
outbreak of equine influenza virus, although the subtype has never been identified (Parrish 
et al., 2015). 
 
EIV was first isolated in 1956 during an outbreak of disease in Prague (Czech 
Republic). This virus was an H7N7 subtype of avian origin. It was first referred to as equine-
1 influenza, and was later identified as A/equine/Prague/1956 (Sovinova and Ludvik, 1959). 
This virus has been associated with sporadic cases of disease in horses for approximately 
twenty years post-isolation (Lewis et al., 2011, Hughes et al., 2012).  
A different subtype of EIV (H3N8), initially designated as equine-2 influenza, was reported 
from horses in Florida during an outbreak of disease that started in January 1963 (Scholtens 
et al., 1964, Waddell et al., 1963). This virus, whose prototype was 
A/equine/Miami/1/1963, was also of avian origin, and is thought to have originated from 
South America when Thoroughbred horses exhibiting signs of respiratory disease arrived in 
Miami (FL, USA) by air from Argentina. Although there was no report of H3N8 EIV circulation 
in Argentina at that time, there was evidence of circulation and disease in horses in Uruguay, 
Chile and Brazil (Olguin Perglione et al., 2016, Berrios, 2005). There is no concrete evidence 
of the origin of this H3N8 EIV, however, Murcia et al. provided evidence that the most recent 
common ancestor of A/equine/Miami/1/1963 likely arose between 1943 and 1962, and 
A/equine/Uruguay/1/1963 is thought to be at the origin of this epidemic (Murcia et al., 
2011b). H3N8 EIV has spread rapidly among equine populations and caused a major 
transcontinental pandemic that reached Europe in early 1965 (Paccaud and Paccaud, 1967). 
This pandemic was distinguished from previous outbreaks (presumably due to H7N7 viruses) 
by its occurrence in horses of all ages rather than being restricted to younger horses, as was 
the case until then.  
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There was an international co-circulation of both H3N8 and H7N7 EIV subtypes in 
horses between the 1960s and 1970s, and since the 1980s H7N7 EIV has not been isolated in 
horses, although serological evidence suggests that the virus was still circulating among 
horses in the early 1990s in Europe and USA (Park et al., 2004, Karamendin et al., 2016). 
There is no clear explanation of why this subtype disappeared, but it is thought to have 
been outcompeted by the H3N8 EIV subtype, potentially due to a lower infectivity or 
transmission efficiency in horses.  
 
For the rest of this work H3N8 EIV will simply be referred to as EIV. 
 
Since viral emergence, H3N8 EIV has been responsible for several outbreaks of 
disease in vaccinated and naïve horse populations, notably in the UK in 1979, 1989 and 2003, 
South Africa in 2003, Japan and Australia in 2007, India in 2008-2009, and more recently 
South America in 2012 (Alves Beuttemmuller et al., 2016, Burrows et al., 1981, Cowled et 
al., 2009, Ito et al., 2008, Livesay et al., 1993, Newton et al., 2006, Perglione et al., 2016, 
Virmani et al., 2010, Yamanaka et al., 2008). Today, H3N8 EIV is present in most of the 
world with the exceptions of New Zealand, Iceland and Australia, which eliminated the virus 
after the important outbreak of 2007 (World organisation for animal health, Equine 
influenza, [cited 2017 December 12] http://www.oie.int/fileadmin/Home/eng/ 
Media_Center/docs/pdf/Disease_cards/EQUINES-EN.pdf).  
Of note, the latest OIE report of field data on worldwide EIV activity indicated that only 
individual animal cases and isolated outbreaks of equine influenza had been reported by 
Ireland, Sweden, the UK and the United State of America (USA). In Europe, there were less 
equine influenza virus infections than in recent years. Clinically affected horses in the UK 
were unvaccinated, a single confirmed case in Sweden was of unknown vaccination history, 
and in Ireland equine influenza cases were confirmed in both vaccinated and unvaccinated 
horses, but only 10% of horses had up to date vaccination records. In the USA, outbreaks 
were detected throughout the year with over 30 confirmed cases from 16 states, but no 
vaccination data were available. Finally, in Asia and South America no equine influenza 
outbreaks were reported (World organisation for animal health, Equine influenza, [cited 
2017 December 12] http://www.oie.int/fileadmin/Home/eng/Media_Center/ 
docs/pdf/Disease_cards/EQUINES-EN.pdf). 
 
As for most IAVs isolated from mammals, the main reservoir of EIV is thought to be 
wild aquatic birds (Parrish et al., 2015). Avian species have been shown to host multiple IAV 
strains, most of which are not transmissible to mammals, however, acquisition of point 
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mutations in the viral genome or segment reassortment among strains can allow IAV to 
successfully infect and transmit in a new mammalian host population. Cross-species jumps 
are usually associated with sporadic outbreaks, but on rare occasions emergent viruses 
manage to establish a lineage in new host species. The compatibility of the viral polymerase 
with the cellular machinery and the nature of the glycoprotein of surface, HA and NA, are 
known to be important for successful inter-species jumps (Parrish and Kawaoka, 2005, 
Parrish et al., 2015, Long et al., 2016), however success or failure of avian-to-mammal 
transmissions is likely a polygenic trait and the contribution of other viral proteins are only 
partially understood.  
 
 
1.1.6. Viral Evolution 
 
The traditional approach to study EIV evolution has been based on HA phylogeny 
(Bryant et al., 2009, Daly et al., 1996, Damiani et al., 2008, Kawaoka et al., 1989, Lai et 
al., 2001, Lai et al., 2004), and investigation of vaccine breakdown. The latter has been 
associated with both inadequately potent H3N8 vaccines and antigenic drift of H3N8 viruses 
(Bryant et al., 2011, Daly et al., 1996, Mumford, 1999, Newton et al., 2000, Lai et al., 2001, 
Lai et al., 2004). Antigenic drift refers to the gradual accumulation of genetic mutations, 
mainly in the highly variable globular head of HA, which causes IAVs to escape recognition 
by virus neutralizing antibodies and allows it to cause seasonal outbreaks. Another 
mechanism employed by IAVs to generate genetic diversity and escape the host immune 
system is the antigenic shift. It occurs when two different IAV strains simultaneously infect 
the same host cell, and undergo a process called genetic reassortment, where two or more 
genomic segments are exchanged. During the period of international co-circulation of H7N7 
and H3N8 EIV subtypes (1960s and 1970s), heterosubtypic reassortments between H3N8 and 
H7N7 have occurred, and resulted mainly in H7N7 viruses carrying H3N8 internal genes, 
notably NP, PB2 and PA segments (see section 1.1.7.1 for more information about the EIV 
genome). No H3N8 viruses carrying H7N7 internal genes, or H3N7 or H7N8 reassortants have 
been identified (Bryant et al., 2009). 
 
EIV was initially thought to be genetically stable and the horse was considered a 
dead-end host for IAVs (Landolt, 2014), but it was later demonstrated that individual EIV 
infections resulted in an ongoing evolutionary process associated with accumulation of 
mutations in the viral segments (Murcia et al., 2010). The HA, NA and NS segments were 
notably identified as sites of localized adaptive evolution (Murcia et al., 2011a). Consistent 
with this, EIV has circulated as a single phylogenetic lineage during the first twenty years 
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post-emergence. Then, in the late 1980s it diverged into two antigenically and genetically 
distinct phylogenetic lineages: the Eurasian and American lineages (Daly et al., 1996, Murcia 
et al., 2011a), named according to the geographic origin of the isolates. These two lineages 
co-circulated for a number of years.  
In the early 1990s, the American lineage divided into three sub-lineages: ‘Kentucky’, ‘South 
America’ and ‘Florida’ (Lai et al., 2001), and no virus from the European lineage has been 
isolated after 1994 (Murcia et al., 2011a). 
Finally, in the late 1990’s the Florida sub-lineage diverged again into two clades: ‘Florida 
clade 1 (FC1) and 2 (FC2)’ (Bryant et al., 2011, Lewis et al., 2011), and ever since FC1 and 
FC2 viruses have been responsible for influenza cases in horses worldwide. FC1 viruses, 
whose prototypes are A/equine/Ohio/2003 and A/equine/South Africa/04/2003, are 
notably endemic in North America, and have also caused major outbreaks in Australia, Japan 
and South Africa (Cowled et al., 2009, Yamanaka et al., 2008). Small outbreaks have also 
been reported in Europe between 2007 and 2009 (Bryant et al., 2011, Gildea et al., 2012, 
Legrand et al., 2013). In contrast, FC2 viruses (prototype: A/equine/Richmond/01/2007) 
predominate in Asia and Europe, with significant outbreaks reported in China, India and 
Mongolia, and small-scale outbreaks in multiple countries of Europe (Damiani et al., 2008, 
Gagnon et al., 2007, Gildea et al., 2013, Landolt, 2014, Virmani et al., 2010, Woodward et 
al., 2014, Yondon et al., 2013). 
 
Importantly, in the early 2000s EIV has jumped species barriers and established a 
new lineage in dogs (Hughes et al., 2012, Murcia et al., 2010, Hoelzer et al., 2010, Stack et 
al., 2013, Yamanaka et al., 2008). H3N8 canine influenza virus (CIV) originated from a direct 
transfer of a single H3N8 EIV to dogs within a large greyhound-training facility in Florida 
(Crawford et al., 2005). The virus, whose prototype strain is A/canine/Florida/2004, was 
then carried to several States of the USA by the infected greyhounds.  
Other transfers of H3N8 EIV to dogs have also been reported (Daly et al., 2011, Murcia et 
al., 2011a), notably in 2002 in the UK (Daly et al., 2008), and in 2007 in Australia (Kirkland 
et al., 2010, Bryant et al., 2010) and Algeria (Myers C, 2006).  
Of note, contemporary EIVs have also been found in pigs (Murcia et al., 2010), and camels 
(Yondon et al., 2013). 
 
Despite close interactions between horses, dogs and humans, to date there has been 
no documented natural transmission of these viruses to humans (Khurelbaatar et al., 2014, 
Burnell et al., 2014). Direct experimental inoculation of human volunteers with EIV in the 
1960s showed that infection did occur, although only to low levels (Kasel et al., 1965). This 
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suggests that high intrinsic barriers to the establishment of H3N8 viruses exist in humans, 
and onward transmission in two mammalian hosts (equine and canine) does not guarantee 
successful infection of another (human) (Parrish et al., 2015). Thus, EIV seems to represent 
a relatively low public health hazard. 
 
 
1.1.7. A closer look at the virus 
 
1.1.7.1. Genome and coding strategy  
 
The genome of Influenza virus is approximately 13 kilobases and made of eight 
segments of single-stranded viral RNA (vRNA) of negative polarity. The vRNAs are packaged 
in distinct viral nucleoprotein complexes (vRNPs) held in a closed pseudo-circular 
conformation by the binding of the trimeric viral RNA-dependent RNA polymerase (PA, PB1, 
PB2) to the partially complementary 5’ and 3’ termini of the vRNA (Figure 1-1) (Eisfeld et 
al., 2015). The remainder of the vRNA segment is coated by viral NP oligomers arranged in 
an anti-parallel, superhelical, flexible rod-shape (Resa-Infante et al., 2011). 
 
 
Figure 1-1: Schematic representation of an Influenza A virus vRNP 
 
Influenza A virus ribonucleoprotein complex. The IAV genome is composed of eight ribonucleoprotein 
complexes (vRNPs), consisting of viral RNA (vRNA) encapsidated by viral ribonucleoproteins (NP) and 
a viral polymerase complex (PA, PB1, PB2) positioned at the extremity of the vRNA segment. 
 
 
The IAV genome encodes up to sixteen proteins via alternative splicing or partially 
overlapping open reading frames (Stubbs and Te Velthuis, 2014, Szewczyk et al., 2014). The 
membrane-associated proteins HA and NA are encoded on segments four and six, 
respectively. The ion channel M2 and the matrix protein M1 are encoded on segment seven, 
either on a colinear mRNA for the latter or via alternative splicing for the former. The 
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constituent of the vRNP, including the three subunits of the viral polymerase (PB2, PB1, and 
PA) are encoded on segment one to three, respectively, and the NP protein on segment five. 
The non-structural proteins, NS1 and NEP (nuclear export protein, formerly known as NS2) 
are encoded on segment eight, and like M proteins, NS1 is encoded on a colinear mRNA, 
while NEP mRNA is generated via alternative splicing (Jagger et al., 2012). Other unspliced 
viral mRNAs encode PB1- and PA-related N-terminally truncated products, notably PB1-F2, 
PA-X. Finally, other viral proteins have been described (i.e. PB1-N40, PA-N155, PA-N182, 
M3, M4, M42, NS3 and NSP/NEG8), however, they are not uniformly expressed among strains 
and subtypes (Muramoto et al., 2013, Wise et al., 2009) and their existence in the case of 
EIVs remain uncertain. 
 
 
1.1.7.2. Virion structure  
 
Influenza A virions are pleomorphic and can be found both under a spherical (ranging 
from 80 to 120 nm) and filamentous form (up to 300 nm of diameter) (Elleman and Barclay, 
2004, Harris et al., 2006, Vijayakrishnan et al., 2013, Elton et al., 2013). The biological 
reasons and consequences of this difference are still under investigation.  
The viral envelope contains HA, NA and M2, which are linked via their cytoplasmic domains 
to an internal layer of M1. In turn, the latter interacts with the viral ribonucleoprotein 
(vRNP) (Hutchinson et al., 2012, Steinhauer and Skehel, 2002, Elton et al., 2013) NEP and 
NS1 have also been found in viral particles, while all other viral proteins have yet to be 
detected (Hutchinson et al., 2014) (Figure 1-2). 
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Figure 1-2: Schematic representation of an Influenza A virus particle 
 
An IAV particle. Three viral proteins are embedded within the viral membrane: hemagglutinin (HA), 
neuraminidase (NA), and ion channel protein (M2). Matrix protein 1 (M1) underlies the viral envelope 
and holds the vRNPs inside the virion. NS1, a major virulence factor and NEP, involved in vRNP 
packaging into viral particles, are also present inside the viral particle. 
 
 
1.1.7.3. Replication cycle 
 
Once the NA protein has broken down mucus bonds within the respiratory mucus 
blanket, the virus gains access to the underlying epithelial cells. The HA protein can then 
bind sugar groups on the surface of epithelial cells (the primary target of IAVs), called sialic 
acids (Imai and Kawaoka, 2012). These sialic acids occur in a variety of modified forms in 
different hosts and tissues, which are likely to affect pathogen-host interactions and 
influence the outcome of infection (Wasik et al., 2017). After binding to the cell surface, 
the virus is internalized by endocytosis, and vRNPs are released in the cytoplasm before 
being imported into the nucleus where they serve as the templates for viral transcription 
and replication (Figure 1-3).  
The vRNP is the minimum unit required for viral transcription and replication. The 
polymerase complex is responsible for initiating primary transcription, and it uses a unique 
method of transcription priming referred to as “cap-snatching” (Gu et al., 2015, Koppstein 
et al., 2015). The PB2 protein binds to the cap structure on the 5′-end of cellular pre-mRNAs, 
which is followed by cleavage of the pre-mRNA by the endonuclease function of PA. This 
produces a 5′-capped primer of ten to thirteen nucleotides, which is then used by the RNA-
dependent RNA polymerase (PB1) to initiate transcription. Replication of the influenza virus 
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genome occurs through the synthesis of full-length complementary copies of the vRNA, the 
complementary RNA (cRNA), which are encapsidated into cRNPs and in turn act as templates 
for the polymerase-directed synthesis of progeny vRNPs. Early in infection, transcription is 
the predominant process allowing the synthesis of a pool of viral proteins. Subsequently, 
newly synthesised polymerase and NP are used to assemble and stabilise cRNPs or progeny 
vRNPs, which are generated through back replication of the anti-genomic cRNA 
intermediate. The same vRNA template can be either copied without modification into 
complementary RNA (cRNA) or transcribed into capped and poly-adenylated viral mRNA. 
(Reich et al., 2014). The viral polymerase is also responsible for poly-adenylating the 3’-end 
of viral transcripts, after which they are exported to the cytoplasm for protein translation 
in a similar fashion as host mRNAs (York and Fodor, 2013). vRNPs are selectively exported 
from the nucleus, transported to the plasma membrane (Lakdawala et al., 2014), and 
packaged together with other structural proteins into progeny virions, which bud from the 
cell surface (Rossman and Lamb, 2011). Specific RNA–RNA interactions between the 
different vRNPs are thought to ensure packaging of a full complement of genomic vRNPs 
(Giese et al., 2016, Hutchinson et al., 2010). Furthermore, M1 and M2 are thought to play a 
pivotal role in viral assembly and budding, while NA is important for the release of replicated 
virus from the host cell. (Steinhauer and Skehel, 2002) 
Since viral replication and production of a new progeny is highly dependent on the cellular 
machinery, compatibility between the viral proteins and the molecular components and 
organelles of host cell is key in determining the outcome of an infection. This is particularly 
relevant for emergent viruses, which by definition are not adapted to replicate in the new 
host cells. Recently, two host factors have been described to specifically promote viral 
genome replication, ANP32A and ANP32B (also known as pp32 and APRIL, respectively) 
(Sugiyama et al., 2015), and the former has been identified as a species specificity host 
factor and shown to impact on the ability of avian IAVs to replicate in mammalian cells 
(Long et al., 2016). 
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Figure 1-3: Influenza A virus replication cycle 
 
Following binding of a virion to cell surface receptors containing sialic acid, the virion is internalised by 
endocytosis (1). The endosomal membranes fuse with the viral membrane and release the vRNPs into 
the cytoplasm (2). The vRNP are transported into the nucleus (3), where the viral RNA polymerase 
transcribes the vRNA segments into mRNAs. These viral mRNAs are 5′ capped and 3′ polyadenylated 
before being exported into the cytoplasm (4) for protein translation by cellular machinery (5). The viral 
RNA polymerase also synthetizes complementary RNA (cRNA) used as templates for the production 
of vRNA. The newly synthesised viral nucleoprotein and polymerase proteins are imported into the 
nucleus (6), bind cRNA and vRNA and assemble vRNPs and cRNPs, respectively. Progeny vRNPs are 
exported out of the nucleus (7) and transported across the cytoplasm to the cell membrane (8), where 
assembly of progeny virions takes place (9). Mature virions incorporate a substantial amount of host 
proteins and are released by budding (10). 
 
 
Without lifelong protection against EIV and the threat of possible future pandemics, 
it is of great importance to have insight in how immunity against IAV infections is formed 
and how the virus manages to evade these immune responses. 
 
 
1.2. Host defence against influenza A virus 
 
In the healthy respiratory tract, the epithelium is ciliated and covered by a 
protective layer of mucus, which limits attachment of viral particles to the epithelium and 
entraps and transports them upward through the action of ciliary apparatus to the pharynx 
where they are swallowed. Once swallowed, viral particles are destroyed in the stomach by 
cytoplasm
nucleus
1. Virus entry
2. Endosomal release
3. Nuclear import (-)
vRNP
(+)
cRNP
(+)
mRNA
Cap
An
7. vRNA export
4. mRNA export
(+)
mRNA
Cap
An
8. vRNA transport
9. Virion
assembly
5. Viral protein 
translation
6. Viral protein import
10. Viral budding
HA
NAPA
PB2
PB1
NP
M2M1 NS1
NEP
endosome 
Chapter 1 - Introduction 
	 31	
the action of acidic secretions and digestive enzymes (Myers C, 2006). A normal architecture 
of the epithelium is essential for successful exclusion of viruses. However, if EIV breaks 
through this first line of defence and infects host cells, it will strongly compromise this 
epithelial barrier. Danger-associated molecular patterns (DAMPs) and pathogen-associated 
molecular patterns (PAMPs) will in turn be recognised by pathogen recognition receptors 
(PRRs) and alert the immune system that a viral invasion is occurring. 
 
 
1.2.1. Detection of IAV 
 
Influenza virus is recognized by at least 3 distinct classes of PRRs: Toll-like receptors 
(TLR), NOD-like receptor family member NOD-LRR- and pyrin domain-containing 3 (NLRP3), 
and cytosolic retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs). 
The Toll-like receptor family of transmembrane proteins are able to recognize a wide range 
of microbial ligands, and signal downstream through either myeloid differentiation primary 
response 88 (MyD88) or TIR-domain-containing adapter-inducing interferon-b (TRIFs) to 
stimulate expression of anti-viral cytokines, such as Interferons (IFNs) (see section 1.2.3 for 
more details about IFNs). Innate responses to IAV infection are primarily triggered by 
recognition of viral nucleic acids by endosomal TLR3 and TLR7. Their respective location 
enables the detection of viral nucleic acids present in the extracellular environment or 
produced by uncoating or degradation of viral particles (Wu et al., 2011). These features 
allow to mount an anti-viral response without the need for viral replication. 
TLR3 has a relatively wide tissue distribution and is highly expressed in myeloid dendritic 
cells (mDCs) (Alexopoulou et al., 2001). Engagement of TLR3 by IAV dsRNA triggers a 
complex signal-transduction pathway starting with the dimerization and tyrosine 
phosphorylation of TLR3 (Sarkar et al., 2004), followed by the recruitment of TRIF 
(Yamamoto et al., 2003,  Hoebe et al., 2003) and phosphatidylinositol 3 kinase (PI3K) (Sarkar 
et al., 2004). Engagement of TRIF activates both NF-kB and IRF-3 transcription factors, 
which in turn leads to IFN induction (Hardy et al., 2004). 
TLR7 is expressed in few cell types and exclusively in endosomes (Kaminski et al., 2012). 
Ligands for this TLR include single-stranded RNA molecules (ssRNA) with no sequence 
specificity (Lund et al., 2004), but requiring the presence of several uridines in close 
proximity (Diebold et al., 2006). The mechanism of IFN induction follows a different profile 
from dsRNA-induced activation of TLR3, in that ssRNA-activated TLR7 recruits the MyD88 
adaptor, which in turn recruits a complex containing the kinases interleukin-1 receptor-
associated kinase 4 (IRAK-4), IRAK-1 and TRAF6 (Hacker et al., 2006), and leads to activation 
of NF-kB and induction of IFN. During an IAV infection TLR7 is particularly important in 
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plasmacytoid dendritic cells (pDCs), while it is dispensable in other cell types (Yoneyama et 
al., 2004, Jeisy-Scott et al., 2012), either because it is not expressed (Mayer et al., 2007) 
or because its localization is non-endosomal (Ioannidis et al., 2013). 
 
NLRP3 forms a multiprotein inflammasome complex consisting of NLRP, pro-caspase 
1, and the bipartite adaptor ASC (apoptosis-associated speck-like protein containing a 
carboxy-terminal CARD) (Lin et al., 2002). NLRP3 is expressed by myeloid cell types 
(monocytes, DCs, neutrophils and macrophages), as well as bronchial epithelial cells. The 
mechanism by which IAV activates the inflammasome is unclear, however, its importance 
has been proven using genetically modified mice lacking NLRP3. These mice have reduced 
viral-mediated inflammation in the lung, but increased mortality and viral clearance defects 
(Allen et al., 2009). Activation of inflammasomes results in the autocatalytic processing of 
pro-caspase 1 into its active form, which then cleaves pro-IL-1b and pro-IL-18 into IL-1b and 
IL-18, respectively (Wattrang et al., 2003). These activated cytokines then recruit 
monocytes and neutrophils into the lung, which are crucial to control infection and regulate 
tissue pathogenesis. In addition, the inflammasome participates in tolerance and tissue 
repair following an influenza virus infection (Iwasaki and Pillai, 2014). Furthermore, the role 
of NLRP3 in the protection against influenza virus is likely viral dose-dependent and maybe 
species-specific (Schaale et al., 2016). 
 
Cytosolic RLRs are probably the most important group of PRRs during an IAV 
infection. This group of viral sensors consist of RNA helicase molecules and comprise RIG-I, 
Melanoma Differentiation-Associated protein 5 (MDA-5) and laboratory of genetics and 
physiology 2 (LGP2) (Pichlmair et al., 2006, Hornung et al., 2006).  
RIG-I and MDA-5 recognize different types of RNAs absent in uninfected cells. RIG-I is most 
efficiently activated by short stretches of 5’ triphosphate (5’-ppp) or 5’ diphosphate (5’-pp) 
dsRNA, while MDA5 is activated by longer stretches of dsRNA in a 5’ phosphate-independent 
manner (Pichlmair et al., 2006, Yoneyama et al., 2004, Hornung et al., 2006, Loo et al., 
2008). In the case of IAV, viral detection and IFN production in airway epithelial cells, DCs, 
and alveolar macrophages is RIG-I-dependent (Le Goffic et al., 2007, Pichlmair et al., 2006, 
Van Reeth, 2000). MDA-5 may still contribute to IFN induction by influenza viruses in certain 
hosts, such as chickens that lack RIG-I (Husser et al., 2011, Liniger et al., 2012). 
 
Both RIG-I and MDA-5 contain two caspase activation and recruitment domains (CARDs) at 
their N-terminus, as well as a RNA helicase domain possessing dsRNA-dependent ATPase 
activity, and a C-terminal regulatory domain (CTD). Upon ligand binding, an ATP-dependent 
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conformational change occurs in RIG-I, leading to exposition of its two CARDs (Myong et al., 
2009, Kowalinski et al., 2011). These domains are then ubiquitinated by E3 ligases TRIM25 
(Gack et al., 2009) and RIPLET (Oshiumi et al., 2013), and/or bound to free poly-ubiquitin 
chains produced by TRIM25 (Zeng et al., 2010). Once activated, RIG-I can then interact with 
a mitochondrial adaptor that acts as an intermediate between detection of viral RNA and 
downstream activation events. This adaptor was discovered in 2005 by four different groups 
and was referred to as mitochondrial antiviral signalling protein (MAVS) (Seth et al., 2005), 
virus-induced signalling adaptor (VISA) (Xu et al., 2005), CARD adaptor inducing IFN-b 
(Cardif) (Meylan et al., 2005), and IFN-b promoter stimulator protein 1 (IPS-1) (Kawai et al., 
2005). This adaptor leads to the oligomerization and scaffolding of RIG-I into a multi-kinase 
signalling platform that will activate NF-kB and the IFN regulatory factors, IRF3 and/or IRF7, 
to stimulate expression of IFNs (Osterlund et al., 2007, Paz et al., 2006)(Figure 1-4-A). 
LGP2 has a similar structure to RIG-I and MDA-5 but lacks the CARDs, and it has been 
proposed to function as a regulator of RIG-I and MDA-5 activity (Childs et al., 2013, Satoh 
et al., 2010) and IFN production (Rothenfusser et al., 2005). Indeed, LGP2 has been shown 
to potentiate IFN induction by synthetic mimic of viral dsRNA through co-operation with 
MDA-5. This co-operation is dependent upon dsRNA binding by LGP2, and the presence of 
helicase domain IV, both of which are required for LGP2 to interact with MDA-5. In contrast, 
LGP2 does not have the ability to enhance IFN induction by RIG-I, and instead acts as an 
inhibitor of RIG-I-dependent poly(I:C) signalling (Childs et al., 2013).  
Interestingly, dendritic cells from mice harbouring a point mutation of Lysine 30 to Alanine 
in LGP2 (Lgp2 (K30A/K30A)), that abrogated the protein’s ATPase activity, showed impaired 
IFN-b productions in response to various RNA viruses. Taken together, these data suggest 
that LGP2 facilitates viral RNA recognition by RIG-I and MDA5 through its ATPase domain 
(Satoh et al., 2010). Finally, the level of LGP2 expression seems to be also critical in 
determining the cellular sensitivity to induction by dsRNA, and this may be important for 
rapid activation of the IFN response at early times post-infection when the levels of inducer 
are low (Childs et al., 2013). 
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Figure 1-4: Type I IFN induction, signalling and action 
 
(A) Induction of type I IFN. Single- and double-stranded (ss/ds)RNA, characteristic by-products of virus 
replication is recognised by RIG-I-like cytosolic sensors, RIG-I, MDA-5 and LGP2. Upon activation, 
RIG-I and MDA-5 will interact with a mitochondrial adaptor (IPS-1) and leads to activation of the 
transcription factors NF-kB, IRF-3/7 and c-jun/ATF-2 and formation of the enhanceasome. This 
complex recruits CBP and promote the formation of the basal transcriptional machinery and RNA 
polymerase II (not shown in this diagram), and allows full activation of the IFN-β promoter and 
production of IFN-β. Although not essential, formation of the enhanceasome is aided by HMGI. LGP2 
has been proposed to function as a negative regulator of RIG-I and MDA-5 activity, and IFN-β induction. 
(B) Newly synthesized IFN-β binds to the type I IFN receptor (IFNAR) in a paracrine and/or autocrine 
manner. TYK2 then phosphorylates STAT2 (P-STAT2), while JAK1 phosphorylates STAT1 (P-STAT1). 
Following phosphorylation, P-STAT1 and P-STAT2 form a heterodimer that interacts with a monomer 
of Interferon Regulatory Factor 9 (IRF9). Together IRF9, P-STAT1 and P-STAT2 form the Interferon-
stimulated gene factor 3 (ISGF3) complex. This complex is then transported into the nucleus, where it 
recognises a distinct DNA response element in the promoter of specific genes, the IFN-stimulated 
response element (ISRE). By binding to ISRE, the ISGF3 complex enhances transcription of hundreds 
of IFN-inducible or -stimulated genes (ISGs) that establish a cellular antiviral state (McBride et al. 2002). 
and activates the expression of numerous ISGs. Mx1, ISG15, OAS, PKR, TRIMs, IFITMs, CH25HC, 
tetherin, and viperin, among others are examples of induced proteins with antiviral activity. Furthermore, 
PRRs, IRFs, and several other signal transducing proteins, such as JAK, STAT1/2 and IRF9 are also 
induced by type I IFN. For details see text. 
 
 
1.2.2. Natural Influenza PAMPs 
 
It is likely that distinct PAMPs are generated at different stages of the virus life cycle.  
Several studies have indicated that incoming influenza A vRNPs are not sufficient to induce 
IFN during infection of epithelial cells and monocyte-derived DCs (moDCs), and that viral 
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RNA synthesis is required (Crotta et al., 2013; Killip et al., 2014; Osterlund et al., 2012). 
Indeed, efficient inhibition of IRF3 and NF-kB activation by the cellular transcription 
inhibitors actinomycin D and alpha-amanitin in influenza-infected cells strongly suggests 
that incoming genomes do not function as a major PAMP in lung epithelial cells (Killip et al., 
2014). Furthermore, expression of IFNs following influenza A virus infection correlates with 
the accumulation of viral RNAs (Osterlund et al., 2012) and can be completely abrogated 
following inactivation of the virus by heat or UV treatment (Crotta et al., 2013; Osterlund 
et al., 2012). A minority of incoming IAV genomes may contribute to IFN induction at very 
early times post-infection, it appears that the viral polymerase products generated later in 
infection represent the most significant IAV PAMPs (Osterlund et al., 2012, Crotta et al., 
2013). Interestingly, the above studies have been limited to a relatively small number of 
influenza A virus strains, so it is conceivable that different influenza A virus strains may vary 
in their capacity to be recognised by RIG-I during vRNP entry. 
Taken together, these observations strongly suggest that the generation of the major 
influenza A virus PAMPs requires the synthesis and nuclear export of an RNA product or 
products from incoming genomes, and that these RNAs can be generated even in conditions 
where cRNP and vRNP accumulation is impaired. Nevertheless, it is likely that distinct PAMPs 
are generated at different stages of the virus life cycle; thus, a minority of incoming 
influenza A virus genomes may contribute to IFN induction at very early points post-
infection, with viral polymerase products (including, but not limited to, progeny genomes) 
functioning as a more significant PAMP population later in infection (Killip et al., 2015). 
Evidence also suggests that activation of the IFN pathway upon infection is not associated 
with ‘normal’ virus replication. The link between the presence of ‘abnormal’ defective 
interfering (DI) particles and IFN induction by negative-strand RNA viruses is well known. DI 
particles, first identified in the 1950s as ‘incomplete’ non-infectious viruses (Von Magnus, 
1951) are readily generated during an IAV infection. They appear to be limited to internal 
deletion of RNA segments that retain their 5’ and 3’ termini. Influenza virus DIs can arise 
from all genome segments, but are more frequent from PB2, PB1, PA segments.  
These DI particles are distinguished from non-defective particles by their inability to 
complete a full replication cycle due to the absence of the coding region for one or more 
viral factors otherwise essential for replication. DI viruses are therefore only able to 
replicate when a co-infecting ‘normal’ virus is present, hence providing the missing factors.  
Their relevance in vivo has been questioned for a long time, however, relatively recent 
studies have confirmed their role in natural infections, and internal deletion DI viruses have 
been detected in samples from infected mice (Tapia et al., 2013), poultry (Jonges et al., 
2014) and humans (Saira et al., 2013, Jonges et al., 2014). DIs are generated de novo during 
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in vivo infections (Tapia et al., 2013) and the transmission between patients has been 
described (Saira et al., 2013). Studies have also correlated the IFN-inducing phenotype of 
influenza viruses with a propensity to generate or accumulate high numbers of DI genomes 
in tissue culture (Perez-Cidoncha et al., 2014). What remains unclear is why DI RNAs should 
be more effective at inducing IFN than non-defective full-length genome segments since 
they are encapsidated into stable nucleocapsids and should therefore be hidden from 
recognition by viral sensors (Strahle et al., 2006). Their ability to induce IFN may simply be 
due to their faster replication rate compared to full-length genomes because of their smaller 
size. Alternatively, DI-mediated interference with viral polymerase and NP expression may 
lead to a reduction in polymerase-induced shut-off of cellular gene expression (Ngunjiri et 
al., 2012) or affect the efficiency of cRNA and vRNA encapsidation. Furthermore, DI-
mediated interference may reduce NS1 expression, thereby contributing to IFN induction by 
limiting its antagonism by the virus. Perhaps also, smaller segments of genomic RNAs form 
a panhandle more readily than full-length RNA when they are unencapsidated, or DI vRNPs 
may be less stable than full-length vRNPs and thus more prone to release free RNA. Finally, 
very small influenza genome templates can be replicated in the absence of NP (Resa-Infante 
et al., 2010). Thus, it is a possibility that small DI RNAs could be replicated without being 
encapsidated and these products could activate more strongly IFN induction. 
 
 
1.2.3. Interferons 
 
Interferons (IFNs) represent a group of secreted cytokines that elicit distinct antiviral 
effects. There are divided in three classes according to their amino acid sequence and the 
type of receptor through which they signal.  
 
The type I IFNs, discovered in 1957 (Isaacs and Lindenmann, 1957) comprises a large 
group of molecules, including multiple IFN-a genes, up to three IFN-b genes, and IFN-w, -e, 
-t, -d, -k genes. IFN-a and -b are induced directly in response to viral infection, whereas 
IFN-w, -e, -t, -d, -k are thought to have different functions. Indeed, IFN-ε is constitutively 
expressed by epithelial cells of the female reproductive tract and is hormonally regulated.  
IFN-ε-deficient mice have notably an increased susceptibility to infection of reproductive 
tract by the common sexually transmitted infections herpes simplex virus 2 and Chlamydia 
muridarum. Thus, IFN-ε is believed to be a potent anti-pathogen and immune-regulatory 
cytokine (Fung et al. Science 2013).  
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IFN-t expression is dependent of the presence of a trophoblast. Polymorphisms have been 
identified in cattle, sheep and goats, and genes and gene alleles encoded proteins do not 
display identical antiviral, antiproliferative and antiluteolytic activities. The need for 
distinct IFN-t activities remains debatable, but the consensus is that this complexity in 
expression and biological activity must be needed to provide the best opportunity for 
pregnancy to be recognized by the maternal system so that gestation may continue (Ealy et 
al., 2017). 
Finally, IFN-k is constitutively expressed in keratinocytes and acts as a type I IFN in hr-HPV-
positive keratinocytes, inducing ISG expression following viral infection (Habiger et al., 
2015). 
 
In horses, thirty-two putative type I IFN loci on chromosome twenty-three have been 
identified. A phylogenetic analysis characterized them into eight different type I IFN classes, 
including six IFN-a, four IFN-b, eight IFN-ω (plus four pseudogenes), three IFN-δ (plus one 
pseudogene), one IFN-κ, one IFN-ε, and 3 loci belonging to what has previously been called 
IFN-aω. Results from cell cultures also showed that leukocytes readily expressed IFN-a, IFN-
b, IFN-δ, IFN-µ, and IFN-ω mRNA on induction with live virus; while fibroblasts only 
expressed IFN-b mRNA on stimulation (Detournay et al., 2013). 
 
From this point onwards, the term ‘type I IFN’ will be used to refer to the virally induced 
IFN-a and -b. 
 
Optimal induction of type I IFN requires the formation of an enhanceasome formed 
by IRF-3/IRF-7, NF-kB and c-jun/ATF-2 (Figure 1-4-A). This complex participates in the 
recruitment of CREB-binding protein (CBP)/p300, which in turn promotes the assembly of 
the basal transcriptional machinery and RNA polymerase II. Each of these transcription 
factors can bind the IFN-b promoter with limited affinity, and optimal induction requires 
cooperativity between these factors. Only IRF-3 and IRF-7 are indispensable for IFN-b 
induction, while activation of both NF-kB and c-jun/ATF-2 may not be essential (King and 
Goodbourn, 1994, Ellis and Goodbourn, 1994, Goodbourn et al., 1985). Formation of the 
enhanceasome can be aided by the high-mobility group (HMG) chromatin-associated protein 
I (HMGI, also known as HMGA) (Munshi et al., 2001, Merika and Thanos, 2001), although this 
protein is not absolutely essential (Berkowitz et al., 2002). 
Interestingly, type I IFN itself can enhance the its yield in a process known as ‘priming’. It 
is believed that direct induction of primary type I IFN genes (IFN-b and a4 in mouse) 
(Erlandsson et al., 1998, Marie et al., 1998) takes place via IRF-3. Then, by positive 
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feedback, IFN-b induces the synthesis of IRF-7, which in the presence of a continued 
infection, enhances dramatically the transcription of primary IFN genes and allows the 
transcription of secondary IFN genes (other IFN-a genes) (Marie et al., 1998, Prakash et al., 
2005).  
All type I IFNs bind a heterodimeric receptor, Interferon-a/-b receptor (IFNAR) 
composed of two chains (IFNAR-I and -II). Prior to activation, the cytoplasmic tail of IFNAR-
I and -II is associated with Tyrosine Kinase 2 (Tyk2) and Janus Kinase 1 (JAK1), respectively 
(Figure 1-4-B). Signal transducer and activator of transcription 2 (STAT2) is also bound to 
IFNAR-II before induction and is weakly associated with STAT1 (Precious et al., 2005). When 
the type I IFNs bind the IFNAR receptor, a conformational change occurs allowing 
phosphorylation of IFNAR-I by Tyk2 on tyrosine 466, which creates a strong docking site for 
STAT2. Tyk2 then phosphorylates STAT2 (P-STAT2) on tyrosine 690, while JAK1 
phosphorylates STAT1 (P-STAT1) on tyrosine 701. Following phosphorylation, P-STAT1 and 
P-STAT2 form a heterodimer, which creates a novel nuclear localisation sequence (NLS) 
(Banninger and Reich, 2004) and inactivates the dominant constitutive nuclear export of 
STAT2 (Frahm et al., 2006). In addition, the transcriptional co-factor CREB-binding protein 
(CBP) is recruited to IFNAR-II and catalyses its acetylation, which creates a docking site for 
a monomer of Interferon Regulatory Factor 9 (IRF9). Together IRF9, P-STAT1 and P-STAT2 
form the IFN-stimulated gene factor 3 (ISGF3) complex. Of note, acetylation of IRF-9, P-
STAT1 and P-STAT2 may also aid in the assembly of the ISGF3 complex (Tang et al., 2007). 
The ISGF3 complex is then transported into the nucleus, where it recognises a distinct DNA 
response element (sequence 5’-AGTTTNNNTTTCC-3’) in the promoter of specific genes, the 
IFN-stimulated response element (ISRE). By binding to ISRE, the ISGF3 complex enhances 
transcription of hundreds of IFN-inducible or -stimulated genes (ISGs) that establish a 
cellular antiviral state (McBride et al., 2002). 
 
The remaining two classes of IFN are represented by type II and III IFNs. Type II IFN 
has a single member, IFN-g, and is secreted by activated T cells and natural killer (NK) cells, 
rather than in direct response to viral infection. Hence it will not be discussed further in 
this review. In contrast, type III IFNs have been described more recently and comprise IFN-
l1, l2 and l3, also referred to as IL-29, IL-28A and IL-28B, respectively (Randall and 
Goodbourn, 2008). These cytokines appear to use the same pathways as type I IFN to sense 
viral infection, and they are directly upregulated following virus infection. Furthermore, 
the panel of ISGs upregulated in airway epithelia in response to type I and type III IFNs 
following an IAV infection completely overlaps (Crotta et al., 2013). Several studies 
suggested that airway epithelial cells are also primarily responsible for type III IFN 
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production, while plasmacytoid dendritic cells and alveolar macrophages are the major 
source of type I IFNs (Crotta et al., 2013, Cheung et al., 2002, Ioannidis et al., 2013). Type 
III IFNs signal through a heterodimeric cell surface receptor composed of the b subunit of 
the IL10-receptor and IFN-l1 receptor. Unlike the type I IFN receptor, the type III IFN 
receptor shows a limited tissue distribution (Crotta et al., 2013, Mennechet and Uze, 2006, 
Zhou et al., 2007), and is primarily expressed on epithelial cells of respiratory and 
gastrointestinal tracts. The role of type III IFNs during an IAV infection remains to be fully 
established, however, they are believed to elicit an equivalent antiviral response to type I 
IFN in airway epithelia, while restricting immune cell activation (Crotta et al., 2013, 
Onoguchi et al., 2007).  
 
The IFN response to viral infection is tightly controlled, and shortly after IFN 
exposure cultured cells enter an IFN-desensitized state that can last for several days. This 
desensitized state is supposed to allow cells to recover from IFN signalling. This state is 
established in cells by multiple mechanisms, either intrinsic or mediated by the actions of 
ISGs. Suppressor of cytokine signalling (SOCS) proteins are induced early in the IFN response 
and play an important role in early IFN desensitization (Schneider et al., 2014). These 
proteins inhibit JAK-STAT signalling by binding to phosphorylated tyrosine residues, on 
either the IFN receptor or the JAK proteins, resulting in inhibition of STAT binding as well 
as JAK activity. Similarly, in the absence of IFN signalling an elevated baseline level of SOCS1 
protein expression renders cells less responsive to IFN. Receptor endocytosis and turnover 
play also an important role in reducing the level of JAK-STAT signalling. IFN signalling is 
further decreased by the action of phosphatases that inactivate the JAKs and STATs. In 
addition, STAT activity can be modulated by members of the family of protein inhibitors of 
activated STAT (PIAS) (Schneider et al., 2014), however the precise mechanisms by which 
these proteins inhibit IFN signalling remain unclear. 
 
 
1.2.4. Interferon-stimulated genes 
 
ISGs are genes whose transcriptional output increases in response to virus-induced 
IFN, largely due to the presence of ISRE sequences in promoter and enhancer regions. Their 
function is to establish a cellular anti-viral state to efficiently limit further replication and 
spread of the virus (Randall and Goodbourn, 2008). ISGs can represent up to 5% of the total 
number of cellular genes, however, this percentage may be underestimated as it only 
represents genes with changes in mRNA abundance. Since several ISGs are present in 
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multiple isoforms and give rise to proteins with differences in cellular localization and 
activity, some ISGs changes upon type I IFN stimulation may remain undetected. 
 
ISGs take on a wide range of activities. Many will control viral infection by directly 
targeting pathways and functions required during pathogen life cycles. Indeed, to complete 
their life cycle, viruses must enter cells, replicate their genome, and exit in order to infect 
new cells. Every stage of the virus life cycle is a potential target for ISGs intervention. In 
addition, a number of ISGs also act to enhance pathogen detection and innate immune 
signalling, while others encode for pro-apoptotic proteins leading to cell death under 
specific conditions. Of these ISGs, several have been identified as having direct anti-IAV 
activities. 
 
Among important and well-studied proteins encoded by ISGs, the myxovirus 
resistance proteins (Mx1 and Mx2) are considered important in the defence against IAV 
infection. Furthermore, diversity of equine Mx gene has been associated with variations in 
susceptibility vis-a-vis resistance against EIV evidence, which suggests an important role of 
these proteins for the resistance to influenza virus infection (Manuja et al., 2014). Mx1 and 
Mx2 belong to a small family of dynamin-like large guanosine triphosphates (GTPases). The 
former broadly inhibits IAV and acts prior to genome replication at a post-entry step in the 
virus life cycle. It contains a middle stalk domain and a GTPase effector domain, which are 
both essential for self-oligomerization and formation of ring-like structures that trap 
incoming viral components, such as NP. In doing so, Mx1 inhibits nuclear import of vRNP, 
and potentially directs them to sites of degradation. Mx2 has been characterized more 
recently as an antiretroviral effector protein against HIV but has less potent or no antiviral 
activity against IAV (Busnadiego et al., 2014). 
 
Many of the proteins involved in ISGylation and de-ISGylation are also induced by 
type I IFN (i.e. TRIM25, ISG25, USP18, …) (Sgorbissa and Brancolini, 2012). ISGylation can 
positively or negatively affect the targeted protein. In the case of IRF3 it increases stability 
by preventing poly-ubiquitination and leads to sustained transcription factor activity. In 
contrast, ISGylation of cyclin-dependent kinase 1 (CDK1) leads to protein destabilization 
and cell cycle inhibition. It is believed that ISGylation is a general, non-specific mechanism 
of host defence, which potentially impacts all viral proteins translated in IFN-stimulated 
cells (Durfee and Huibregtse, 2010). A small IFN-induced ubiquitin-like protein, Interferon-
stimulated gene 15 (ISG15) is one of the most highly induced ISGs. However, despite reports 
describing ISG15 function and targets in vitro, its role in vivo remains controversial 
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(Bogunovic et al., 2012). ISG15 is also secreted from immune cells and enhances the 
production of type I IFN (Bogunovic et al., 2013). Removal of ISG15 conjugates 
(deISGylation) is performed by USP18. USP18 maintains long-term IFN desensitization 
through an interaction with IFNAR-II, which suggests that USP18-mediated inhibition may be 
restricted to type I IFN signalling (Schneider et al., 2014). 
The tripartite motif (TRIM) family of proteins are also induced by virus-induced IFNs. 
This family is composed of more than 60 members and exhibits a wide range of activities 
including E3 ubiquitin ligase activity, SUMOylation and ISGylation. Among them is found 
TRIM25 responsible for ubiquitination and activation of RIG-I as described previously (section 
1.2.1).  
 
Another important ISG-encoded protein is the 2’-5’-oligoadenylate synthase (OAS). 
Upon binding dsRNA, OAS becomes enzymatically active and converts ATP into 2’-5’-
oligoadenylate, which then functions as a second messenger to activate latent RNase L. OAS 
and activated RNAse L act together to degrade viral RNA in the cytosol. They also generate 
short fragments with 3’ monophosphates, which lead to protein synthesis inhibition and viral 
growth arrest. By-products of this degradation might also be recognized by RLRs, hence 
participating in the positive feedback in the IFN response (Silverman et al., 2007). In 
accordance with this, the magnitude of IFN induction is enhanced by the activation of RNase 
L (Malathi et al., 2007). 
 
The double-stranded RNA (dsRNA)-activated protein kinase (PKR) is an RNA-binding 
protein kinase constitutively expressed in an inactive conformation in mammalian cells. The 
binding of dsRNA to PKR release its auto-inhibition and thereby activates it. PKR also 
becomes upregulated upon interferon treatment (Hovanessian, 1989). Once activated, it 
phosphorylates a number of substrates and activates different signal transduction pathways 
to counteract potential threats. PKR notably phosphorylates the a–subunit of eukaryotic 
translation initiation factor 2a (EIF2a) in parallel of binding viral dsRNA, thus inhibiting 
translation of both cellular and viral proteins (Garcia et al., 2006). Moreover, PKR plays an 
important role in signal transduction and transcriptional control through activation of IkB, 
the inhibitor of NF-kB. Activation of PKR in infected cells results in apoptosis, cell growth 
arrest and autophagy, all of which limit viral replication and spread in the host. In addition, 
PKR has been shown to stabilize IFN-a/b mRNAs, thereby ensuring robust type I IFN 
production (Munir and Berg, 2013).  
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The Cholesterol 25-Hydroxylase (CH25HC) gene is also upregulated by type I IFNs. 
The product of this gene is an enzyme that converts cholesterol into 25-hydroxycholesterol 
(25HC). CH25H mediates protection against IAV at an early stage in the infectious cycle, 
possibly at the step of virus-host membrane fusion (Schoggins and Randall, 2013). However, 
25HC may impact virus infection by additional mechanisms, such as directly altering 
membrane properties, inhibiting sterol biosynthesis, and affecting prenylation of both virus 
and host proteins, which plays an important role in the virus life cycle (Matsumiya et al., 
2013). In addition, high concentrations of 25HC change the physical properties of 
membranes, which prevents virus-host membrane fusion (Matsumiya et al., 2013). 
The only ISGs shown to have a bona fide role in blocking virus entry are members of 
the IFN-inducible transmembrane (IFITM) family. The IFITM family of proteins is composed 
of four members, IFITM1, IFITM2, IFITM3 and IFITM5, that have been shown to be potent 
inhibitors of IAV infection (Brass et al., 2009). These proteins are enriched in late endosomes 
and lysosomes. The most potent member of the IFITM family against IAVs is IFITM3, which 
interfere with fusion between viral and endosomal membranes thereby limiting the viral 
entry (Brass et al., 2009, Everitt et al, 2012). 
 
During late stages of the virus life cycle, viral nucleic acids are packaged into 
capsids, and viral particles exit cells either by cell lysis, exocytosis, or direct budding from 
the plasma membrane. Relative to other stages in the virus life cycle, few ISGs are known 
to inhibit viral assembly and viral egress. Viperin, encoded by the ISG RSAD2, is one of the 
best-studied, most highly induced antiviral effectors. It can be induced by at least two 
different innate immune pathways, such as the JAK-STAT signalling pathway or via direct 
activation by IRF3. Viperin normally resides in the endoplasmic reticulum (ER) and in ER-
derived lipid droplets, organelles important for lipid metabolism. Viperin inhibits IAV 
budding at the host cell membrane by inhibiting farnesyl diphosphate synthase (FFPS), an 
enzyme involved in isoprenoid biosynthesis (Wang et al., 2007). 
 
Another ISG-encoded protein important at the late stage of the virus life cycle is 
Tetherin. This protein is encoded by the ISG BST2, and it inhibits virus budding by using two 
membrane anchors to trap virions on the plasma membrane (Swiecki et al., 2011). 
 
Finally, PRRs, IRFs, and several other signal transducing proteins, such as JAK, 
STAT1/2 and IRF9, are present at baseline, but are also ISGs and reinforce the IFN response. 
Upon induction, this set of ISGs are directly induced by IRF activation independently of the 
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JAK-STAT pathway, which likely evolved to counteract pathogen strategies of immune 
evasion (Iwasaki and Pillai, 2014). 
 
 
1.2.5. Other immune players 
 
Although innate immune responses control virus replication during the early phase 
of influenza virus infection, clearance and recovery from infection requires adaptive 
immune responses (van de Sandt et al., 2012). Virally infected epithelial cells become the 
targets of natural killer cells (NK cells), which are cytotoxic lymphocytes of the innate 
immune system responsible for viral clearance. In addition, monocytes and neutrophils are 
rapidly recruited to the lung after an IAV infection, and together with alveolar macrophages 
they help clear dead cells. In addition to alveolar macrophages, tissue-resident macrophages 
are found within the pulmonary interstitia. These cells have the capacity to transport 
antigens from the lungs to the draining lymph nodes and they may serve as antigen 
presenting cells (APCs) for activation of effector T cells (Iwasaki and Pillai, 2014). However, 
the professional APCs are conventional dendritic cells (cDCs). They reside below the airway 
epithelial cells within the pulmonary interstitia, and extend processes between airway 
epithelial cells (Iwasaki and Pillai, 2014). They are crucial for the induction of adaptive 
immune responses by the presentation of viral antigens to naïve and memory T and B 
lymphocytes. Plasmacytoid DCs (pDCs), distinct from cDCs, are activated during influenza 
virus infection. These cells are weak activators of naïve T cells but are major producers of 
type I IFNs. 
 
B lymphocytes are the first cells of the adaptive immune system to encounter the 
virus (Iwasaki and Pillai, 2014). Once activated, they differentiate into plasmocytes, also 
known as antibody-producing cells. In the lung, these cells generate mainly IgG and IgM, 
whereas in the upper respiratory tract the vast majority of antibodies produced are IgA 
(Waffarn and Baumgarth, 2011). Antibodies are generated against most viral proteins, 
although at different levels and kinetics. Best understood are the strong and often 
neutralizing responses against HA. Serum antibody titres are detected around six to seven 
days post-infection and are delayed by at least three days compared with the respiratory 
tract. Antibody titres increase for about one month, and IgG and IgA memory B cells are 
maintained for months in the respiratory tract (Waffarn and Baumgarth, 2011). Virus-
specific antibody-producing cells also reside transiently in the spleen, starting around six to 
seven days post infection, but remain in the bone marrow in the long-term. Interestingly, a 
small subset of B cells, distinct from conventional B cells, contribute to protection from IAV 
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infection by generating natural IgM, even prior to any encounter with the virus. They 
contribute to host protection by virus neutralization and are required for maximal induction 
of IAV-specific IgG. Moreover, they are strong producers of IL-10, and could be involved in 
the regulation of local immune responses (Braciale et al., 2012). 
 
T lymphocytes can be categorized into three groups: T cells responsible for lysis of 
infected cells by exocytosis of perforin- and granzyme-containing granules; T cells that can 
induce apoptosis of infected cells by expressing CD95 ligand (also known as FAS ligand) or 
TNF-related apoptosis-inducing ligand (TRAIL); and T cells that can produce pro-
inflammatory mediators and regulatory mediators in response to encounter with virus-
infected cells (van de Sandt et al., 2012). 
Recent evidence strongly suggests that activation and function of effector T cells in virus-
infected lungs are sculpted by the local milieu generated by the resident and infiltrating 
inflammatory cells, as well as by factors produced in response to virus infection (Braciale 
et al., 2012). 
 
 
1.2.6. Particularities of the athletic horse 
 
Exercise is considered a physical stress and has been shown to have profound effects 
on the immune system of man, pigs, dogs, cattle and rats (Tiollier et al., 2005, Pedersen 
and Toft, 2000). In horses, evidence suggest that a strenuous exercise is associated with a 
reduction of TNF-a and IFN-b production by pulmonary leukocytes treated with 
poly(rI).poly(rC) (structurally similar to double-stranded RNA) for 24h compared to controls 
(Folsom et al., 2001). In addition, after five days of intense exercise a significant decrease 
of lympho-proliferation was noted as well as a decrease in type II IFN expression, which is 
mainly produced by CD4+ helper T cells (of Th1 subtype), CD8+ cytotoxic T cells (Mignot et 
al., 2012). Taken together, these data suggest that young untrained horses subjected to 
strenuous exercise have an increased susceptibility to EIV infection. 
 
 
1.3. Virus strategies to counteract type I IFN  
 
When IAV enters the body, a race begins between the host immune system and the 
infecting virus. Eventually, most viral infection will be successfully controlled by the host 
immune response, however, IAVs have evolved various strategies to control the early step 
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of this response, by notably blocking the type I IFN system, in order to open a window for 
replication and transmission and thus survive in nature. 
 
 
1.3.1. Non-structural protein 1 
 
NS1 is the main viral antagonist of the host interferon response in infected cells. It 
can block these responses at multiple levels with a striking degree of redundancy. More 
importantly, viruses unable to express NS1 are only able to replicate in type I IFN 
compromised systems (Garcia-Sastre et al., 1998, Kochs et al., 2007c), which demonstrates 
how relevant for the virus is to possess an NS1 protein blocking efficiently the host IFN 
responses. 
 
As previously mentioned, NS1 is encoded on a colinear mRNA derived from the NS 
segment, and upon splicing, this segment also encodes NEP mRNA (Inglis et al., 1979, Lamb 
and Choppin, 1979) (Figure 1-4). NS1 and NEP share their first 10 amino acids (nucleotide 
27 to 57 on the NS segment), while nucleotides 530 to 719 are shared between NS1 and NEP 
ORFs, however on a shifted reading frame (Lamb and Lai, 1980). 
 
 
Figure 1-5: NS segment coding strategy. 
 
Schematic representation of the NS genes and gene transcripts. In-frame NS1 mRNA is indicated by a 
white box, with nucleotide length indicated by vertical dotted lines and numbers. Viral NEP mRNA is 
also shown, with white box indicating the in-frame mRNA sequence shared between viral NS1 and NEP 
ORFs, and grey box representing the unique ORFs of the viral NEP mRNA transcript. 5’-cap and 3’-
polyA tails are indicated by a black circle and A(n) joint to each ORF, respectively. 5’- and 3’-UTRs are 
indicated. UTR: untranslated region, A(n): polyA tail, nt: nucleotide, ORF: Open-reading frame. 
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In infected cells, the steady-state amount of spliced NEP mRNA is approximately 10% 
of un-spliced NS1 mRNA (Lamb and Lai, 1980). Regulation of splicing is controlled in part by 
NS1 itself and may represent a mechanism of autoregulation of protein levels within infected 
cells (Garaigorta and Ortin, 2007). 
 
NS1 mRNA translates into a 26 kDa polypeptide, which varies in length. EIV NS1 
ranges between 217 and 230 amino acids, and in IAVs isolated from other host species NS1 
can be as short as 202 amino acids and as long as 237 (Dundon and Capua, 2009). 
Furthermore, NS1 proteins can be divided into three distinct variants: alleles A and B, and 
H17-H18 bat virus NS1 proteins (Ludwig et al., 1991, Turkington et al., 2015, Scholtissek 
and von Hoyningen-Huene, 1980). Among the same allele, 90 to 100% of residues are 
conserved, while between alleles conservation can be as low as 60%. As for the majority of 
mammalian IAVs, all EIVs possess an allele A NS1 protein. Allele B NS1s are found in avian 
IAVs (Guo et al., 1992), and may represent an archaic version of NS1, which has undergone 
strong selection pressure and mutated to give rise to allele A after entering in mammalian 
host populations (Ludwig et al., 1991). 
 
 
1.3.1.1. Structure 
 
The NS1 polypeptide comprises a N-terminal RNA binding domain (RBD) (amino-acids 
1-73) formed of three a-helices, and a C-terminal effector domain (ED) (residue 85 to end) 
made of seven b-strands and three a-helices, separated by a short linker region (Qian et 
al., 1994) (Figure 1-5). NS1 RBD can homodimerize in a six-helix antiparallel bundle and 
form a tract of conserved basic and hydrophilic residues capable of binding with low affinity 
to several RNA species. The binding is independent of the RNA sequence and follows a 
dimer:dsRNA stoichiometry of 1:1 (Chien et al., 2004, Hatada and Fukuda, 1992, Qian et 
al., 1994). Residue R38 and K41 are particularly important for this function, and additional 
amino acids also contribute (i.e. T5, P31, D34, R35, G45, R46, T49) although to a lesser 
extent (Liu et al., 1997, Chien et al., 1997). NS1 ED can also dimerize and W187, located at 
the helix-helix interface, is essential for it (Hale et al., 2008a). It has been proposed that 
NS1 could adopt various dimeric states in a strain- or ligand-specific manner, which would 
likely contribute to NS1 multifunctional potential. The short linker region between RBD and 
ED is thought to be flexible and would allow NS1 homodimer to adopt different 
conformations. Additionally, the linker length and amino acid composition, as well as the 
nature of neighbouring residues are likely to be involved in NS1 quaternary structure. 
Evidence also suggests that the RBD association is highly stable and has the properties of an 
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obligate dimer, whereas the ED dimerization is likely to be transient (Kerry et al., 2011a, 
Aramini et al., 2011). Furthermore, it is not clear whether ED dimerization takes place 
within the same RBD dimer or with neighbouring dimers to promote NS1 multimerization, or 
both (Wang et al., 2002, Bornholdt and Prasad, 2006, Carrillo et al., 2014). Importantly, it 
has been suggested that the tridimensional disposition that NS1 can adopt may influence its 
interactions with cellular partners in a strain specific manner (Ayllon and Garcia-Sastre, 
2015). 
 
There is currently no structure available for the last 25 amino acids of NS1. This part 
of the protein is thought to form an intrinsically disordered and flexible “tail”, which may 
only adopt an ordered structure upon binding to the appropriate ligand (Hale et al., 2008c). 
Interestingly, this is one of the most variable regions of the protein and the main cause of 
diversity in NS1 lengths. Indeed, naturally occurring C-terminal truncations are relatively 
common among IAVs (Suarez and Perdue, 1998, Hale et al., 2010, Dundon and Capua, 2009). 
For example, EIV NS1 was initially composed of 230 amino acids, however, in the late 1990’s 
a non-sense mutation of codon 220 resulted in a loss of eleven amino acids at its C-terminus 
(Rivailler et al., 2010, Dundon and Capua, 2009, Barba and Daly, 2016). Of note, three 
isolates from the early 1970’s (A/equine/Sachiyama/1971; A/equine/Tokyo/2/1971; 
A/equine/Algiers/1/1972) harboured a 217-amino-acid-long NS1 protein. Work done by 
Quinlivan and colleagues on EIV NS1 deletion mutants revealed that the length of the protein 
did not correlate with the level of viral attenuation as initially thought, and they speculated 
that the basis for EIV attenuation was related to the level of expression of the protein rather 
than its length (Quinlivan et al., 2005)). 
Variation in NS1 length has also been seen in human isolates, which acquired seven 
additional residues in their C-terminus in the late 1940s, extending NS1 length from 230 to 
237 amino acids (Hale et al., 2008c). For the following 40 years, all NS1 proteins of human 
isolates (H1N1, H2N2 and H3N2) were 237 residues long. This extension was retained until 
the late 1980s, when both co-circulating H1N1 and H3N2 viruses reverted to 230 amino acids. 
Despite some evidence of being functionally implicated in NS1 nuclear and nucleolar 
localization, there is no clear evolutionary advantage associated with these extension or 
truncation events (Melen et al., 2007).  
 
Chapter 1 - Introduction 
	 48	
 
Figure 1-6: Tri-dimensional structure of NS1. 
 
Cartoon representation of NS1. The full length NS1 protein of H6N6 avian virus has been used for this 
cartoon representation (Carrillo et al., 2014, Bornholdt and Prasad, 2006). Of note, to solve the 
structure of the full length NS1, the introduction of a double substitution R38A-K41A was necessary 
to prevent aggregation of the recombinant protein. In addition, the C-terminal tail is not apparent 
in crystal structure. Grey shading indicates the part of NS1 ED in complex with the F2/F3 region of 
CPSF30.  
 
 
Interestingly, not all NS1 proteins rely equally on the same anti-interferon functions 
(Kochs et al., 2007a, Geiss et al., 2002, Hayman et al., 2006). Current evidence indicates 
that NS1 can limit IFN-b induction by both pre-transcriptional (cytoplasmic) and/or co- and 
post-transcriptional (nuclear) processes. The existence and evolution of two synergistic 
anti-IFN mechanisms could increase the capacity of some IAVs to adapt to new hosts (Kochs 
et al., 2007c). In this regard, it is also possible that some virus strains may have lost one or 
other of these mechanisms, either naturally or during laboratory passage. 
 
 
1.3.1.2. Pre-transcriptional activities 
 
NS1 counteracts the type I IFN pathway at multiple levels, and notably mediates a 
pre-transcriptional block of IFN-b induction by interfering with the RIG-I signalling pathway 
(Mibayashi et al., 2007, Rehwinkel et al., 2010). NS1 is believed to form a complex with 
RIG-I, although there is no clear consensus on whether this complex involves direct 
inhibitory contacts between the two proteins or if it is mediated through other interactions 
(Pichlmair et al., 2006, Guo et al., 2007, Opitz et al., 2007, Mibayashi et al., 2007). 
NS1 has also been reported to prevent RIG-I activation indirectly by associating with two 
positive regulators: the ubiquitin ligases TRIM25 (Gack et al., 2009) and RIPLET (Rajsbaum 
et al., 2012). The apparent redundancy in NS1’s ability to interfere with two activators of 
Chapter 1 - Introduction 
	 49	
RIG-I could be explained by both viral strain- and host species differences (Rajsbaum et al., 
2012). Whether RIPLET and TRIM25 can both ubiquitinate the same residues in the CARD 
domains of RIG-I remains controversial, however, RIPLET seems to be specifically driving a 
distinct modification of the N-terminus of the sensor allowing it to change its initial 
conformational and the subsequent activation by TRIM25 (Oshiumi et al., 2013). According 
to this model, NS1 could be independently blocking two required regulatory steps for the 
activation of RIG-I. Furthermore, by binding TRIM25, NS1 can block its oligomerization and 
subsequent E3 ligase activity on the CARD domains of RIG-I. NS1 residue E96 and E97 are 
important for this function, and disrupting NS1-TRIM25 interaction via E96A/E97A 
substitutions have been associated with viral attenuation and higher induction of IFN-b 
(Gack et al., 2009). Of note, E96/E97 residues are not involved in NS1 inhibition of RIPLET 
(Rajsbaum et al., 2012). 
NS1 has also been reported to block the function of both a constitutively active RIG-I 
construct lacking its RNA-binding helicase domain, as well as its downstream effector IPS-1 
(Mibayashi et al., 2007), however, the mechanism involved is still under investigation. 
The dsRNA binding activity of NS1 has also been suggested to participate in RIG-I inhibition 
by sequestering PAMPs away from the sensor (Talon et al., 2000). The ability to bind 
different species of RNA was among the first features ascribe to NS1 (Hatada et al., 1999, 
Hatada and Fukuda 1992). NS1 Dimerization is essential for binding dsRNA (Wang et al., 
1999) and the stoichiometry of dimer:dsRNA is 1:1 (Chien et al., 2004). Furthermore, NS1 
has previously been reported to interact with the viral polymerase complex (Marion et al., 
1997) and with high affinity to dsRNA in the form of vRNA-like panhandle structures (Hatada 
& Fukuda, 1992; Hatada et al., 1997). Indeed, evidence is accumulating for a number of 
functional interactions between NS1 and replicating RNPs during infection (Twu et al., 
2007). Although one report suggested that NS1 RBD was binding dsRNA with low affinity 
compared to RIG-I (Chien et al., 2004), several other research groups reported that NS1 had 
a high affinity for dsRNA,notably in the form of vRNA-like panhandle structures (Hatada & 
Fukuda, 1992; Hatada et al., 1997). Moreover, mutation of amino-acid R38 and K41 required 
for NS1 dsRNA binding greatly impairs NS1’s ability to block interferon production (Pichlmair 
et al., 2006). Remarkably, R38/K41 substitutions also abrogate NS1 interaction with RIG-I, 
TRIM25 and RIPLET (Pichlmair et al., 2006, Gack et al., 2009, Rajsbaum et al., 2012). Thus, 
it is believed that thanks to its RNA binding properties NS1 can localize into multicomponent 
and dynamic RNA-protein complexes in which it exerts its inhibition. Furthermore, some 
pieces of data suggest that such complexes are formed during influenza virus infection 
(Onomoto et al., 2012). 
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NS1 has also been shown to prevent activation and nuclear translocation of IRF-3, 
NF-kB and c-Jun/ATF-2 otherwise essential for IFN-b induction (Ludwig et al., 2002, Talon 
et al., 2000, Mibayashi et al., 2007, Wang et al., 2000). It was initially proposed that NS1 
could inhibit IRF3 activation by binding TRIM-25 and inhibiting RIG-I activation (Gack et al., 
2009). However, this hypothesis is debated as some NS1 proteins can bind efficiently TRIM25 
(i.e. human seasonal H3N2 viruses) without inhibiting IRF3 activation or IFN-b transcription 
(Kuo et al., 2010). Of note, the impact of RIPLET-NS1 interaction on IRF3 activation is 
unknown (Rajsbaum et al., 2012). Work done by Kuo and colleagues also demonstrated that 
the nature of residue 196 in NS1 ED determines its ability to block IRF3 activation, and 
subsequently IFN-b induction. These authors demonstrated that viruses harbouring K196 did 
not block IRF3 activation, whereas viruses harbouring E196 did (Kuo et al., 2010). However, 
to date the exact mechanisms remain undefined. 
 
While the interaction of IAV NS1 with components of the RIG-I signalling axis are 
relatively well conserved among virus isolates, the extent and efficacy of inhibition varies 
significantly among viral strains. Thus, viruses less efficient at controlling the type I IFN 
pathway at pre-transcriptional level must rely on a different strategy, such as crippling host 
gene expression at a co- or post-transcriptional level, including that of IFN and IFN-
stimulated genes. 
 
 
1.3.1.3. Co- and post-transcriptional functions 
 
General inhibition of nucleo-cytoplasmic transport of all poly(A)-containing mRNAs 
was one of the first functions ascribed to NS1 (Fortes et al., 1994, Qiu and Krug, 1994). At 
the time, it was speculated that global nuclear retention of cellular mRNAs by NS1 was 
increasing priming of viral mRNA transcription by providing a pool of cap-donors for the viral 
polymerase complex. However, it is now apparent that blocking cellular mRNA processing 
goes beyond this and represents an effective mean to limit a number of host-cell processes, 
including the innate antiviral response. 
In eukaryotic cells, the 3’-end of primary transcripts are cleaved upon recognition of a 
conserved AAUAAA sequence some 10-30 bases upstream of the cleavage site (Figure 1-6). 
This is the task of the Cleavage and Polyadenylation Specificity Factor (CPSF), a polyprotein 
complex formed by four subunits (160, 100, 70 and 30 kDa), which recognizes the AAUAAA 
sequence and binds to nascent mRNAs. It then catalyses an endonucleolytic step and 
subsequent addition of a poly(A) tail (Wahle and Keller, 1996, Colgan and Manley, 1997). 
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The smallest components of the CPSF complex, called CPSF30, contains five C3H zinc fingers 
(Barabino et al., 1997), and in infected cells NS1 bind two of the CPSF30 zinc fingers (F2 
and F3). In doing so it inhibits the binding of the whole CPSF complex to pre-mRNA, and 
subsequently prevents their cleavage and polyadenylation (Nemeroff et al., 1998, Das et 
al., 2008, Twu et al., 2006). This allows NS1 to inhibit the expression of cellular genes, 
including those of IFNs and ISGs at a post-transcriptional level. Importantly, viral transcripts 
are not affected by the repression of CPSF because their polyadenylation is directly 
catalysed by the viral polymerase (Poon et al., 1999).  
NS1 inhibition of CPSF30 may also impact mRNA splicing, in which CPSF is involved (Alonso-
Caplen et al., 1992, Alonso-Caplen and Krug, 1991, Fortes et al., 1994, Qian et al., 1994, Li 
et al., 2001), as well as the nucleo-cytoplasmic transport of mRNAs as it requires 
polyadenylation (Fortes et al., 1994, Qiu and Krug, 1994). NS1 can also block specifically 
the nuclear export of fully processed mRNAs that partially escape 3’-end formation 
inhibition by interacting with the poly(A)-binding protein II (PABPII) through residues 223-
237 (Chen et al., 1999) (Figure 1-6). 
 
 
Figure 1-7: NS1 blockade of the cellular mRNA 3’-end processing system. 
 
(A) Normal processing of cellular pre-mRNA by the cleavage and poly-adenylation machinery. (B) NS1 
prevents the normal processing of cellular pre-mRNA. Mechanism by which IAV NS1 inhibits the 3’-end 
processing of cellular mRNA in infected cells. Pathway I: the binding of the NS1 protein (and PABII) to 
the 30 kDa subunit of CPSF blocks the binding of CPSF to the AAUAAA sequence of some cellular pre-
mRNA molecules, thereby blocking 3 -cleavage of these pre-mRNAs. The un-cleaved pre-mRNAs 
remain in the nucleus. Pathway II: CPSF binds to the AAUAAA sequence of other cellular pre-mRNA 
molecules, despite the binding of the NS1 protein and PABII to the 30kDa CPSF subunit. A short poly(A) 
sequence is then added to these cleaved pre-mRNAs by PAP in a CPSF-dependent reaction. 
Subsequent elongation of the short poly(A) sequence is blocked by the binding of the NS1 protein to 
PABII, resulting in the nuclear accumulation of cleaved pre-mRNAs containing short poly(A) tails. 
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Residues involved in NS1-CPSF30 interaction have been characterized by mutagenesis 
(Noah et al., 2003, Twu et al., 2007, Li et al., 2001, Kochs et al., 2007b) and by solving the 
three-dimensional structure of NS1 ED in complex with the CPSF30 F2F3 region (Das et al., 
2008). A patch of highly conserved hydrophobic residues (184 to 188) was shown to embed 
into a pocket on the F2F3 loop of CPSF30, with G184 standing in a central position. 
Interestingly, G184A substitution abrogates NS1 binding to CPSF30 (Das et al., 2008). In 
addition, based on crystal structures NS1 ED dimerization is incompatible with CPSF30 
binding (Kerry et al., 2011b), and W187 plays a pivotal role in driving both interactions 
(Kerry et al., 2011a, Aramini et al., 2011). Such incompatibilities are likely to play a role on 
the spatial-temporal regulation of NS1 functions.  
Additional residues are important for stabilizing NS1-CPSF30 interaction, and notably F103, 
M106, K108, D125, L144, and D189, although they are not strictly part of the binding 
interface (Kochs et al., 2007a, Li et al., 2001, Noah et al., 2003, Twu et al., 2007, Twu et 
al., 2006, Das et al., 2008, Hale et al., 2010). Glu-96 may also be functionally significant 
(Shimizu et al., 1999). 
Of note, the polymerase subunits (PB1, PB2, PA) and the NP protein are important to 
stabilise NS1-CPSF interactions in a strain-specific manner (Twu et al., 2006, Kuo et al., 
2010).  
 
Although CPSF30 and its F2F3 loop are relatively well conserved among mammals, as 
seen in the alignment of human and equine CPSF30 (Figure 1-7), variations in CPSF30 binding 
seem to arise commonly during viral adaptation to different hosts (Hossain et al., 2008, 
Brown et al., 2001).  
 
 
Figure 1-8: Human and equine CPSF30. 
 
Alignment of human (top) and equine (bottom) CPSF30 amino acid sequences 
(ENSECAG00000007525 and ENSG00000160917, respectively). Red residues highlight amino acid 
differences. Red square indicates the F2F3 loop of CPSF30 bound by some IAV NS1 proteins. 
 
 
In general, mouse-, egg- and swine adapted viruses have NS1s that bind weakly to 
CPSF30, whereas those from human-circulating strains are strong binders, with the 
exception of the human pandemic H1N1 virus from 2009 (2009pH1N1), whose NS1 is of swine 
origin. In the case of avian strains both NS1 phenotypes can be found (Twu et al., 2006, Hale 
F2F3
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et al., 2010). For PR8/NS1, the lack of CPSF30 binding is due to substitutions of residues 103 
and 106 (Kochs et al., 2007b), while for 2009pH1N1/NS1 the defect in CPSF30 binding is due 
to K108R, D125E, D189G substitutions (Hale et al., 2010). Interestingly, restoring NS1 
binding to CPSF30 slightly decreased replication and virulence of the 2009pH1N1 virus in 
mice. 
 
While inhibition of CPSF30 is presumed to non-specifically block general gene 
expression, some NS1 proteins may have evolved mechanisms to repress the expression of 
specific gene sets. This is the case of human seasonal H3N2 viruses isolated after 1989. As 
previously mentioned, the NS1 protein of these viruses reverted back from 237 to 230 amino 
acids (Hale et al., 2008c) As a result, their C-terminal residues became 226-ARSKV-230, a 
very similar motif to the ‘ARTKQ’ motif found on cellular histone H3 (H3). Consequently, 
the tail of these NS1 proteins can act as histone-mimics. By doing so, these NS1 proteins 
could repress expression of specific cellular genes by competing with H3 for binding to the 
Polymerase Associated Factor 1 (PAF1)-transcription-elongation complex (Marazzi et al., 
2012). Interestingly, PAF1-regulated genes include those involved in the IFN response. 
 
Finally, the NS1 protein of the A/WSN/1933-H1N1 (WSN) strain has been reported to 
interact with several components of the cellular mRNA nuclear export machinery (NXF1, 
p15, Rae1, E1B-AP5, Nup98) and block their function (Satterly et al., 2007). As different 
cellular mRNAs use different export factors to translocate to the cytoplasm (Satterly et al., 
2007), inhibition of cellular mRNA export may give some specificity for inhibition of cellular 
gene expression to WSN/NS1. 
 
 
1.3.1.4. Inhibition of antiviral gene products 
 
NS1 IFN antagonism goes beyond the pre- and post-transcriptional repression of IFN 
genes. Indeed, NS1 also blocks directly the antiviral effects of some ISG-products, such as 
PKR (Min et al., 2007) and the OAS/RNAse L-pathway (Min and Krug, 2006). As mentioned 
previously (see section 1.2.4), both OAS and PKR are key regulators of viral 
transcription/translation processes, and play additional roles in other innate defences, such 
as IFN-b induction and the host apoptotic response to infection (Silverman, 2007). 
Importantly, thanks to this downstream activity of NS1, viral replication could take place in 
cells that have been set in an active antiviral state by a prior IFN treatment (Newby et al., 
2007, Min and Krug, 2006). 
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IAV was found to inhibit PKR activity in early studies (Katze et al., 1986, Katze et 
al., 1988), and it was postulated to antagonize it via two mechanisms: the regulation of 
p58IPK function, a regulator of PKR activity (Melville et al., 1999, Goodman et al., 2007), 
and by the action of NS1. Several studies have suggested that NS1 exerted its PKR inhibitory 
action by sequestering dsRNA away from PKR (Hatada and Fukuda, 1992). However, the 
affinity of NS1 for dsRNA is much lower than that of PKR, thus out-competition seems 
unlikely (Li et al., 2006). Furthermore, a R38A-RNA-binding defective NS1 protein was shown 
to limit PKR activation efficiently in response to dsRNA activation (Li et al., 2006). Based 
on domain mapping studies, it has been proposed that NS1 binds to a linker region in PKR, 
which requires residue 123 to 127 (Li et al., 2006, Min et al., 2007), and thereby prevents a 
conformational change that is normally required for release of PKR auto-inhibition (Li et al., 
2006). 
The proposed mechanism of NS1 inhibition of the OAS-RNAse L pathway is the 
sequestration of dsRNA away from OAS, as in this case the dsRNA binding affinity of OAS is 
low enough to be outcompeted by NS1 (Min and Krug, 2006). Furthermore, no direct 
interaction has been described between NS1 and OAS and/or RNAse L. Given the role of 
RNAse L in augmenting the production of IFN-b (Silverman, 2007), it is possible that NS1-
mediated OAS inactivation also contributes to suppression of IFN-b synthesis (Donelan et al., 
2004, Talon et al., 2000). 
 
 
1.3.1.5. Activation of PI3K pathway and regulation of the apoptotic 
response 
 
Phosphoinositide-3-kinases (PI3K) are ubiquitously expressed and highly conserved 
cytoplasmic heterodimeric enzymes (Engelman et al., 2006). Cellular responses involving 
PI3K signalling include survival, proliferation, trafficking, and regulation of the immune 
function (Engelman et al., 2006). Upon activation, PI3K catalyses the formation of PIP3 
(phosphatidylinositol (3,4,5) triphosphate), a membrane-embedded second messenger, 
which acts as docking platform for proteins involved in signalling, the best characterized 
being the Serine/Threonine kinase Akt.  
Influenza A virus is known to activate PI3K signalling twice during infection, as detected by 
the phosphorylation state of Akt (Ayllon et al., 2012, Ehrhardt and Ludwig, 2009). A first 
early and transient PI3K activation peak takes place during viral attachment and entry, 
probably related to virus uptake by endocytosis (Ehrhardt et al., 2006), whereas a second 
and sustained activation appears 2-3h post-infection and is due to NS1 (Hale et al., 2006, 
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Shin et al., 2007). The heterodimeric PI3K is kept at its basal state due to inhibitory contacts 
exerted by the regulatory subunit (termed p85) over the catalytic one (termed p110). This 
inhibition is mediated by two SH2 domains on p85. NS1 binds to p85 and displaces the N-
terminal SH2 domain from its position on the heterodimer, thus releasing the inhibition over 
p110 (Hale et al., 2008b). A highly conserved tyrosine residue at position 89 in NS1 settles 
in the centre of the NS1-p85 interphase (Shin et al., 2007), and substitution of this amino 
acid for a phenylalanine (Y89F) abrogates p85 binding and PI3K/Akt activation (Hale et al., 
2006). 
 
 
1.3.1.6. Regulation of viral RNA and protein synthesis 
 
Upon infection, IAV takes over the cellular machinery by preferentially translating 
its own viral products over the host’s. NS1 contributes to this process by shutting off cellular 
gene expression, as described above, and by directly enhancing the translation of viral 
mRNAs. The first 113 amino acids of NS1 are important for this function (Marion et al., 
1997), and so is its interaction with proteins involved in eukaryotic translation, such as the 
elongation initiation factor 4GI (eIF4GI) (Aragon et al., 2000), polyadenylate binding protein 
I (PABPI) (Burgui et al., 2003) and hStaufen (Falcon et al., 1999). It has been proposed that 
NS1 selectively relocalises these factors to the 5’-UTRs of the viral genomic segments in 
cytoplasmic polysomes (Krug and Etkind, 1973). 
 
NS1 can also affect vRNA temporal regulation. Viral genes have traditionally been 
divided into early and late stage genes, with the NS and NP genes being selectively expressed 
early and all the eight genomic segments showing higher expression levels at latter stages 
(Shapiro et al., 1987, Skehel, 1973). Alanine substitutions of NS1 amino acids 123 and 124 
resulted in a temporal deregulation of vRNA synthesis, with late genes being generated 
earlier and in greater numbers (Min et al., 2007). Further evidence that NS1 plays a role in 
regulating viral RNA synthesis came from recombinant PR8 viruses carrying deletions of the 
whole NS1 ED, which specifically impair the mRNA levels of HA (Maamary et al., 2012). 
Although the mechanism involved is unknown, it has been suggested to be related to NS1 
interaction with the vRNP through its direct binding to NP (Robb et al., 2011). Relatively 
recent data also suggested that NS1 inhibition of DDX21 might be key for this process. 
Indeed, DDX21 is a cellular helicase able to block the viral polymerase complex formation 
and can also interact with both the NS1/CPSF30 complex and PB1 (Chen et al., 2014). 
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1.3.1.7. Interaction with other host factors 
 
In full length NS1 proteins (230 amino acids), a PSD-95 Discs-large ZO-1 (PDZ)-binding 
motif (PBM) has been identified from residue 227 to 230 (Obenauer et al., 2006). PBMs are 
important protein recognition signals relevant in the assembly of multi-component signalling 
complexes (Javier and Rice, 2011). They recognize and bind short C-terminal peptide motifs 
of 4-5 amino acids, called the PDZ domain ligand (PL). The most common PBM found in avian 
IAV NS1 proteins is “ESEV/EPEV”, while in human IAV NS1s the most common motif found is 
“RSKV/RSEV”. Although scarce information is available for NS1 of IAVs isolated from other 
species, sequence analysis revealed that full length NS1 EIVs possessed an avian PBM (Barba 
and Daly, 2016). The avian PBM has been shown to interact with up to thirty human PDZ 
domain-containing proteins, whereas human NS1 proteins could not (Obenauer et al., 2006). 
By interacting with PDZ domain-containing proteins, IAVs may disrupt certain cellular 
pathways and cause virulence. Avian motifs have been found to interact with PDZ domain-
containing proteins, such as Scribble and Dlg1 involved in cellular junctions and apoptotic 
responses (Golebiewski et al., 2011, Javier and Rice, 2011, Liu et al., 2010). The relevance 
of this avian-specific motif is unclear, and has been shown to increase replication of some 
IAV strains, e.g. WSN (Jackson et al., 2008) and avian H7N1 viruses (Soubies et al., 2010), 
while not affecting others, e.g. A/VN/1203/04 H5N1 HPAI virus (Zielecki et al., 2010). The 
specific targets, mechanisms and strain specificity of this avian PBM remain to be fully 
identified. 
 
 
1.3.1.8. Intracellular distribution 
 
NS1 was originally described as a nuclear protein and is predominantly found in the 
nucleus of infected cells, especially at early times post-infection (Lazarowitz et al., 1971). 
The nucleo-cytoplasmic location of NS1 can be regulated by a monopartite nuclear location 
signal (NLS) (amino acids 35-41), which overlaps with critical residues for dsRNA binding 
(R38 and K41) and is mediated through interaction with importin-a (Greenspan et al., 1988). 
NS1 also possesses a nuclear export signal (NES) found in its ED, within amino acids 138 to 
147 (Li et al., 1998). In addition, a bipartite NLS can also be found in 237 residue-long NS1 
proteins (position 219 to 232) (Melen et al., 2007). As some NS1 activities must take place 
in the nucleus (e.g. interference with CPSF30 and PABPII function), while others should 
happen in the cytoplasm (e.g. inhibition of RIG-I and activation of PI3K), the subcellular 
location of the protein must play a role in determining which functions are executed during 
infection. 
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1.3.1.9. Post-translational modifications 
 
Post-translational modification is a common mechanism to regulate multi-functional 
proteins. As such, several studies have addressed which of these modifications can affect 
NS1. To date, NS1 has been shown to be modified by phosphorylation and by coupling to the 
ubiquitin-like proteins ISG15 and SUMO. 
 
Early studies showed that the WSN/NS1 was phosphorylated soon after infection, 
probably in the nucleus (Privalsky and Penhoet, 1978, Privalsky and Penhoet, 1981). 
Structural analysis suggested different serine and threonine residues were available for 
phosphorylation (Bornholdt and Prasad, 2006), and residues T215 (Hale et al., 2009), S42 
and S48 (Hsiang et al., 2012) were later identified. Only phosphorylation of serine 42 by 
cellular PKCa, has been shown to play a relevant role for the virus, as its substitution on 
Ud/NS1 affected dsRNA binding and consequently replication (Hsiang et al., 2012). Serine 
48 is not completely conserved and its substitution has no impact on viral replication (Hsiang 
et al., 2012); while Threonine 215, which can be phosphorylated in vitro by CDK and ERK 
kinases, is a distinctive feature of human-adapted strains, and avian isolates usually display 
a proline at this position (Hale et al., 2009). 
 
Several lysine residues can be ISGylated in NS1, and K41 seems to be the main target 
during infection (Tang et al., 2010). As mentioned earlier, K41 is involved in both dsRNA 
binding and nuclear import. Different studies have described covalent binding of NS1 to 
ISG15 (Zhao et al., 2013, Tang et al., 2010, Kuo et al., 2010). ISG15 modification of K41 
impairs NS1 interaction with the karyopherin without affecting its dsRNA-binding properties. 
The proposed mechanisms for ISG15-based suppression of the NS1 function, are prevention 
of PKR binding, abrogation of RBD dimerization and overall subpar antagonism of the IFN 
system (Tang et al., 2010). As with most NS1-associated features, ISGylation has a strong 
strain-specific component, and naturally occurring K41R substitutions have been described 
in certain human H3N2 virus strains without affecting their anti-IFN function (Tang et al., 
2010, Zhao et al., 2013). 
 
As mentioned above, another ubiquitin-like protein that can be conjugated to NS1 is 
SUMO (Pal et al., 2011, Xu et al., 2011, Santos et al., 2013). These proteins can regulate 
function, stability, location, and interactivity of numerous proteins, both of cellular and 
viral origins (Everett et al., 2013). NS1 can be modified by the three main isotypes of SUMO, 
such as SUMO 1 and SUMO 2/3 (Santos et al., 2013). Unsurprisingly, NS1 SUMOylation is 
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strain-dependent, and NS1 SUMOylation is even required for optimal IFN antagonism for 
some IAV strain (e.g. PR8) (Xu et al., 2011).  
 
 
1.3.1.10. NS1 contribution to virulence 
 
Viruses expressing NS1 proteins with large C-terminal deletions or a total lack of NS1 
altogether are generally attenuated in mammalian and avian cells and are strong inducers 
of type I IFN (Solorzano et al., 2005, Cauthen et al., 2007).  
 
The outcome of disease also depends on the balance between pro-inflammatory 
cytokine production and the ability of NS1 to overcome it (Hyland et al., 2006). The H5N1 
highly pathogenic avian influenza (HPAI) virus (HK97) responsible for an outbreak in 1997 in 
human populations was associated with hyper-cytokinemia, which was consistent with the 
detailed post-mortem results of individuals that died during the 1997 H5N1 HPAI outbreak. 
This virus was also resistant to the antiviral effects of type I IFN and TNF-a (Cheung et al., 
2002, Seo et al., 2002). It was later shown that this cytokine imbalance required E92 in NS1 
(Seo et al., 2002). However, E92 seemed to be specific to these H5N1 HPAI viruses from 
1997, and it has never been found in NS1 of other IAV subtypes. This highlights the species-
specificity of NS1 and its impact on virulence.  
 
NS1 species-specific activities and correlation with virulence was also illustrated by 
Basler and colleagues’ work, who exchanged the NS segment of the mouse-lethal WSN strain 
for that of the 1918pH1N1. The recombinant virus obtained replicated well in tissue-culture 
but was attenuated in mice compared to wild-type WSN (Basler et al., 2001). It was 
speculated that attenuation of the recombinant virus may be due to the human origin of the 
1918pH1N1/NS1, which is adapted to function well in human cells, but is unable to work 
optimally in murine cells.  
 
Another mechanism by which NS1 may affect virulence is by binding to and 
interfering with cellular signalling proteins via its PBM (Obenauer et al., 2006). Indeed, the 
introduction of an avian PBM into WSN/NS1 increased WSN virulence in mice, and infections 
were characterized by a severe loss of body weight, decreased survival, severe alveolitis 
and increased viral spread in the lung. This work supported the hypothesis of Obenauer and 
Colleagues indicating that avian NS1 proteins, when present in human cells, may interact 
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with PDZ domain-containing proteins, disrupt certain cellular pathways, and increase 
virulence (Obenauer et al., 2006).  
 
The contribution of host adaptation and NS1 species-specific functions to viral 
pathogenesis has been of interest to the scientific community for many years. However, 
little is known about the contribution of NS1 evolution to EIV pathogenesis. 
 
 
1.3.2. Other viral players 
 
NS1 is not the only viral protein capable of restraining the innate immune system. 
Indeed, IAVs encode several other proteins that counteract the interferon pathway either 
directly or indirectly. For example, both PB2 and PB1-F2 limit the production of IFN-b 
through association with IPS-1 (Iwai et al., 2010, Varga et al., 2012), especially variants 
containing D9 in PB2 and N66 in PB1-F2 (Varga et al., 2011) (Long and Fodor, 2016, Varga et 
al., 2012). Some virus strains possess highly efficient polymerase complexes that allow the 
virus to outrun the interferon effects and contribute to immune evasion of IAVs (Grimm et 
al., 2007). The viral polymerase is also involved in cap-snatching of host mRNAs and thereby 
reduces host cell gene expression, including that of IFN (Nakhaei et al., 2009). The recently 
discovered PA-X viral protein is also able to repress cellular gene expression, and notably 
genes involved in regulating the initiation of the cellular immune response (Feng et al., 
2016). The NP protein has also been shown to interfere with PKR function by promoting its 
inhibition by p58IPK (Sharma et al., 2011). Furthermore, by encapsidating the vRNA, NP is 
likely to reduce the formation of dsRNA, which could otherwise activate viral sensors and 
lead to activation of the anti-viral response. In addition, since most PRRs are located in the 
cytoplasm, the nuclear replication strategy of IAV also prevents recognition of vRNA by 
cytosolic PRRs. Also, IAV can directly infect and kill NK cells (van de Sandt et al., 2012), or 
reduce its recognition of virus-infected cells due to the gradual mutation of glycosylation 
sites of the HA protein (Medina et al., 2013). 
 
Besides interfering with innate signalling, IAVs are also able to counteract cells of 
the adaptive immune system. For example, infection of monocytes impairs their ability to 
differentiate into mature dendritic cells, which indirectly limits induction of virus-specific 
CD8+ T cell responses (van de Sandt et al., 2012). In addition, antigenic drift or shift allow 
IAV to evade antiviral humoral responses and may affect antigen presentation in the context 
of an MHC molecule, hence preventing T cell activation (Bryant et al., 2009, van de Sandt 
et al., 2012). 
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Cross-species jumps from avian reservoirs to mammalian hosts are usually associated 
with sporadic outbreaks, but on rare occasions emergent viruses manage to establish a 
lineage in the new host species. The immune pressure exerted by the new host on the 
emergent virus forces it to evolve and adopt new strategies to evade immunity in order to 
survive in nature. Understanding the biological mechanisms that allow successful inter-
species transmission and adaptation to mammals is crucial to develop the theoretical tools 
required to predict and/or control emergence of new viruses in humans and animals. H3N8 
EIV represents an interesting model to study the dynamic of within-host variation of avian-
origin IAVs, as this virus has emerged from a bird reservoir in 1963 and has now circulated 
for more than fifty years in horse populations despite the availability of vaccines with barely 
any reassortment events. Importantly, forty years post emergence this virus has jumped the 
species barrier and established a new lineage in dogs, which suggest that H3N8 EIV has 
successfully adapted to mammals. Evidence of evolution of EIV virulence factor NS1 also 
exists, however, little is known about its impact on EIV infection phenotype and adaptation 
to horses. This virus represents then a unique tool to study NS1 contribution to virus-host 
interaction and successful adaptation to mammals. 
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2. Aims  
 
The overall aim of this project was to characterise the molecular evolution of NS1 during 
the post-transfer adaptation process of H3N8 EIV, utilizing reverse genetics and site-directed 
mutagenesis techniques, in association with a phylogenetic analysis and high-throughput 
sequencing technologies.  
 
Specifically, I aimed to:  
 
(i) To identify molecular determinants of EIV NS1 evolution.   
(ii) To analyze the role of specific mutations on NS1 function at the protein level.   
(iii) To confirm the role of the NS1 gene in EIV infection phenotype. 
(iv) To evaluate the impact of NS1 evolutionary markers on EIV infectivity in mammalian cells.  
(v) To identify which advantages are associated with NS1 evolutionary markers E186K and C-
terminal truncation.  
(vi) To compare the early genes expression pattern of equine cells infected with two 
evolutionary distinct EIVs. 
(vii) To evaluate the impact of NS1 evolutionary markers on virus-host interaction. 
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3. Materials and Methods 
 
3.1. Generation of mammalian expression constructs for NS and untagged NS1  
 
3.1.1. Virion RNA extraction 
 
vRNA was extracted from 140Pl of the corresponding viral stocks using the QIAamp® 
Viral RNA Mini kit (Qiagen) according to the manufacturer protocol. AVL buffer and absolute 
ethanol were used to inactivate the virus. Samples were then loaded into RNeasy mini-spin 
columns and RNA was bound to the column membrane by centrifugation at 8000xg for 30 
seconds. The membrane was washed once with 700Pl of Buffer WT1 and twice with 500Pl 
Buffer RPE (provided with the kit). The RNA was then eluted into a new microcentrifuge 
tube with 50Pl RNase-free water pipetted directly onto the silica-gel membrane of the 
column and centrifuged at 13000xg. RNA eluted from the columns was quantified using a 
spectrophotometer (NanoDropTM 1000, Thermo Scientific). The ratio of absorbance at 
260nm and 280nm, and 260nm and 230nm were used to assess the purity of RNA. A ratio of 
2.0 for both was considered optimal for RNA. Samples were then stored in RNAse-free, low 
binding tubes at -80oC until further use. 
 
 
3.1.2. Retro-transcription 
 
Reverse transcription was performed using Uni12 primer (5'-
GCCGGAGCTCTGCAGATATCAGCRAAAGCAGG-3') (Hoffmann et al., 2001), 500ng of total RNA, 
and SuperScript III Reverse Transcriptase (Invitrogen) following the manufacturer's protocol, 
and the cycling parameters provided below (Table 3-1).  
 
Table 3-1: Retro-transcription cycling parameters 
Steps Temperature Duration 
Annealing 65oC 5 minutes 
Incubation ice 1 minute 
First strand cDNA synthesis 
(1 cycle) 
55oC 30 minutes 
Inactivation 70oC 15 minutes 
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3.1.3. PCR 
 
Amplification of the NS1 gene or the full NS segment was performed using specific 
primers (Table 3-2 and 3-3, respectively) by Polymerase Chain Reaction (PCR) with 100ng of 
cDNA, and the Pfu-Ultra II fusion HS DNA polymerase (Agilent) following the manufacturer's 
protocol. Primers designed to amplify the full NS segment or the NS1 gene possessed an 
EcoRI restriction site at the 5’-end of the forward primer and an XhoI restriction site at the 
5’-end of the reverse primer. The amplification reactions were performed in the Applied 
Biosystem® 2720 thermocycler and indicated cycling parameters (Table 3-4). Amplified 
products were examined by electrophoresis on 1% agarose gel. 
 
Table 3-2: Primers for NS1 gene cloning 
Viruses Primers 
U/63, M/63, F/79, 
S/89, K/91, LP/95, 
K/95, K/99, K/02, 
N/03, O/03, M/13 
FW: 5’-AGGCGAATTCGCCACCATGGATTCCAACACTGTGTCAAGCTTTCAG-3’ 
SP/69 FW:5’-AGGCGAATTCGCCACCATGGATCCCAACACTGTGTCAAGCTTTCAG-3’ 
U/63, M/63, 
SP/69, F/79 
RV: 5’-CGGGCTCGAGTCAAACTTCTGACTCAATTGTTCTCG-3’ 
S/89, LP/95, K/91 RV: 5’-CGGGCTCGAGTCAAACTTCTGGCTCAATTGTTCTC-3’ 
K/99, K/02, O/03, 
N/03, M/13 
RV: 5’-CGGGCTCGAGTCATTTCTGCTTTGAAGGGAAT-3’ 
K/95 RV: 5’-CCCGCTCGAGTCAAATTTCTGGCTCAATTGTT-3’ 
 
Table 3-3: Primers for NS segment cloning 
Viruses Primers 
U/63, O/03 FW: 5’-TATTGAATTCCGTCTCAGGGAGCAAAAGCAGGGTG-3’ 
U/63, O/03 RV: 5’-CGGTCTCGAGCGTCTCGTATTAGTAGAAACAAGGGTGTTTTTTT-3’ 
 
Table 3-4: Cycling parameters for NS and NS1 gene cloning 
Steps  Temperature Duration 
Initial activation  95oC 1 minute 
3 steps cycling 
(30 cycles) 
Denaturation 
Annealing 
Extension 
95oC 
65oC 
72oC 
20 seconds 
20 seconds 
30 seconds 
Final extension  72oC 3 minutes 
 
Chapter 3 - Materials and Methods 
 
 66 
3.1.4. Restriction digest 
 
NS1 and NS PCR products were purified with the QIAquick PCR Purification Kit 
(Qiagen), following the manufacturer protocol. To clone NS1 genes in pcDNA3.1+ or pCAGGS 
plasmid and NS segments in pcDNA3.1+, NS1 or NS PCR products and pCAGGS or pcDNA3.1+ 
plasmids were digested with XhoI and EcoRI (Promega) for 3 hours at 37oC, following the 
manufacturer protocol. To clone NS segments in pDP2002, NS PCR products and pDP2002 
plasmid were digested with BsmBI restriction enzyme (Promega) for 3 hours at 37oC, 
following the manufacturer protocol. Digested plasmids and PCR products were then 
examined on 1% agarose gel electrophoresis, and the bands of interest were extracted and 
purified with QIAquick Gel Extraction Kit (Qiagen). DNA purity and concentrations were 
analysed by Nanodrop.  
 
 
3.1.5. DNA ligation 
 
The T4 DNA Ligase (Promega) was used to ligate NS PCR products into pcDNA3.1+ or 
pDP2002, and NS1 PCR products into pCAGGS with a vector:insert ratio of 1:5. The ligation 
was carried out at 4oC overnight. 
 
 
3.1.6. Bacterial transformation and plasmid preparation 
 
One Shot TOP10 Chemically Competent E. coli (Invitrogen) were transformed 
following the manufacturers protocol with 5Pl of ligation product. Transformed colonies 
were grown in 0.1mg/ml Ampicillin-containing Luria-Bertani (LB) agar plates (Fast-Media® 
Base Agar, Invivogen; ampicillin, Sigma-Aldrich), and incubated at 37oC overnight. Ten 
colonies per construct were selected and cultured in 5ml of LB-Broth supplemented with 
0.1mg/ml Ampicillin for 24h at 30°C in a shaker incubator at 220rpm.  
Transformation of XL-10 Gold Ultracompetent Cells (Agilent) was performed using 2Pl of 
ligation product. The bacteria were then cultured on 0.1mg/ml Ampicillin-containing LB 
agar plates overnight at 37oC. Bacterial cultures containing the recombinant plasmid were 
purified using the QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer’s 
protocol. Purified plasmids were quantified using NanoDrop Spectrophotometer.  
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3.1.7. Agarose gel electrophoresis 
 
For agarose gel preparation, 10X TAE buffer (0.4M Tris, 1.142% (v/v) acetic acid, 
0.01M EDTA, pH adjusted to 8, Sigma-Aldrich) was generated and diluted to 1X in H2O prior 
to use. 0.8-1% (w/v) molecular grade agarose (Bioline) diluted in 1X TAE. 1Kb DNA ladder 
(Promega). Gels were stained with ethidium bromide (10mg/ml, Biotechnology grade, 
AMRESCO).  
 
 
3.1.8. Quick-change PCR 
 
Silent mutations were introduced by site-directed mutagenesis into the splice 
acceptor site (intron/exon junction: 525-CCAC↓GA-530 changed to 525-CCCGGG-530) of the 
NS1 pcDNA3.1+ inserts generating NS1 splice-acceptor mutant (SAM) to avoid the expression 
of NEP. To engineer NS1 and NS mutants for residue 186, Lysine (K)-to-Glutamic acid (E) 
(codon 186 ‘AAA’ changed for ‘GAA’) or E-to-K substitutions (codon 186 ‘GAA’ changed for 
‘AAA”) for O/03 and K/95 or U/63, respectively, were introduced into the NS1 SAM- or NS-
pcDNA3.1+ inserts using the PFU-Turbo DNA polymerase (Agilent) and specific sets of primers 
(Table 3.5), and cycling parameters (Table 3.6). To engineer NS1 C-terminus mutant in NS1 
or NS inserts, Stop Codon-to-Arginine (R) (codon 220 ‘TGA’ replaced by ‘CGA’) or Arginin-
to-Stop Codon (codon 220 ‘CGA’ to ‘TGA’) for O/03 and K/95 or U/63, respectively, were 
introduced into the NS1 SAM- or NS-pcDNA3.1+ as described above. A similar strategy was 
used to engineer U/63 and O/03 NS1 112 mutants (Alanine (A)-to-Threonine (T) codon ‘GCA’ 
changed for ‘ACA” or T-to-A codon ‘ACA’ changed for ‘GCA’). 
Purified recombinant plasmids carrying either NS1 SAM, NS1 or NS 186 and/or C-terminus 
mutants were used as templates to amplify the corresponding inserts, which were then sub-
cloned into either pCAGGS for NS1 or pDP2002 for NS. This was performed using the PFU-
Ultra specific primers and cycling parameters (Table 3.5 and 3.6, respectively). 
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Table 3-5: Primers for site-directed mutagenesis in NS or NS1 genes 
Viruses Mutation Primers 
U/63, M/63, 
SP/69, F/79, 
S/89, K/91 
SAM FW: 5’-CATTGCCTTCTCTTCCCGGGCATACTAATGAGGATGTC-3'  
RV: 5’-GACATCCTCATTAGTATGCCCGGGAAGAGAAGGCAATG-3' 
LP/95, K/95, 
K/99, K/02, N/03, 
O/03, M/13 
SAM FW: 5’-CATTACCTTCTCTTCCCGGGCATACTAATGAGGATGTC-3'  
RV: 5’-GACATCCTCATTAGTATGCCCGGGAAGAGAAGGTAATG-3' 
U/63 A112T FW: 5'-CATGCCCAAGCAAAAAGTAACAGGCTCCCTATGTATAAG-3'  
RV: 5’-CTTATACATAGGGAGCCTGTTACTTTTTGCTTGGGCATG-3’ 
O/03 T112A FW: 5’-CATGCCCAAGCAAAAAGTAGCAGGCTCCCTATGTATAAG-3’  
RV: 5’-CTTATACATAGGGAGCCTGCTACTTTTTGCTTGGGCATG-3' 
U/63 E186K FW: 5'-CCTCATCGGAGGACTTAAATGGAATGATAACAC-3'  
RV: 5’-GTGTTATCATTCCATTTAAGTCCTCCGATGAGG-3’ 
O/03 
K/95 
K186E FW: 5’-CCTCATCGGAGGACTTGAATGGAATGATAATAC-3’ 
RV: 5’-GTATTATCATTCCATTCAAGTCCTCCGATGAGG-3’ 
U/63 
K/95 
R220* FW: 5’-CCAAAGCAGAAATGAAAAATGGCGAGAACAATTGAG-3’  
RV: 5’-CTCAATTGTTCTCGCCATTTTTCATTTCTGCTTTGG-3’ 
O/03 
 
*220R FW: 5’-CCCTTCAAAGCAGAAACGAAAAATGGAGAGAAC-3’  
RV: 5’-GTTCTCTCCATTTTTCGTTTCTGCTTTGAAGGG-3’ 
 
Table 3-6: Cycling parameters for site-directed mutagenesis in NS or NS1 genes 
Steps  Temperature Duration 
Initial activation  95oC 2 minutes 
3 steps cycling 
(25 cycles) 
 
Denaturation 
Annealing 
Extension 
95oC 
60oC 
72oC 
30 seconds 
1 minute 
11 minutes 
Final extension  72oC 10 minutes 
 
 
3.1.9. Plasmids sequencing 
 
The sequence of each pCAGGS- or pcDNA3-NS1 inserts and pDP2002- and pcDNA3.1-
NS inserts were confirmed by Sanger sequencing and compared to those available in the 
NCBI Influenza Database (Appendices 3 to 6 and 32 to 33) 
 
 
3.2. Luciferase assays 
 
For analysis of IFN-E and ISRE promoter activation and control of general gene 
expression, HEK293T cells (12-well plate format, 2.5x105 cells/well) were transiently co-
transfected using TransIT-LT1 transfection reagent (Cambridge Biosciences), with either 
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50ng of pIFN-E-FF-Luc or 50ng of pISRE-FF-Luc (reporter plasmids encoding Firefly luciferase 
[FF-Luc] under the control of the IFN-E promoter or the ISRE promoter, respectively), 50ng 
of a plasmid constitutively expressing Renilla luciferase (pREN-Luc) under the SV40 promoter 
(kindly provided by Benjamin G. Hale), as well as 3 different amounts (1000ng, 200ng or 
20ng) of the indicated NS1 SAM-pCAGGS expressing plasmids (or empty pCAGGS,1000ng). 
The total amount of transfected plasmid DNA was kept constant (1000ng) with empty 
plasmid (pCAGGS). After 24h of transfection, cells were infected with 50 hemagglutinating 
units (HAU) of SeV for 18h, then lysed with 250μl of passive lysis buffer (Promega). IFN-E-
FF-Luc, ISRE-FF-Luc and REN-Luc activities were measured using the Dual-luciferase 
reporter assay system (Promega), as directed by the manufacturer protocol and a Glomax® 
20/20 luminometer (Promega). All transfections were carried out in triplicates, and 
experiments were repeated independently three times. 
 
 
3.3. Co-immunoprecipitation of NS1 with CPSF30 
 
The equine CPSF30 was cloned as previously described for the human CPSF30 (Kochs 
et al., 2007). The equine CPSF30 gene was amplified by RT-PCR from equine cells using oligo 
d(T) and PCR with specific primers (Forward 5’-ATGCAGGAAATCATCGCCAG-3’, reverse 
primer: 5’-CCTTTCTCAGTGGACAGTGA-3’). The RT-PCR product was then cloned into the 
pCAGGS HA-COOH plasmid as described previously [35]. NS1 proteins were synthesized in 
vitro using pcDNA3.1+ plasmid and the TNT7 transcription/translation kit (Promega) 
following the manufacturer's recommendations. HEK293T cells (1.5x106 cells/well, 6-well 
format, triplicates) were transiently transfected with 2Pg/well of an HA-equine CPSF30-
pCAGGS-expressing plasmid. At 48 hours post-transfection (hpt), cells were lysed in 20mM 
Tris-HCl (pH 7.5), 100mM NaCl, 0.5mM EDTA, 5% glycerol, 1% Triton X-100 supplemented 
with a complete mini protease inhibitor cocktail (Pierce). Cleared cell lysates were 
incubated overnight at 4°C with the in vitro-synthesized O/03 and revertant NS1 proteins 
and 20Pl of an anti-HA affinity resin (Sigma-Aldrich). After extensive washing, precipitated 
proteins were dissociated from the resin using Laemmli buffer + E-mercaptoethanol. Total 
proteins from cells lysates were then analysed by SDS-PAGE and Western blotting (as 
described below) using a primary specific rabbit polyclonal antibody against NS1 (Genscript) 
or HA-tag for CPSF30 (Sigma-Aldrich) (Table 3-8). 
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3.4. Cell culture 
 
3.4.1. Cell maintenance 
 
Sterile standard tissue culture conditions were maintained in all experiments. Madin-
Darby Canine Kidney (MDCK, ATCC CCL-34) and Human Embryonic Kidney cells (HEK293T, 
ATCC CRL-11268) were grown at 37oC, 5% CO2 in Dulbecco’s modified Eagle’s medium 
(DMEM) high glucose, GlutaMax and pyruvate supplemented (ThermoFisher Scientific), 10% 
of Fetal Calf Serum (Gibco Life Technologies), and 1% PS (penicillin, 100 units/ml; 
streptomycin, 100Pg/ml; Gibco Life Technologies).  
Equine Dermal fibroblasts (E.Derm, NBL-6; ATCC CCL-57) were grown at 37oC, 5% CO2 in 
DMEM high glucose, GlutaMax and pyruvate supplemented, 15% of Fetal Calf Serum, 1% Non-
Essential Amino acids (Gibco, Life Technologies), 1% PS. 
 
 
3.4.2. Subculture 
 
Cells were routinely grown in 150cm2 flasks and passaged when reaching confluence. 
For propagation, cell monolayer was rinsed with phosphate buffered saline without calcium 
(PBS, 137mM NaCl, 15mM KCL, 10mM Na2HPO4/KH2PO4, pH 7.4, ThermoFisher Scientic), 
and incubated with 5ml of 0.05% trypsin solution containing 200mg/L 
Ethylenediaminetetraacetic acid (EDTA) (ThermoFisher Scientific) for 3 minutes at room 
temperature for E.Derm and HEK293T cells and 20 minutes at 37oC, 5% CO2 humidified 
atmosphere for MDCK cells. Once detached cells were re-suspended in growth medium and 
pelleted at 200xg for 5 minutes. The medium was then discarded and replaced by fresh 
growth medium, and cells were seeded in new sterile 150cm2 flasks or used for assays. 
 
 
3.4.3. Long-term storage 
 
For long term storage in liquid nitrogen, cells were harvested and pelleted at 200xg 
for 5 minutes and re-suspended in 90% (v/v) Fetal Calf Serum, 10% (v/v) dimethyl sulfoxide 
(DMSO) (ThermoFisher Scientific). The suspension was divided in 1ml aliquots (1x106 
cells/vial) in 2ml cryogenic tubes (ABC Scientific) gradually brought at -80oC using a freezing 
container (Mr. Frosty™ Freezing Container, ThermoFisher Scientific) over 24h before being 
transferred to liquid nitrogen. 
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3.5. Virus 
 
3.5.1. Isolates and reverse genetic viruses 
 
Experiments were performed using isolates or reverse genetic versions of H3N8 
equine influenza virus (EIVs). Full name, accession number of NS segment, type of virus, 
and abbreviation used in this work can be found at Table 3-7. For virus isolates, the mode 
of isolation, origin and potential passage(s) in chicken egg is unknown. Viruses were grown 
in MDCK cells at 37oC, 5% CO2 humidified atmosphere and virus stocks were grown at passage 
2 in MDCK cells (MOI 0.1), and stored at -80oC.  
For infections, virus stocks were diluted in infection medium composed of DMEM, 0.3% 
Bovine Albumin Fraction V (BSA, 7.5% solution, ThermoFisher Scientific), 1% PS, and 1μg/ml 
of tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (Sigma-Aldrich) 
(Martinez-Sobrido and Garcia-Sastre, 2010).  
 
Table 3-7: Viruses used in this work  
Virus Acce sion number Type of virus Abbreviation 
A/equine/Uruguay/1/1963 ACD85423 Isolate and Reverse genetic U/63 
A/equine/Miami/1/1963 ABY81497 Isolate M/63 
A/equine/SaoPaulo/1/1969 ACD85390 Isolate SP/69 
A/equine/Sussex/1/1989 ACD97430 Isolate S/89 
A/equine/Fontainebleau/1/1979 ACD85401 Isolate F/79 
A/equine/Kentucky/1/1991 ACA24672 Isolate K/91 
A/equine/LaPlata/1995 MF182460 Isolate LP/95 
A/equine/Kentucky/1995 MF182451 Isolate K/95 
A/equine/Kentucky/1999 MF182443 Isolate K/99 
A/equine/Kentucky/5/2002 ABA42429 Isolate K/02 
A/equine/Newmarket/5/2003 ACI48802 Isolate N/03 
A/equine/Ohio/1/2003 ABA42431 Isolate and Reverse genetic O/03 
A/equine/Mongolia/3/2013 MF182459 Isolate M/13 
 
The sequence of each NS segment, as well as NS1 coding sequence (CDS) and amino 
acid sequence, with corresponding accession numbers are available in Appendices 7 
to 19. 
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3.5.2. Other viruses 
 
Sendai virus (SeV), Cantell strain, was purchased from Charles River Laboratories and 
stored at -80oC. The rVSV-GFP virus stock used in the bioassay assay was generated by 
transiently transfecting HEK293T cells in Opti-MEM with an expression plasmid encoding the 
Vesicular Stomatitis Virus (VSV) glycoprotein of surface (pVSV-G, kindly provided by Brian 
Willett) (Martinez-Sobrido et al., 2006) using TransIT-LT1 transfection reagent (Cambridge 
Biosciences) at 37oC, 5% CO2 for 36h (100mm sterile dish format, 5x106 cells). At the end of 
the transfection period, the cells were infected with a previous stock of rVSV-GFP virus 
(2.5x102 TCID50) for 4h at 37oC, 5% CO2 humidified atmosphere in growth medium, then 
washed with PBS and maintained at 37oC, 5% CO2 humidified atmosphere in growth medium 
for a further 16h. The supernatant was then collected and filtered through a 0.45μm filter 
(Fisher Scientific), before being aliquoted and stored at -80oC. 
 
 
3.5.3. Virus rescue 
 
Viruses were rescued using the eight-plasmid system of A/equine/Uruguay/1/1963 
and A/equine/Ohio/1/2003 (Hoffman 2001). In this system, the cDNA of each eight influenza 
virus segments is inserted between the Polymerase I promoter (PolI h) and the Polymerase I 
terminator (ti). This PolI transcription unit is flanked by the Polymerase II promoter of the 
human cytomegalovirus (PolII CMV) and the polyadenylation signal of the gene encoding 
bovine growth hormone (aII BGH). After transfection of the eight plasmids in a co-culture 
(2:3) of HEK293T/MDCK cells (6-well plate format, 2x106 cells/well), two types of molecules 
are synthesized: negative-sense vRNA by the cellular PolI, and transcription of mRNAs with 
5’-cap structures and 3’-poly(A) tails by PolII. These mRNAs are translated into viral proteins. 
(Figure 3-1). Co-cultures were seeded 24h prior to viral rescue, and reverse genetic viruses 
are generated within 2–3 days following transfection. For transfection, cells were incubated 
in Opti-MEM (Opti-Minimum Essential Medium, Life Technologies) and transiently co-
transfected using TransIT-LT1 (Mirus, Cambridge Bioscience), with 2.5Pg of seven-ambisense 
O/03 or U/63 plasmids (PB2-, PB1-, PA-, HA-, NP-, NA-, M-pDP2002 plasmids) plus ambisense 
O/03 NS- or U/63 NS-pDP2002 plasmids or the NS mutant-pDP2002 constructs (O/03-K186E, 
O/03-230 and O/03-K186E-230; U/63-E186K, U/63-219, U/63-E186K-219, respectively). 
After 24h, the medium was replaced by infection medium. Virus-containing tissue culture 
supernatants (passage 0, P0) were collected 3 days post-transfection, clarified, and stored 
at -80oC. 
Chapter 3 - Materials and Methods 
 
 73 
 
 
Figure 3-1: Eight-plasmid system for generation of Influenza A virus 
 
Schematic representation of the IAV eight-plasmid rescue system. The left-hand side illustrates the co-
culture system of HEK293T and MDCK cells. Cells are co-transfected with eight plasmids encoding for 
the eight segments of the IAV of interest. Reverse genetic viruses are generated within 2–3 days post 
transfection. On the right-hand side, a schematic representation of the polymerase (Pol) I–polymerase 
(Pol) II transcription system for synthesis of vRNA and mRNA is shown. The cDNA of each of the eight 
influenza virus segments is inserted between the Polymerase I promoter (PolI h) and the PolI terminator 
(ti). This PolI transcription unit is flanked by the Polymerase II promoter of the human cytomegalovirus 
(PolII CMV) and the polyadenylation signal of the gene encoding bovine growth hormone (aII BGH). 
After transfection of the eight expression plasmids, two types of molecules are synthesized: negative-
sense vRNA by the cellular PolI, and transcription of mRNAs with 5’ cap structures and 3’ poly(A) tails 
by PolII. These mRNAs are translated into viral proteins. Of note, the start codon (ATG) of each viral 
cDNA is directly following the PolII transcription start site. 
 
 
3.5.4. Creating virus stocks 
 
For experimental infection, a minimum of two viral stocks of each virus was rescued 
and grown independently. P0 stocks were used to infect fresh MDCK cells to generate a 
passage 1 (P1) stock. After 2 to 3 days of infection (when 80% of the monolayer was 
destroyed), supernatant was collected, cleared and stored at -80oC. Viral titres of P1 stocks 
were determined as described below. The P1 stocks were then used to generate passage 2 
(P2) viral stocks. To this end, MDCK cells were infected with P1 stocks at MOI 0.01 and after 
2 to 3 days of infection (when 80% of the monolayer was destroyed), supernatants were 
collected, cleared and stored at -80oC. The sequence of each genomic segment was checked 
by Sanger sequencing and the size of each segment was checked by PCR and 1% agarose gel 
electrophoresis (Appendices 20 to 31). Viral titres of P2 stocks were determined as described 
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below. For experimental infections, a minimum of two viral stocks for each virus were 
rescued and grown independently. 
 
 
3.5.5. Experimental viral infections 
 
Confluent monolayers of MDCK cells (12-well plate format, triplicates, 5x105 
cells/well) or E.Derm cells (12-well plate format, triplicates, 2.5x105 cells/wells) were 
infected (MOI 0.01 and 0.1, respectively) with the indicated viruses and placed at 37oC, 5% 
CO2. After 1h incubation, cells were washed with PBS and infection medium was replaced 
with 500Pl of fresh growth medium. Tissue culture supernatants were collected at various 
times pi and stored at -80oC, and cells were fixed in 0.1% buffered formalin at 4oC for 16h 
and kept for flow cytometry analysis. Each experiment was repeated three times 
independently. Viral titres were determined by immunofocus assay in MDCK cells. Titrations 
were repeated three times independently, and the mean value and standard error mean 
were calculated using GraphPad Prism7 (GraphPad Software Inc. San Diego, CA, USA).  
Of note, the presence of deficient interfering particles in viral stocks was not assessed. In 
addition, the level infectious particles versus genomic information was not compared 
between viruses. Thus, the differences observed throughout this work could either reflect 
differences due to the mutations introduced in NS1 of /03 and U/63 or NS segment swap 
between O/03 and U/63, or be due to differences in infectivity levels and ability to induce 
an IFN response between WT and mutant viruses. 
 
 
3.5.6. Determination of viral titre and plaque phenotype by immunofocus 
assay 
 
Viral titres were determined by immunofocus assay (focus forming units, FFU/ml) in 
MDCK cells. Confluent monolayers of MDCK cells (48-well plate format, triplicates, 1.25x103 
cells/well) were infected with serial dilution (1:10) of the viral stock of interest and placed 
at 37oC, 5% CO2. Plates were gently rocked every 10 minutes. After 1h incubation, cells were 
washed with PBS and infection medium was replaced with a 50:50 2.4% Avicell:2X MEM 
overlay for 48h. 2.4% Avicell solution was prepared as follow: 2.4% (w/v) of Avicell (Avicell 
RC/CL, Microcrystalline cellulose & Sodium carboxymethylcellulose1, Sigma-Aldrich) in 
100ml of H2O. Autoclaved and stored at room temperature until use. At 48hpi, the overlay 
was discarded, cells were washed 3 times with PBS and fixed with 80% ice-cold acetone 
solution (Acetone AR, >99.5%, Sigma-Aldrich) for 10 minutes at room temperature. The 
Chapter 3 - Materials and Methods 
 
 75 
plates were let to dry overnight at room temperature. then treated with 1% Triton X-100 
PBS solution (TritonTM X-100, Sigma-Aldrich-Aldrich) for 10 minutes at room temperature, 
followed by 1h of incubation with 10% NGS PBS solution at room temperature. This was 
followed by 3h of immunoblotting at room temperature in 10% Normal Goat Serum plus PBS 
with a monoclonal anti-influenza A virus nucleoprotein (NP) antibody (clone HB65, European 
Veterinary Laboratory) (Table 3-8). After a 3-step washing with PBS, a horseradish 
peroxidase-conjugated rabbit anti-mouse IgG antibody (AbD Serotec, UK) (Table 3-8) was 
used in PBS solution for a further 1h at room temperature. A color development method was 
used to reveal the immunofocus using the TrueBlue peroxidase substrate (Insight 
Biotechnology). 50Pl of substrate per well was used under agitation for 10 minutes of 
incubation, and stop with water. Viral titres were calculated by counting the number of 
blue plaques and were expressed as log10 PFU per millilitre. 
For plaque phenotype, a confluent monolayer of MDCK cells (6-well plate format, 
triplicates, 6.4x104 cells/well) were infected with serial dilution (1:2) of the viral stock of 
interest and placed at incubation at 37oC, 5% CO2, humidified atmosphere. The same 
protocol as described above was then followed. For colour development, 2ml of TrueBlue 
peroxidase substrate was used per well. 
 
 
3.5.7. Viral protein staining for flow cytometry and confocal microscopy 
 
Cells were permeabilized with 1% Triton X-100 for 10 minutes, and blocked in PBS 
10% Normal Goat Serum (Gibco, Life Technologies) for 1h. Cells were then incubated with 
anti-NP antibody, rabbit polyclonal anti-NS1 protein antibody (Genscript) or rabbit STAT1 
polyclonal antibody (Santa Cruz) overnight at 4oC. Cells were then washed twice with PBS 
and incubated for 4h with a rabbit anti-mouse IgG Alexa fluor 488 (Cell signalling) or donkey 
anti-rabbit IgG Alexa fluor 555 (Cell signalling), before  analysis by flow cytometry (Guava 
Flow Cytometer, Merck) or fixed in VECTASHIELD Mounting Medium with DAPI 
(VECTASHIELD Hard+SetTM Mounting Medium with 1.5Pg/ml DAPI, Vector laboratories) and 
analysed by confocal microscopy. 
 
 
3.5.8. Viral growth kinetics with Ruxolitinib or universal IFN 
 
Ruxolitinib (Selleck Chemicals), a JAK1/2 inhibitor (Stewart et al., 2014), was 
prepared as 10mM stocks in dimethyl sulfoxide (DMSO). Several doses of Ruxolitinib were 
tested in the presence of 500 Units (U) of universal type I IFN alpha (uIFN, pbl Assay Science) 
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(Figure 3-2). To measure virus growth kinetics in cells rendered un-responsive to type I IFN 
or in the presence of exogenous type I IFN, E.Derm cells were treated with Ruxolitinib at a 
concentration of 4PM as determined in or with 500U of uIFN. Treatments were started 24h 
prior to infection and maintained at the same concentration for the whole experiment.  
 
 
 
Figure 3-2: Test of Ruxolitinib concentrations 
 
E.Derm cells were treated with different amounts of Ruxolitinib (0.5 to 40PM) or mock treated with 0.4% 
of DMSO for 24 h prior to treatment with universal IFN (uIFN). At the indicated time post infection (hpi) 
(A) Mx proteins expression was assessed by Western blot (78 and 76 kDa), and (B) cytopathic effect 
was evaluated using a confocal microscope (transmitted light mode). 
 
 
3.6. Antiviral cytokine production and general protein shutdown. 
 
E.Derm cells (12-well plate format, triplicates, 2.5x105 cells/well) were infected 
(MOI 0.1) with the indicated viruses for a total of 72h. At the indicated times post-infection, 
supernatants were collected and stored at -80oC for further analysis by bioassay, while cells 
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were treated for 1h at 37oC, 5% CO2 with Puromycin (20µg/ml in DMEM, 15% FBS) prior to 
lysis in protein disruption buffer + E-mercaptoethanol and stored at -80oC for further analysis 
by western blot. Puromycin is a well-known antibiotic that competes against aminoacyl tRNA 
on the ribosome A site (Monro et al., 1968). As such, puromycin enables examination of total 
protein production without requiring transfection, radio-labeling, or the prior choice of a 
candidate gene (Starck et al., 2004). If cells are incubated with puromycin, lysed and 
immunoblotted using an anti-puromycin antibody, all the proteins being produced will be 
immunostained as puromycin will be incorporated at the C-terminus of all nascent proteins.  
For the IFN bioassay, supernatants were UV-inactivated for 5 minutes at room temperature 
and used to treat fresh E.Derm cells (48-well plate format, 6x104 cells/well, triplicates) for 
24h. The cells were then infected with rVSV-GFP virus (2.5x102 TCID50) for 8h, then 
trypsinized and fixed in 0.1% buffered formalin for 16h at 4oC. The percentage of GFP-
expressing cells were then analysed by flow cytometry. For controls, E.Derm cells were 
mock treated or treated with 500U of uIFN. GFP expression of mock-treated cells infected 
with rVSV-GFP was considered as 100% and GFP expression of uIFN-treated cells infected 
with rVSV-GFP was considered as 0%. Mean values and standard error means were calculated 
with GraphPad Prism7. 
 
3.7. SDS-PAGE & Western blot analysis 
 
Cells were lysed in protein disruption buffer (0.125 M Tris-HCl (pH 6.8), 4% (w/v) 
SDS, 25% (v/v) glycerol, 0.02% (w/v) bromophenol blue) + E-mercaptoethanol and stored 
immediately at -80oC. Samples were boiled for 15 minutes at 95oC prior to polypeptide 
separation by SDS-PAGE on NuPAGE Novex 4-12% Bis-Tris protein gels (ThermoFisher 
Scientific) using 20X NuPAGE MES SDS Running Buffer (Invitrogen), diluted in H2O. Proteins 
were detected by Western blotting following to transfer to nitrocellulose membranes using 
20X NuPAGE Transfer Buffer (Novex, Life technologies) diluted in H2O. The membranes were 
blocked for 1h at room temperature in 5% blotting-grade blocker (nonfat dry milk, Bio-Rad) 
TBS 0.1% Tween-20 (TWEEN 20, Sigma-Aldrich) and immunoblotted overnight at 4oC in 5% 
blotting-grade blocker TBS-0.1% Tween-20 with the antibody of interest. 10X TBS buffer 
(Tris base 48.4g, NaCl 160g, H2O up to 2L, pH adjusted at 7.6, Sigma-Aldrich) was diluted to 
1X in H2O for use. Antibodies used in this study are summarized in table 3-8. The 
chemiluminescent signal was detected using Amersham ECL Prime Western Blotting 
Detection Reagent (GE-Healthcare) and captured with ChemiDoc XRS+ System (Biorad). 
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3.8. RNA sequencing 
 
Confluent monolayers of E.Derm cells (12-well plates, triplicates, 2.5x105 
cells/wells) were infected with O/03 and revertant viruses (MOI 0.1 to 1) or mock infected 
at least three times independently. At 8 hpi cells were washed with PBS, immunostained 
with the anti-NP antibody and the proportion of infected cells was determined by flow 
cytometry. The samples containing a similar proportion of infected cells were selected for 
transcriptomic analysis, and cells were lysed with 500Pl of TRIzol (ThermoFisher Scientific) 
for further RNA extraction. Total RNA was extracted using the TRIzol method and further 
purified using the RNeasy mini spin columns (Qiagen), including an on-column DNase I 
digestion step (Qiagen) according to the manufacturer’s protocol. RNA concentration was 
measure with Qubit and the Qubit RNA HS Assay Kit (ThermoFisher Scientific) following the 
manufacturer's protocol. The ribosomal (r)RNA integrity number was measured using an 
Agilent 2100 BioAnalyzer (Agilent Technologies). Library preparation and sequencing were 
carried out by the Viral Genomics and Bioinformatic team of the MRC University of Glasgow 
Centre for Virus Research. 4.5ug of total RNA was enriched by selectively depleting rRNA 
using the RiboMinusTM Eukaryote Kit v2 (Ambion, Life Technologies). The sequence reads 
were processed according to the Tuxedo pipeline (Trapnell et al., 2013). Read quality was 
assessed using FastQC, and TopHat2 and Bowtie2 were used to map short reads against the 
Equus caballus 2 genome (GCA_000002305.1). A list of differentially expressed genes (DEGs) 
to mock-infected samples was generated using CuffDiff2 (genes with Benjamini Hochberg-p 
value <0.05 were considered significant) (Ratinier et al., 2016). A complete list of DEGs in 
all samples can be found in Appendices 35 to 67. 
 
 
3.9. Analysis of EIV NS1 amino acid sequences 
 
For the phylogenetic analysis of EIV NS1, a total of 170 NS sequences were collected 
from the NCBI Influenza Virus Resource database. Four NS segments sequenced for this study 
were also added (42). SeaView (Version 4.6.1) (43) was used to align the NS1 coding regions 
and the final alignment (http://datadryad.org/review?doi=doi:10.5061/dryad.673bj) was 
edited manually to remove NEP coding regions. BEAST (Version 1.8.4) (44) was used to infer 
maximum clade credibility trees, as well as a strict molecular clock and HKY85+G model of 
nucleotide substitution. Each codon position was estimated with separate substitution rates 
and nucleotide frequencies. Two individual chains were run until convergence was achieved. 
To analyse NS1 single nucleotide polymorphisms (SNP), the 175 NS1 amino acid sequences 
were aligned with CLC genomic workbench 8 (QIAGEN Bioinformatics) (Appendices 1 and 2) 
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and the frequency of each amino acid found at each of the 230 composing the NS1 protein 
was recorded. A threshold of 7% was used in accordance with the “best practices for 
evaluating single nucleotide variant calling” (Olson Frontiers in Genetics 2015). 
 
3.10. Graphing and statistical analysis 
 
All statistical analyses were conducted using GaphPad Prism software. Unless stated 
otherwise, significance was calculated by Two-way ANOVA and a Bonferroni's multiple 
comparisons post hoc test. 
 
3.11. Antibodies 
 
All primary and secondary antibodies used in this work can be found in Table 3.8.  
 
Table 3-8. Antibodies 
Target Antibody Dilution 
NS1 Polyclonal rabbit, IgG,  
(GenScript) 
1:1000 WB 
1:500 IF 
NP Monoclonal mouse, IgG2D, clone HB65 (European Veterinary 
Laboratory) 
1:1000 WB 
1:1000 IF 
MX1 Monoclonal mouse, IgG2D, clone M143 
(kindly provided by Georg Kochs) 
1:500 
ISG15  
 
Polyclonal rabbit, IgG, fusion protein ag8782 (Proteintech) 1:500 
STAT1 
(p84/p91) 
Polyclonal rabbit, IgG, clone M-22  
(Santa Cruz) 
1:1000 
Caspase 3 Polyclonal rabbit, IgG 
(Cell signaling) 
1:1000 
Cleaved 
caspase 3 
Polyclonal rabbit, IgG, clone Asp175 
(Cell signaling) 
1:500 
HA-tag Rabbit polyclonal, IgG 
(Sigma-Aldrich) 
1:1000 
Puromycin Monoclonal mouse, IgG2DN, clone 12D10 (Millipore) 1:1000 
J-Tubulin Polyclonal rabbit, IgG, clone AK-15  
(Sigma-Aldrich) 
1:2000 
Rabbit Polyclonal donkey, IgG, HRP-conjugate  
(GE-healthcare) 
1:2000 
Mouse Polyclonal rabbit, IgG, HRP-conjugated  
(Starlab, Biorad) 
1:2000 
Mouse Polyclonal donkey, IgG, Alexa Fluor 488-linked  
(ThermoFisher Scientific) 
1:2000 
Rabbit Polyclonal mouse, IgG, Alexa Fluor 647-linked 
(ThermoFisher Scientific) 
1:2000 
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4. Evolution of NS1 during EIV post-transfer adaptation 
 
4.1. Introduction 
 
The principal natural reservoir of IAVs is wild aquatic birds, and these viruses also 
circulate in some mammalian host populations, including horses (Parrish et al., 2015, 
Donatelli et al., 2017). Interspecies transmission events, notably from bird to mammal 
occur periodically, but most infections result in spillover events or isolated outbreaks, and 
very few lead to the establishment of novel endemic lineages (Parrish et al., 2015, Webby 
and Webster, 2001). In this work, H3N8 EIV was used as a model to study the adaptation 
process of an avian-origin IAV to a mammal. EIV was first reported in January 1963 in 
Florida (USA) from horses recently imported from Argentina (Scholtens et al., 1964, 
Waddell et al., 1963), and within two years following emergence, this virus was 
responsible for a major transcontinental pandemic (Paccaud and Paccaud, 1967). This 
virus has been circulating since then in the equine population, causing major outbreaks of 
disease worldwide (Burrows et al., 1981, Cowled et al., 2009, Livesay et al., 1993, Ito et 
al., 2008, Newton et al., 2006, Virmani et al., 2010, Alves Beuttemmuller et al., 2016, 
Perglione et al., 2016, Yamanaka et al., 2008).  
 
To establish a new lineage in a mammal, an avian IAV has to overcome multiple 
barriers, such as the immune system of the new host or molecular incompatibilities 
between the host cellular machinery and the viral proteins (Long et al., 2016). The 
occurrence of multiple advantageous mutations might have been important for the virus to 
successfully overcome species boundaries and adapt to the new host (Duffy et al., 2008). 
The role of HA mutations in virus-host interaction has been one of the main focus of the 
scientific community for decades (Lipsitch et al., 2016). Mutations in other viral segments 
such as PB2, NP, NA, M, and NS also occur (Le et al., 2009, Sakabe et al., 2011, Dankar et 
al., 2013), but their contribution to IAV adaptation to a new host is still incompletely 
understood.  
 
The evolution of the EIV lineage has resulted in accumulation of mutations in each 
of the viral genomic segments (Murcia et al., 2010), and the lineage has been divided in 
different clades (Daly et al., 1996, Murcia et al., 2011b, Lai et al., 2001). Since the late 
1990’s, viruses that have caused disease in horses belonged to the Florida clade 1 (FC1) or 
clade 2 (FC2) (Bryant et al., 2009, Lewis et al., 2011), which are endemic in North 
America, or Europe and Asia, respectively (Yamanaka et al., 2008, Cowled et al., 2009, Qi 
et al., 2010, Virmani et al., 2010, Gildea et al., 2013, Yondon et al., 2013, Woodward et 
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al., 2014, Gagnon et al., 2007, Damiani et al., 2008, Landolt, 2014). The Florida clades 
are notably distinguished from other clades by several amino acid changes in NS1, such as 
residue 44, 59, 71, 86, 216, and by an 11-amino acid C-terminal truncation of the protein 
(Barba and Daly, 2016). 
 
The NS1 protein is encoded on a collinear mRNA derived from the NS segment, 
which also encodes for the nuclear export protein (NEP) upon splicing (Inglis et al., 1979, 
Lamb and Choppin, 1979). NS1 and NEP share their first 10 amino acids, and NS1 bases 
503-690 overlap with NEP bases 31-221, although on a shifted reading frame (Lamb and 
Lai, 1980). NS1 is a major virulence factor common to all IAVs, whose best described 
function is to antagonise the IFN pathway (Garcia-Sastre et al., 1998, Kochs et al., 2007a, 
Egorov et al., 1998), an essential component of the host immune response to viral 
infection.  
 
NS1 can act both at pre-transcriptional and co-/post-transcriptional levels, 
although variations exist between viral strains (Geiss et al., 2002, Kochs et al., 2007a, 
Twu et al., 2007, Hayman et al., 2007).  
NS1 pre-transcriptional activities involve the interference with the RIG-I pathway, mainly 
by associating with two positive regulators: the ubiquitin ligases TRIM25 (Gack et al., 
2009) and RIPLET (Rajsbaum et al., 2012). NS1 residues R38, K41, E96, E97 seem to play a 
central role in this function (Wang et al., 1999, Talon et al., 2000) (Pichlmair et al., 2006, 
Gack et al., 2009, Rajsbaum et al., 2012). Residue 196 has also been shown to regulate 
NS1 antagonism of IFN-b induction (Kuo et al., 2010) through an IRF3-dependent 
mechanism (Talon et al., 2000, Krug, 2015).  
While the interaction of NS1 with the components of the RIG-I signaling axis are conserved 
among virus isolates, the extent and efficacy of the inhibitory effect varies significantly 
among strains (Hayman et al., 2006, Kuo et al., 2010). The same applies for NS1 
interference with IRF3 function (Kuo et al., 2010).  
NS1 co-/post-transcriptional activities comprise the prevention of nuclear processing of 
RNA polymerase II transcripts (Twu et al., 2007, Hayman et al., 2006, Hayman et al., 
2007, Kochs et al., 2007b, Noah et al., 2003). In eukaryotic cells, the 3’-end of primary 
transcripts are cleaved upon recognition of a conserved ‘AAUAAA’ sequence some ten to 
thirty bases upstream of the cleavage site. The Cleavage and Polyadenylation Specificity 
Factor (CPSF) is a polyprotein complex formed by four subunits that recognizes the 
‘AAUAAA’ sequence, binds to the nascent mRNA and catalyzes the endo-nucleolytic step 
and the subsequent addition of a poly(A) tail. The smallest component of the CPSF 
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complex is a 30 kDa protein (CPSF30), which possess five C3H zinc fingers (Tian and 
Manley, 2017). NS1 can bind CPSF30 through two of these zinc fingers (F2F3), and in doing 
so it inhibits the binding of the whole CPSF complex to pre-mRNA, thus preventing 
cleavage and polyadenylation of cellular pre-mRNA (Das et al., 2008). Of note, viral 
transcripts are not affected by the repression of CPSF, because their polyadenylation is 
directly catalyzed by the viral polymerase (Ayllon and Garcia-Sastre, 2015). The CPSF30 
binding site of NS1 is composed of a patch of highly conserved hydrophobic residues 
centered around amino acid 186 (184 to 189) (DeDiego et al., 2016), and these amino 
acids embed into a pocket on the F2F3 domain of CPSF30 (Hale et al., 2010b). Other 
amino acids have been described to stabilize NS1-CPSF30 interaction, such as G96, F103, 
M106, K108R, D125E, although they are not strictly part of the binding interface (Hale et 
al., 2010b, Kochs et al., 2007b, Das et al., 2008, Shimizu et al., 1999). Interestingly, 
variations in CPSF30 binding seem to arise commonly upon viral adaptation to different 
hosts or during laboratory passage (Kochs et al., 2007a, Twu et al., 2007, Hayman et al., 
2007). Indeed, mouse-, egg- and swine-adapted viruses generally have NS1 proteins that 
bind weakly to CPSF30, whereas those from most human-circulating strains are strong 
binders (Hossain et al., 2008, Brown et al., 2001, Elderfield et al., 2014, Hale et al., 
2010b). However, to date there is no clear evolutionary advantage associated with NS1-
CPSF30 interaction. 
NS1 has also been shown to interfere with the function of another protein involved in the 
processing of pre-mRNA, the poly(A)-binding protein II (PABPII) through residues 223-237 
(Li et al., 2001). Although, the exact mechanism is still unclear, NS1 would further 
reinforce viral shutoff of host gene expression during infection by binding to PABPII (Chen 
et al., 1999).  
 
Interestingly, successive truncation/elongation events in the NS1 C-terminus have 
been described during evolution of different IAV subtypes, including EIV (Suarez and 
Perdue, 1998, Dundon and Capua, 2009). However, to date no clear evidence of 
evolutionary advantage has been associated with these events. The C-terminal tail of NS1 
also accounts for other functional differences between viral strains. Indeed, based on 
bioinformatics and sequence analysis, residues 227 to 230 in the C-terminus of many 230-
amino acid long NS1 proteins possess a PDZ binding motif (PBM) (Obenauer et al., 2006). 
PDZ domains are protein-protein recognition modules within a multitude of proteins that 
organize diverse cell-signaling assemblies (Javier and Rice, 2011). The most common PBMs 
found in avian IAV NS1s is composed of ‘ESEV/EPEV’, which have been found to interact 
with PDZ domain-containing proteins. This implies that when present in mammalian cells, 
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avian NS1 proteins can interact with PDZ domain-containing proteins and disrupt 
important cellular pathways (Obenauer et al., 2006). The majority of EIVs in circulation 
until the late 1990s, expressed a full length NS1 (230 amino acids) possessing an avian PBM 
‘ESEV/EPEV’ at residue 227-230. This motif was lost after the late 1990s when the protein 
got truncated of eleven amino acids at its C-terminus (Murcia et al., 2011b, Barba and 
Daly, 2016). The loss of the ESEV/EPEV motif likely affected NS1’s ability to interact with 
PABPII or PDZ-containing proteins, however to date, no clear evolutionary advantage has 
been associated with this change.  
 
Many caveats in our understanding of the NS1 protein function remain, with 
notably little knowledge on the impact of NS1 amino acid changes on viral evolution and 
adaptation to horses. In this chapter, a phylogenetic approach was associated with cloning 
techniques and in vitro assays to identify genetic markers of adaptation of EIV to horses in 
the NS1 protein. 
 
 
Aims: The aims of this chapter were to identify molecular determinants of EIV NS1 
evolution; and to analyze the role of specific mutations on NS1 function at the protein 
level. 
 
 
4.2. Results 
 
4.2.1. Evolution of NS1 amino acid sequence from 1963 to 2014 
 
To assess EIV NS1 phylogeny, 175 full length NS sequences of equine H3N8 IAVs 
were used. A maximum clade credibility tree was generated following the methodology 
described in Chapter 3, section 3.10. As shown in Figure 4-1, several clades in the NS1 
phylogenetic tree could be distinguished. Following the nomenclature found in previous 
work (Murcia et al., 2011a), the different clades were named in a chronological fashion 
from clade I to X. The so-called clades IV and VI mentioned in Murcia and colleagues’ work 
were not distinguishable in this analysis, however, for consistency viruses from these 
clades were referred to as ‘clade IV-VI’. Each of these clades included a number of viruses 
that shared a common ancestor supported by high bootstrap values. Clade III and IX 
contained viruses from Europe, clade II comprised viruses isolated from Japan and Algiers, 
clade I and VIII included viruses from South America, and clades IV-VI, V and VII were 
composed of viruses isolated from North America (Georgia & Kentucky, Kentucky, and 
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California, respectively). Two major bifurcation events could be observed along the main 
trunk of the tree (late 1980s and 1990s), and during the second bifurcation the Florida 
clades 1 and 2 (FC1 and FC2) emerged. As mentioned previously, EIVs in circulation in the 
equine population today belong to FC1 or FC2, and are mainly isolated from North 
America, or Asia and Europe, respectively. 
 
The 175 NS1 amino acid sequences were then aligned and the frequency of amino 
acid found at each of the 230 residues composing the NS1 protein was recorded. To 
evaluate single nucleotide polymorphisms (SNP) variants with a viral population, a 
threshold of 5% is generally applied (The 1000 genomes consortium Nature 2010). 
However, Olson and colleagues published in 2015 the “best practices for evaluating single 
nucleotide variant calling” in which they showed that errors associated with Illumina 
sequencing can be as high as 6% (Olson Frontiers in Genetics 2015), thus, placing a SNP 
threshold at 7% would reduce the risk of false positives when defining a SNP of high 
frequency. Using this threshold, 149 residues were found completely conserved among NS1 
proteins, while 66 residues were changed throughout evolution, but were considered as 
punctual SNP as the number of isolates carrying these mutations remained below the 7% 
threshold (Table 4-1). More importantly, 15 residues changed at high frequency (>7%) were 
found and most of these changes were fixed at the population level.  
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Figure 4-1: Phylogenetic relationship of EIV NS1 genes from 1963 to 2014. 
 
A total of 175 EIV NS1 sequences were used to infer a maximum clade credibility tree. Horizontal 
branches are drawn to a scale of nucleotide substitutions per site, and the tree is rooted on 
A/equine/Uruguay/1/1963. Bootstrap values above 0.99 are shown in red. Colored boxes represent 
distinct clades of EIV numbered from I to IX in a chronological fashion. The two major bifurcations of 
the main trunk are indicated in black. The 2nd bifurcation in the late 1990s gave rise to the Florida 
clade 1 (FC1) and clade 2 (FC2). 
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Table 4-1: Residue changes in EIV NS1 from 1963 to 2014. 
 
The first column divides into 3 categories the NS1 residues found in the EIV population: conserved, 
substitution at low and high frequency. The second column indicates the total number of residues 
found in each category. The third column details the nature of the amino acid found at each residue. 
Residues marked in black are 100% conserved in all EIV NS1 sequences studied. Green residues 
indicate the main amino acid found at each specific position. Small grey residues indicate variants 
present at low frequency in NS1 in the EIV population. Red residues indicate the amino acid 
substitution found in viruses that follow the main trunk of the NS1 phylogenetic tree. *, indicates a stop 
codon; >, indicates a substitution fixed throughout evolution; <>, indicates an amino acid reversion. Of 
note, residues in NS1 C-terminal tail that are not present in the short version of NS1 (221 to 230) are 
represented in italic. 
Residue 
evolution
Number of 
residues
Position & type of amino acid found
Conserved 149
Substitution 
at low 
frequency
66
Substitution 
at high 
frequency
15
1    M
2    D
4 N
6    V
8    S
9    F
10  Q
11  V
12  D
13 C
14  F
15  L
16 W
17  H
20 K
21  R
22 F
23 A
25  Q
26  E
27  L
29  D
30  A
31  P
32 F
33  L
34  D
35  R
36  L
37  R
38  R
39  D
40  Q
41 K
42  S
43 L 
46  R
50 L
54 I
55  E
57 A
60  A
61 G
63  Q
65  V
68  I
73 S
75  E
78 K
80  T
82  A
83  S
85  P
88  R
89 Y
90  L
92  D
93 M
94  T
97  E
99    S 
100  R
102  W
103 F
105  L 
106  M
107  P
108  K
109  Q
110  K
113 G
114  S 
115 L
116 C
118  R
119  M
120  D
121  Q
123  I
125 D 
126  K 
127  N
128  I
130  L
131  K
132  A
133  N
134  F
135  S
136  V
137  I
141  L
142  E
143  T
145  I
147  L
148  R
149  A
150  F
151  T
152  E
153  E
154  G
157  V
158  G
159  E
160  I
161  S
162  P
163  L
164  P
165  S
167  P
168  G
169  H
170  T
171  N
172  E
173  D
174  V
175  K
176  N
177  A
178  I
182  I
183  G
184  G
187  W
188  N
189  D
190  N
193  R
195  S
196  E
198  L
199  Q
200  R
201  F
203  W
208  E
211  R
214  F
215  P
217  K
219  K
221  K
222  M
225  T
226  I
3    S PF
5    T P
7    S L
18  V I
19  R C
24  D N
28  G S
45  G R
47  G S
49  T A
51  G AD
52  L MQ
53 D GN
56  T I
58  T AI
62  K R
64  I M
66 E GK
69 L M
70  E K
72  E K
74  D N
76  A E
77  L FP
79  M R
81  I T
87  S P
91  T I
95    L F
96    D EG
98    M I
101  D E
104  M T
111  V I
117  I V
122  A T
124  M V
129  I V
138  F L
139  E KA
140 R MKT
144  L V
146  L I
155  A TS
156  V I
166  L F
179  G ER
180 V I
181  L I
185  L F
191  T K
192  V I
197  T AI
202  A T
204  R K
205  S N
206  S C
207  H NY
209  N ID
210  G R
212  P S
213  S T
218  Q *
224  R K
227  E K
229  E K
44   K<>R E
48   S>I GN
59   R>H
67   R>Q G
71   E>K
84   V>I
86   A>T/V
112 A>T I
186 E>K
194 V>I
216 P>S
220 R>* Q
223 A>E
228 S>P
230 V>I
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Of the 15 high frequency SNPs, 14 coded for non-synonymous substitutions: K44R, 
S48I, R59H, R67Q, E71K, V84I, A86T/V, A112T, E186K, V194I, P216S, A223E, S228P, V230I, 
and one for a non-sense mutation: R220*. The introduction of this premature stop codon 
was responsible for a 11-amino acid C-terminal truncation of the protein, as previously 
described (Quinlivan et al., 2005). Of note, only one substitution (K44R) reverted to the 
original amino acid, while the 14 others were maintained at the population level.  
 
A schematic representation of these 15 residue changes were then represented 
along a time scale in order to compare their respective introduction during NS1 
evolutionary history (Figure 4-2). It became apparent that some of these changes occurred 
at the same period. In example, A112T and E186K substitutions appeared both in the early 
1970s, while R44K reversion occurred at the same period than R59H, E71K, A86T and V230I 
substitutions (early 1990s). This last event was closely followed by P216S substitution and 
NS1 C-terminal truncation (R220*) in the late 1990s. Interestingly, some clades that 
separated from the main trunk of the tree did not introduce some of these residue 
changes. This was notably the case for clade IX, which maintained R59, E71, V194, P216, 
R220, V230 in the 1990s, or for clade III, which kept S228 in the mid-1970s. In both cases, 
the clades died out shortly after separation from the main trunk (early 1980s for clade III 
and mid-2000s for clade IX).  
In addition, an arginine (R) could be found at position 67 in the main trunk until the 1980s 
when it changed for a glutamine (Q). Q67 was already found at earlier times in minor 
clades, i.e. clade I and V, in the early 1960s and mid-1970s, respectively. Surprisingly, 
these two clades disappeared only a few years after circulation (late 1960s and early 
1980s, respectively).  
Furthermore, two substitutions only occurred in one of the currently circulating Florida 
clades, S48I and V84I. Indeed, NS1 of FC1 viruses maintained S48 and V84, while NS1 of 
FC2 viruses introduced I48 and I84 in the early 2000s. 
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Figure 4-2: Schematic representation of NS1 high frequency residue changes from 1963 to 
2014. 
 
Red residues indicate amino acid substitutions found in viruses that follow the main trunk of the NS1 
phylogenetic tree (Figure 4-1). A change of direction of the main trunk (light blue) indicates the 
estimated date of apparition a substitution. Dotted lines represent a period during which the nature of 
the residue found at the corresponding position is unknown. Residues found in other clades for the 
indicated positions are shown. The estimated time of extinction of each clade are indicated. 
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When looking for amino acids important for NS1/CPSF30 interaction (D96, F103, 
M106, K108, D125, L144, and 184-GLEWND-189) (Hale et al., 2010b, Kochs et al., 2007b, 
Das et al., 2008) it appeared that only residue 186 was changed at high frequency 
throughout evolution (Table 4-1). Of note, L144, L185 and D96, the latter being also 
involved in TRIM25 inhibition (Gack et al., 2009) were changed in a limited number of 
isolates, while all others were 100% conserved (Table 4-1 & Appendices 1&2). 
Furthermore, among residues important for NS1 dsRNA binding and inhibition of IFN 
induction (via IRF3 or TRIM25) (Wang et al., 1999, Talon et al., 2000, Pichlmair et al., 
2006, Gack et al., 2009, Rajsbaum et al., 2012, Kuo et al., 2010) (Liu et al., 1997, Chien 
et al., 1997), the majority were conserved at 100% (P31, D34, R35, R38, K41, R46, E97, 
E196), while others changed in a small number of isolates (T5, G45, T49). 
Most residues important for NS1 subcellular localization were also conserved. Indeed, all 
residues important for the protein nuclear import (residues 35 to 41) were 100% 
maintained (Greenspan et al., 1988; Li et al., 1998), while residues important for nuclear 
export (residues 138 to 147) (Tynell et al., 2014) were mostly conserved (141 to 143 and 
145, 147), with a few exceptions that changed at low frequency in the population (138 to 
140 and 144). 
Additionally, Y89 important for PI3K activation (Hale et al. 2006, 2010) was 100% 
conserved, and residues important for PKR inhibition (123 to 127) (Li et al., 2006, Min et 
al., 2007, Tan & Katze, 1998) were mostly conserved, with the exception of residue 124, 
which was changed at low frequency. Of note, residue 123 and 124 are also important in 
regulation of vRNA synthesis (Min et al., 2007). 
Moreover, NS1 phosphylation sites P215 (Hale et al., 2009), S42 (Hsiang et al., 2012) were 
100% conserved, while residue 48 was changed at high frequency in the population. 
However, as mentioned previously, S48 is not completely conserved among IAVs, and its 
substitution is thought to have no impact on viral replication (Hsiang et al., 2012). 
Of note, contrarily to human H3N2 viruses, no histone mimic sequence was found in EIV 
NS1 (Marazzi et al., 2012). 
Additionally, NS1 PBM changed during evolution (Figure 4-3). Indeed, from emergence to 
the mid-1990s, NS1 PBM was of the avian type ‘ESEV/EPEV’ (Obenauer et al., 2006). Then, 
it then changed to EPEI for a few years before the NS1 C-terminal truncation in the late 
1990s. Of note, one virus isolated in 2003 (A/equine/Wisconsin/1/2003) still expressed a 
full-length version of NS1 with a ‘KPKI’ motif at residues 227-230. The significance of this 
motif remains uncertain. 
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Figure 4-3: Schematic representation of NS1 PBM evolution from 1963 to 2014. 
 
The evolution of NS1 PDZ-binding motif (PBM, residues 227-230) from emergence to 2014 is 
represented. NS1 PBM was an avian type between 1963 to the early 1990s (ESEV/EPEV) (Obenauer 
et al., 2006). In the mid-1990s it changed for EPEI, and soon after NS1 C-terminus was truncated of 
eleven amino acids (represented by ‘----‘) resulting in the loss of PBM. One virus isolated in 2003 
(A/equine/Wisconsin/2003) still expressed a full-length version of NS1 with a KPKI PBM motif at 
residue 227-230. 
 
 
4.2.2. Selection and cloning of phylogenetically distinct NS1 proteins 
 
To experimentally study the functional evolution of EIV NS1 and determine which 
residue changes identified above could affect protein function, I selected thirteen isolates 
that included at least one representative virus per decade since 1963 (Table 4-2). I aligned 
their amino acid sequences and confirmed the presence of the previously described 15 
high frequency residue changes (Figure 4-4). Full NS segment, NS1 coding sequence and 
amino acid sequence for each of the thirteen viruses can be found in Appendices 7 to 19. 
 
Figure 4-4: Alignment of the NS1 amino acid sequence of EIVs used in this work.  
 
Red shadings highlight high frequency residue polymorphisms in the EIV NS1 population.  
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Table 4-2: EIVs used in this study. 
 
The name, NS segment accession number and abbreviation of the thirteen EIVs used in this work are 
listed. Their phylogenetic relationship is indicated in blue in the phylogenetic tree obtained as in 
Figure 4-1. 
Virus name NS segment accession number Abbreviation
A/equine/Uruguay/1/1963 ACD85423 U/63
A/equine/Miami/1/1963 ABY81497 M/63
A/equine/SaoPaulo/1/1969 ACD85390 SP/69
A/equine/Fontainebleau/1/1979 ACD85401 F/79
A/equine/Sussex/1/1989 ACD97430 S/89
A/equine/Kentucky/1/1991 ACA24672 K/91
A/equine/LaPlata/1995 MF182460 LP/95
A/equine/Kentucky/1995 MF182451 K/95
A/equine/Kentucky/1999 MF182443 K/99
A/equine/Kentucky/5/2002 ABA42429 K/02
A/equine/Ohio/1/2003 ABA42431 O/03
A/equine/Newmarket/5/2003 ACI48802 N/03
A/equine/Mongolia/3/2013 MF182459 M/13
U/63 SP/69
M/63
F/79
S/89
K/91
LP/95
K/95
K/99 O/03
K/02
N/03
M/13
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Each NS1 proteins was then cloned into a pCAGGS expression plasmid through EcoRI 
and XhoI restriction sites (Figure 4-5-A & -B) and the size of each NS1 insert (693 or 660bp 
for full length and truncated NS1, respectively) and expression vector (4.7kb) were 
confirmed by digesting the corresponding plasmid with EcoRI and XhoI restriction enzymes 
and running the digested product on a 1% Agarose gel (Figure 4-5-C).  
 
 
Figure 4-5: Generation of EIV NS1-pCAGGS expression constructs. 
 
A total of thirteen NS1 proteins were cloned into a pCAGGS expression vector through EcoRI and 
XhoI restriction sites. (A) The plasmid map indicates important components of the pCAGGS plasmid 
as well as the position of the insert. (B) A schematic representation the NS1 insert is shown. A Kozak 
sequence was added after the EcoRI restriction site and the NS1 gene was directly followed by XhoI 
restriction site. (C) The size of each vector (4.7kb) and insert (693 and 660bp, for full length and 
truncated NS1, respectively) were checked by digesting each plasmid with EcoRI and XhoI, and 
running the digested products on a 1% agarose gel. 
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To avoid NEP expression, the splice acceptor site of each NS1 inserts (Figure 4-6-A) 
was changed from 525-CCAGGA-530 to 525-CCCGGG-530. The size of each NS1 splice-
acceptor mutant (SAM) insert and expression vector (Figure 4-6-B) was checked in a similar 
fashion to Figure 4-4. Finally, the nucleotide sequence of each NS1 insert (WT and SAM) 
was confirmed by Sanger sequencing (Appendices 4 to 6). A full description of the 
methodology employed can be found in Chapter 3, section 3.1. 
 
 
Figure 4-6: Generation of NS1 splice acceptor mutants. 
 
In order to prevent the expression of the nuclear export protein (NEP) in NS1 pCAGGS expression 
plasmids, a silent mutation in the splice acceptor site (525-CCAG|GA-530) of NS1 was introduced in 
each insert. (A) A schematic representation of the Intro-Exon junction is shown, as well as the amino 
acid encoded by each codon. (B) To check for the size of each NS1 SAM and pCAGGS expression 
plasmid, NS1 SAM-expressing plasmids were digestion with EcoRI and XhoI restriction enzymes, and 
the digested products were run on a 1% agarose gel. 
 
 
4.2.3. Evolution of NS1 function in the EIV lineage 
 
As mentioned previously, NS1 is a well-known blocker of the IFN system via pre-
transcriptional and co-/post-transcriptional mechanisms. The gold standard assay to test 
NS1 function is a reporter assay in which cells are co-transfected with an NS1 expression 
plasmid together with reporter plasmids expressing a reporter gene (i.e. luciferase gene) 
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under the control of a promoter of interest (Chapter 3, section 3.2). Then a dual 
luciferase assay allows the measurement of luciferase activities, which are inversely 
proportional to the blockade that NS1 exerts on the corresponding promoters. NS1 
inhibition of general gene expression (co-/post-transcriptional level) is usually measured 
by using a reporter plasmid expressing a luciferase gene (i.e. Renilla luciferase gene) 
under the control of a constitutively expressed promoter (pREN-Luc) (Turkington et al., 
2015). In addition, to measure NS1’s ability to block the production of type I IFN (pre-
transcriptional level), the NS1 expressing-vector is co-transfected with a plasmid 
expressing a reporter gene (i.e. Firefly luciferase gene) under the control of the inducible 
IFN-b promoter (pIFN-b-FF-Luc) (Turkington et al., 2015) together with pREN-Luc, which is 
then used as an internal control. After a period of incubation, the cells are infected with a 
virus, i.e. Sendai virus (SeV) (Hale et al., 2010b), to induce the IFN promoter. At the end 
of the infection period a dual luciferase assay is carried out, and once again, NS1 
repression of the inducible IFN-b promoter is inversely proportional to the level of FF-Luc 
activity detected. Furthermore, the capacity of NS1 to block the induction of ISGs upon 
IFN treatment can be measured by using a reporter plasmid expressing the Firefly 
luciferase gene under the control of an inducible ISRE-containing promoter (pISRE-FF-Luc). 
This promoter will be induced by treating the cells with exogenous IFN (i.e. uIFN) 
(Martinez-Sobrido et al., 2006), and the capacity of NS1 to repress this promoter will again 
be measured by a dual luciferase assay. Finally, the level of expression of each NS1 
protein can be measured by Western blot on parallel transfected cell lysates. 
 
Similar reporter assays were used to study the evolution of EIV NS1 function, and to 
compare the ability of the thirteen NS1 proteins to block IFN-b and ISRE-inducible 
promoters, as well as a constitutively expressed promoter. However, prior to this, 
choosing the most appropriate cell line for this assay was necessary. 
 
 
4.2.4. Transfection efficiency of two mammalian cell types 
 
The cell type of choice to study EIV NS1 function was equine cells. However, no equine cells 
from the respiratory tract were available when this work was carried out. Thus, equine 
dermal fibroblasts (E.Derm/NBL-6, ATCC CCL-57), a commercially available equine cell line 
previously used to study various equine viruses was chosen (Balasuriya et al., 2014, Soboll 
Hussey et al., 2011, Maestre et al., 2011). Since their ability to express foreign DNA was 
unknown and the reporter assay requires cell transfection, their transfection efficiency was 
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compared to that of HEK293T cells, well known for their high transfection efficiency 
(Thomas and Smart, 2005), and their faithful protein translation (Ooi et al., 2016). To this 
end, HEK293T and E.Derm cells were transfected in parallel with a reporter plasmid 
expressing a green fluorescent protein (GFP) gene under the control of a cytomegalovirus 
promoter (pCMV-GFP) (Figure 4-7). At 24 hpt the number of cells expressing GFP was 
analyzed by flow cytometry or fluorescence microscopy. E.Derm cells displayed a very low 
transfection efficiency, as only 16.3 % [+/-1.0] of cells expressed GFP (Figure 4-7-B). In 
addition, the examination of the cellular monolayer with a fluorescent microscope 
confirmed that only a small fraction of cells was expressing GFP (Figure 4-7-A). In contrast, 
parallel transfections of HEK293T cells confirmed their high transfection efficiency either by 
fluorescence microscopy (Figure 4-7-C) or by  flow cytometry (97.6 % [+/-2.0] of transfected 
cells expressing GFP) (Figure 4-7-D). 
 
Taken together, these results suggested that HEK293T cells would likely be a 
better model to test EIV NS1 function in a reporter assay than E.Derm cells. 
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Figure 4-7: Comparison of E.Derm and HEK293T cells transfection efficiency. 
 
(A,B) E.Derm cells and (C,D) HEK293T cells were transiently transfected with a pCMV-GFP 
expression plasmid (1000ng) for 24h as described in the method section. At the end of the 
transfection period the cellular monolayer was (A,C) examined with a fluorescent microscope to 
confirm the presence of green fluorescent cells, and A representative picture of each condition is 
shown. (B,D) Cells were then detached and fixed in Formalin as indicated in the method section, and 
the number of green fluorescent cells was determined by flow cytometry. The experiment was 
repeated three times independently and means and error margins are indicated by the black and grey 
values respectively. 
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4.2.5. Function of phylogenetically distinct NS1 proteins 
 
First, the ability of the thirteen NS1 proteins to limit the production of IFN-b was 
compared. To this end, HEK293T cells were co-transfected with three different amounts 
of NS1 expression plasmids (1000ng, 200ng, 20ng) or with an empty vector (pCAGGS, 
1000ng), together with 50ng of pIFN-b-FF-Luc, and with 50ng of pREN-Luc used for 
normalization (Figure 4-8). Total plasmid concentration was kept constant (1000ng) with 
an empty expression vector. At 24 hpt, the cells were infected with 50 HAU of SeV for a 
further 18 h in order to stimulate the IFN-b promoter, and at the end of the infection 
period, both luciferase activities were measured. As shown in (Figure 4-8-A), SeV infection 
resulted in high increase of IFN-b-FF-Luc activity in cells co-transfected with the empty 
vector (set to 100%) compared to uninfected controls. However, the IFN-b promoter was 
strongly antagonized in a dose-dependent manner in cells expressing each NS1 proteins 
tested.  
The ability of these NS1 proteins to block induction of ISGs upon IFN treatment was then 
compared by co-transfecting HEK293T cells with NS1 expressing plasmids (1000ng, 200ng 
and 20ng), together with 50ng of the pISRE-FF-Luc reporter plasmid, and pREN-Luc. At 24 
hpt, cells were treated with 500U of uIFN to stimulate the ISRE-containing promoter, and 
18 h later ISRE-FF-Luc and REN-Luc activities were measured. Interestingly, the NS1 
proteins of EIVs isolated in 1963 (U/63 and M/63) displayed a relatively low repression of 
the ISRE-containing promoter (Figure 4-8-B). NS1’s blockade of this promoter progressively 
increased between 1969 and 1995 (SP/69 to K/95), while most NS1 from 1999 to 2013 
(K/99 to M/13) showed a dose-dependent control of this promoter.  
To compare the ability of the thirteen NS1 protein to inhibit general gene expression, 
individual NS1 expression plasmids (1000ng, 200ng, 20ng) were co-transfected together 
with pREN-Luc (50ng), and REN-Luc activity was measured 24 h later. Renilla luciferase 
activity was strongly antagonized by NS1 proteins from the 1960s (U/63, M/63, SP69) 
(Figure 4-8-C). In contrast, NS1 from 1979 onwards (F/79 to M/13) were unable to block 
general gene expression, as shown by high REN-Luc expression levels. Furthermore, for 
some of these recent NS1 proteins an increase in gene expression was observed (increase 
in REN-luc activity) (Figure 4-8-C). These results were consistent with the western blot 
results (Figure 4-8-D), as NS1 proteins that strongly antagonized the constitutively 
expressed promoter (i.e. U/63, M/63, SP/69) could not be detected, while the ones that 
did not (F/79 to M/13) were easily detectable. Interestingly, the level of expression of NS1 
of viruses isolated between 1979 and 1995 (F/79 to LP/95) was lower than that of more 
recent NS1 proteins (K/95 to M/13).  
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Figure 4-8: Functional characterization of evolutionary distinct EIV NS1 proteins in 
HEK293T cells. 
 
HEK293T cells were transiently co-transfected with a pCAGGS expression plasmid (1000, 200, 20ng) 
encoding the indicated NS1 proteins (or empty plasmid) together with either (A) a Firefly luciferase 
(FF-Luc)-IFN-b promoter reporter construct (pIFN-b-FF-Luc), or (B) a FF-Luc-IFN-stimulated 
regulatory element reporter construct (pISRE-FF-Luc), as well as a constitutively active Renilla 
luciferase expression plasmid (pREN-Luc). At 24 hpt, cells were either (A) infected with SeV (+) or 
mock infected (-), or (B) treated with universal interferon (uIFN) (+) or mock treated (-) for 18h. (A-B) 
The relative activity of FF-Luc was determined as the ratio between FF-Luc and REN-Luc in each 
corresponding sample. Values were normalized to (A) empty pCAGGS plasmid (+) SeV or (B) empty 
pCAGGS plasmid (+) uIFN (set to 100%). (C) HEK293T cells were transiently co-transfected 
individually with the indicated NS1-expression plasmids (1000, 200, 20ng) together with pREN-Luc. 
Total REN-Luc levels were measured 24 h later, and values were normalized to empty pCAGGS 
transfected cells. (A, B and C) Bars correspond to mean of three independent experiments and error 
bars represent SEM. A Two-way ANOVA with Bonferonni post hoc test was used to determined 
significance. (A and B) ****, p<0.0001 for pCAGGS+SeV or +uIFN (1000, 200, 20ng) against all other 
conditions; (A) ££££, p<0.0001 for U/63 versus F/79 to M/13; £££, p<0.001 for M/13 versus F/79 to 
M/13; ££, p<0.01 for SP/69 versus F/79 to M/13 (20ng); (B) ££££, p<0.0001 for U/63 and M/63 versus 
F/79 to M/13 (1000, 200, 20ng); €€€€, p<0.0001, K/99 to M/13 versus U/63 to K/95 (20ng); (C) £££, 
p<0.001 for U/63 and M/13 versus F/79 to M/13 (1000, 200ng). (D) The level of expression of the 
indicated NS1 protein was analysed by Western blot on parallel transfected lysates (1000ng) using a 
rabbit polyclonal anti-EIV NS1 antibody. The Western blot was run 3 times independently and a 
representative picture is shown.  
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Despite their low transfection efficiency, similar reporter assay were tested in 
E.Derm cells. Three NS1 expression plasmids (U/63, K/95, O/03) were selected based on 
their phenotype in HEK293T cells (Figure 4-8). E.Derms were then transfected with 1000ng 
of plasmid together with 500ng of pIFN-b-FF-Luc or pISRE-FF-Luc, and 500ng of pREN-Luc 
used for normalization (Figure 4-9-A & 4-9-B). At 24 hpt, cells were either infected with 50 
HAU of SeV or treated with 500U of uIFN, to induce the IFN-b promoter or the ISRE-
containing promoter, respectively. At 18 h post infection/treatment, a dual luciferase 
assay was I carried out. In addition, to assess NS1 capacity to block general gene 
expression, the three NS1 expression plasmids (1000ng) were co-transfected with pREN-
Luc (500ng), and REN-Luc activity was measured 24 h later (Figure 4-9-C). Finally, the 
level of expression of the three NS1 proteins was analyzed by western blot from parallel 
transfected cell lysates (Figure 4-9-D).  
As shown in (Figure 4-9-A & -B), similar results to what was found in HEK293T cells were 
observed in E.Derm, where all NS1 proteins blocked efficiently IFN-b induction (Figure 4-9-
A). However, since the level of induction of the IFN-b promoter was very low, these 
results are controversial. In addition, as obtained with HEK293T cells, only U/63 NS1 
efficiently blocked the constitutively expressed promoter (Figure 4-9-C). However, 
contrarily to what was found in HEK293T cells, only K/95 could efficiently repress the 
ISRE-containing promoter in E.Derm (Figure 4-9-B). Moreover, none of the NS1 protein 
tested could be detected by Western blot (Figure 4-9-D), which was likely due to the low 
transfection efficiency of these cells.  
Hence, HEK293T cells were confirmed to be a more reliable model for this experiment. 
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Figure 4-9: Functional characterization of evolutionary distinct EIV NS1 proteins in E.Derm 
cells. 
 
E.Derm cells were transiently co-transfected with a pCAGGS expression plasmid (1000ng) encoding 
the indicated NS1 proteins (or empty plasmid), together with either (A) pIFN-b-FF-Luc (500ng), or (B) 
pISRE-FF-Luc (500ng), as well as pREN-Luc (500ng). At 24 hpt, cells were either (A) infected with 
SeV (+) or mock infected (-), or (B) treated with universal interferon (uIFN) (+) or mock treated (-) for 
18h. (A-B) The relative FF-Luc activities were determined as for Figure 4-7. (C) E.Derm cells were 
transiently co-transfected with the indicated NS1-expression plasmids (1000ng) together with pREN-
Luc. Total REN-Luc levels were determined as for Figure 4-7. (A-C) Bars correspond to mean of three 
independent experiments and error bars represent SEM. Significance was calculated as for Figure 4-
7: (A) ***, p<0.001 for pCAGGS-SeV versus U/63 to O/03; (B) ***, p<0.001 for K/95 versus 
pCAGGS+SeV; **, p<0.01 for K/95 versus U/63; *, p<0.05 for K/95 versus O/03. (C) ****, p<0.0001 for 
U/63 versus all other conditions. (D) The level of expression of the indicated NS1 was analysed as for 
Figure 4-7.  
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4.2.6. Impact of residues 112 and 186 on NS1 function 
 
As seen in (Figure 4-8-C) and (Figure 4-9-C), the NS1 protein of EIVs that circulated 
in the 1960s (U/63, M/63, SP69) strongly blocked the otherwise constitutively expressed 
Renilla luciferase, while the NS1 protein of EIVs isolated after 1979 (F/79 to M/13) did 
not. Interestingly, in the early 1970s two amino acid substitutions (E186K and A112T) arose 
in EIV NS1 (Figure 4-2) Since residue 186 lies within the NS1 CPSF30-binding domain, and 
by binding to CPSF30 NS1 can block host gene expression (Ayllon and Garcia-Sastre, 2015, 
Hale et al., 2010a), E186K substitution was strongly suspected to be responsible for the 
observed change of function.  
However, to thoroughly test which substitution(s) was(were) responsible for the observed 
change, residue 186 and 112 single and double NS1 mutants were generated for two 
phylogenetically distinct EIVs, which naturally harbor A112 and E186 (U/63), and T112 and 
K186 (O/03) (Figure 4-10). The three mutant versions of each protein were generated by 
mutagenesis (Figure 4-11 & 4-12), and the presence of the desired mutation(s) was 
checked by Sanger sequencing (Figure 4-11-A & 4-11-B & Figure 4-12-A & 4-12-B). In 
addition, the size of each insert and vector were checked prior to use (Figures 4-11-C & 4-
12-C). 
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Figure 4-10: Generation of residue 112 & 186 NS1 mutants. 
 
Two phylogenetically distinct EIV NS1 proteins (U/63 and O/03 NS1), which naturally contain either A 
or T at position 112 and E or K at position 186 were selected. Single and double mutants of these 
NS1 proteins were generated. A schematic representation of each NS1 WT and mutant is shown 
below the tree.  
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Figure 4-11: Generation of U/63 NS1 mutants for residue 112 and 186. 
 
(A) NS1 WT, single and double mutant inserts were sequenced by Sanger sequencing. 
Corresponding traces are shown.  (B) Alignment of the amino acid sequence of WT and mutant NS1 
inserts are shown. Red shadings indicate a different amino acid. (C) Each NS1 (WT and mutant) 
expression plasmid was digested with EcoRI and XhoI restriction enzymes and digested products 
were ran on a 1% agarose gel to verify plasmid (4.7kb) and insert (693bp) sizes. 
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Figure 4-12: Generation of O/03 NS1 mutants for residue 112 and 186. 
 
As for Figure 4-10, (A) NS1 WT, single and double mutant inserts were sequenced by Sanger 
sequencing. Corresponding traces are shown.  (B) Alignment of the amino acid sequence of WT and 
mutant NS1 inserts are shown. Red shadings indicate a different amino acid. (C) Each NS1 (WT and 
mutant) expression plasmid was digested with EcoRI and XhoI restriction enzymes and digested 
products were ran on a 1% agarose gel to verify plasmid (4.7kb) and insert (660bp) sizes. 
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As expected, none of the introduced mutations affected NS1 control of IFN-b 
induction (Figure 4-13-A), while NS1 proteins harboring E186 (i.e. U/63 WT, U/63 A112, 
O/03 K186E and O/03 T112A K186E) strongly repressed general gene expression, and K186-
containing NS1 proteins (i.e. U/63 E186K, U/63 EA112T E186K, O/03 WT and O/03 T112A) 
did not (Figure 4-13-C). Consistent with this the NS1 proteins harboring E186 were not 
detectable by western blot. In addition, the expression of K186-containing U/63 NS1 
protein remained lower than that of K186-containing O/03 NS1 proteins (Figure 4-13-D). 
Surprisingly, the presence of K186 in U/63 NS1 proteins did not fully rescue the phenotype 
observed for K186-containing O/03 NS1 proteins. This suggested that U/63 NS1 control of 
general gene expression is not fully due to E186, and other mutations are likely involved in 
this function. 
Additionally, the presence of K186 seemed to be associated with a better control of the 
ISRE-containing promoter, as K186-containing NS1 proteins (i.e. U/63 E186K, U/63 A112T 
E186K and O/03 WT or O/03 T112A) repressed more pISRE-FF-Luc activity than their E186-
containing counterparts (i.e. U/63 WT, U/63 A112, O/03 K186E and O/03 T112A K186E) 
(Figure 4-13-B). 
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Figure 4-13: Functional characterization of U/63 and O/03 NS1 112 & 186 mutants in 
HEK293T cells. 
 
As for Figure 4-7, HEK293T cells were transiently co-transfected with a pCAGGS expression plasmid 
(1000ng) encoding the indicated NS1 proteins (or empty plasmid), together with either (A) pIFN-b-FF-
Luc (50ng), or (B) pISRE-FF-Luc (50ng), as well as with pREN-Luc (50ng). (A-B) Inducible promoters 
were activated, and the relative FF-Luc activities were determined as for Figure 4-7. (C) Human 293T 
cells were transiently co-transfected with the indicated NS1-expression plasmids (1000ng) together 
with pREN-Luc (50ng), and total REN-Luc levels were determined as for Figure 4-7.  (A-C) Bars 
correspond to mean of three independent experiments and error bars represent SEM. Significance 
was calculated as for Figure 4-7: (A and B) ****, p<0.0001 for pCAGGS+SeV or +uIFN versus all 
other conditions; ££££, p<0.0001 for indicated NS1 contructs versus all others. (D) The level of 
expression of the indicated NS1 was analyzed by Western blotting as for Figure 4-7.  
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4.2.7. Impact of residue 186 and C-terminus on NS1 function 
 
Another factor than residue 186 seemed to affect NS1 control of gene expression 
and ISG induction, as O/03 NS1 phenotype could not be fully rescued by introducing K186 
in U/63 NS1 (Figure 4-13-B, 4-13-C & 4-13-D). Interestingly, another major difference 
between U/63 and O/03 NS1 was their respective length. Indeed, as other EIVs isolated 
between 1963 and the early 1970s, U/63 expressed a full length NS1 protein, which is 
composed of 230 amino acids. In contrast, as for EIVs isolated after the late 1990s, O/03 
contained a short version of NS1, truncated of 11 amino acids at its C-terminus. (Figure 4-
14). As a consequence, U/63 NS1 possesses an ‘ESEV’ PBM motif and a PABPII binding site, 
while O/03 NS1 does not. These motifs could allow U/63 NS1 to control signal transduction 
(Obenauer et al., 2006) and general gene expression (Li et al., 2001, Chen et al., 1999) 
either independently or in complement to E186. To test this hypothesis, three 
phylogenetically distinct EIVs displaying functional differences in the reporter assay 
(Figure 4-8) were selected. U/63, K/95, and O/03, possessing the early (E186, 230 amino 
acids), intermediate (K186 230 amino acids) and late (K186, 219 amino acids) version of 
NS1, respectively (Figure 4-14), were used to generate single and double mutants for 
residue 186 and C-terminus (Figure 4-15, 4-16, & 4-17).  
As for earlier constructs, the presence of the desired mutation(s) was verified by Sanger 
sequencing (Panel A & B of Figure 4-15, 4-16, & 4-17), and the size of each insert and 
vector were checked on a 1% agarose gel (Panel C of Figure 4-15, 4-16, & 4-17) prior to 
the reporter assay.  
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Figure 4-14: Generation of residue 186 & C-terminus NS1 mutants. 
 
Three phylogenetically distinct EIVs (U/63, K/95 and O/03), which naturally contain either E or K at 
position 186 and long and short C-terminal tail (230 or 219 amino acids, respectively) were selected, 
and single or double mutant versions of these NS1 proteins were generated. A schematic 
representation of NS1 WT and mutants is shown.  
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Figure 4-15: Generation of U/63 NS1 mutants for residue 186 and C-terminus. 
 
As for Figure 4-10, (A) NS1 WT, single and double mutant inserts were sequenced by Sanger 
sequencing. Corresponding traces are shown.  (B) Alignment of the amino acid sequence of WT and 
mutant NS1 inserts are shown. Red shadings indicate a different amino acid. (C) Each NS1 (WT and 
mutant) expression plasmid was digested with EcoRI and XhoI restriction enzymes and ran on a 1% 
agarose gel to verify plasmid (4.7kb) and insert (660 and 693bp) sizes. 
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Figure 4-16: Generation of K/95 NS1 mutants for residue 186 and C-terminus. 
 
As for Figure 4-10, (A) NS1 WT, single and double mutant inserts were sequenced by Sanger 
sequencing. Corresponding traces are shown.  (B) Alignment of the amino acid sequence of WT and 
mutant NS1 inserts are shown. Red shadings indicate a different amino acid. (C) Each NS1 (WT and 
mutant) expression plasmid was digested with EcoRI and XhoI restriction enzymes and ran on a 1% 
agarose gel to verify plasmid (4.7kb) and insert (660 and 693bp) sizes.  
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Figure 4-17: Generation of O/03 NS1 mutants for residue 186 and C-terminus. 
 
As for Figure 4-10, (A) NS1 WT, single and double mutant inserts were sequenced by Sanger 
sequencing. Corresponding traces are shown.  (B) Alignment of the amino acid sequence of WT and 
mutant NS1 inserts are shown. Red shadings indicate a different amino acid. (C) Each NS1 (WT and 
mutant) expression plasmid was digested with EcoRI and XhoI restriction enzymes and ran on a 1% 
agarose gel to verify plasmid (4.7kb) and insert (660 and 693bp) sizes. 
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Their ability to block IFN-b and ISG induction, and to control general gene 
expression was then assessed in a reporter assay (Figure 4-18). Consistent with previous 
results, none of the introduced mutations affected NS1 control of IFN-b induction (Figure 
4-18-A). In contrast, the presence of E186 in NS1 was associated with a strong repression 
of general gene expression (Figure 4-18-C), and these proteins were not detectable by 
western blot (Figure 4-18-D). Also, K186-containing-K/95 and -O/03 NS1 proteins strongly 
induced REN-Luc expression (Figure 4-18-C) and were strongly expressed in transfected 
cells (Figure 4-18-D). Furthermore, residue 186 seemed to affect NS1 control of ISG 
induction (Figure 4-18-B), as all E186-containing NS1 proteins were controlling less 
efficiently the ISRE-containing promoter compared to their K186 counterparts. These 
results were consistent with observation made in Figure 4-13. Surprisingly, K/95-K186E 
mutant lost the ability to control the ISRE-containing promoter when transfected at 200ng 
(middle dose) (Figure 4-18-B). Whether this result is artefactual or real would require 
further investigation. 
The effect of NS1 C-terminus on protein function seemed to be context-dependent (Figure 
4-18-B). Indeed, in the context of U/63, the C-terminal truncation (U/63-219) slightly 
increased NS1 control over the ISRE-containing promoter, particularly at middle and low 
doses (200ng, 20ng). However, when introduced in K/95 (K/95-219), no effect was 
observable at low dose (20ng) and a reduction of control was observable at middle and 
high doses (1000ng, 200ng) compared to WT (Figure 4-18-B). Finally, for O/03 NS1 no 
difference was observable for the ISRE-containing promoter, but it seemed to stimulate 
general gene expression at high dose (1000ng) (Figure 4-18-C). 
Of note, no synergistic effect between 186 substitution and C-terminal 
truncation/extension was observable in this assay. 
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Figure 4-18: Functional characterization of U/63, K/95 and O/03 NS1 186 and C-terminus 
mutants in HEK293T cells. 
 
As for Figure 4-7, HEK293T cells were transiently co-transfected with a pCAGGS expression plasmid 
(1000ng, 200ng, 20ng) encoding the indicated NS1 proteins (or empty plasmid), together with either 
(A) pIFN-b-FF-Luc (50ng), or (B) pISRE-FF-Luc (50ng), as well as with pREN-Luc (50ng). (A-B) 
Inducible promoters were activated, and the relative FF-Luc activities were determined as for Figure 
4-7. (C) HEK293T cells were transiently co-transfected with the indicated NS1-expression plasmids 
(1000ng, 200ng, 20ng) together with pREN-Luc (50ng), and total REN-Luc levels were determined as 
for Figure 4-7. (A-C) Bars correspond to mean of three independent experiments and error bars 
represent SEM, and significance was calculated as for Figure 4-7: (A and B) ****, p<0.0001 for 
pCAGGS+SeV or +uIFN versus all NS1 constructs and pCAGGS-SeV or –uIFN. (A) ££££, p<0.0001 
for U/63-WT & -219 versus U/63-E186K-containing NS1s; $, p< 0.05 for K/95-K186E versus K/95 WT 
& $$, p< 0.01 for K/95-K186E versus K/95-219; (B) £££ to £, p<0.0001 to p<0.05 for indicated dose of 
NS1 construct against similar dose of respective NS1 WT construct. $$, p<0.01 for O/03-K186E-230 
against O/03-K186E. (D) NS1 level of expression was analysed by Western blotting.  
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4.2.8. Impact of residue 186 and C-terminus on NS1-CPSF30 interaction 
 
Since, residue 186 is located in the middle of NS1-CPSF30 binding interface (185-
GLEWND-189), and this binding has previously been associated with the blockade of 
general gene expression (Ayllon and Garcia-Sastre, 2015, Hale et al., 2010a), it became 
evident to test if residue 186 was influencing NS1-CPSF30 interaction. To do so, co-
immunoprecipitation assays between an equine CPSF30 and the O/03 NS1 WT and mutants 
were performed (Figure 4-19). As suspected, the presence of E186 was associated with 
O/03 NS1 interaction with CPSF30, independently of the protein length.  
 
 
Figure 4-19: Evaluation of residue 186 as a determinant of NS1-CPSF30 interaction. 
 
The 4 O/03 NS1 variants were synthesized in vitro, and HEK293T cells were transiently transfected 
with 2000ng of a pCAGGS plasmid expressing a HA-tagged version of the human CPSF30. At 30 hpt, 
cells were lysed and cleared cell lysates expressing HA-CPSF30 were incubated overnight with the in 
vitro-synthesized NS1 proteins and 20 μl of an anti-HA affinity resin, as described in the method 
section. Precipitated proteins were dissociated from the resin and analysed by Western blotting. The 
experiment was repeated three times independently and representative pictures of protein expression 
levels (‘input’, left panel) and co-immunoprecipitation results (IP anti-HA, right panel) are shown. 
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4.3. Discussion 
 
In this chapter, the evolution of H3N8 EIV NS1 during fifty years of circulation of 
the virus in the equine population was studied. By analyzing the phylogenetic relationship 
of 175 NS1 genes of the EIV lineage (Figure 4-1), and by comparing the amino acid 
sequence of these proteins (Appendices 1 & 2), 15 amino acid changes fixed throughout 
evolution were identified: K44R, S48I, R59H, R67Q, E71K, V84I, A86T/V, A112T, E186K, 
V194I, P216S, R220*, A223E, S228P, V230I (Table 4-1). These findings correlated with 
previous reports from the literature identifying residue 67 (Murcia et al., 2011b) and 
substitution S228P and V194I (Murcia et al., 2011a) as point of selection pressure and host 
marker sites in the EIV genome, respectively. In addition, substitutions 44, 59, 71, 86, 216 
and C-terminal truncation were previously identified as genetic signatures of viruses of the 
Florida clades currently circulating in the equine population (Barba and Daly, 2016).  
 
Interestingly, apart from substitution K44R that reverted to the original amino acid 
(R44K), all changes were fixed at the population level (Table 4-1 & Figure 4-2). More 
importantly, the clades that did not introduce them died out shortly after separation from 
the main trunk (Figure 4-1 & 4-2). Although further work would be needed to determine 
their exact contribution to NS1 function, this suggests that these residue changes may play 
a role in EIV fitness and must have been selectively advantageous for the virus. In addition, 
other residue changes may have occurred at the population level and could have remained 
below the threshold of detection due to an insufficient number of virus isolates.  
 
Additionally, several mutations seemed to have occurred synchronously in the EIV 
population (i.e. A112T and E186K; R44K reversion and R59H, E71K, A86T, V230I 
substitutions; P216S substitution and R220*) (Figure 4-2). However, their role in NS1 
function and their impact on NS1 evolution remain uncertain. Their apparition could have 
been the result of the so-called ‘genetic hitchhiking’ (Morley and Turner, 2017), wherein a 
beneficial mutation sweeps to fixation and carries along any other neutral or mildly 
deleterious mutations occurring on the same genetic background. This is likely the case 
for E186K and A112T substitution, as residue 112 did not seem to affect NS1 function 
(Figure 4-13). Alternatively, two independent beneficial mutations may have occurred on 
the same genetic background and sweep to fixation together. Furthermore, if two or more 
of these mutations were beneficial in combination it could have driven genomes 
containing them to rise in frequency. It would be interesting to evaluate in which of these 
categories the high-frequency NS1 residue changes belong. 
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To move forward with the study of EIV NS1 function evolution, the ability of 13 
phylogenetically distinct NS1 proteins to block general gene expression, and to control 
type I IFN and ISG induction were tested using a reporter assay (Figure 4-8). It was 
observed that during the first 10 years post-emergence, EIV NS1 strongly repressed general 
gene expression (Figure 4-8-C), due to the presence of a glutamic acid at position 186 
(Figure 4-13-C & 4-18-C), which in turn allowed NS1 to interact with CPSF30 (Figure 4-19). 
These early NS1 proteins also displayed a relatively low repression on ISG induction (Figure 
4-8-B). The introduction of E186K substitution in the early 1970s led to a loss of shutoff of 
general gene expression (Figure 4-13-C & 4-18-C) due to a loss of CPSF30-binding (Figure 
4-19). These findings are in accordance with previous reports from the literature showing 
that specific substitutions destabilizing the NS1-CPSF30 complex were reported to arise 
when viruses adapted to replicate in certain host species, i.e. duck to quail (Hossain et 
al., 2008), or human to mouse (Brown et al., 2001). Also, other groups also reported 
several nonhuman-adapted virus strains (either through laboratory passages or natural 
selection) encoding NS1 proteins that lacked the ability to interact with CPSF30 (Hale et 
al., 2010b), i.e. the egg- and mouse-adapted PR8 (Hayman et al., 2006, Kochs et al., 
2007b), the highly pathogenic H5N1 and its presumed precursor H6N1 (Twu et al., 2007), 
and the swine-origin 2009pH1N1 (Hale et al., 2010b).  
The E186K substitution was also associated with an increased repression of ISG induction 
(Figure 4-8-B, 4-13-B). Interestingly, residue 186 is directly neighboring W187, known to 
regulate NS1 ED dimerization (Hale et al., 2008, Aramini et al., 2011, Kerry et al., 2011), 
and to strengthen dsRNA binding, thus reinforcing NS1 anti-IFN activity (Aramini et al., 
2011). This ED dimerization was also shown to be incompatible with the CPSF30 binding 
(Kerry et al., 2011). Thus, it is possible that the loss of CPSF30 binding ten years post 
emergence has allowed EIV NS1 to interact with new binding partners or unmasked or 
reinforced important functions that were selectively advantageous for the virus. 
However, the normalization used in these reporter assays was suboptimal. Indeed, the 
promoter of a control vector should be compatible with the experimental conditions and 
provide consistent expression under the experimental conditions being tested. To test 
NS1’s repression of IFN-b and ISRE promoters pREN-Luc was used for normalization (Figure 
4-8-A&B, 4-9-A&B, 4-13-A&B, and 4-18-A&B), but variability in NS1’s control over pREN-
Luc was notably observed between E186- versus K186-containing NS1 proteins (Figure 4-8-
C, 4-9-C, 4-13-C, and 4-18-C). Furthermore, no internal control was used when testing 
NS1’s control over general gene expression (Figure 4-8-C, 4-9-C, 4-13-C, and 4-18-C).  
For our transfection experiments, it would have been preferable to use an eukaryotic cell 
system expressing the T7 RNA polymerase and a T7 promoter control (Nogales et al., 
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2017). Indeed, this expression system is independent of the RNA pol II and is not 
controlled by NS1. 
 
Interestingly, the control over IFN-b induction was strongly maintained throughout 
evolution. More importantly, none of the amino acids described as important for this 
function were changed (apart from punctual changes) during EIV NS1 evolution, i.e. R38, 
K41, P31, D34, R35, R46, E97, E196, T5, G45, T49) (Wang et al., 1999, Talon et al., 2000, 
Pichlmair et al., 2006, Gack et al., 2009, Rajsbaum et al., 2012, Kuo et al., 2010). In 
addition, residues important for PKR inhibition were conserved during evolution, with 
some rare exceptions. This suggests that maintaining an NS1 protein with a strong control 
over IFN-b induction was selectively advantageous for EIV.  
Surprisingly, no specific control of IFN-b induction could be detected for the C-
terminal truncation, while it seemed to affect NS1 control over general gene expression 
and ISG induction (Figure 4-18-B & 4-18-C). This result in contradiction with previous 
reports from the literature showing that ponies experimentally infected with an EIV from 
2003, possessing a truncated NS1 protein, were producing higher levels of type I IFN than 
ponies infected with earlier strains containing a full length NS1 protein (Daly et al., 2011, 
Wattrang et al., 2003). Similar results were found with swine and turkey influenza viruses 
(Cauthen et al., 2007, Solorzano et al., 2005). This discrepancy could be due to the 
difference in methodology, or perhaps some differences could not be detected in an 
artificial reporter assay done in human HEK293T cells. 
Finally, residues controlling NS1 subcellular localization or important for the protein post-
translational modification or activation of the PI3K pathway were in vast majority 
conserved. Thus, these functions may be important for EIV NS1. In addition, this implies 
that we would not expect change in NS1 subcellular localization upon infection. 
 
Overall, the results of this chapter suggest that an emergent IAV relies on an NS1 
protein with strong abilities to repress general gene expression after inter-species jump, 
but as the virus evolves in its new host, it accumulates mutations in the NS1 gene and the 
ones that target specifically the cellular anti-viral response are positively selected, while 
the ones controlling shutoff of cellular gene expression are preferentially eliminated.  
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5. Impact of NS1 evolution on EIV infection phenotype 
 
5.1. Introduction 
 
Upon influenza virus infection, a variety of intracellular signalling pathways and vital 
cellular processes are activated. They are in part required to mount an antiviral response 
to infection, but they can also be exploited by the virus to support its replication (Ludwig 
et al., 2003, Ludwig et al., 2006). For example, the translation machinery remains 
competent for protein synthesis during an IAV infection and functional cellular mRNAs are 
still present in the cytoplasm of infected cells, however, the virus causes a switch from 
cellular to viral protein synthesis (Katze and Krug, 1984), and viral mRNAs are preferentially 
translated at the expense of cellular mRNAs (Garfinkel and Katze, 1993). The NS1 protein, 
which is expressed at high levels in infected cells (Krug and Etkind, 1973, Hutchinson et al., 
2014), plays a major role in this function. It has notably been described to enhance viral 
translation (de la Luna et al., 1995, Enami et al., 1994), and alter cellular gene expression 
during infection (including those of type I IFN and ISGs) by interfering with the function of 
CPSF30 (Nemeroff et al., 1998) and PABPII (Chen et al., 1999). NS1 has also been shown to 
act as a type I IFN antagonist at different stages during viral infection (Garcia-Sastre et al., 
1998) by blocking IRF-3, NF-kB, and c-Jun/ATF2 activation (Ludwig et al., 2002, Talon et 
al., 2000a, Wang et al., 2000), by repressing RIG-I (Mibayashi et al., 2007, Opitz et al., 2007, 
Pichlmair et al., 2006) and IPS-1 (Iwai et al., 2010), by inhibiting STAT1 and STAT2 
phosphorylation (Wang et al., 2017), or by interfering with the function of ISGs, such as PKR 
and the OAS/RNase L pathway (Hale et al., 2008, Min and Krug, 2006).  
A more recent addition to NS1 functions is the activation of PI3K (Ehrhardt et al., 2006), 
presumably by association with its regulatory subunits p85b. In eukaryotic cells, PI3K 
controls various cellular processes, such as cell growth, proliferation, and survival (Brazil et 
al., 2004, Cantley, 2002, Franke et al., 2003), and is involved in dsRNA-induced activation 
of IRF3 in infected cells (Sarkar et al., 2004). In doing so, IAV exploits the PI3K/Akt pathway 
to regulate virus-supportive functions, notably at later stages of viral replication to confers 
an anti-apoptotic signal via activation of Akt (Ehrhardt et al., 2006). Thus, despite initial 
work attributing to NS1 the capacity to promote apoptosis in infected cells (Schultz-Cherry 
et al., 2001), NS1 would prevent the premature induction of apoptosis via activation of PI3K, 
hence ensuring efficient replication for longer period (Ehrhardt et al., 2007, Hale et al., 
2006). Interestingly, an intact C-terminus downstream of position 125, as well as amino 
acids 181 to 185 seem to be important for this function (Ehrhardt et al., 2007). 
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NS1 is not absolutely essential for virus replication in cell culture, as viruses lacking 
the NS1 gene (delNS1) or carrying large C-terminal deletions of the protein are able to 
replicate efficiently in interferon incompetent systems (Bergmann et al., 2000, Garcia-
Sastre et al., 1998, Kochs et al., 2007b, Talon et al., 2000b, Nogales et al., 2014, Egorov et 
al., 1998). However, these viruses have are strongly attenuated in normal tissue culture 
cells (Egorov et al., 1998, Garcia-Sastre et al., 1998), which highlight the importance of NS1 
in virus-host cell interplay. Previous studies have also shown that the NS segment, encoding 
for the NS1 protein, impact on IAV pathogenesis (Vergara-Alert et al., 2014), and specific 
mutations in NS1 RBD, ED or PBM have been shown to affect viral replication (Ehrhardt et 
al., 2006, Ehrhardt et al., 2007, Hale et al., 2006, Shin et al., 2007a, Shin et al., 2007b, 
Shin et al., 2007c), and to modulate virulence in a strain- and host-dependent manner 
(Zielecki et al., 2010, Seo et al., 2002, Jiao et al., 2008, Li et al., 2006, Jackson et al., 
2008, Dankar et al., 2011, Soubies et al., 2010). More importantly, as little as one amino 
acid change in NS1 can significantly affect viral infection phenotype (Jackson et al., 2008, 
DeDiego et al., 2016, Steidle et al., 2010). 
 
A great deal of work has aimed at correlating strain-specific differences of NS1 
function with infection phenotype and virulence (reviewed in (Hale et al., 2008, Ayllon and 
Garcia-Sastre, 2015)). However, which specific NS1 mutations are preferentially selected 
during viral adaptation to a mammal, and how they affect virus infection phenotype remain 
unclear. 
 
 
Aims: The aims of this chapter were to confirm the role of the NS1 gene in EIV infection 
phenotype; to evaluate the impact of NS1 evolutionary markers on EIV infectivity in 
mammalian cells; and to identify which advantages are associated with NS1 evolutionary 
markers E186K and C-terminal truncation. 
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5.2. Results 
 
5.2.1. In vitro characterization of U/63 and O/03-WT and -NS reassortant 
viruses is mammalian cell lines 
 
In order to determine whether the NS segment, which encodes for the NS1 protein, 
was a determinant of EIV infection phenotype, an eight plasmid-based reverse genetics 
system was used to generate U/63 and O/03 viruses, as well as NS segment reassortant of 
these two viruses (U/63-NS O/03 and O/03-NS U/63), as described in Chapter 3, section 3.5. 
The genotype of each virus was checked after viral rescue as described in Chapter 3.5.4 
(Bavagnoli et al., 2015). A comparison of the replication efficiency of all viruses was carried 
out in MDCK and E.Derm cells, and their ability to spread between neighbouring cells 
(Hossain et al., 2008, Na et al., 2016) was also evaluated. 
 
 
5.2.1.1. Growth kinetics of U/63 and O/03-WT and -NS reassortant 
viruses in MDCK cells 
 
To compare the replication efficiency of U/63 and O/03 WT and NS reassortant 
viruses, MDCK cells were infected with each virus with 0.01 FFU/cell, or mock infected, and 
their growth kinetics was monitored over a 72h period.  
As shown in (Figure 5-1), U/63 WT displayed a high replication efficiency early post-
infection. Indeed, at 12 hpi the viral titre was already above 107 FFU/ml. U/63 maintained 
a similar titre for the following 36 h of infection (between 107 and 108 FFU/ml) after which 
it progressively declined to 106 FFU/ml at 72 hpi. In contrast, the growth rate of O/03 WT 
virus was slower, and increased progressively from 4 to 24 hpi, then peaked at 24 hpi at 109 
FFU/ml and maintained a similar titre for the remaining of the monitored time period.  
 
Interestingly, the introduction of O/03 NS segment into the U/63 backbone (U/63-
NS-O/03) was associated with a reduction in viral growth rate and the maintenance of a 
high titre for a longer period of time (Figure 5-1). Indeed, at 12 hpi the U/63-NS-O/03 
reassortant virus was two logs lower than its WT counterpart (105 FFU/ml versus 107 FFU/ml, 
respectively), but it reached a higher titre between 24 and 72 hpi (up to 2 logs higher than 
WT). In contrast, the introduction of the U/63 NS segment into the backbone of O/03 (O/03-
NS-U/63) did not significantly affect O/03 viral growth, as O/03-NS-U/63 reassortant virus 
showed a similar growth pattern as its WT counterpart. 
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Figure 5-1: Growth kinetics of U/63 and O/03-WT and -NS swap mutants in MDCK cells. 
 
MDCK cells were infected with U/63 and O/03-WT and -NS swap mutant viruses (0.01 FFU/cell), and 
viral growth kinetics were determined by measuring virus titres in supernatants at indicated times post-
infection. Bars correspond to mean of three independent experiments and error bars represent SEM. 
Significance was calculated by Two-way ANOVA followed by Bonferroni's multiple comparisons test. 
***, p<0.001 for U/63-WT and U/63-NS-O/03 versus O/03-WT and O/03-NS-U/63; **, p<0.01 for U/63-
WT versus O/03-WT. The number of infectious particles inoculated (at 0h) is indicated by a dotted line. 
 
 
5.2.1.2. Plaque phenotype of U/63 and O/03-WT and -NS reassortant 
viruses in MDCK cells 
 
The ability of WT and NS reassortant mutant viruses to spread between neighbouring 
cells was then evaluated in MDCK cells at 48 hpi (Figure 5-2). It was observed that O/03-WT 
was able to spread from cell-to-cell more efficiently than the three other viruses. Indeed, 
the mean in O/03-WT plaque size was 12mm2 in diameter compared to 3mm2 for U/63-WT 
and both NS reassortant viruses. 
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Figure 5-2: Plaque phenotype of U/63 and O/03-WT and -NS swap mutants in MDCK cells. 
 
(A) Plaque phenotype of U/63 and O/03-WT and -NS swap mutant viruses were determined in MDCK 
cells at 48 hpi. A representative picture of three independent experiments is shown. (B) The average 
plaque size of each virus was measured by counting 100 plaques per conditions. Dots represent 
individual plaque size, bars correspond to mean, and error bars represent SEM. Significance was 
calculated as for Figure 5-1, with ****, p<0.0001 between O/03-WT and the three other viruses. 
 
 
5.2.1.3. Growth kinetics of U/63 and O/03-WT and -NS reassortant 
viruses in E.Derm cells 
 
When the replication efficiency of WT and NS reassortant viruses was compared in 
equine cells (Figure 5-3), it was noticed that O/03-WT grew to significantly higher titre than 
the three other viruses. This virus produced an increasing number of infectious particles 
from 4 to 24 hpi, and reached the infection peak at 24 hpi at 107 FFU/ml. This virus also 
maintained a titre above 106 FFU/ml for the 72 hpi monitored.  
In contrast, U/63-WT only reached 104 FFU/ml (level of inoculum) at 24 hpi and maintained 
a similar titre for the remaining 48 hpi.  
The introduction of O/03 NS segment in U/63 backbone did not affect the growth pattern 
of U/63, as previously observed in MDCK cells (Figure 5-1).  
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Interestingly, in these cells the introduction of U/63 NS segment in O/03 backbone strongly 
affected O/03 viral replication efficiency. This was particularly evident between 24 and 72 
hpi, where the titre of O/03-NS-U/63 reassortant virus remained two logs lower than WT 
(between 105 FFU/ml and 104 FFU/ml). 
 
 
Figure 5-3: Growth kinetics of U/63 and O/03-WT and -NS swap mutants in E.Derm cells. 
 
E.Derm cells were infected with U/63 and O/03-WT and -NS swap mutant viruses (0.1 FFU/cell), and 
viral growth kinetics were determined by measuring virus titres in the cell supernatant at indicated times 
post-infection. Bars correspond to mean of three independent experiments and error bars represent 
SEM. Significance was calculated as for Figure 5-1. ***, p<0.001 and **, p<0.001 for O/03-WT versus 
the three other viruses. The number of infectious particles inoculated (at 0h) is indicated by a dotted 
line. 
 
 
Taken together these results confirmed that the NS segment, encoding for the NS1 
protein, is a determinant of EIV infection phenotype. Furthermore, the effect of NS 
reassortment on viral growth kinetics and cell-to-cell spread seemed to be viral context- 
and cell type-dependent.  
 
 
5.2.2. In vitro characterization of U/63 and O/03-WT and NS1 mutants in 
mammalian cells 
 
5.2.2.1. Introduction of codon 186 and 220 mutations in U/63 and O/03 
NS segment 
 
The NS segment of U/63 and O/03 possess a total of thirty different nucleotides, 
which result in three different amino acids for NEP, and twelve for NS1. In addition, U/63 
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expresses a full-length NS1 (230 amino acids), while O/03 expresses a truncated version of 
the protein (219 amino acids) (Appendix 31). Thus, to discriminate between these 
differences, and evaluate the role of NS1 residue 186 and C-terminus on EIV infection 
phenotype, a more targeted approach was necessary. The use of a reverse genetic system 
in association with a site-directed mutagenesis approach allowed the generation of isogenic 
mutants of U/63 and O/03 for NS1 codon 186 and 220 (Chapter 3, section 3.1.8 and 3.5.3). 
Briefly, U/63-E186K-containing mutants (U/63-E186K and U/63-E186K-219) were generated 
by changing NS1 codon 186 for ‘GAA’ to ‘AAA’ in the NS segment (Figure 5-4, Appendix 32). 
In a similar fashion, U/63-219-containing mutants (U/63-219 and U/63-E186K-219) were 
generated by changing NS1 codon 220 from ‘CGA’ to ‘TGA’. The opposite mutations were 
introduced in O/03 NS segment to generate O/03-K186E-containing mutants (O/03-K186E 
and O/03-K186E-230), and O/03-230 mutants (O/03-230 and O/03-K186E-230) (Figure 5-5, 
Appendix 33). None of the introduced mutations affected the NEP open reading frame 
(Appendices 34).  
The growth kinetics and plaque phenotype of U/63 and O/03 WT and NS1 mutant viruses 
was then carried out in MDCK and equine cells.  
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Figure 5-4: Generation of U/63 NS mutants for residue 186 and C-terminus. 
 
In a similar fashion to Figure 4-10, (A) the NS segment of WT, single or double mutant viruses were 
sequenced by Sanger sequencing and the corresponding traces are shown. (B) The size of each 
segment (890bp) were checked. 
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Figure 5-5: Generation of O/03 NS mutants for residue 186 and C-terminus. 
 
In a similar fashion to Figure 4-10, (A) the NS segment of WT, single or double mutant viruses were 
sequenced by Sanger sequencing and the corresponding traces are shown. (B) The size of each 
segment (890bp) were checked. 
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5.2.2.2. Growth kinetics of U/63 and O/03-WT and mutants in MDCK cells 
 
As shown in (Figure 5-6), U/63 NS1 single and double mutants showed differences in 
growth kinetics in MDCK cells compared to their WT counterpart. These differences were 
particularly marked at 12, 16, 48 and 72 hpi. Indeed, the titre of mutant viruses were 3 to 
4 logs lower than WT at 12 and 16 hpi (103 and 105 FFU/ml for E186K mutants versus 107 and 
108 FFU/ml for WT), while being 2 logs higher than WT between 48 and 72 hpi (109 and 108 
FFU/ml for E186K mutants versus 107 and 106 FFU/ml for WT, respectively).  
The titre of U/63 E186K-containing mutant viruses also peaked 24 h later than WT (48 versus 
24 hpi, respectively), but the mutant viruses reached a higher titre at the peak of infection 
(109 FFU/ml for E186K-containing mutants versus 108 FFU/ml for WT).  
The U/63-219 mutant showed an intermediate phenotype. Indeed, between 12 and 16 hpi 
U/63-219 titre was 2 logs higher than E186K-containing mutants (105 and 107 FFU/ml versus 
103 and 105 FFU/ml, respectively), but remained 2 logs lower than WT (105 and 107 FFU/ml 
versus 107 and 108 FFU/ml, respectively). In addition, U/63-219 titre peaked 24 h later and 
1 log higher than WT (109 FFU/ml versus 108 FFU/ml, respectively). 
 
 
Figure 5-6: Growth kinetics of U/63-WT and mutant viruses in MDCK cells. 
 
MDCK cells were infected with U/63-WT and mutant viruses (0.01 FFU/cell), and viral growth kinetics 
were determined as for Figure 5-2. Bars correspond to mean of three independent experiments and 
error bars represent SEM. Significance was calculated as in Figure 5-1, and **, p<0.01 for U/63-WT 
versus the three other viruses. The number of infectious particles inoculated (at 0h) is indicated by a 
dotted line. 
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When the growth rate of O/03-WT and mutant viruses was compared, different 
results were obtained. Indeed, the single introduction of E186K substitution or C-terminal 
extension in NS1 did not significantly affect O/03 replication efficiency in MDCK cells (Figure 
5-7). However, when introduced together, NS1 K186E and C-terminal extension strongly 
modified the replication pattern of O/03. The double mutant virus (O/03-K186E-230) grew 
faster than WT and reached a higher titre than any other viruses at 12 hpi (107 FFU/ml). 
Then, the virus titre plateaued between 12 and 72 hpi (at 107 and 108 FFU/ml). Interestingly, 
this virus never reached a titre as high as the three other viruses during the entire course 
of infection. 
 
 
Figure 5-7: Growth kinetics of O/03-WT and mutant viruses in MDCK cells. 
 
MDCK cells were infected with O/03-WT and mutant viruses (0.01 FFU/cell), and viral growth kinetics 
were determined as for Figure 5-2. Bars correspond to mean of three independent experiments and 
error bars represent SEM. Significance was obtained as for Figure 5-1. ***, p<0.001 for O/03-K186E-
230 versus all the three other viruses, and £££, p<0.001 for O/03-K186E-230 versus O/03-WT. The 
number of infectious particles inoculated (at 0h) is indicated by a dotted line. 
 
 
5.2.2.3. Plaque phenotype of U/63 and O/03-WT and mutants in MDCK 
cells 
 
The capacity of isogenic mutants to spread between neighbouring cells was then 
compared to WT. As shown below, U/63 mutant viruses displayed similar plaque phenotypes 
than WT (Figure 5-8). 
 
4h 8h 12h 16h 24h 48h 72h
100
101
102
103
104
105
106
107
108
109
1010
1011 O/03 WT
O/03 K186E
O/03 230
O/03 K186E 230
PF
U
/m
l (
Lo
g1
0)
Time post-infection (hpi)
inoculum
O/03-WT
O/03-K186E
O/03-230
O/03-K186E-230
£££
***
Chapter 5 - Impact of NS1 evolution on EIV infection phenotype 
 
 131 
 
Figure 5-8: Plaque phenotype of U/63-WT and mutant viruses in MDCK cells. 
 
(A) Plaque phenotype of U/63-WT and mutant viruses was determined in MDCK cells at 48 hpi. A 
representative picture of three independent experiments is shown. (B) The average plaque size of each 
virus was measured as for Figure 5-3. Dots represent individual plaque size, bars correspond to mean, 
and error bars represent SEM. Significance was calculated as for Figure 5-1, *, p<0.05 for U/63-WT 
versus the three mutant viruses. 
 
 
However, in the case of O/03, K186E substitution and/or C-terminal extension 
affected cell-to-cell spread in MDCK cells (Figure 5-9). Indeed, all mutant viruses displayed 
smaller plaque sizes than WT, and the most dramatic effect was observed with the double 
mutant virus (O/03-K186E-230). 
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Figure 5-9: Plaque phenotype of O/03-WT and mutant viruses in MDCK cells. 
 
(A) Plaque phenotype of O/03-WT and mutant viruses was determined in MDCK cells at 48 hpi. A 
representative picture of three independent experiments is shown. (B) The average plaque size of each 
virus was measured as for Figure 5-3. Dots represent individual plaque size, bars correspond to mean, 
and error bars represent SEM. Significance was calculated as for Figure 5-1. ****, p<0.0001 for O/03-
WT versus all other viruses; *, p<0.05 for O/03-K186E-230 versus O/03-K186E. 
 
 
5.2.2.4. Growth kinetics of U/63 and O/03-WT and mutants in E.Derm 
cells 
 
When growth of WT and mutant viruses was compared in E.Derm cells (Figure 5-10), 
it was observed that E186K substitution and/or C-terminal truncation of NS1 of U/63 did not 
improve viral growth rate, and after 24 hpi, it even seemed to reduce it as all mutant virus 
titres were 1 to 2 logs lower than WT (between 103 and 102 FFU/ml for mutant viruses versus 
104 FFU/ml for WT).  
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Figure 5-10: Growth kinetics of U/63-WT and mutant viruses in E.Derm cells. 
 
E.Derm cells were infected with U/63-WT and mutant viruses (0.1 FFU/cell), and viral growth kinetics 
were determined as for Figure 5-4. Bars correspond to mean of three independent experiments and 
error bars represent SEM. Significance was calculated as for Figure 5-1. ****, p<0.0001 for U/63-WT 
versus the mutant viruses. The number of infectious particles inoculated (at 0h) is indicated by a dotted 
line. 
 
 
In the context of O/03, all mutations introduced affected viral replication efficiency 
(Figure 5-11). The most dramatic effect was observed for O/03-E186K single mutant, which 
did not seem to grow (titres below 102 FFU/ml for the 72h of infection). In addition, viruses 
expressing full length NS1 proteins (O/03-230 and O/03-K186E-230) grew to similar titres 
than WT during the first 16 hpi (from 102 to 104 FFU/ml), after which their titres declined 
(104 to 102 FFU/ml). 
 
 
Figure 5-11: Growth kinetics of O/03-WT and mutant viruses in E.Derm cells. 
 
E.Derm cells were infected with O/03-WT and mutant viruses (0.1 FFU/cell), and viral growth kinetics 
were determined as for Figure 5-4. Bars correspond to mean of three independent experiments and 
error bars represent SEM. Significance was obtained as for Figure 5-1, ***, p<0.001 and **, p<0.01 
between O/03-WT and the three other viruses. The number of infectious particles inoculated (at 0h) is 
indicated by a dotted line. 
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Taken together these results confirmed the importance of NS1 and the nature of 
residue 186 and the C-terminal tail length on EIV infection phenotype. Moreover, they 
confirmed that NS1 impact on EIV growth kinetics and plaque phenotype in a different 
manner depending on the viral background and the cell type used.  
 
 
5.2.3. Impact of K186E and C-terminal extension on EIV control of infected 
cells 
 
To study in more details the role of NS1 amino acid 186 and C-terminal tail on virus-
host interaction, O/03 viruses were selected. First the ability of O/03-WT and mutant 
viruses to shutdown total protein production upon infection was evaluated. Protein 
shutdown upon infection was also compared to viral protein production, total antiviral 
cytokines production in cell supernatant, as well as expression of ISGs and induction of 
apoptosis during infection in equine cells. Finally, the replication efficiency of these four 
viruses was compared in equine cells either pre-exposed to type I IFN or after having blocked 
the cellular response to type I IFN by a chemical approach. 
 
 
5.2.3.1. Shutdown of general protein production upon infection 
 
To determine the effects of NS1 K186E and C-terminal extension on O/03 ability to 
control cellular protein synthesis, puromycin assays were performed at various times post-
infection in equine cells, as described in Chapter 3, section 3.6. Under appropriate 
conditions, puromycin can be incorporated at the C-terminus of all nascent proteins in 
eukaryotic cells ((Tabuchi, 2003)). After cell lysis, an immunoblotting against puromycin 
can performed and allows the detection of nascent proteins that were being produced at 
the moment of cell lysis. Total protein production will appear as a black smear, and the 
darker and longer the smear is, the more proteins were being produced at the moment of 
cell lysis. 
As shown in (Figure 5-12), only the double mutant virus induced a strong protein shutoff 
upon infection. This was particularly marked at 8 and 12 hpi. While this result is consistent 
with E186 playing an important role in blocking general gene expression via a CPSF30-
dependent mechanism (Chapter 4), it also suggests that a complementary role of NS1 C-
terminus might be necessary to induce a strong protein shutoff in equine cells, as O/03-
K186E did not strongly block protein synthesis at any time post infection. However, we 
cannot rule out the possibility that O/03-K186E’s lack of protein shutoff was due to a low 
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level of infection or expression of NS1, as this virus was strongly attenuated in equine cells. 
Interestingly, O/03-WT induced a significant increase in protein synthesis at 12 hpi, and a 
low but significant protein shutoff at 24 hpi 
 
 
Figure 5-12: Protein shutoff in E.Derm cells upon infection with O/03 WT and mutant 
viruses. 
 
E.Derm cells were infected with O/03-WT and mutant viruses (0.1 FFU/cell). (A) At the indicated time 
points, culture media were replaced with a puromycin-containing suspension and incubated for 1h. The 
cells were then lysed and immunoblotted for puromycin, as described in the methods section. Gamma 
tubulin was used as a loading control. The experiment was repeated three times independently and a 
representative picture of each western blot is shown. The quantification of the puromycin signal 
expressed relatively to mock has been obtained for three independent experiments, as described in the 
method section. Significance was obtained as in Figure 5-1. At 8 hpi: £££, p<0.001 for O/03-K186E-
230 versus mock and O/03-WT; ££, p<0.01 for O/03-K186E-230 versus O/03-K186E; £, p<0.05 for 
O/03-K186E-230 versus O/03-230. At 12 hpi: ***, p<0.001 for O/03-WT versus all other conditions. $, 
p<0.05 for O/03-K186E-230 versus O/03-K186E and $$$, p<0.001 for O/03-K186E-230 versus O/03-
230 and mock, respectively. At 24 hpi: *, p<0.05 for O/03-WT and O/03-K186E-230 versus mock and 
O/03-K186E. (B) Cells of parallel samples were collected, fixed in formalin and immunostained for the 
NP viral protein, as described in the method section. The percentage of infected cells and cell viability 
for each condition was then determined by flow cytometry. Significance was obtained as previously 
described and ****, p<0.0001 for O/03-WT versus all other conditions. Bars correspond to mean of three 
independent experiments and error bars represent SEM.  
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To rule out the possibility that differences in protein shutoff were due to different 
levels of infection, the number of E.Derm cells expressing the viral nucleoprotein (NP) was 
analysed by flow cytometry at 8, 12 and 24 hpi, as described in Chapter 3, section 3.5.7. As 
seen in (Figure 5-12-B), a comparable percentage of cells were infected with WT and mutant 
viruses at 8 and 12 hpi. At 24 hpi, a greater proportion of cells were expressing the viral NP 
upon O/03-WT infection, which confirms that this virus was more infectious than mutants 
in E.Derm cells (Figure 5-11). 
 
 
5.2.3.2. Cellular response to viral infection 
 
To compare WT and mutant virus abilities to limit the establishment of a cellular 
antiviral state upon infection, E.Derm cells were infected (0.1 FFU/cell) with WT and 
mutant viruses, or mock infected, and the level of expression of ISG15 and Mx1 was 
evaluated, as described in Chapter 3, section 3.8. Since the establishment of an antiviral 
state is associated with induction of apoptosis, the expression of both total and cleaved 
caspase 3 was evaluated by western blot at different times post infection. In addition, the 
level of expression of the NP and NS1 proteins were also monitored.  
Interestingly, ISG15 and Mx1 were detected in cell lysates upon infection with both O/03-
230 and O/03-K186E-230 mutant viruses, but not WT (Figure 5-13) at 24 and 48 hpi. 
Surprisingly, these proteins were not detected in cells infected with O/03-K186E. 
When the level of apoptosis was compared in WT and mutant virus-infected cells, it was 
observed that cleaved caspase 3 was already detectable at 24 hpi in cells infected with the 
double mutant of O/03 as well as with O/03-230. Instead, apoptosis induction was 
detectable 24 h later during O/03-WT infection. Of note, no apoptosis induction upon O/03-
K186E mutant infection was detected. 
High levels of NS1 and NP proteins were also detected in cells infected with O/03-double 
mutant between 8 and 24 hpi. In O/03-WT-infected cells NP was detected at 24 and 48 hpi, 
and NS1 could only be detected at 48 hpi. Of note, no viral protein could be detected for 
O/03-K186E single mutant virus. 
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5.2.3.3. Production of antiviral cytokines upon infection 
 
To assess whether the IFN system was the limiting factor of O/03 mutant virus 
replication, the antiviral activity of the supernatant of equine cells infected with the 
different viruses were measured at several time points post infection using a VSV-GFP-based 
bioassay (Martinez-Sobrido et al., 2006) (Chapter 3, section 3.6). Antiviral cytokine 
production was also compared with viral growth kinetics (Figure 5-14).  
Surprisingly, the highest level of antiviral cytokines was detected upon O/03-WT infection, 
peaking at 24 hpi (Figure 5-14-A). This did not seem to affect virus growth since this virus 
reached rapidly a very high titre (107 FFU/ml at 24 hpi).  
The pattern of antiviral cytokine production upon O/03-230 and O/03-K186E-230 infection 
(Figure 5-14-C & -D) were very similar. Indeed, in both cases low levels of antiviral cytokines 
were produced, and this was associated with viral growth, although at a much lower level 
than O/03-WT. In contrast, in cells infected with O/03-K186E mutant virus, a relatively high 
peak of antiviral cytokines was detected at 8 hpi, and no viral growth was measured (Figure 
5-14-B). 
 
 
Figure 5-14: Comparison of growth kinetics and production of antiviral cytokine in equine 
cells infected with O/03 WT and mutant viruses.  
 
E.Derm cells were infected (0.1 FFU/cell) for 72h with (A) O/03-WT, (B) -K186E, (C) -230, and (D) -
K186E-230. Supernatants were collected, and cells fixed at indicated times pi. The total amount of 
antiviral cytokines produced upon infection was measured using an IFN bioassay and virus growth was 
determined by immunofocus assay. Error bars represent SEM. Significance was calculated as for 
Figure 5-1. ****, p<0.0001 for antiviral cytokine production upon infection with indicated viruses at 
indicated time pi compared to all other conditions. £, p<0.05 and ££, p<0.01 for antiviral cytokine 
production upon infection with indicated viruses at indicated time pi compared to WT. 
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5.2.4. Evaluation of WT and mutant virus replication efficiency after blockade 
of the cellular response to type I IFN 
 
To confirm the role of the IFN pathway in limiting O/03 NS1 mutant replication, 
E.Derm cells were treated with Ruxolitinib (JAK inhibitor) for 24h prior to infection (Stewart 
et al., 2014) (Chapter 3, section 3.5.8). The number of infected cells (Figure 5-15-A) and 
the growth kinetics of each virus in the presence of Ruxolitinib (Figure 5-15-C) were 
monitored.  
Interestingly, in the presence of Ruxolitinib, all viruses replicated to similar titres, and 
infected a growing number of cells. Surprisingly, the number of cells infected with the 
double mutant virus was significantly higher at early time points post infection compared 
to the three other viruses. These results confirmed the central role of the type I IFN pathway 
in limiting viral replication of mutant viruses in equine cells. 
 
 
Figure 5-15: JAK inhibition restores growth kinetics of O/03 NS1 mutant viruses. 
 
E-derm cells were treated for 24h with 4uM Ruxolitinib prior to infection (0.1 FFU/cell) with O/03-WT, -
K186E, -230, and -K186E-230. Cells and supernatants were collected at different times post-infection. 
(A) Percentage of infected cells and cell viability was determined by flow cytometry. (B) Viral titers were 
measured as described in Methods. Bars correspond to mean of three independent experiments and 
error bars represent SEM. Significance was calculated as for Figure 5-1. ****, p<0.0001 for indicated 
virus at indicated time post infection versus all other conditions at the same time post infection. 
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5.2.5. Evaluation WT and mutant virus replication efficiency in type I IFN 
primed-equine cells 
 
To confirm the importance of NS1 evolutionary markers K186 and C-terminal 
truncation, for efficient viral replication in the presence of type I IFN, E.Derm cells were 
pre-treated with Universal IFN for 24 h prior to infection (0.1 FFU/cell). As done previously, 
viral replication and percentage of infected cells were monitored for 72 h (Chapter 3, 
section 3.5.7 and 3.5.8).  
While all viruses exhibited a reduction in viral growth (Figure 5-16-A), only the WT virus 
managed to infect an increasing number of cells (Figure 5-16-A) and produce an increasing 
quantity of infectious particles (Figure 5-16-B) in IFN-primed cells.  
 
 
Figure 5-16: Growth kinetics of O/03 WT and NS1 mutant viruses in universal IFN-primed 
equine cells. 
 
E.Derm cells were treated for 24h with universal IFN prior to infection (0.1 FFU/cell) with O/03-WT, -
K186E, -230, and -K186E-230. Cells and supernatants were collected at different times post-infection. 
(A) Percentage of infected cells and cell viability was determined by flow cytometry. (B) Viral titres were 
measured as described in Methods. Bars correspond to mean of three independent experiments and 
error bars represent SEM. Significance was calculated as for Figure 5-1. ****, p<0.0001 for indicated 
virus at indicated time post infection versus all other conditions at the same time post infection. 
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5.3. Discussion 
 
In this chapter, the effect of NS1 on EIV infection phenotype was evaluated. First, it 
was demonstrated that the NS segment, encoding the NS1 protein, affected EIV replication 
efficiency and cell-to-cell spread in mammalian cells. To do so, viral growth kinetics and 
plaque phenotype of WT and NS reassortant of U/63 and O/03 viruses were compared in 
MDCK and E.Derm cells. It was shown that the WT viruses displayed differences in growth 
kinetics (Figure 5-1 & -3) in both cell lines and plaque phenotype in MDCK cell (Figure 5-2). 
Although U/63-WT grew poorly in E.Derm cells (Figure 5-3), it replicated at high rate in 
MDCK cells and reached its peak of infection earlier (although at a lower titre) than O/03-
WT (Figure 5-1). In contrast, O/03-WT grew more progressively and reached high titres in 
both cell lines (Figure 5-1 & -3). In addition, O/03-WT displayed larger plaques than U/63-
WT in MDCK cells (Figure 5-2). Interestingly, reassortment of U/63 and O/03 NS segments 
modified these infection phenotypes. Furthermore, the effect was dependent on the viral 
context- and the cell type. Indeed, introduction of O/03 NS segment into U/63 backbone 
only changed U/63 growth pattern in MDCK cells (Figure 5-1), while its plaque phenotype 
(Figure 5-2) and growth kinetics were mostly unchanged in E.Derm cells (Figure 5-3). In 
contrast, O/03 growth pattern in E.Derm cells (Figure 5-3) and plaque phenotype in MDCK 
cells (Figure 5-2) were strongly affected by the NS segment reassortment, while its growth 
kinetic in MDCK cells was maintained (Figure 5-1). These results are in accordance with 
Shelton et al.’s work, who studied the replication capacity of NS reassortants between the 
human 2009pH1N1 virus and a human seasonal H3N2 virus, two viruses that express a short 
non-CPSF30 binder NS1 protein and a full-length NS1 that interacts with CPSF30, 
respectively (Shelton et al., 2012). They showed that the introduction of the H3N2 NS 
segment into the p2009pH1N1 virus reduced the replication efficiency of the latter in an IFN 
competent model. In addition, Twu and colleagues showed that the replication efficiency 
and plaque phenotype of an IAV expressing an NS1 protein that binds CPSF30 was strongly 
affected in MDCK cells when this binding was altered (Twu et al., 2006). Other reports have 
also described that for other IAVs, the two NS1 proteins could be swapped without affecting 
viral growth between (Kim et al., 2014). This further reinforce the hypothesis of species-
specific functions of NS1. 
 
To study in more details the effect of NS1 evolutionary markers on EIV infection 
phenotype, three isogenic mutants for U/63 and O/03 viruses carrying a mutation at codon 
186 and/or codon 220 (Figure 5-4 & -5) in their respective NS segment –were generated. By 
comparing the replication efficiency and plaque phenotype (Figure 5-8 & -9) of mutant and 
WT viruses in MDCK (Figure 5-6 & -7) and E.Derm cells (Figure 5-10 & -11), it was confirmed 
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that the introduced mutation affected viral growth and cell-to-cell spread in a viral context- 
and cell type-dependent manner. Indeed, in MDCK cells substitution E186K resulted in a 
strong reduction of U/63 replication rate, a delay in the peak of infection, and an increase 
in virus titre at the peak of infection (Figure 5-6). However, in the context of O/03, K186E 
substitution did not change viral growth kinetic (Figure 5-7).  
Furthermore, the plaque phenotype of U/63 did not seem to be affected by residue 186 
(Figure 5-8). In contrast, K186E substitution significantly reduced O/03 plaque size (Figure 
5-9). Furthermore, in E.Derm cells E186K substitution did not improve U/63 viral growth 
kinetics (Figure 5-10), but significantly reduced O/03 growth abilities (Figure 5-11). These 
findings are in accordance with the results obtained earlier with the NS reassortant viruses 
(Figure 5-1). Taken together, these data seem to indicate that in cells that do not possess 
an efficient antiviral response, like MDCK cells (Seitz et al., 2010), an avian-like virus such 
as U/63 can tolerate mutations in the NS1 gene that alter important functions of the protein, 
such as the CPSF30 binding. It is possible that other functions of NS1 or other viral proteins 
may compensate for the loss of CPSF30 binding of U/63 and allow the virus to maintain 
fitness in cells permissive for influenza virus. However, the results shown above also 
highlight that by losing the CPSF30 binding, U/63 lost the capacity to quickly take control 
of infected cells and rapidly produce new virions, a characteristic that would likely provide 
a great advantage when jumping hosts. In contrast, for a mammalian-adapted virus, like 
O/03, viral fitness seems to strongly depend on NS1 and on the maintenance of its 
evolutionary markers, E186K and C-terminal truncation. The gain of a new NS1 activity 
(CPSF30 binding) may have disrupted the subtle virus-host equilibrium, leading to 
attenuation of the virus in interferon competent E.Derm cells. This hypothesis is reinforced 
by the work of others showing that destabilisation of NS1-CPSF30 complex may arise during 
the adaptation process of IAV strains to certain hosts (i.e. duck to quail, human to mouse) 
(Hayman et al., 2006, Kochs et al., 2007a, Twu et al., 2007, Brown et al., 2001, Hossain et 
al., 2008).  
Interestingly, as commented earlier (Chapter 1 section 1.3.1), the surface involved in NS1 
ED dimerization is also involved in CPSF30 binding (Hale et al., 2008), and previous work has 
reported that the disruption of ED-ED interaction by substitution of W187 (direct neighbour 
of residue 186) resulted in attenuation of a recombinant PR8 virus in vivo (Ayllon et al., 
2012). The ED dimerization has been shown to play a key role in reinforcing the dsRNA 
binding of NS1, hence reinforcing NS1’s control of the host IFN response. It is possible that 
restoring the CPSF30 binding in O/03 NS1 has disrupted more important functions that are 
crucial to support viral replication in IFN competent cells. Additionally, the presence of 
E186 in O/03 NS1 seemed to have a high fitness cost in equine cells when introduced in the 
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context of a short NS1 protein, as O/03-K186E replicated poorly in equine cells compared 
to the O/03-K186E-230 mutant (Figure 5-11). This could indicate that the potential new 
functions provided by the extension of O/03 NS1 C-terminal tail, e.g. PABPII binding or 
interaction with PDZ-containing proteins, could partially compensate for fitness cost 
associated with the reintroduction of CPSF30 binding.  
 
The modification of NS1 C-terminus on its own seemed also to affect EIV infection 
phenotype, although to a lesser extent than substitution 186. Indeed, the U/63 NS1 
truncated mutant virus (U/63-219) displayed a reduced growth rate compared to WT in 
MDCK cells (Figure 5-6). The growth pattern of U/63-219 resembled the one of U/63-NS-
O/03 reassortant virus (Figure 5-1). Furthermore, as for residue 186 substitution, the 
truncation of NS1 did not seem to affect U/63 plaque phenotype (Figure 5-8), nor improve 
viral replication in E.Derm cells (Figure 5-10).  
In the context of an adapted virus, like O/03, NS1 C-terminal extension alone strongly 
affected viral replication in interferon competent cells (Figure 5-11), as well as viral spread 
between neighbouring cells (Figure 5-9). This extension had even more dramatic effects 
when introduced in association with K186E substitution (Figure 5-7, -9 & -11). Taken 
together, these data suggest that introduction or suppression of the CPSF30 binding had 
bigger consequences on viral fitness than a PBM or PABPII binding sites.  
 
When the response of equine cells to O/03 WT and mutant virus infection was 
assessed, it was observed that only the WT virus was able to replicate to high titres (Figure 
5-11) in the presence of high levels of antiviral cytokines (Figure 5-14-A). Moreover, the 
O/03-230 and O/03-K186E-230 mutant viruses seemed to be able to control better than WT 
the production of antiviral cytokines upon infection (Figure 5-14-C & -D). These results are 
in accordance with a previous report from Daly & colleagues, who showed that ponies 
infected with an EIV from 2003 expressing a truncated version of NS1 
(A/equine/Newmarket/5/2003) was inducing larger amounts of type I IFN than an EIV 
expressing a full length version of NS1 (A/equine/Sussex/1/1989) (Daly et al., 2011, 
Wattrang et al., 2003). Of note, similar results were found with swine and turkey influenza 
viruses (Cauthen et al., 2007, Solorzano et al., 2005). Additionally, others reported that 
decreasing NS1-mediated inhibition of host gene expression correlated with increased 
innate immune responses after infection (Twu et al., 2007, Hale et al., 2010).  
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The O/03-WT virus was also able to infect an increasing number of cells and replicate 
in equine cells primed with universal IFN (Figure 5-16). The ability to replicate in the 
presence of type I IFN is a significant fitness trait, as it renders an important arm of the 
host antiviral response ineffective. Moreover, K186 and C-terminal truncation seemed to be 
detrimental in this process. Interestingly, no Mx1 and ISG15 expression could be detected 
upon O/03-WT infection in equine cells (Figure 5-13) despite the presence of large amounts 
of antiviral cytokines secreted (Figure 5-14). This suggests that O/03-WT was able to repress 
ISG expression, although further work would be needed to determine the mechanism 
involved. Furthermore, the role of the JAK/STAT pathway in limiting viral replication of 
O/03-NS1 mutant viruses in E.Derm cells was confirmed with the use of Ruxolitinib prior to 
viral infection (Figure 5-15).  
 
Finally, when looking at protein production upon infection it was observed that O/03-
K186E-230 induced a cellular protein shutdown, particularly at early times post infection 
(Figure 5-12). This was associated with a premature induction of apoptosis compared to WT 
(Figure 5-13). This was followed by expression of Mx1 and ISG15 starting at 24 hpi and 
increasing at 48 hpi (Figure 5-13). The extension of NS1 C-terminus on its own also increased 
ISG proteins expression compared to WT and resulted in early induction of apoptosis in 
infected cells (Figure 5-13). However, similarly to WT no protein shutdown was detectable 
for the O/03-230 mutant virus (Figure 5-12). These results are in accordance with data 
obtained by others (Golebiewski et al., 2011, Javier and Rice, 2011, Liu et al., 2010) showing 
that full length NS1 proteins are involved in early induction of apoptosis, likely due to 
interaction with PDZ-domain containing proteins important in the maintenance of cellular 
homeostasis (Harris and Lim, 2001, Hung and Sheng, 2002, Kim and Sheng, 2004). It is also 
possible that the premature induction of apoptosis by O/03-K186E-230 was an indirect 
consequence of the many cellular-disturbing functions due to CPSF30 binding. Finally, we 
cannot rule out the possibility that premature apoptosis is due to a lack of control of PKR 
(Takizawa et al., 1996, Fujimoto et al., 1998, Takizawa et al., 1995, Wada et al., 1995), or 
a lack of activation of the PI3K/Akt-pathway. Indeed, the presence of viral dsRNA activates 
PKR and starts a cascade of events eventually leading to protein shutoff (Bergmann et al., 
2000, Hatada et al., 1999, Wang et al., 2000) and induction of apoptosis (Takizawa et al., 
1996, Van Campen et al., 1989, Gil and Esteban, 2000). NS1 has been shown to inhibit PKR 
function by several mechanisms (Tan and Katze, 1998, Hatada et al., 1999, Talon et al., 
2000a), and delay apoptosis by activation of the PI3K/Akt-pathway (Ehrhardt et al., 2006, 
Ehrhardt et al., 2007, Hale et al., 2006, Shin et al., 2007c). In the future, it would be 
interesting to test if E186K substitution and C-terminal truncation modified EIV NS1 blockade 
Chapter 5 - Impact of NS1 evolution on EIV infection phenotype 
 
 145 
of PKR function, or altered its interaction with the p85b subunit of PI3K, and subsequent 
activation of PI3K/Akt pathway.  
 
 
Taken together, these data indicate that the genetic constellation of an equine-
adapted virus, like O/03, could already be optimized to function efficiently in equine cells 
and any disruption in viral-host interaction has a high fitness cost. Interestingly, a similar 
evolution pattern has been observed for the North American ‘classical’ swine H1N1 lineage, 
whose NS segment is of avian origin (related to the 1918 pandemic H1N1 influenza A virus). 
This virus maintained a full length NS1 protein (230 amino acids) until the mid-1960s, before 
introducing of a stop codon at position 219 that resulted in the same 11-amino acid C-
terminal truncation of than EIV NS1. These changes have subsequently been retained in the 
‘classical’ swine H1N1 lineage until the present day (Hale et al., 2010). Thus, the loss of 
CPSF30 binding and C-terminal truncation of NS1 seem to be a common evolutionary trait 
between swine and equine Influenza A viruses. Interestingly, human influenza A viruses 
seem somewhat different, and preferentially select for NS1 proteins binding CPSF30. For 
example, the NS1 protein of H5N1 viruses presented a defect in inhibiting general gene 
expression when the transmission occurred from birds to humans in 1997, however the 
viruses isolated since 1998 have gained this function (Twu et al., 2007, Clark et al., 2017). 
It would be interesting to compare the advantages and downsides of losing CPSF30 binding 
and variations of the C-terminal in different mammalian hosts, such as horses, pigs, dogs 
and humans. 
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6. Effect of NS1 residue 186 and C-terminus on virus-host interaction 
 
6.1. Introduction 
 
The interface between an infectious agent and its host represents an ultimate 
battleground for survival, as the virus must secure a niche for replication, while the host 
must limit the pathogen’s advance. To mount a productive antiviral response against IAVs, 
multiple intracellular signalling pathways must be activated, and the virus can exploit these 
pathways to support its own replication (Ludwig et al., 2006, Ludwig et al., 2003, Ehrhardt 
et al., 2007, Kochs et al., 2007). This is notably the task of the NS1 protein, an accessory 
factor important for the blockade of the host innate immune response, which targets the 
IFN system at different steps. NS1 can limit induction of IFN by blocking the activation of 
transcription factors such as IRF3 (Talon et al., 2000), NF-kB (Wang et al., 2000) and AP-1 
(Ludwig et al., 2002), or by interfering with the RIG-I signalling pathway (Pichlmair et al., 
2006, Mibayashi et al., 2007) notably through the binding to TRIM25 (Gack et al., 2009) and 
RIPLET (Rajsbaum et al., 2012). NS1 is also important for taking over the cellular machinery, 
shutting down the host’s own protein production, including those of type I IFN, while 
promoting viral-only gene expression. This is notably achieved by blocking splicing of pre-
mRNA and export of poly-adenylated mRNA molecules out of the nucleus through the binding 
to CPSF30 (Nemeroff et al., 1998, Das et al., 2008) and PABPII (Chen et al., 1999). The 
dsRNA binding ability of NS1 could also play a role in pre-transcriptional inhibition of the 
interferon pathway by sequestering PAMPs away from host viral sensors (Pichlmair et al., 
2006). More recently, NS1 RNA-binding activity has been involved in the control of gene 
expression by preventing the loading of the transcriptional machinery to the host DNA 
(Anastasina et al., 2016), and by suppressing RNA interference and RNA silencing activities 
(Li et al., 2016b). These NS1 pro-viral activities will ultimately disrupt host cell homeostasis 
and promote cell death. Interestingly, NS1 has also developed mechanisms to interfere with 
the PI3K signalling network (Hale et al., 2008b, Hale et al., 2006) in order to increase 
infected cell viability and maintain the availability of cellular resources. However, many of 
these NS1 functions are not conserved between IAV strains (de Vries et al., 2009), and this 
will likely impact on virus-host interaction and on virus replication efficiency.  
 
In the previous chapters, two evolutionary markers of NS1’s function were identified, 
e.g. NS1 E186K substitution and C-terminal truncation. These markers were further 
confirmed as important for EIV infection phenotype, and their impact seemed to be viral 
context- and cell type-dependent. Indeed, viral fitness of a mammalian-adapted EIV (O/03) 
was strongly dependent on the maintenance of NS1 evolutionary markers, as the 
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reintroduction of the CPSF30 binding via K186E substitution led to viral attenuation. A 
similar observation was made for the extension of NS1 C-terminus (Chapter 5). These 
changes resulted in a reduction of infectivity, in the incapacity to replicate in the presence 
of antiviral cytokines, in the inability to block the establishment of an anti-viral state and 
in premature induction of apoptosis. In contrast, for an emergent virus like U/63, the NS1 
C-terminal truncation did not strongly modify viral infection phenotype, however, the loss 
of CPSF30 binding (via E186K substitution) was associated with a reduction in replication 
rate early post infection. Although the effect of NS1 residue 186 and C-terminus clearly 
affected virus-host interaction in a viral-context dependent manner, the mechanisms 
involved remained elusive. A better understanding of the global gene changes following 
wild-type and mutant virus infection could help identify cellular pathways involved.  
 
High-throughput RNA sequencing (RNA-seq) technology is a powerful way to analyse 
the transcriptome of infected cells with high efficacy and accuracy (Josset et al., 2014, Park 
et al., 2015, Wang et al., 2015). Limited work associating reverse genetic techniques and 
gene expression profiling in infected cells is available, but Geiss et al. reported that NS1 C-
terminus was important for controlling host transcriptome and the initial cellular antiviral 
response. They notably demonstrated that NS1 deletion mutants (full deletion or important 
C-terminal deletions) were unable to alter host gene expression profile, and this was 
associated with a rapid clearance of the virus in vitro (Geiss et al., 2002). 
 
In this chapter, a global transcriptomic profiling to equine cells infected with O/03 
and U/63 WT and isogenic mutants for codon 186 and/or codon 220 was applied in order to 
broadly characterize the impact of NS1 evolutionary markers on host response to viral 
infection.  
 
 
Aims: The aims of this chapter were to compare the early genes expression pattern of 
equine cells infected with two evolutionary distinct EIVs, and to evaluate the impact of NS1 
evolutionary markers on virus-host interaction. 
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6.2. Results 
 
6.2.1. Preparation of samples for RNA sequencing 
 
E.Derm cells were infected with O/03 (Figure 6-1A) and U/63 (Figure 6-1B) WT and 
mutant viruses or mock infected them for 8h (end of eclipse phase) (Figure 5-7) in order to 
avoid any bias due to different replication efficiency between viruses. The MOI was adjusted 
for each independent infection to ensure that a similar number of cells were infected in all 
cells. The level of infection in each sample was then analysed by evaluating the percentage 
of live cells expressing the viral nucleoprotein by flow cytometry, as described in Chapter 
3, section 3.5.7.  
 
In O/03-infected cells (Figure 6-1A), the percentage of cells expressing the viral NP 
among live cells was between 23.1% to 31.6%, and the mean cellular viability ranged from 
77.51% to 88.97%. In U/63-infected cells (Figure 6-1B), the percentage of live cells 
expressing the viral NP ranged between 16.8% and 29.0%, with a cellular viability ranging 
between 77.59% and 88.97%. Importantly, U/63 double-mutant virus had significantly fewer 
infected cells compared to the two other mutant viruses, thus it was not possible to compare 
the transcriptome of single mutant-infected cells with the one of double mutant virus-
infected cells. 
Of note, the majority of cells (approximately 70%) for both O/03 and U/63 infected cells 
whose transcriptome was analysed were not infected. 
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Figure 6-1: Level of infection and cell viability 
 
E.Derm cells were infected with (A) O/03- and (B) U/63-WT and mutant viruses or mock infected for 8 
h. The percentage of cells expressing the viral nucleoprotein among live cells and total cell viability was 
determined by flow cytometry. Bars correspond to mean of three independent experiments and error 
bars represent SEM. A Two-way ANOVA with Bonferonni post hoc test was used to determined 
significance. *, p<0.05 for U/63-E186K-219 versus indicated cells. £, p<0.05 for U/63-219 versus mock-
infected cells. No statistical difference was observed for O/03-infected cells. 
 
 
Total RNA was then extracted for each sample, and the RNA quality was analysed 
using a bioanalyzer, as described in Chapter 3, section 3.9. All cells had an RNA Integrity 
Number (RIN) above 9.5 on a scale from 1 to 10 (Figure 6-2). 
The RNA samples were then sequenced and analysed as described in Chapter 3, section 3.9. 
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Figure 6-2: RNA Integrity Number (RIN) 
 
The average RIN of mock-infected or (A) O/03- and (B) U/63-WT and mutant viruses infected cells. 
Bars correspond to mean of three independent experiments and error bars represent SEM. No 
significant difference was found. 
 
 
6.2.2. Transcriptome of O/03 wild-type and mutant virus-infected cells 
 
6.2.2.1. Degree of dissimilarity between samples 
 
To evaluate the degree of dissimilarity between mock and virus-infected cells and 
among biological replicates, a multi-dimensional scaling (MDS) plot was generated (Figure 
6-3). This plot is used to visualize Euclidian distances between each transcriptomic profile 
in two dimensions (Josset et al., 2014). In this plot, each individual sample is represented 
by a dot, and cells with similar transcriptomic profiles (small Euclidian distance) will be 
found close to each other, while increasing distances between dots reveal increasing 
transcriptomic dissimilarities. Overall, all biological replicates for each condition were 
closely distributed. In addition, O/03-WT-, O/03-K186E-, and O/03-K186E-230-infected cells 
were closely clustered, while O/03-230-infected cells were clustering with mock-infected 
cells. 
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Figure 6-3: Multidimensional scaling plot for O/03-WT- and mutant-infected samples. 
 
Variation between cells and biological replicates was analysed using a multidimensional scaling (MDS) 
plot. 
 
 
6.2.2.2. Distribution of sequencing reads 
 
The total number of reads as well as the number of reads aligning with the horse 
genome (Equus caballus 2, GCA_000002305.1) or the viral genome (A/equine/Ohio/1/2003) 
were analysed in each sample (Figure 6-4). A mean of 41.2 million reads were obtained per 
sample, with 36.6 million horse genome reads, and 3.5 million viral genome reads. 
 
 
 
Figure 6-4: Average number of reads in O/03-WT- and mutant-infected samples. 
 
The mean of total number of reads was determined for each condition, as well as the mean of reads 
matching the viral genome or the horse genome. The exact numbers of reads for each condition is 
indicated. Bars correspond to mean of three independent experiments and error bars represent SEM. 
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6.2.2.3. Viral reads 
 
To determine if the mutations introduced in NS1 affected viral gene expression, the 
transcript per kilobase million (TPM) per genomic segment was compared between 
conditions. As seen in (Figure 6-5), no significant differences was observed. 
 
  
Figure 6-5: Sequencing reads per viral genomic segment in O/03-WT- and mutant-infected 
cells. 
 
To compare the proportion of reads that mapped to specific viral genomic segment in each condition 
transcripts per kilobase million were calculated by normalizing sequencing reads for the respective gene 
length and sequencing depth. Bars correspond to mean of three independent experiments and error 
bars represent SEM. No significant difference was found using by Two-way ANOVA with Bonferonni 
post hoc test. 
 
 
6.2.2.4. Differential gene expression between O/03 virus- and mock-
infected cells 
 
The total number of differentially expressed genes (DEGs) in virus-infected cells 
compared to mock-infected cells (Figure 6-6) was then evaluated. A total of 429 DEGs 
compared to mock were observed in O/03-WT-infected cells, with 248 genes up-regulated 
and 181 down-regulated. In O/03-K186E-infected cells 193 genes were differentially 
expressed compared to mock, with 65 up-regulated and 128 down-regulated. In O/03-230-
infected cells, a total of 241 genes were differentially expressed compared to mock, with 
179 up-regulated and 62 down-regulated. Finally, in O/03-K186E-230-infected cells, 158 
genes were differentially expressed compared to mock, with 101 up-regulated genes and 57 
down-regulated genes. The entire list of DEGs for each condition is available in Appendices 
35 to 45. 
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Figure 6-6: Plots representing DEGs compared to mock in O/03-WT- and mutant-infected 
cells. 
Each plot displays the range of host genes found significantly differentially expressed compared to 
mock-infected cells (Log2FC≥0.58 and p value<0.05) in cells infected with each virus. Total number of 
DEGs are indicated in black, and up-regulated genes and down-regulated genes are indicated in red 
and green (with total number in bold and percentage over total DEGs in brackets), respectively. 
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The degree of overlap between gene sets was then analysed (Figure 6-7). It was 
observed that the O/03-WT virus alone modified the expression of the largest number of 
cellular genes (171 up-regulated and 113 down-regulated), whereas the two K186E-
containing mutant viruses alone regulated the fewest number of genes (22 up-regulated and 
59 downregulated for O/03-K186E and 25 up-regulated and 22 down-regulated for O/03-
K186E-230). The O/03-230 virus regulated an intermediate number of cellular genes, with 
127 up-regulated and 44 down-regulated.  
Two genes were regulated in opposite directions by O/03-WT and the single mutant viruses. 
The Heat shock 70 kDa protein 6 (HSPA6) was up-regulated in O/03-WT-infected cells but 
down-regulated in O/03-K186E (Log2FC = 1.50962 and -1.31121, respectively). This gene is 
the 6th member of the Heat Shock Protein family A (Hsp70), whose induction is a direct 
consequence of HSP90 inhibition (Kuballa et al., 2015), a chaperone that plays a key role in 
many important cellular processes, including DNA repair, development, immune response 
(Schopf et al., 2017). The Urocortin-2 (UCN2) was down-regulated in O/03-WT and up-
regulated in O/03-230-infected cells (Log2FC = -1.089180 and 0.835742, respectively). This 
gene encodes for a peptide previously shown to induce the expression of IL-8 and promote 
cell survival and proliferation (Lee et al., 2014, Shi et al., 2006). 
 
 
Figure 6-7: Venn diagram representing DEGs compared to mock in common between O/03-
infected samples. 
 
DEGs compared to mock in infected cells with a Log2FC≥0.58 and p value<0.05 were used this study. 
Up-regulated and down-regulated genes are indicated in red and green, respectively, while a black 
number indicates a gene differentially expressed in the opposite direction in two different conditions. 
Asterisks indicate four primary groups of DEGs: black asterisk (*) indicates DEGs of primary group O1, 
purple asterisk (*) indicates DEGs of primary group O2, yellow asterisk (*) is for DEGs of primary group 
O3, and blue asterisk (*) are DEGs of primary group O4. 
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From the gene sets overlap analysis (Figure 6-7), four primary groups were identified: 
(O1) genes whose expression was similar between WT and mutant virus infected cells (black 
asterisk); (O2) genes whose expression was similar between cells infected with mutant 
viruses but absent in WT-infected cells (purple asterisk); (O3) genes whose expression was 
differentially regulated compared to mock in K186E-containing mutant virus-infected cells 
(yellow asterisks); and (O4) genes whose expression was differentially regulated compared 
to mock in 230-containing mutant virus-infected cells (blue asterisks).  
 
In group O1 (Figure 6-8), five genes were up-regulated and three down-regulated. 
Among up-regulated genes, two IFN-induced genes involved in the cellular response to viral 
infection (interferon-induced protein with tetra-tricopeptide repeats 3 and 1, IFIT3 and 
IFIT1, respectively) were identified (Pinto et al., 2015, Moll et al., 2011). Both of these 
genes were strongly up-regulated in mutant-infected cells, particularly with O/03-K186E, 
and less so in O/03-WT-infected cells.  
The function of the three other up-regulated genes remains unknown: LYRM7 (LYR motif 
containing 7), a gene coding for a component of the mitochondrion; 5_8S_rRNA, a novel 
ribosomal RNA; and ENSECAG00000004574, an unannotated gene.  
Among the three down-regulated genes shared between all conditions was the LSS gene 
(lanosterol synthase), encoding a key intermediate in cholesterol biosynthesis (Chen et al., 
2015); TYSND1 (trypsin domain containing 1), a key regulator of the peroxisomal b-oxidation 
pathway (Okumoto et al., 2011); and CH25H (cholesterol 25-hydrolase), a known ISG 
involved in fatty acid and cholesterol biosynthetic processes (Gold et al., 2014, Chen et al., 
2014, Serquina et al., 2017). These genes were regulated in a similar fashion between 
samples. 
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Figure 6-8: Heatmap highlighting DEGs compared to mock in O/03-WT and mutant virus-
infected cells. 
 
Genes whose expression is statistically over-represented (up or down-regulated with Log2FC≥0.58 and 
p value<0.05) in all virus-infected cells compared to mock-infected ones. 
 
 
In group O2 (Figure 6-9), twelve genes were up-regulated and the majority were 
associated with the type I IFN pathway and the regulation of host defence against viral 
infection. Among these genes were DExH-box helicase 58 (DHX58), also known LGP2, 
interferon-induced protein 4 (IFI44), interferon-induced protein 44 like (IFI44L), ISG15, 
ubiquitin specific peptidase (USP41), Mx1, OAS-like protein 2 (OASL2), OAS2, IRF9, and 
interferon-induced 35 kDA (IFI35) (Malur et al., 2012, Hallen et al., 2007, Moal et al., 2013, 
Haller et al., 2007, Li et al., 2016a, Das et al., 2014, Qashqari et al., 2013, Fan et al., 2017). 
These genes were strongly expressed in O/03-K186E-infected cells.  
Two other genes were upregulated: the 7SK gene, a non-coding RNA that positively regulates 
the transcription elongation factor, P-TEFb, which plays an essential role in the regulation 
of RNA polymerase II transcription in eukaryotes; and an uncharacterized gene 
(ENSECAG00000014226).  
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Furthermore, three genes were down-regulated: FDFT1 (farnesyl-diphosphate 
farnesyltransferase 1) (Serquina et al., 2017), MVK (mevalonate kinase (Fenini et al., 2017)), 
and ACSS2 (Acyl-CoA synthetase short-chain family member 2, (Xu et al., 2017)), all involved 
in lipid metabolism and regulation of inflammatory processes. 
 
 
Figure 6-9: Heatmap highlighting DEGs compared to mock in O/03 mutant virus-infected 
cells. 
 
Genes whose expression is statistically over-represented (up or down-regulated with Log2FC≥0.58 and 
p value<0.05) in mutant virus-infected cells compared to mock-infected condition. 
 
 
Gene Key words/functions
DHX58 Negative and positive regulation of MDA-5 and RIG-I signaling pathways
IFI44 Defense response to virus
IFI44L Defense response to virus
ISG15 Defense response to virus, regulation of IFN-gamma production, modification-
dependent protein catabolic process, negative regulation of protein ubiquitination
USP41 Proteasome-mediated ubiquitin-dependent protein catabolic process
MX1 Defense response to virus, negative regulation of viral genome replication
OASL2 Defense response to virus, purine nucleotide biosynthetic process
OAS2 Defense response to virus, RNA catabolic process, protein glycosylation
IRF9 Transcription factor activity, type I IFN signaling pathway
IFI35 Type I IFN signaling pathway
ENSECAG00000014226 Uncharacterized protein
7SK Novel non-coding RNA that regulates the general transcription factor P-TEFb
FDFT1 Lipid biosynthetic process
MVK Lipid metabolic process, negative regulation of inflammatory response
ACSS2 Metabolic process, lipid biosynthetic process, acetyl-CoA biosynthetic process
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In group O3 (Figure 6-10), twelve genes were up-regulated, with higher Log2FC 
values in single mutant- than in double mutant virus-infected cells. These up-regulated 
genes were mainly involved in the type I IFN pathway, such RIG-I (also known as DEXD/H 
box helicase 60, DDX60), MDA-5 (also known as interferon-induced with helicase C domain, 
IFIH1), interferon-induced transmembrane protein 3-like (IFITM3L), PKR (or eukaryotic 
translation initiation factor 2 alpha kinase 2, EIF2AK2), viperin (also known as radical S-
adenosyl methionine domain containing 2, RSAD2), guanylate binding protein 3 (GBP3) and 
poly-ADP-ribose polymerase family member 9 (PARP9), and sterile alpha motif domain 
containing 9 and 9-like (SAMD9 and SAMD9L) (Zhang et al., 2015, Wang et al., 2008, Sato et 
al., 2015, Kato et al., 2006, Haller et al., 2015, Hale et al., 2008a, Liu and McFadden, 2015).  
Additionally, three up-regulated genes were not annotated: ENSECAG00000010185, 
ENSECAG00000025328, ENSECAG00000027056.  
In this group, four genes were down-regulated: guanylate-binding protein (GBP1), a known 
ISG (Niu et al., 2016); low-density lipoprotein receptor (LDLR), described as an entry port 
for different viruses (Chen et al., 2014, Finkelshtein et al., 2013); mevalonate diphosphate 
decarboxylase (MVD), previously shown to favour Dengue virus replication (Rothwell et al., 
2009); and insulin gene enhancer protein 1 (ISL1) involved in RNA pol II activation (Whitney 
et al., 2015). 
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Figure 6-10: Heatmap highlighting DEGs compared to mock in O/03 K186E-containing 
mutant virus-infected cells. 
 
Genes whose expression is statistically over-represented (up or down-regulated with Log2FC≥0.58 and 
p value<0.05) in O/03 NS1-K186E-containing mutant virus-infected cells compared to mock-infected 
condition. 
 
 
Gene Key words/functions
DDX60 Defense response to virus, positive regulation of MDA-5 and RIG-I signaling 
pathways
IFIH1 Defense response to virus, protein sumoylation, positive regulation of type I IFN 
production, MDA-5 signaling pathway, regulation of apoptotic process
ENSECAG00000010185 Novel pseudogene, unknown function
ENSECAG00000025328 Mi-RNA, unknown function
IFITM3L IFN-induced transmembrane dispanin subfamily A member
ENSECAG00000027056 Mi-RNA, unknown function
SAMD9L Endosomal vesicle fusion
GBP3 Response to type I IFN, GTPase activity, unknown function
PARP9 Double-strand break repair, regulation of response to IFNg
EIF2AK2 Response to type I IFN, positive regulation of cytokine and chemokine production, 
negative regulation of translation and viral genome replication, regulation of 
hematopoietic stem cell proliferation and differentiation
SAMD9 Endosomal vesicle fusion
RSAD2 Defense response to virus, positive regulation of TLR7 and TLR9 signaling 
pathways, CD4-positive, a/b-T cell activation and differentiation, positive regulation 
of T-helper 2 cell cytokine production
ISL1 RNA pol II activating transcription factor binding,RNA pol II transcription co-
activator activity, enhancer sequence-specific DNA binding
GBP1 Response to type I IFN, nucleotide binding, GTPase activity
LDLR Amyloid-beta binding, protease binding, low-density lipoprotein receptor activity, 
low-density particle binding
MVD Hsp70 protein binding, ATP binding
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In group O4 (Figure 6-11), three genes were up-regulated and five downregulated. 
Among up-regulated genes was found the gene encoding for the Nexilin F-actin binding 
protein (NEXN), a known ISG in primary B cells (Khsheibun et al., 2014); the interleukin 22 
receptor subunit alpha 1 gene (IL22RA1), involved in lung repair post influenza infection 
(Noyama et al., 2017, McAleer and Kolls, 2014); and the ATP-binding cassette subfamily A 
member 1 gene (ABCA1), which encodes for a protein that modulates the bioavailability of 
cholesterol in the lipid raft and favours viral entry (Pirillo et al., 2015).  
Among the five down-regulated genes, was the gene coding for Fibin, a protein of the 
endoplasmic reticulum and Golgi involved in wnt signalling and organogenesis in zebrafish 
(Wakahara et al., 2007). The four other genes were involved in lipid homeostasis, such as 
the elongation of long-chain fatty acids family member 6 gene (ELOVL6), which encodes an 
enzyme that catalyses saturated fatty acids elongation and has been associated with lung 
homeostasis regulation (Sunaga et al., 2013); the stearoyl-CoA desaturase gene (SCD), 
encoding a protein involved in the biosynthesis of unsaturated fatty acids (Lyn et al., 2014); 
the 3-hydroxy-3-methylglutaryl-CoA synthase 1 gene (HMGCS1), which is involved in the 
mevalonate/cholesterol pathway (Serquina et al., 2017); and a gene encoding for the 
endothelial lipase G (LIPG), an enzyme determining plasma lipoprotein cholesterol (Otera 
et al., 2009). 
 
Figure 6-11: Heatmap highlighting DEGs compared to mock in O/03 230-containing mutant 
virus-infected cells. 
 
Genes whose expression is statistically over-represented (up or down-regulated with Log2FC≥0.58 and 
p value<0.05) in O/03 NS1-230-containing mutant virus-infected cells compared to mock-infected 
condition. 
Gene Key words/functions
NEXN Regulation of cell migration and cytoskeleton organization
IL22RA1 Cytokine receptor activity, defense response to Gram-negative bacterium
ABCA1 ATPase activity coupled to transmembrane movement of substances
ELOVL6 Fatty acid elongase activity, acyl groups transferase activity
SCD Oxidoreductase activity
FIBIN Protein associated with the endoplasmic reticulum and Golgi apparatus, unknown function
HMGCS1 Isoprenoid biosynthetic process
LIPG Cholesterol homeostasis, phospholipid homeostasis, regulation of lipoprotein metabolic process
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6.2.2.5. Top canonical signalling pathways modified by O/03 viruses 
 
To identify possible biological interactions of DEGs and important functional 
networks, the sets of genes with altered expression in O/03-WT and mutant virus infected 
cells were imported into the Ingenuity pathway analysis (IPA) tool. As seen in (Figure 6-12), 
the O/03-WT virus activated a larger number of pathways compared to mutant viruses. 
Infection with this virus was associated with up-regulation of genes involved in cell survival, 
such as the PI3K/AKT pathway, and down-regulation of genes associated with cell cycle 
arrest and cell death (i.e. apoptosis signalling, telomerase signalling, cell cycle G1/S 
checkpoint regulation, p53 signalling, role of BRCA1 in DNA damage response, cell cycle 
G2/M checkpoint regulation). Some inflammatory pathways were also downregulated in 
these cells (i.e. IL-17A signalling in airway cells, IL-6 signalling, LXR/RXR activation or TNFR1 
signalling), while other were activated (i.e. LPS/IL-1 mediated inhibition of RXR function, 
FceRI signalling, IL-8 signalling) (Al-Garawi et al., 2012).  
In addition, in O/03 mutant virus-infected cells several key innate immune receptor 
pathways involved in virus sensing were activated, such as interferon signalling, activation 
of IRF by cytosolic pattern recognition receptors, RIG-I-like receptors and antiviral innate 
immunity, or pattern recognition receptors of bacteria and viruses.  
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Figure 6-12: Top canonical signalling pathways activated by O/03-WT and mutant viruses. 
 
The Ingenuity Pathway Analysis (IPA) tool was used to generate a list of significant canonical pathways 
activated in virus-infected cells compared to mock-infected cells based on the lists of transcripts found 
as significantly differentially expressed compared to mock-infected cells. 
 
 
 
The U/63 WT and mutant-infected samples were analysed in a similar fashion to O/03-
infected samples. 
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Figure 6-11: Top canonical signaling pathways activated by O/03-WT and mutant viruses.
The Ingenu ty pathway analy is (IPA) tool was used to generat a list of significant canonical pathways
activated in virus-infected samples compared to mock-infected samples based on the lists of transcripts found
as differentially expressed compared to the mock-infected conditions with Log2FC³0.58 and p value<0.05.
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6.2.3. Transcriptome of U/63 wild-type and mutant virus-infected cells 
 
6.2.3.1. Degree of similarity between samples 
 
The degree of dissimilarity between conditions and biological replicates were 
analysed with a MDS plot (Figure 6-13). All biological replicates were distributed relatively 
closely to each other, although not as closely as observed for O/03-infected cells (Figure 6-
3). In addition, U/63-WT and U/63-E186K-infected cells were closely clustered, while U/63-
219-infected cells were clustering with mock-infected cells. In addition, U/63-E186K-219-
infected cells were equally distributed between U/63-WT- and mock-infected cells.  
 
 
Figure 6-13: Multidimensional scaling plot for U/63-WT- and mutant-infected samples. 
 
Variation between cells and biological replicates was analysed using a multidimensional scaling (MDS) 
plot. 
 
 
6.2.3.2. Distribution of sequencing reads 
 
The total number of reads as well as the number of reads aligning to the horse or 
viral genome were determined for all conditions. As seen in (Figure 6-14), all samples had 
an average of 35.2 million reads in total, with 32.3 million horse genome reads, and 0.4 
million viral genome reads.  
 
U/63 WT
U/63 E186K
U/63 219
U/63 E186K 219
Mock
Figure 6-14: Multidimensional scaling plot for U/63-WT- and mutant-infected
samples.
Variations between biological replicates were clustered closely using a multidimensional scaling (MDS)
plot to evaluate the samples relationship and check for variations among replicates and samples.
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Figure 6-14: Average number of reads in U/63-WT- and mutant-infected samples. 
 
The mean of total number of reads was determined for each condition, as well as the mean of reads 
matching the viral genome or the horse genome. The exact numbers of reads for each condition is 
indicated. Bars correspond to mean of three independent experiments and error bars represent SEM. 
 
 
6.2.3.3. Viral reads 
 
When the viral reads per genomic segments were compared between in all 
conditions, it was observed that expression of U/63-WT PB2 gene was significantly higher 
than that of all mutant viruses. In addition, U/63-WT NA gene expression was significantly 
increased compared to E186K-containing mutants (Figure 6-15). 
  
Figure 6-15: Sequencing reads per viral genomic segment in U/63-WT- and mutant-infected 
samples. 
 
To compare the proportion of reads that mapped to specific viral genomic segment in each condition 
transcripts per kilobase million were calculated by normalizing sequencing reads for the respective gene 
length and sequencing depth. Bars correspond to mean of three independent experiments and error 
bars represent SEM. Significance was calculated by Two-way ANOVA with Bonferonni post hoc test. 
****, p<0.0001 for indicated U/63-WT versus all other conditions. £££, p<0.001 and £, p<0.05 for U/63-
WT versus E186K-containing mutant virus. 
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6.2.3.4. Differential gene expression between U/63 virus and mock-
infected cells 
 
The total number of DEGs in U/63-WT and mutant virus-infected cells was then 
evaluated (Figure 6-16). In total, U/63-WT-infected cells showed 398 DEGs compared to 
mock, among which 140 were up-regulated and 258 were down-regulated. 
In U/63-E186K-infected cells, 205 genes were differentially expressed compared to mock 
with 146 up-regulated and 59 down-regulated. In U/63-219-infected cells there was 216 
DEGs compared to mock, with 117 up- and 99 down-regulated genes. Interestingly, in U/63-
E186K-219-infected cells, a total of 1126 genes were differentially expressed compared to 
mock, with 1060 up-regulated and 66 down-regulated.  
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Figure 6-16: Plots representing DEGs compared to mock in U/63-WT- and mutant-infected 
cells. 
 
Each plot displays the range of host genes found significantly differentially expressed compared to 
mock-infected cells (Log2FC≥0.58 and p value<0.05) in cells infected with each virus. The total number 
of DEGs in each condition is indicated in black, up-regulated genes in red and down-regulated genes 
in green. 
 
 
The entire list of DEGs for each sample is presented in Appendices 46 to 67. 
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The analysis of gene sets overlap (Figure 6-17) revealed that U/63-E186K-219 virus 
modified the expression of the largest number of cellular genes, which were not shared with 
other conditions (894 up- and 19 down-regulated); whereas the gene expression pattern of 
E186K single mutant virus-infected cells was the least distinct from other conditions, with 
18 up- and 31 down-regulated genes in this condition only. In U/63-WT-infected cells, the 
majority of genes were alone down-regulated, most of which were not shared with other 
conditions. Finally, upon U/63-219 infection, a balance between up- and down-regulated 
genes was observed, with most DEGs not shared with other conditions.  
One gene was down-regulated in U/63-E186K-infected cells and up-regulated in U/63-219-
infected cells: aldehyde dehydrogenase 1 family member A3 (ALDH1A3), with Log2FC=-
1.138555 and 0.652271, respectively. Aldehyde dehydrogenases oxidize aldehydes using 
either NAD or NADP as co-enzymes, and play important roles in numerous physiological and 
pathological processes ((Muzio et al., 2012). ALDH1A3 is notably important in the 
detoxification of exogenous toxicants, risk factors for pulmonary diseases, such as 
environment pollutant and lipid peroxidation products (Liu et al., 2010). 
 
 
Figure 6-17: Venn diagram representing DEGs compared to mock in common between U/63-
infected samples. 
 
DEGs compared to mock in U/63-infected cells with a Log2FC≥0.58 and p value<0.05 were used this 
study. Up-regulated and down-regulated genes are indicated in red and green, respectively, while a 
black number indicates a gene differentially expressed in opposite direction in two different conditions. 
Asterisks indicate four primary groups of DEGs: black asterisk (*) indicates DEGs of primary group U1, 
purple asterisk (*) indicates DEGs of primary group U2, yellow asterisk (*) is for DEGs of primary group 
U3, and blue asterisk (*) are DEGs of primary group U4. 
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As for O/03 gene sets analysis (Figure 6-7), four primary groups were identified: (U1) 
genes whose expression was similar between WT and mutant virus infections (black 
asterisk), (U2) genes whose expression was similar between mutant viruses, but absent in 
WT virus infected cells (purple asterisk), (U3) genes whose expression was differentially 
regulated compared to mock in E186K-containing mutant virus-infected cells (yellow 
asterisks), and (U4) genes whose expression was differentially expressed compared to mock 
in 230-containing mutant virus-infected cells exclusively (blue asterisks).  
 
In group U1 (Figure 6-18), fifteen genes were up-regulated and three were down-
regulated. The vast majority of up-regulated genes were involved in the type I IFN pathway: 
IFIT3, LGP2, IFI44, IFIT1, IFI44L, Mx1, ISG15, OAS1, OAS2, IRF9, SAMD9L, IFI35, viperin. 
These genes were strongly up-regulated in all infected samples, and more so in U/63-WT- 
and U/63-219-infected cells.  
The MYB proto-oncogene like 1 gene (MYBL1), involved in regulation of RNA pol II promoter-
dependent gene transcription, was also up-regulated, and so was LYRM7, previously 
mentioned in section 6.2.2.4 (group O1, Figure 6-7).  
Among down-regulated genes, two were previously found down-regulated in group O1: LSS 
and TYSND1. Furthermore, leucine rich repeat containing 73 (LRRC73), whose function 
remains un-explored, was also down-regulated. 
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Figure 6-18: Heatmap highlighting DEGs compared to mock in U/63-WT and mutant virus 
infected-cells. 
 
Genes whose expression is statistically over-represented (up- or down-regulated with Log2FC≥0.58 
and p value<0.05) in U/63-WT- and mutant virus infected-cells compared to mock-infected cells. 
 
 
 
 
Gene Key words/functions
IFIT3 Defense response to virus and cellular response to type I IFN, negative regulation of cell proliferation
DHX58 Negative and positive regulation of MDA-5 and RIG-I signaling pathways
IFI44 Defense response to virus
IFIT1 Defense response to virus and cellular response to type I IFN. Intracellular transport of viral protein in host cell, negative regulation of protein binding and helicase activity
IFI44L Defense response to virus
MX1 Defense response to virus, negative regulation of viral genome replication
OAS1 Defense response to virus, negative regulation of viral genome replication, glucose homeostasis
OAS2 Defense response to virus, RNA catabolic process, protein glycosylation
IRF9 Transcription factor activity, type I IFN signaling pathway
SAMD9L Endosomal vesicle fusion
IFI35 Type I IFN signaling pathway
LYRM7 Component of mitochondrion,unknown function
RGS2 Negative regulation of G-protein coupled receptor protein signaling pathway, regulation of adrenergic receptor signaling pathway, negative regulation of MAP kinase activity
MYBL1 Regulation of transcription from RNA pol II promoter
LRRC73 Unknown function
TYSND1 Regulation of fatty acid beta-oxidation
LSS Steroid biosynthetic process, cholesterol biosynthetic process, regulation of protein stability
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In group U2 (Figure 6-19), only one gene was found: MICAL C-terminal like gene 
(MICALCL), which encodes for a protein that binds mitogen-activated protein kinases 
(MAPKs) and affects multiple biological processes, such as cell differentiation, and organism 
development (Miura, 2008). 
 
 
Figure 6-19: Heatmap highlighting DEGs compared to mock in U/63 mutant virus infected-
cells. 
 
Genes whose expression is statistically over-represented (up- or down-regulated with Log2FC≥0.58 
and p value<0.05) in U/63 mutant virus infected-cells compared to mock-infected cells. 
 
 
In group U3 (Figure 6-20) a large number of up-regulated genes were observed (57 
DEGs in total), while no down-regulated genes were found. Among up-regulated genes, 
several were involved in immune responses, such as phosphodiesterase 4B (PDE4B) an 
enzyme induced by LPS (Ma et al., 1999) (Selige et al., 2011, Jin et al., 2010); Interleukin 
13 receptor alpha 2 gene (IL13RA2) that encodes for the receptor of IL-13 (Daines et al., 
2006); Cluster differentiation 80 gene (CD80, also called B7-1), encoding for a molecule 
classically found on antigen presenting cells where it plays a pivotal in the activation and 
regulation of T cell function (Chen and Flies, 2013), but interestingly has also been found 
on fibroblasts (Pechhold et al., 1997, Corrigall et al., 2000); Matrix metallopeptidase 1 gene 
(MMP1), encoding one of the 23 family members of calcium and zinc dependent enzymes 
implicated in physiological and inflammatory pathological processes of the airways and lung 
parenchyma, such as asthma, chronic obstructive pulmonary disease (COPD) and 
emphysema (Cataldo et al., 2003); Sphingosine-1-phosphate receptor 1 gene (S1PR1) 
encoding a G protein-binding receptor , which plays important immune functions, such as 
promoting pro-inflammatory responses, T cell trafficking and development (Chi, 2011), and 
diverse physiological processes (Rivera et al., 2008, Aoki et al., 2016); Oncostatin M receptor 
gene (OSMR), encoding for the receptor of oncostatin-M (OSM), an IL-6 family member able 
to stimulate the eosinophil-selective CC chemokine eotaxin-1 in vitro, and eosinophil 
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accumulation in mouse lung in vivo (Hermanns, 2015); Kit ligand gene (KITLG) that encodes 
a pleiotropic factor thought to impact on cell development, hematopoiesis, and mast cell 
proliferation disorders (Cruse et al., 2014); COMM domain containing 8 gene (COMMD8) 
encodes a protein that interacts with the coiled-coil domain-containing protein 22 (CCDC22) 
and regulate the turnover of I-kappa-B and activation of NF-kappa-B, a master regulator of 
inflammation (Starokadomskyy et al., 2013); the NF-kB repressing factor gene (NKRF), 
encoding a DNA-binding nuclear transcriptional repressor of NF-kB, which has been 
associated with suppression of IP-10 and IL-8 in alveolar macrophages during pulmonary 
tuberculosis (Huang et al., 2013); the b-1,3-N-acetylglucosaminyltransferase 2 gene 
(B3GNT2), which encodes for a poly-lactosamine synthase that generates putative immune 
regulatory factors, presumably suppressing excessive responses during immune reactions 
(Togayachi et al., 2007); Leucine rich repeat protein 1 gene (LRR1), which encodes a protein 
that specifically interacts with and negatively regulates member 9 of the tumor necrosis 
factor receptor (TNFR) superfamily (TNFRSF9, also called 4-1BB), which result in the 
activation of NF-kB and JNK1 (Jang et al., 2001); and Glutaredoxin 2 gene (GLRX2) encodes 
an antioxidant enzyme that facilitates the maintenance of mitochondrial redox homeostasis 
(Reynaert et al., 2007), and more importantly the Glutaredoxin/S-glutathionylation axis 
regulates interleukin-17A-induced pro-inflammatory responses in lung epithelial cells (Nolin 
et al., 2014) 
Some genes were involved in fibroblasts differentiation and migration and tissue 
remodelling, such as Hyaluronan synthase 2 gene (HAS2), which encodes the enzyme 
producing hyaluronan, a major component of extracellular matrix secreted by airway 
structural cells (Walker et al., 2017) and important in fibroblast to myofibroblast 
differentiation (Midgley and Bowen, 2015); Integrin subunit alpha 10 gene (ITGA10), 
encoding a protein of the integrin alpha family, which are transmembrane adhesion 
molecules mediating cell-cell and cell-extracellular matrix attachment, and also  regulate 
cell growth, proliferation, migration and apoptosis (Lenci et al., 2012); Plasminogen 
receptor with a C-terminal lysine gene (PLGRKT) that encodes for the plasminogen receptor 
and favours its activation to plasmin (Herren et al., 2003), which in turn is important for 
extracellular matrix remodelling and cell migration; ADAM metallopeptidase with 
thrombospondin type 1 motif 1 gene (ADAMTS1), encoding a protein that belongs to the 
ADAMTS protein family and plays a role in extracellular matrix proteoglycan (versican) 
processing (Cross et al., 2005, Cal et al., 2002); Neuroepithelial cell transforming 1 gene 
(NET1), which encodes the NET1 protein, a Ras homolog family member A-specific guanine 
nucleotide exchange factor induced by TGF-b and controls the formation of stress fibers and 
reorganisation of cytoskeletal structures (Shen et al., 2001); Tensin 4 gene (TNS4, also 
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called cten) encoding one of the four members of the Tensins family (Lo, 2004), cytoplasmic 
proteins that are localized to integrin-linked focal adhesions and weaken cellular adhesion 
and increases cell migratory activity (Mouneimne and Brugge, 2007); Ubiquitin associated 
and SH3 domain containing B gene (UBASH3B, also called p70S6K) (Pei et al., 2006), which 
encodes a protein that inhibits endocytosis of epidermal growth factor receptor (EGFR) and 
platelet-derived growth factor receptor (Lee et al., 2013); Cellular repressor of E1A 
stimulated genes 2 (CREG2) that encodes for a secreted glycoprotein inhibiting cell 
proliferation and enhancing differentiation of pluripotent stem cells (Kunita et al., 2002); 
Follistatin gene (FST), which encodes for an angiogenic protein (Frezzetti et al., 2016) that 
binds and inhibits activins, members of the transforming growth factor beta superfamily 
that play a significant role in lung regeneration (George et al., 2017, Zhao et al., 1996); and 
the sprouty RTK signaling antagonist 2 gene (SPRY2) that encodes a protein known to 
downregulate angiogenesis during wound healing (Wietecha et al., 2011). 
Other up-regulated genes from this group were involved in DNA stability and gene 
expression, such as Helicase lymphoid specific gene (HELLS) encoding a novel member of 
SNF2 family (Yano et al., 2004), which possess an helicase and ATPase activity and is thought 
to regulate transcription of certain genes by altering the chromatin structure around those 
genes (von Eyss et al., 2012). The endothelial cell specific molecule 1 gene (ESM1, also 
called Endocan) that encodes an endothelial cell-associated proteoglycan preferentially 
expressed by renal and pulmonary endothelium, which is upregulated by pro-angiogenic and 
pro-inflammatory cytokines and reflects endothelial activation and dysfunction (Kechagia 
et al., 2016); GEN1 gene, a member of the Rad2/XPG nuclease family shown to promote 
Holliday junction (HJ) resolution (Chan and West, 2015), which link sister chromatids or 
homologous chromosomes and are essential for the repair of stalled/collapsed replication 
forks in mitotic cells (Rass et al., 2010); the DNA replication helicase/nuclease 2 (DNA2) 
gene, which encodes a conserved helicase/nuclease involved in the maintenance of 
mitochondrial and nuclear DNA stability (Budd and Campbell, 2013); the MMS22L gene that 
encodes a protein interacting with the scaffold-like protein Nfkbil2 (Piwko et al., 2010), and 
forms a complex that contributes to genome stability by regulating the chromatin state at 
stalled replication forks (O'Connell et al., 2010); SMC5-SMC6 complex localization factor 1 
gene (SLF1) whose encoded-protein forms a complex with SLF2 and RAD18 involved in DNA 
post-replication repair and homologous recombination repair (Liu et al., 2012, Raschle et 
al., 2015); Origin recognition complex gene (ORC) that encodes a protein involved in the 
initiation of chromosomal replication (Gibson et al., 2006); Establishment of sister 
chromatid cohesion N-acetyltransferase 2 gene (ESCO2) encoding a protein belonging to the 
highly conserved Eco1/Ctf7 family involved in establishment of sister chromatid cohesion 
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during S phase and has acetyltransferase activity (Nishihara et al., 2010); Centromere 
protein Q gene (CENPQ) encoding a subunit of the centromeric complex required for proper 
kinetochore function and mitotic progression (Okada et al., 2006); ATPase family AAA 
domain containing 5 gene (ATAD5, also known as ELG1), which encodes a protein playing an 
important role in S phase to preserve genomic stability (Maleva Kostovska et al., 2016, 
Shiomi and Nishitani, 2013), and is induced during recovery from a variety of DNA damage 
(Sikdar et al., 2009); and Small nuclear ribonucleoprotein polypeptide G gene (SNRPG) 
encoding a component of the U1, U2, U4, and U5 small nuclear ribonucleoprotein complex, 
precursors of the spliceosome (Urlaub et al., 2001).  
Several genes were involved in regulation of the cell cycle and cell survival, such as the cell 
division cycle 7 (CDC7) gene, which encodes a cell division cycle protein with kinase activity 
critical for the G1/S transition (Datta et al., 2017); Excision repair cross-complementation 
group 6 like (ERCC6L), a gene encoding for a DNA helicase of the SNF2 family (Xu et al., 
2005, Pu et al., 2017); Heat shock transcription factor 2 gene (HSF2) encoding a protein that 
belongs to the HSF family of transcription factors and binds specifically to heat-shock 
promoter element and activate transcription and cellular differentiation in response to 
cellular stresses (Tateishi et al., 2009); E2F transcription factor 8 gene (E2F8), encoding a 
novel identified E2F family member, which controls the mammalian cell cycle (Ye et al., 
2016); Cyclin dependent kinase 1 gene (CDK1, formerly called cdc2) encoding an ISG (Sze et 
al., 2013) that controls entry into S- and M-phase (Heim et al., 2017); RB binding protein 6, 
ubiquitin ligase (RBBP6) interacts with both p53 and Rb (Dlamini et al., 2016), and plays a 
role in apoptosis induction and regulation of the cell cycle (Pugh et al., 2006); Ribosomal 
protein L22 like 1 gene (RPL22L1) encoding a minor ribosomal component belonging to the 
ribosomal protein L22e family, ubiquitously expressed and whose deletion induces p53 
expression and cell death of a/b-lineage T lymphocytes specifically; F-box protein 5 (FBXO5) 
and 43 (FBXO43) genes encoding E3 ubiquitin ligase receptors (Jin et al., 2004), shown to 
regulate the G(1)/S transition of the eukaryotic cell cycle (Chiaur et al., 2000); Dual 
specificity phosphatase 5 gene (DUSP5), which encodes an inducible nuclear protein (Temple 
et al., 2001) ubiquitously expressed that specifically interacts with and deactivates 
extracellular signal-regulated kinases (ERK1 and ERK2) responsible for cell proliferation, 
differentiation, and survival (Talipov et al., 2016); and SHC adaptor protein 3 encoding gene 
(SHC3) which encodes a member of the Shc family of multifunctional docking proteins 
involved in Ras-extracellular signal-regulated kinase (ERK) and the PI3K/Akt pathways (Conti 
et al., 2001). 
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Two genes were involved in synthesis and bioavailability of lipids: ABCA1 gene, which has 
previously been found in group O4 (Figure 6-11); and a/b hydrolase domain containing 18 
gene (ABHD18), whose function is unknown (Thomas et al., 2014).  
Two genes were involved in protein folding: Small glutamine rich tetratricopeptide repeat 
containing beta gene (SGTB), induced by IL-1b (Bao et al., 2016); and Prefoldin subunit 4 
gene (PFDN4) (Hartl and Hayer-Hartl, 2002). 
Finally, several genes were involved in metabolic processes and minerals homeostasis, such 
as the zinc finger protein 280C gene (ZNF280C) encoding a member of the Cys2His2 zinc 
finger domain-containing protein family (Gamsjaeger et al., 2007) extremely abundant in 
higher eukaryotes and which seem to act as redox-sensitive molecular switches controlling 
crucial cellular processes (Kroncke and Klotz, 2009); Ring finger protein 19 gene (RNF219), 
ubiquitously expressed in various tissues (Huh et al., 2008), and encodes a RING finger type 
E3 ubiquitin ligase, which binds the intracellular carboxyl terminus of Calcium-sensing 
receptors, and regulate calcium homeostasis (Huang et al., 2006); Polypeptide N-
acetylgalactosaminyltransferase 1 gene (GALNT1), which encodes a member of the family 
of glycosyltransferases (GalNAc-Ts) responsible for the initiation of mucin-type O-
glycosylation (Tian et al., 2015); Glycine cleavage system protein H gene (GCSH) encodes 
one of the four mitochondrial protein components of the glycine cleavage system (Kure et 
al., 2001); Mitochondrial ribosomal protein L42 gene (MRPL42), which encodes a 
mitochondria-specific protein helping in protein synthesis within the mitochondrion 
(Lightowlers et al., 2014); Muscle glycogen Phosphorylase gene (PYGM) encoding a protein 
that catalyses the degradation of glycogen to glucose-1-phosphate (Nam et al., 2011); SLIT 
and NTRK like family member 4 gene (SLITRK4), which belongs to the SLITRK family, along 
with the axonal growth-controlling protein SLIT and neurotrophin receptors (Aruga et al., 
2003); Vitamin K epoxide reductase complex subunit 1 gene (VKORC1), which encodes the 
catalytic subunit of the vitamin K epoxidase reductase, complex responsible for the 
reduction of inactive vitamin K 2,3-epoxide to active vitamin K (Bodin et al., 2005). 
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Finally, group U4 (Figure 6-21) counted 9 up-regulated and 5 down-regulated genes. 
Among up-regulated genes was TNFAIP3 interacting protein 3 (TNIP3, also known as ABIN-
3), an IL-10-induced gene product expressed by negative regulation of TNF receptor- and 
TLR4-induced NF-kB activation (Verstrepen et al., 2008); Mab-21 domain containing 1 gene 
(MB21D1, also known as cyclic GMP-AMP synthase (cGAS)) that encodes a cytosolic sensor of 
dsDNA, which induces an antiviral state and the secretion of type I IFN (Ablasser et al., 
2013, Mackenzie et al., 2017); Sec62 gene that encodes a critical constituent of the 
translocon complex, which is important for the maintenance of endoplasmic reticulum 
homeostasis (Fumagalli et al., 2016); the 3'-phosphoadenosine 5'-phosphosulfate synthase 2 
gene (PAPSS2), which encodes an enzyme that synthesizes high energy sulfate donor (PAPS) 
used in all sulfonation reactions (Schroder et al., 2012); Claspin protein-encoding gene 
(CLSPN), which controls cell cycle arrest in response to DNA damage (Chini and Chen, 2003, 
Chini and Chen, 2004); Small nuclear ribonucleoprotein polypeptide F gene (SNRPF) 
encoding one of the seven Sm proteins constituent of the nuclear pre-mRNA processing 
machinery and involved in pre-mRNA splicing (Kambach et al., 1999); A-kinase anchoring 
protein 12 gene (AKAP12) encoding a scaffold protein that associates with protein kinases A 
and C, and plays a role in signal transduction (Chen and Malbon, 2009), regulation of cell 
migration (Lee et al., 2011), cell cycle progression and suppression of apoptosis (Yoon et 
al., 2007); and PIN2/TERF1 interacting telomerase inhibitor 1 gene (PINX1) encoding a 
telomerase inhibitor (Cheung et al., 2012) implicated in telomere maintenance (Yoo et al., 
2014). In addition, one novel pseudogene whose function is unknown was also up-regulated 
in this group (ENSECAG00000003783). 
Among down-regulated genes was the ADAM metallopeptidase with thrombospondin type 1 
motif 15 gene (ADAMTS15), encoding a protein that belongs to the ADAMTS protein family 
and plays a role in extracellular matrix proteoglycan processing (Cross et al., 2005, Cal et 
al., 2002); Transmembrane protein 160 gene (TMEM160) encoding a component of the 
mitochondrion, whose function is unknown; Keratin 5 gene (KRT5) expressed by lung 
progenitor cells (krt5+) important in lung remodelling (Xi et al., 2017) and regeneration of 
epithelial cells following an influenza virus infection (Yee et al., 2017, Quantius et al., 
2016). H1 histone family member X gene (H1FX, also called NCAMP-1) encoding the least 
characterized member of the H1 family (Ichihara-Tanaka et al., 2017), which is ubiquitously 
expressed (Evans et al., 2009) and has important functions in mitotic progression (Takata et 
al., 2007). Finally, ENSECAG00000027624 is a non-coding RNA, whose function is unknown.  
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Figure 6-21: Heatmap highlighting DEGs compared to mock in U/63-219-containing virus 
infected-cells. 
 
Genes whose expression is statistically over-represented (up- or down-regulated with Log2FC≥0.58 
and p value<0.05) in U/63-219-containing mutant virus infected-cells compared to mock-infected cells. 
 
 
6.2.3.5. Top canonical signalling pathways modified by U/63 viruses 
 
Finally, as performed for O/03-infected cells (Figure 6-11), the datasets of DEGs 
identified in U/63-WT and mutant virus-infected cells were imported into the IPA tool. 
Figure 6-22 represents a hierarchical clustering heatmap showing the list of activated 
canonical pathways after U/63-WT and mutant virus infection.  
Gene Key words/functions
TNIP3 Positive regulation of transcription from RNA pol II promoter, TLR4 signaling pathway
MB21D1 Defense response to virus, positive regulation of type I IFN production
SEC62 Post-translational protein targeting to endoplasmic reticulum membrane
PAPSS2 Sulfate assimilation
CLSPN G2 DNA damage checkpoint
SNRPF mRNA splicing via spliceosome
AKAP12 Positive regulation of protein kinase A and C signaling, signal transduction
ENSECAG00000003783 Novel pseudogene, unknown function
PINX1 Maintain telomere integrity by regulating TRF1
ADAMTS15 Metallopeptidase activity
TMEM160 Integral component of mitochondrion, unknown function
KRT5 Structural molecule activity, scaffold protein binding
H1FX Nucleosome assembly
ENSECAG00000027624 Non-coding RNA, unknown function
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Very few pathways were significantly modified in U/63 single mutant virus-infected cells, 
and the largest number of activated pathways were observed for U/63-E186K-219-infected 
conditions, closely followed by U/63-WT-infected cells. In addition, the majority of 
pathways were negatively-regulated in U/63-WT-infected samples, while being positively-
regulated in cells infected with U/63 double mutant virus, e.g. inflammatory pathways with 
positive z-score for U/63-double mutant virus and negative z-score for WT (FceRI signalling, 
IL-17A signalling in airway cells, IL-6 signalling, LPS-stimulated MAPK signalling, CXCR4 
signalling).  
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Figure 6-22: Top canonical signalling pathways activated by U/63-WT and mutant viruses. 
 
As for Figure 6-12, the Ingenuity Pathway Analysis (IPA) tool was used to generate a list of significant 
canonical pathways activated in virus-infected cells compared to mock-infected cells. 
 
 
 
PTEN Signaling
PPAR Signaling
Cyclins and Cell Cycle Regulation
Interferon Signaling
Retinoic acid Mediated Apoptosis Signaling
LPS/IL-1 Mediated Inhibition of RXR Function
PPARα/RXRα Activation
EIF2 Signaling
Role of p14/p19ARF in Tumor Suppression
RhoGDI Signaling
VDR/RXR Activation
Activation of IRF by Cytosolic Pattern Recognition Receptors
Ceramide Signaling
Aryl Hydrocarbon Receptor Signaling
IL-3 Signaling
G Beta Gamma Signaling
ErbB4 Signaling
Death Receptor Signaling
IGF-1 Signaling
Toll-like Receptor Signaling
TGF-β Signaling
BMP signaling pathway
Role of CHK Proteins in Cell Cycle Checkpoint Control
ATM Signaling
ERK5 Signaling
Role of RIG1-like Receptors in Antiviral Innate Immunity
Corticotropin Releasing Hormone Signaling
14-3-3-mediated Signaling
Remodeling of Epithelial Adherens Junctions
cAMP-mediated signaling
AMPK Signaling
HMGB1 Signaling
UVA-Induced MAPK Signaling
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses
Actin Nucleation by ARP-WASP Complex
Role of IL-17F in Allergic Inflammatory Airway Diseases
TWEAK Signaling
PI3K/AKT Signaling
HGF Signaling
Ephrin Receptor Signaling
FGF Signaling
Apoptosis Signaling
SAPK/JNK Signaling
p53 Signaling
Acute Phase Response Signaling
Fc Epsilon RI Signaling
Antiproliferative Role of Somatostatin Receptor 2
HIPPO signaling
Role of BRCA1 in DNA Damage Response
IL-8 Signaling
Insulin Receptor Signaling
IL-17A Signaling in Airway Cells
GNRH Signaling
JAK/Stat Signaling
Lymphotoxin β Receptor Signaling
Telomerase Signaling
Regulation of eIF4 and p70S6K Signaling
STAT3 Pathway
Mitotic Roles of Polo-Like Kinase
mTOR Signaling
NF-κB Signaling
LXR/RXR Activation
PDGF Signaling
Cell Cycle: G2/M DNA Damage Checkpoint Regulation
TNFR1 Signaling
Calcium Signaling
Cell Cycle: G1/S Checkpoint Regulation
ILK Signaling
IL-6 Signaling
NRF2-mediated Oxidative Stress Response
NF-κB Activation by Viruses
Gα12/13 Signaling
p70S6K Signaling
Protein Kinase A Signaling
Neurotrophin/TRK Signaling
GM-CSF Signaling
EGF Signaling
IL-2 Signaling
Growth Hormone Signaling
Prolactin Signaling
IL-9 Signaling
TNFR2 Signaling
Signaling by Rho Family GTPases
ERK/MAPK Signaling
PCP pathway
LPS-stimulated MAPK Signaling
PAK Signaling
Gαq Signaling
Actin Cytoskeleton Signaling
Rac Signaling
CXCR4 Signaling
Paxillin Signaling
Wnt/Ca+ pathway
Integrin Signaling
NGF Signaling
Figure 6-22: Top canonical signaling pathways activated by U/63-WT and mutant viruses.
As for figure 6-9, t e IPA tool was used to generate a list of significant canonical pathways activated in virus-
infected samples compared to mock-infected samples.
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6.3. Discussion 
 
In this chapter, high-throughput RNA sequencing technologies were used to analyse 
the host response to two phylogenetically distinct EIVs, O/03 and U/63. In addition, the 
impact of two NS1 evolutionary markers on virus-host interaction, E186K substitution and 
C-terminal truncation, was evaluated by comparing the transcriptional profile of equine 
cells infected with WT and NS1 186 and C-terminus mutant viruses.  
 
To prepare the samples for sequencing, E.Derm cells were infected with each virus 
or mock infected for 8h, which corresponds to the end of the eclipse phase in these cells 
(seen in the previous chapter, Figure 5-7). The MOI was also adjusted for each independent 
infection to ensure that a similar number of cells were infected in all conditions, which was 
checked by flow cytometry (Figure 6-1). In doing so, variations in levels of infection between 
samples were limited. However, both for O/03- and U/63-infected samples the majority of 
cells (approximately 70%) whose transcriptome was analysed was not infected. Thus, the 
transcriptomic results should be interpreted as a result of the cellular response to infection 
in foci of infection as well as the cellular response of cells surrounding these foci. Although 
this situation is likely to arise during a natural infection (Pociask et al., 2017), the relevance 
of RNAseq experiment in cells with such a low level of infection is debatable. In addition, 
using a virus stock generated from a cell line without purifying to suspension to discard any 
soluble factors secreted by infected cells (e.g. cytokines, growth factors, etc.) would have 
been preferable. To obtain a higher percentage of infection and a purer viral suspension the 
use of a density gradient (e.g. conventional gradient of sucrose and a gradient of iodixanol) 
(Hutchinson & Fodor, 2014) coupled with centrifugal inoculation (or spinoculation) (Guo et 
al., 2011, Chaipan et al., 2009) would have been preferable.  
 
In this work, three biological replicates were used for each condition, and 
differentially expressed genes compared to mock were considered statistically significant 
with fold change superior or equal to 1.5 (Log2FC≥0.58). In addition, the total number of 
reads for each sample was relatively high with a mean of 41.2 million reads for mock- and 
O/03-infected cells (Figure 6-4), and a mean of 35.2 million reads for U/63-infected cells 
(Figure 6-14). The RNA quality for all samples was also high, with RINs above 9.5 on a scale 
from 1 to 10 (Figure 6-2). According to a survey of best practices for RNA sequencing data 
analysis (Conesa et al., 2016), these parameters gave a statistical power of 43% (Consortium, 
2013). The statistical power to detect differential gene expression varies with effect size 
(fold change), sequencing depth and number of replicates. To reach 100% of statistical 
Chapter 6 - Effect of NS1 residue 186 and C-terminus on virus-host interaction 
 
 182 
power, ten biological replicates per condition and a fold change of 2 would have been 
necessary. 
 
Overall, all biological replicates were closely distributed (Figure 6-3 & 6-13), which 
indicated a low variability between each independent experiment. In addition, O/03-WT 
and K186E-containing mutant virus-infected cells were closely clustered, while O/03-230-
infected cells were clustering with mock-infected cells. Similarly, U/63-WT and U/63-
E186K-containing mutant virus infected cells were closely clustered, while U/63-219-
infected cells were more closely distributed to mock-infected cells. The underlying reasons 
remain unclear, however, it is possible that modifying the NS1 tail alone alters virus-host 
interaction more strongly than modifying NS1 codon 186.  
 
Unsurprisingly, the large majority of reads aligned to the host genome (Equus 
caballus 2, GCA_000002305.1) in all samples, with 36.6 million reads in O/03-infected cells 
and 32.3 million reads in U/63-infected cells (Figure 6-4 and 6-14, respectively). Only a 
small fraction of reads aligned to the viral genome, with a mean of 3.5 million of reads in 
O/03-infected cells (Figure 6-4) and a mean of 0.4 million of viral genome reads in U/63-
infected cells (Figure 6-14). The level of infection was slightly higher for O/03 viruses (23.1% 
to 31.6%) (Figure 6-1A) than for U/63 viruses (16.8% to 29.0%) (Figure 6-1B), thus fewer viral 
reads were expected in U/63-infected conditions than in O/03-infected conditions. 
However, this difference could also be explained by variations in polymerase efficiency 
between O/03 and U/63 virus. This idea is further supported by results obtained with mini-
replicon technologies showing differences in polymerase efficiency between U/63 and O/03 
in human cells (Coburn, 2017). These results also correlate with the lack of replication of 
U/63 in equine cells compared to O/03 (Figure 5-10 & 5-11). 
 
The characterization of virus-host interaction confirmed the importance of NS1 
amino acid 186 and the C-terminal tail on viral control of cellular and viral gene expression. 
Indeed, mutations introduced in U/63 and O/03 NS1 altered viral gene expression. Indeed, 
U/63-WT expressed significantly more PB2 and NA genes than the corresponding isogenic 
mutant viruses, and the truncation of U/63 NS1 led to an increased in expression of the M 
gene (Figure 6-15). In the case of U/63, no synergistic effect was found between mutation 
of codon 186 and 220. In contrast, for O/03 the concomitant introduction of K186E 
substitution and NS1 C-terminus extension increased viral expression of HA as well as NA 
and NS, and decreased expression of NP (Figure 6-5). Interestingly, Park et al. showed that 
an increased expression of HA, NA and NS were associated with the ability to replicate with 
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better efficiency at earlier times post infection (Park et al., 2015), which correlated with 
the data collected in Chapter 5 (Figure 5-7 & 5-11). Thus, it seemed that for a contemporary 
virus like O/03, the reversion of NS1 adaptive markers strongly disrupted viral gene 
expression, and their introduction in an emergent virus like U/63 had minimal effects. 
 
The total number of differentially expressed genes compared to mock in WT virus-
infected cells were comparable between O/03 and U/63 (429 and 398 DEGs, respectively) 
(Figure 6-6 & 6-16). However, close to 60% of DEGs were up-regulated in O/03-WT-infected 
cells, while 65% of DEGs were down-regulated in U/63-WT-infected cells. This indicated that 
the strategy of control of infected cells were fundamentally different between O/03 and 
U/63. Indeed, the equine-adapted virus O/03 promoted up-regulation of host genes, while 
the emergent U/63 virus favoured a downregulation. Finally, both U/63 single mutants 
seemed strongly attenuated in equine cells, as very few cellular pathways were modified 
during infection. In addition, the changes introduced in NS1 seemed to have impacted on 
U/63’s ability to shutdown gene expression, as the total number of DEGs were strongly 
reduced and the majority of genes were up-regulated (Figure 6-16). This seems to indicate 
that U/63 requires E186 and a full length NS1 to shutoff host gene expression, and the 
introduction of an evolutionary markers in NS1 in the context of an emergent virus only 
reduced viral fitness. 
 
Moreover, the gene expression pattern of cells infected with O/03-WT was highly 
distinct from that of cells infected with O/03 mutant viruses (Figure 6-7). In contrast, in the 
context of U/63 infection, the virus inducing the most distinct cellular gene expression 
pattern was the double mutant virus (Figure 6-17). In addition, the introduction of E186 in 
O/03 NS1 favoured the downregulation of genes, while the extension of O/03 NS1 tail 
increased the percentage of up-regulated genes. Consistent with these results, introducing 
both changes in O/03 NS1 mitigated this effect (Figure 6-6). In the context of U/63 however, 
introduction of K186 in NS1 or the truncation of the protein increased the number of up-
regulated genes. Taken together these data further supports the idea that E186 plays an 
important role in the virus-induced host gene expression shutoff during infection, while a 
short NS1 protein harbouring K186 favours cellular gene expression and the activation of a 
large number of cellular pathways. 
 
Infection of equine cells with the WT version of the mammalian-adapted O/03 virus 
was also associated with up-regulation of a very small number of ISGs (IFIT3 and IFIT1) 
(Figure 6-8). In contrast, all O/03 isogenic mutants up-regulated a large range of ISGs (e.g. 
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LGP2, IFI44, ISG15, USP41, Mx1, OASL2, OAS2, IRF9, IFI35) (Figure 6-9). In addition, the virus 
the least capable of controlling ISG induction was the O/03 E186-containing mutant viruses. 
Indeed, apart from the genes described above, these viruses also up-regulated other PRRs 
and ISGs (such as RIG-I, MDA5, IFITM3L, PKR, viperin, GBP3, PARP9, SAMD9, and SAMDL9) 
(Figure 6-10). In contrast, infection of equine cells with WT and mutant U/63 viruses was 
associated with an up-regulation of a comparable number of ISGs (e.g. IFIT3, LGP2, IFI44, 
IFIT1, IFI44L, Mx1, ISG15, OAS1, OAS2, IRF9, SAMD9L, IFI35, viperin) (Figure 6-18). Thus, it 
seemed that a short NS1 harbouring K186 impacts on the ability of a mammalian adapted 
virus, like O/03, to control the antiviral response of the host at a transcriptional level, 
however, these markers are not sufficient to grant this ability to an emergent virus, like 
U/63. These results were in accordance with another study, which analysed the cellular 
response to infection with an avian influenza virus. These authors showed that infection of 
mammalian cells with an avian virus increased expression of IFN, ISGs and viral sensors (Park 
et al., 2015), and this was associated with a limited replication efficiency, as found in with 
O/03 mutants or U/63 viruses (Chapter 5). 
 
Interestingly, the extension of O/03 NS1 tail led to an up-regulation of the alpha 
subunit of the receptor for IL-22, a cytokine important for pulmonary repair post IAV 
infection (Noyama et al., 2017, McAleer and Kolls, 2014). This C-terminal extension of O/03 
was also associated with a downregulation of ELOVL6, important for lung homeostasis 
(Sunaga et al., 2013). This raises the questions of the impact of Influenza virus exposure on 
lung inflammation and repair, and the implication of NS1 in these mechanisms. 
 
Surprisingly, only one gene (MICALC) was shared between cells infected with U/63 
mutant viruses (Figure 6-19), while a large number of up-regulated genes (57 in total) were 
found in common between cells infected with U/63 E186K-containing viruses. Importantly, 
these genes were involved in immune responses, fibroblasts differentiation, migration and 
tissue remodelling, DNA stability, gene expression, regulation of the cell cycle and cell 
survival, synthesis and bioavailability of lipids, metabolic processes and minerals 
homeostasis. This tends to suggest that while NS1 C-terminus has only a negligible impact 
on U/63’s control of infected cells, E186 plays a major role in virus-host interaction and is 
necessary for general gene shutoff upon infection (Figure 6-20).  
 
Additionally, as seen in Figure 6-12, the O/03-WT virus activated a large number of 
cellular pathways, and notably up-regulated pathways involved in cell survival, such as the 
PI3K/AKT pathway, and down-regulated pathways associated with cell cycle arrest and cell 
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death (i.e. apoptosis signalling, telomerase signalling, cell cycle G1/S checkpoint 
regulation, p53 signalling, role of BRCA1 in DNA damage response, cell cycle G2/M 
checkpoint regulation). Interestingly, activation of AKT during an influenza virus infection 
is important to favour viral protein expression and regulate cell death in infected cells (Kuss-
Duerkop et al., 2017). Furthermore, activation of death receptor signalling pathways was 
previously associated with high pathogenicity in vivo (Park et al., 2015). Taken together, 
this data seems to indicate that O/03 possesses mechanisms to maintain cells alive and 
favour viral protein production, and a short version of NS1 with K186 may be important for 
this function. As the phosphorylation status of AKT during an influenza virus infection yields 
different outcomes (Kuss-Duerkop et al., 2017), it would be interesting to evaluate the 
different phosphorylation states of AKT in cells infected with O/03-WT and to compare it 
with the situation upon U/63 infection. Moreover, evaluating the impact of residue 186 and 
C-terminal tail on AKT phosphorylation status would be interesting. 
 
 
In summary, combining cellular gene profiling with reverse genetic techniques has 
given new insights into the cellular responses of equine cells to EIV infection. This approach 
has also highlighted the strain-specific roles of NS1. Although further work would be 
necessary to go beyond the current results, the data collected tends to indicate that NS1 
evolutionary markers E186K and the C-terminal truncation have a high impact on virus-host 
interaction and were likely detrimental for EIV adaptation to horses.  
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7. Final reflection and potential for future research 
 
The primary aim of this project was to identify molecular markers of adaptation of 
EIV to horses in the NS1 protein, the main viral antagonist of the host immune response. To 
aid with this investigation, a phylogenetic analysis was associated with cloning and site-
directed mutagenesis techniques, as well as with reporter assays in order to identify markers 
of evolution of NS1 function. Then, the impact of NS1 evolutionary markers on EIV infection 
phenotype and virus-host interaction was evaluated using by reverse genetic systems and 
high-throughput sequencing technologies. 
 
First by analysing the phylogenetic relationship of one-hundred-and-seventy-five EIV 
NS1 sequences (Chapter 4), and by comparing their amino acid sequences, fifteen residue 
changes fixed throughout evolution were identified. These changes correlated with previous 
reports from the literature (Murcia et al., 2011, Murcia et al., 2010, Barba and Daly, 2016). 
These changes comprised A112T and E186K substitutions in the early 1970s, R44K reversion 
and R59H, E71K, A86T and V230I substitutions in the early 1990s, and P216S substitution and 
C-terminal truncation (R220*) in the late 1990s. Although it was beyond the scope of this 
work, analysing in more detail the impact of each residue on NS1 function, as well as 
evaluating potential synergistic effects of these amino acids on NS1 function would be 
interesting. 
 
To move forward with the characterization of EIV NS1, thirteen phylogenetically 
distinct NS1 proteins spanning the entire EIV lineage were cloned into an expressing vector, 
and tested in reporter assays (Hale et al., 2010, Kochs et al., 2007, Turkington et al., 2015) 
to compare their function. It was observed that during the first decade post viral 
emergence, NS1 strongly repressed general gene expression through a CPSF30-dependent 
mechanism, which required the presence of a glutamic acid at position 186. However, 
approximately 10 years post emergence this amino acid changed for a lysine, which 
abolished NS1 interaction with CPSF30 and the subsequent block of general gene expression 
(Chapter 4). These findings were in accordance with previous reports from the literature 
describing a link between viral adaption to certain host species and the loss of CPSF30 
binding (Hale et al., 2010, Brown et al., 2001, Hossain et al., 2008). Interestingly, NS1 
residue 186 is a direct neighbour of the highly conserved tryptophan 187, which is known to 
regulate NS1 effector domain (ED) dimerization (Hale et al., 2008, Kerry et al., 2011). This 
dimerization has been shown to reinforce NS1 anti-IFN activity by strengthening dsRNA 
binding (Aramini et al., 2011). More importantly NS1 ED dimerization was shown to be 
incompatible with CPSF30 binding (Kerry et al., 2011). Thus, it is possible that the loss of 
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CPSF30 binding of EIV NS1 ten years post emergence, has allowed the protein to interact 
with new binding partners or unmasked or reinforced important functions that were 
selectively advantageous for EIV, such as anti-IFN activities. In accordance with this 
hypothesis, transfection experiments also revealed that the repression exerted by NS1 over 
the IFN-b induction remained strong throughout evolution, which suggested that maintaining 
control over one of the main anti-viral defence of the host was selectively advantageous for 
the virus (Chapter 4). 
Twenty years post emergence EIV NS1 was truncated of eleven-amino acids at its C-
terminus, due to a non-sense mutation at codon 220. Although the effect of this truncation 
on NS1 function was not as marked as the E186K substitution, it seemed to affect NS1 control 
of general gene expression and ISG induction in transfection experiments.  
In the future, it would be interesting to dissect in more details the contribution of NS1 
residue 186 and C-terminal tail in the protein anti-IFN action, as well as their potential 
contribution to other NS1 function. 
 
The impact of NS1 evolutionary markers, E186K and C-terminal truncation, on viral 
infection phenotype were then evaluated. To this end, two eight-plasmid reverse genetic 
systems, A/equine/Uruguay/1/1963 and A/equine/Ohio/1/2003, were used. U/63 is 
believed to be at the origin of the H3N8 EIV lineage and it naturally possesses a full-length 
NS1 protein harbouring E186. O/03 is the representative of Florida Clade 1 viruses currently 
circulating in the equine population, and expresses naturally a C-terminally truncated NS1 
protein harbouring K186. By site-directed mutagenesis (Chapter 5), mutant versions of these 
two viruses for NS1 residue 186 and C-terminus were engineered. Their ability to grow and 
spread infection in mammalian cells were then evaluated and compared with that of their 
respective wild-type viruses. Surprisingly, NS1 evolutionary markers appeared to affect viral 
infection phenotype in a virus-context and cell type-dependent manner. For instance, the 
viral fitness of the contemporary virus (O/03) seemed to strongly depend on the 
maintenance of both NS1 evolutionary markers, K186 and C-terminal truncation. Indeed, a 
short NS1 with K186 was essential for O/03 replication in the presence of type I IFN, as well 
as to limit the establishment of an antiviral state, and delay apoptosis (Chapter 5). These 
characteristics are likely to be significant fitness traits, as they not only render an important 
arm of the host antiviral response ineffective, but they also maintain the cellular resources 
available for longer. Unexpectedly, NS1 K186E substitution seemed to have a high fitness 
cost for the contemporary virus in equine cells, particularly when introduced in the context 
of a short NS1 protein (Chapter 5). Indeed, the O/03-K186E mutant virus did not grow in 
equine cells, and did not induce protein shutdown or apoptosis, and no ISG or viral protein 
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could be detected during infection. Interestingly, the O/03 double mutant virus containing 
also the K186E substitution was not as strongly attenuated. Indeed, this virus could replicate 
in equine cells, produce its own viral proteins, and shutdown cellular protein production at 
early times post infection. Several hypotheses can be formulated to explain these 
discrepancies: (1) potential new functions provided by the extension of the NS1 C-terminal 
tail, e.g. PABPII binding or interaction with PDZ-containing proteins (Obenauer et al., 2006), 
could have partially compensated for the loss of other functions following the restitution of 
CPSF30 binding; (2) the lack of protein shutoff by O/03-K186E single mutant virus could 
simply be due to the inability of this virus to express its own proteins, including NS1; (3) 
finally, to be able to shutdown protein production in equine cells a full length NS1 protein 
with a glutamic acid at position 186 could be necessary. Further work would be needed to 
test these hypotheses. 
 
In addition, both O/03 mutant viruses expressing a full-length NS1 protein were 
inducing apoptosis prematurely, and even more so when associated with E186K substitution. 
Accordingly, amino acids 181 to 185 have previously been involved in apoptosis delay via 
activation of the PI3K/Akt-pathway (Ehrhardt et al., 2006, Ehrhardt et al., 2007, Hale et 
al., 2006, Shin et al., 2007). However, the introduced mutations could also have affected 
the potential control of PKR activation (Fujimoto et al., 1998, Takizawa et al., 1996, 
Takizawa et al., 1995, Wada et al., 1995). Indeed, following dsRNA sensing, PKR is activated 
and starts a cascade of events leading to shutoff of protein production (Bergmann et al., 
2000, Hatada et al., 1999) and induction of apoptosis (Takizawa et al., 1996, Van Campen 
et al., 1989). It would be worth testing if O/03 WT NS1 and mutant can equally interfere 
with PKR function or activate the PI3K pathway. 
For U/63, although the effect of NS1 C-terminal truncation was negligible, the loss of CPSF30 
binding (via E186K substitution) reduced significantly growth kinetics at early times post 
infection. Since the capacity to rapidly produce a new progeny is likely to be important for 
viral emergence, the glutamic acid at position 186, and subsequent ability to interact with 
CPSF30 must have played an important role in EIV emergence.  
Interestingly, a similar evolution pattern to EIV NS1 has been observed for the North 
American ‘classical’ swine H1N1 lineage, whose NS segment is of avian origin. This virus 
maintained a full length NS1 protein until the mid-1960s, before introducing of a stop codon 
at position 220, as for EIV NS1, which resulted in an eleven-amino acids C-terminal 
truncation of the protein. These changes have subsequently been retained in the ‘classical’ 
swine H1N1 lineage until the present day (Hale et al., 2010).  
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Thus, the loss of CPSF30 binding and C-terminal truncation of NS1 seem to be a 
common evolutionary trait between swine and equine Influenza A viruses. Interestingly, 
human influenza A viruses seem somewhat different, and preferentially select for NS1 
proteins binding CPSF30. For example, the NS1 protein of H5N1 viruses presented a defect 
in inhibiting general gene expression when the transmission occurred from birds to humans 
in 1997, however the viruses isolated since 1998 have gained this NS1 function (Twu et al., 
2007, Clark et al., 2017). It would be interesting to compare the advantages and downsides 
of losing the CPSF30 binding and or the C-terminal tail in different hosts species. 
  
To evaluate the impact of NS1 evolutionary markers on virus-host interaction the 
early gene expression profile of equine cells infected with wild-type and NS1 mutant viruses 
were analysed (Chapter 6). NS1 residue 186 and C-terminal tail were shown to affect host 
and viral gene expression in a virus-context dependent manner. The concomitant 
introduction of K186E substitution and C-terminal extension in O/03 NS1 led to an increased 
expression of HA, NA and NS viral genes, and decreased NP gene expression. Interestingly, 
previous reports from the literature showed that an increased expression of HA, NA and NS 
were associated with an increased replication efficiency early post infection (Park et al., 
2015). Feature that was also observed for O/03-K186E-230 (Chapter 5). Although it was 
beyond the scope of this work, it would be of great interest to analyse in details the 
mechanisms behind this phenotype. 
 
To identify possible biological interactions of cellular genes differentially expressed 
upon infection and identify important functional networks affected by EIV and modulated 
by NS1 evolutionary markers, the Ingenuity pathway analysis tool was used (Chapter 6). It 
was observed that the wild-type O/03 virus was able to activate a large number of cellular 
pathways, and notably to up-regulate cell survival pathways, such as the PI3K/AKT pathway, 
while down-regulating pathways associated with cell cycle arrest and cell death. More 
importantly, a short NS1 protein with K186 was important for these functions, as none of 
the O/03 mutants were able to do so. 
 
In addition, all viruses apart from the wild-type O/03 virus were unable to control 
several key anti-viral players, such as IFN, IRF, or RIG-I pathways (Chapter 6), which was 
consistent with their attenuated phenotype in interferon competent equine cells (Chapter 
5). This further emphasises the importance of NS1 evolutionary markers in EIV adaptation 
to horses, but also suggests that NS1 in not sufficient to improve viral fitness of an emergent 
virus. 
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Finally, some inflammatory pathways were downregulated by the wild-type O/03 
virus, such as IL-17A, IL-6 or TNFR1 signalling, while others were activated, such as LPS/IL-
1, FceRI, or IL-8 signalling. More importantly, the U/63 double mutant virus positively 
regulated the FceRI signalling pathway as well, which has previously been associated with 
asthma pathogenesis (Lloyd and Marsland, 2017). This raises questions of the impact of 
exposure to Influenza viruses on exacerbation of chronic lung diseases. 
 
Altogether these data suggest that the emergent EIV, which lacked the ability to 
control efficiently the host antiviral response, relied on a strong shutdown of general gene 
expression via an NS1-CPSF30-dependent mechanism. In doing so, the un-adapted virus 
created a short window during which it could take control of host gene expression, and 
produce and transmit a new progeny, before being outcompeted by the host immune 
response. But, this approach had strong negative impacts on host cell homeostasis, and was 
associated with to a premature induction of apoptosis. However, as the virus evolved in the 
new host, genetic mutations arose, and those that improved control of the host anti-viral 
responses while promoting cell survival were preferentially selected. This allowed the 
maintenance of the cellular resources for longer by delaying apoptosis induction, and overall 
increased replication efficiency (Figure 7.1). 
 
 
Figure 7.1: Summary of the functional evolution of the EIV NS1 protein from viral emergence 
to date 
 
A schematic representation of the molecular evolution of the NS1 protein of the H3N8 EIV during 50 
years of circulation of the virus in the equine population is shown. Markers of evolution of the NS1 
protein are indicated in red, and the consequences of these changes on virus-host interaction and 
consequences on EIV infection phenotype are indicated.  
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Ø A/equine/Uruguay/1/1963 
 
NS segment (CY032425): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TTGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAGAGG  AAGAGGCAGC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CATGCAGGAA  AGCAGATAGT  GGAGCGGATT  CTGGAAGAGG 
 241  AGTCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TGCTTCACGC  TACCTAACTG 
 301  ACATGACTCT  TGATGAGATA  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAAAAAGTAG 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATCATGGA  TAAGAACATC  ATACTAAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AGACACTAAT  ACTACTTAGG  GCTTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTGCCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TGAATGGAAT  GATAACACAG 
 601  TTAGAGTCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  GATGGGAGAC 
 661  CTTCATTCCC  TCCAAAGCAG  AAACGAAAAA  TGGCGAGAAC  AATTGAGTCA  GAAGTTTGAA 
 721  GAAATAAGGT  GGTTGATTGA  AGAAGTGCGA  CATAGACTGA  AAATTACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTGGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (ACD85423): 693 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTTGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  GAGGAAGAGG  CAGCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCATGCA 
 181  GGAAAGCAGA  TAGTGGAGCG  GATTCTGGAA  GAGGAGTCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTGCTTC  ACGCTACCTA  ACTGACATGA  CTCTTGATGA  GATATCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAAAAA  GTAGCAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATCA  TGGATAAGAA  CATCATACTA  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAGACAC  TAATACTACT  TAGGGCTTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTGC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTGAATG  GAATGATAAC  ACAGTTAGAG  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA  TGAGGATGGG  AGACCTTCAT  TCCCTCCAAA  GCAGAAACGA 
 661  AAAATGGCGA  GAACAATTGA  GTCAGAAGTT  TGA 
 
 
NS1 amino acid sequence (ACD85423): 230 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLRGRGSTL  GLDIETATHA 
 61  GKQIVERILE  EESDEALKMT  IASVPASRYL  TDMTLDEISR  DWFMLMPKQK  VAGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLEWNDN  TVRVSETLQR  FAWRSSHEDG  RPSFPPKQKR  KMARTIESEV 
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Ø A/equine/Miami/1/1963 
 
NS segment (CY028840): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TTGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAGAGG  AAGAGGCAGC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CGTGCAGGAA  AGCAGATAGT  GGAGCGGATT  CTGGAAGAGG 
 241  AGTCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TGCTTCACGC  TACCTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAGAAAGTAG 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATCATGGA  TAAGAACATC  ATACTAAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AGACACTAAT  ACTACTTAGG  GCTTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTGCCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TGAATGGAAT  GATAACACAG 
 601  TTAGAGTCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TCCAAAGCAG  AAACGAAAAA  TGGCGAGAAC  AATTGAGTCA  GAAGTTTGAA 
 721  GAAATAAGGT  GGTTGATTGA  AGAAGTGCGA  CATAGACTGA  AAATTACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTGGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (ABY81497): 693 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTTGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  GAGGAAGAGG  CAGCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCGTGCA 
 181  GGAAAGCAGA  TAGTGGAGCG  GATTCTGGAA  GAGGAGTCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTGCTTC  ACGCTACCTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAGAAA  GTAGCAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATCA  TGGATAAGAA  CATCATACTA AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAGACAC  TAATACTACT TAGGGCTTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTGC  CTTCTCTTCC AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTGAATG  GAATGATAAC  ACAGTTAGAG  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA TGAGAATGGG  AGACCTTCAT  TCCCTCCAAA  GCAGAAACGA 
 661  AAAATGGCGA  GAACAATTGA  GTCAGAAGTT  TGA 
 
 
NS1 amino acid sequence (ABY81497): 230 aa  
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLRGRGSTL  GLDIETATRA 
 61  GKQIVERILE  EESDEALKMT  IASVPASRYL  TDMTLDEMSR  DWFMLMPKQK  VAGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLEWNDN  TVRVSETLQR FAWRSSHENG  RPSFPPKQKR  KMARTIESEV 
 
 
 
  201 
APPENDIX 9: Sequences of 13 representative EIVs – Part 3  
 
 
Ø A/equine/SaoPaulo/1/1969 
 
NS segment (CY032401): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATCCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TTGCGGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAGAGG  AAGAGGCAGC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CGTGCAGGAA  AGCAGATAGT  GGAGCAGATT  CTGGAAGAGG 
 241  AGTCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TGCTTCACGC  TACCTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAGAAAGTAG 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATCATGGA  TAAGAACATT  ATACTAAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AAACACTAAT  ACTACTTAGG  GCTTTCACCG 
 481  AAGAAGGAGC  AATCGTTGGC  GAAATTTCAC  CATTGCCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TGAATGGAAT  GATAACACAG 
 601  TTAGAGTCTC  TGAAACTCTA  CAGAGATTCA  CTTGGAGAAG  CAGTCATGAG  GATAGGAGAC 
 661  CTTCATTCCC  TCCAAAGCAG  AAACGAAAAA  TGGCGAGAAC  AATTGAGTCA  GAAGTTTGAA 
 721  GAAATAAGGT  GGTTGATTGA  AGAAGTGCGA  CATAGACTGA  AAATTACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTGGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (ACD85390): 693 bp 
 
 1  ATGGATCCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTTGCGG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  GAGGAAGAGG  CAGCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCGTGCA 
 181  GGAAAGCAGA  TAGTGGAGCA  GATTCTGGAA  GAGGAGTCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTGCTTC  ACGCTACCTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAGAAA  GTAGCAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATCA  TGGATAAGAA  CATTATACTA  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAAACAC  TAATACTACT  TAGGGCTTTC  ACCGAAGAAG  GAGCAATCGT  TGGCGAAATT 
 481  TCACCATTGC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTGAATG  GAATGATAAC  ACAGTTAGAG  TCTCTGAAAC  TCTACAGAGA 
 601  TTCACTTGGA  GAAGCAGTCA  TGAGGATAGG  AGACCTTCAT  TCCCTCCAAA  GCAGAAACGA 
 661  AAAATGGCGA  GAACAATTGA  GTCAGAAGTT  TGA 
 
 
NS1 amino acid sequence (ACD85390): 230 aa 
 
 1  MDPNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLRGRGSTL  GLDIETATRA 
 61  GKQIVEQILE  EESDEALKMT  IASVPASRYL  TDMTLDEMSR  DWFMLMPKQK  VAGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAIVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLEWNDN  TVRVSETLQR  FTWRSSHEDR  RPSFPPKQKR  KMARTIESEV 
 
  202 
APPENDIX 10: Sequences of 13 representative EIVs – Part 4 
 
 
Ø A/equine/Fontainebleau/1/1979 
 
NS segment (CY032409): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TTGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAAAGG  AAGAGGCAGC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CGTGCAGGAA  AGCAAATAGT  GGAGCGGATT  CTGGAAGAGG 
 241  AGTCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TGCTTCACGC  TACTTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAGAAAGTAA 
 361  CAGGCTCCCT  ATGTGTAAGG  ATGGACCAGG  CAATCATGGA  TAAGAACATC  ATACTAAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AGACACTAAT  AATACTTAGA  GCTTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTGCCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TAAATGGAAT  GATAACACAG 
 601  TTAGAGTCTC  TGAAGCTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTAATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TCCAAAACAG  AAACGAAAAA  TGGCGAGAAC  AATTGAGTCA  GAAGTTTGAA 
 721  GAAATAAGAT  GGTTGATTGA  AGAAGTGCGA  CATAGATTGA  AAAATACAGA  AAATAGTTTT 
 781  GAACAAATCA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTAGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (ACD85401): 693 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTTGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  AAGGAAGAGG  CAGCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCGTGCA 
 181  GGAAAGCAAA  TAGTGGAGCG  GATTCTGGAA  GAGGAGTCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTGCTTC  ACGCTACTTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAGAAA  GTAACAGGCT  CCCTATGTGT  AAGGATGGAC 
 361  CAGGCAATCA  TGGATAAGAA  CATCATACTA  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAGACAC  TAATAATACT  TAGAGCTTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTGC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTAAATG  GAATGATAAC  ACAGTTAGAG  TCTCTGAAGC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTAA  TGAGAATGGG  AGACCTTCAT  TCCCTCCAAA  ACAGAAACGA 
 661  AAAATGGCGA  GAACAATTGA  GTCAGAAGTT  TGA 
 
 
NS1 amino acid sequence (ACD85401): 230 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLKGRGSTL  GLDIETATRA 
 61  GKQIVERILE  EESDEALKMT  IASVPASRYL  TDMTLDEMSR  DWFMLMPKQK VTGSLCVRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLIILRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLKWNDN  TVRVSEALQR  FAWRSSNENG  RPSFPPKQKR  KMARTIESEV  
 
 
 
  203 
APPENDIX 11: Sequences of 13 representative EIVs – Part 5 
 
 
Ø A/equine/Sussex/1/1989 
 
NS segment (CY032321): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TTGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAAAGG  AAGAGGTAGC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CGTGCAGGAA  AGCAGATAGT  GGAGCAGATT  CTGGAAGAGG 
 241  AATCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TGCTTCACGC  TACTTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAGAAAGTAA 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAAG  CAATCATGGA  TAAGAACATC  ATACTTAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AGACACTAAT  ACTACTTAGA  GCCTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTGCCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TAAATGGAAT  GATAATACGG 
 601  TTAGAGTCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TCCAAAGCAG  AAACGAAAAA  TGGAGAGAAC  AATTGAGCCA  GAAGTTTGAA 
 721  GAAATAAGAT  GGTTGATTGA  AGAAGTGCGA  CATAGATTGA  AAAATACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTAGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (ACD97430): 693 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTTGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  AAGGAAGAGG  TAGCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCGTGCA 
 181  GGAAAGCAGA  TAGTGGAGCA  GATTCTGGAA  GAGGAATCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTGCTTC  ACGCTACTTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAGAAA  GTAACAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAAGCAATCA  TGGATAAGAA  CATCATACTT  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAGACAC  TAATACTACT  TAGAGCCTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTGC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTAAATG  GAATGATAAT  ACGGTTAGAG  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA  TGAGAATGGG  AGACCTTCAT  TCCCTCCAAA  GCAGAAACGA 
 661  AAAATGGAGA  GAACAATTGA  GCCAGAAGTT  TGA 
 
 
NS1 amino acid sequence (ACD97430): 230 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLKGRGSTL  GLDIETATRA 
 61  GKQIVEQILE  EESDEALKMT  IASVPASRYL  TDMTLDEMSR  DWFMLMPKQK  VTGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLKWNDN  TVRVSETLQR  FAWRSSHENG  RPSFPPKQKR  KMERTIEPEV 
 
 
  204 
APPENDIX 12: Sequences of 13 representative EIVs – Part 6 
 
 
Ø A/equine/Kentucky/1/1991 
 
NS segment (CY030177): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TTGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAAAGG  AAGAGGTAGC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CGTGCAGGAA  AGCAGATAGT  GGAGCAGATT  CTGGAAGAGG 
 241  AATCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TGCTTCACGC  TACTTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAGAAAGTAA 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATCATGGA  TAAGAACATC  ATACTTAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AGACACTAAT  ACTACTTAGA  GCCTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTGCCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TAAATGGAAT  GATAATACGG 
 601  TTAGAATCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TCCAAAGCAG  AAACGAAAAA  TGGAGAGAAC  AATTGAGCCA  GAAGTTTGAA 
 721  GAAATAAGAT  GGTTGATTGA  AGAAGTGCGA  CATAGATTGA  AAAATACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTAGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (ACA24672): 693 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTTGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  AAGGAAGAGG  TAGCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCGTGCA 
 181  GGAAAGCAGA  TAGTGGAGCA  GATTCTGGAA  GAGGAATCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTGCTTC  ACGCTACTTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAGAAA  GTAACAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATCA  TGGATAAGAA  CATCATACTT  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAGACAC  TAATACTACT  TAGAGCCTTC  ACCGAAGAAG  GAGCAGTCGT TGGCGAAATT 
 481  TCACCATTGC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTAAATG  GAATGATAAT  ACGGTTAGAA  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA  TGAGAATGGG  AGACCTTCAT  TCCCTCCAAA  GCAGAAACGA 
 661  AAAATGGAGA  GAACAATTGA  GCCAGAAGTT  TGA 
 
 
NS1 amino acid sequence (ACA24672): 230 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLKGRGSTL  GLDIETATRA 
 61  GKQIVEQILE  EESDEALKMT  IASVPASRYL  TDMTLDEMSR  DWFMLMPKQK  VTGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLKWNDN  TVRISETLQR  FAWRSSHENG  RPSFPPKQKR  KMERTIEPEV  
 
 
 
  205 
APPENDIX 13: Sequences of 13 representative EIVs – Part 7 
 
 
Ø A/equine/LaPlata/1/1995 
 
NS segment (MF182460): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TTGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAAAGG  AAGAGGTAGC  ACTCTTGGTC 
 181  TAGACATCGA  AACAGCCACT  CGTGCAGGAA  AGCAGATAGT  GGAGCAGATT  CTGGAAGAGG 
 241  AATCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TGCTTCACGC  TACTTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAGAAAGTAA 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATCATGGA  TAAGAACATC  GTACTTAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AAACACTAAT  ACTACTTAGA  GCCTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTGCCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TAAATGGAAT  GATAATACGG 
 601  TTAGAATCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TCCAAAGCAG  AAACGAAAAA  TGGAGAGAAC  AATTGAGCCA  GAAGTTTGAA 
 721  GAAATAAGAT  GGTTGATTGA  AGAAGTGCGA  CATAGATTGA  GAAATACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTAGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (unassigned): 693 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTTGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  AAGGAAGAGG  TAGCACTCTT  GGTCTAGACA  TCGAAACAGC  CACTCGTGCA 
 181  GGAAAGCAGA  TAGTGGAGCA  GATTCTGGAA  GAGGAATCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTGCTTC  ACGCTACTTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAGAAA  GTAACAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATCA  TGGATAAGAA  CATCGTACTT  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAAACAC  TAATACTACT  TAGAGCCTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTGC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTAAATG  GAATGATAAT  ACGGTTAGAA  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA  TGAGAATGGG  AGACCTTCAT  TCCCTCCAAA  GCAGAAACGA 
 661  AAAATGGAGA  GAACAATTGA  GCCAGAAGTT  TGA 
 
 
NS1 amino acid sequence (unassigned): 230 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLKGRGSTL  GLDIETATRA 
 61  GKQIVEQILE  EESDEALKMT  IASVPASRYL  TDMTLDEMSR  DWFMLMPKQK  VTGSLCIRMD 
 121  QAIMDKNIVL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLKWNDN  TVRISETLQR  FAWRSSHENG  RPSFPPKQKR  KMERTIEPEV 
 
 
  206 
APPENDIX 14: Sequences of 13 representative EIVs – Part 8 
 
 
Ø A/equine/Kentucky/1995 
 
NS segment (MF182451): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TCGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAGGGG  AAGAGGTAGC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CATGCAGGAA  AGCAGATAGT  GGAGCAGATT  CTGGAAAAGG 
 241  AATCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TACTTCACGC  TACTTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAGAAAGTAA 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATCATGGA  TAAGAACATC  ATACTTAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AAACACTAAT  ACTACTTAGA  GCCTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTACCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TAAATGGAAT  GATAATACGG 
 601  TTAGAATCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TCCAAAGCAG  AAACGAAAAA  TGGAGAGAAC  AATTGAGCCA  GAAATTTGAA 
 721  GAAATAAGAT  GGTTGATTGA  AGAAGTGCGA  CATAGATTGA  AAAATACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTAGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (unassigned): 693 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTCGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  GGGGAAGAGG  TAGCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCATGCA 
 181  GGAAAGCAGA  TAGTGGAGCA  GATTCTGGAA  AAGGAATCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTACTTC  ACGCTACTTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAGAAA  GTAACAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATCA  TGGATAAGAA  CATCATACTT  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAAACAC  TAATACTACT  TAGAGCCTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTAC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTAAATG  GAATGATAAT  ACGGTTAGAA  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA  TGAGAATGGG  AGACCTTCAT  TCCCTCCAAA  GCAGAAACGA 
 661  AAAATGGAGA  GAACAATTGA  GCCAGAAATT  TGA 
 
 
NS1 amino acid sequence (unassigned): 230 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLRGRGSTL  GLDIETATHA 
 61  GKQIVEQILE  KESDEALKMT  IASVPTSRYL  TDMTLDEMSR  DWFMLMPKQK  VTGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLKWNDN  TVRISETLQR  FAWRSSHENG  RPSFPPKQKR  KMERTIEPEI * 
 
 
  207 
APPENDIX 15: Sequences of 13 representative EIVs – Part 9 
 
 
Ø  A/equine/Kentucky/1999 
 
NS segment (MF182443): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TCGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAGGGG  AAGAGGTAGC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CATGCAGGAA  AGCAGATAGT  GGAGCAGATT  CTGGAAAAGG 
 241  AATCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TACTTCACGC  TACTTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAAAAAGTAA 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATCATGGA  TAAGAACATC  ATACTTAAAG 
 421  CAAACTTTAG  TGTGATTKTC  GAAAGGCTGG  AAACACTAAT  ACTACTTAGA  GCCTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTACCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TAAATGGAAT  GATAATACGG 
 601  TTAGAATCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TTCAAAGCAG  AAATGAAAAA  TGGAGAGAAC  AATTGAGCCA  GAAATTTGAA 
 721  GAAATAAGAT  GGTTGATTGA  AGAAGTGCGA  CATAGATTGA  AAAATACAGA  GAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTAGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (unassigned): 660 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTCGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  GGGGAAGAGG  TAGCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCATGCA 
 181  GGAAAGCAGA  TAGTGGAGCA  GATTCTGGAA  AAGGAATCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTACTTC  ACGCTACTTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAAAAA  GTAACAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATCA  TGGATAAGAA  CATCATACTT  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAAACAC  TAATACTACT  TAGAGCCTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTAC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTAAATG  GAATGATAAT  ACGGTTAGAA  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA  TGAGAATGGG  AGACCTTCAT  TCCCTTCAAA  GCAGAAATGA 
 
 
NS1 amino acid sequence (unassigned): 219 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLRGRGSTL  GLDIETATHA 
 61  GKQIVEQILE  KESDEALKMT  IASVPTSRYL  TDMTLDEMSR  DWFMLMPKQK  VTGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLKWNDN  TVRISETLQR  FAWRSSHENG  RPSFPSKQK 
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APPENDIX 16: Sequences of 13 representative EIVs – Part 10 
 
 
Ø A/equine/Kentucky/5/2002 
 
NS segment (DQ124185): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TCGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAGGGG  AAGAGGTATC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CATGCAGGAA  AGCAGATAGT  GGAGCAGATT  CTGGAAAAGG 
 241  AATCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TACTTCACGC  TACTTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAAAAAGTAA 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATCATGGA  TAAGAACATC  ATACTTAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AAACACTAAT  ACTACTTAGA  GCCTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTACCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TAAATGGAAT  GATAATACGG 
 601  TTAGAATCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TTCAAAGCAG  AAATGAAAAA  TGGAGAGAAC  AATTAAGCCA  GAAATTTGAA 
 721  GAAATAAGAT  GGTTGATTGA  AGAAGTGCGA  CATAGATTGA  AAAATACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTAGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (ABA42429): 660 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTCGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  GGGGAAGAGG  TATCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCATGCA 
 181  GGAAAGCAGA  TAGTGGAGCA  GATTCTGGAA  AAGGAATCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTACTTC  ACGCTACTTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAAAAA  GTAACAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATCA  TGGATAAGAA  CATCATACTT  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAAACAC  TAATACTACT  TAGAGCCTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTAC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTAAATG  GAATGATAAT  ACGGTTAGAA  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA  TGAGAATGGG  AGACCTTCAT  TCCCTTCAAA  GCAGAAATGA 
 
 
NS1 amino acid sequence (ABA42429): 219 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLRGRGITL  GLDIETATHA 
 61  GKQIVEQILE  KESDEALKMT  IASVPTSRYL  TDMTLDEMSR  DWFMLMPKQK  VTGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLKWNDN  TVRISETLQR  FAWRSSHENG  RPSFPSKQK 
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APPENDIX 17: Sequences of 13 representative EIVs – Part 11 
 
 
Ø  A/equine/Newmarket/5/2003 
 
NS segment (FJ375209): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TCGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAGGGG  AAGAGGTATC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CATGCAGGAA  AGCAGATAGT  GGAGCAGATT  CTGGAAAAGG 
 241  AATCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTATTCC  TACTTCACGC  TACTTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAAAAAGTAA 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATCATGGA  TAAAAACATC  ATACTTAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AAACACTAAT  ACTACTTAGA  GCCTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTACCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TAAATGGAAT  GATAATACGG 
 601  TTAGAATCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TTCAAAGCAG  AAATGAAAAA  TGGAGAGAAC  AATTAAGCCA  GAAATTTGAA 
 721  GAAATAAGAT  GGTTGATTGA  AGAAGTGCGA  CATAGATTGA  AAAATACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTAGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (ACI48802): 660 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTCGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  GGGGAAGAGG  TATCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCATGCA 
 181  GGAAAGCAGA  TAGTGGAGCA  GATTCTGGAA  AAGGAATCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTA  TTCCTACTTC  ACGCTACTTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAAAAA  GTAACAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATCA  TGGATAAAAA  CATCATACTT  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAAACAC  TAATACTACT  TAGAGCCTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTAC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTAAATG  GAATGATAAT  ACGGTTAGAA  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA  TGAGAATGGG  AGACCTTCAT  TCCCTTCAAA  GCAGAAATGA 
 
 
NS1 amino acid sequence (ACI48802): 219 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLRGRGITL  GLDIETATHA 
 61  GKQIVEQILE  KESDEALKMT  IASIPTSRYL  TDMTLDEMSR  DWFMLMPKQK  VTGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLKWNDN  TVRISETLQR  FAWRSSHENG  RPSFPSKQK 
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APPENDIX 18: Sequences of 13 representative EIVs – Part 12 
 
 
Ø A/equine/Ohio/1/2003 
 
NS segment (DQ124186): 890 bp 
 
 1  AGCAAAAGCA GGGTGACAAA AACATAATGG ATTCCAACAC TGTGTCAAGC TTTCAGGTAG 
 61 ACTGTTTTCT  TTGGCATGTC  CGCAAACGAT  TCGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAGGGG  AAGAGGTAGC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CATGCAGGAA  AGCAGATAGT  GGAGCAGATT  CTGGAAAAGG 
 241  AATCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTGTTCC  TACTTCACGC  TACTTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAAAAAGTAA 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATCATGGA  TAAGAACATC  ATACTTAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AAACACTAAT  ACTACTTAGA  GCCTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTACCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TAAATGGAAT  GATAATACGG 
 601  TTAGAATCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TTCAAAGCAG  AAATGAAAAA  TGGAGAGAAC  AATTAAGCCA  GAAATTTGAA 
 721  GAAATAAGAT  GGTTGATTGA  AGAAGTGCGA  CATAGATTGA  AAAATACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTAGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (ABA42431): 660 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGCAAA 
 61  CGATTCGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  GGGGAAGAGG  TAGCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCATGCA 
 181  GGAAAGCAGA  TAGTGGAGCA  GATTCTGGAA  AAGGAATCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTG  TTCCTACTTC  ACGCTACTTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAAAAA  GTAACAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATCA  TGGATAAGAA  CATCATACTT  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAAACAC  TAATACTACT  TAGAGCCTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTAC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTAAATG  GAATGATAAT  ACGGTTAGAA  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA  TGAGAATGGG  AGACCTTCAT  TCCCTTCAAA  GCAGAAATGA 
 
 
NS1 amino acid sequence (ABA42431): 219 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLRGRGSTL  GLDIETATHA 
 61  GKQIVEQILE  KESDEALKMT  IASVPTSRYL  TDMTLDEMSR  DWFMLMPKQK  VTGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLKWNDN  TVRISETLQR  FAWRSSHENG  RPSFPSKQK  
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APPENDIX 19: Sequences of 13 representative EIVs – Part 13 
 
 
Ø A/equine/Mongolia/3/2013 
 
NS segment (MF182459): 890 bp 
 
 1  AGCAAAAGCA  GGGTGACAAA  AACATAATGG  ATTCCAACAC  TGTGTCAAGC  TTTCAGGTAG 
 61  ACTGTTTTCT  TTGGCATGTC  CGTAAACGAT  TCGCAGACCA  AGAACTGGGT  GATGCCCCAT 
 121  TCCTTGACCG  GCTTCGCCGA  GACCAGAAGT  CCCTAAGAAG  AAGAGGTATC  ACTCTTGGTC 
 181  TGGACATCGA  AACAGCCACT  CATGCAGGAA  AGCAGATAGT  GGAGCAGATT  CTGGAAAAGG 
 241  AATCAGATGA  GGCACTTAAA  ATGACCATTG  CCTCTATTCC  TACTTCACGT  TACTTAACTG 
 301  ACATGACTCT  TGATGAGATG  TCAAGAGACT  GGTTCATGCT  CATGCCCAAG  CAAAAAGTAA 
 361  CAGGCTCCCT  ATGTATAAGA  ATGGACCAGG  CAATTATGGA  TAAGAACATC  ATACTTAAAG 
 421  CAAACTTTAG  TGTGATTTTC  GAAAGGCTGG  AAACACTAAT  ACTACTTAGA  GCCTTCACCG 
 481  AAGAAGGAGC  AGTCGTTGGC  GAAATTTCAC  CATTACCTTC  TCTTCCAGGA  CATACTAATG 
 541  AGGATGTCAA  AAATGCAATT  GGGGTCCTCA  TCGGAGGACT  TAAATGGAAT  GATAATACGG 
 601  TTAGAATCTC  TGAAACTCTA  CAGAGATTCG  CTTGGAGAAG  CAGTCATGAG  AATGGGAGAC 
 661  CTTCATTCCC  TTCAAAGCAG  AAATGAAAAA  TGGAGAGAAC  AATTAAGCCA  GAAATTTGAA 
 721  GAAATAAGAT  GGTTGATTGA  AGAAGTGCGA  CATAGATTGA  AAAATACAGA  AAATAGTTTT 
 781  GAACAAATAA  CATTTATGCA  AGCCTTACAA  CTATTGCTTG  AAGTGGAACA  AGAGATAAGA 
 841  ACTTTCTCGT  TTCAGCTTAT  TTAATGATAA  AAAACACCCT  TGTTTCTACT 
 
 
NS1 CDS (unassigned): 660 bp 
 
 1  ATGGATTCCA  ACACTGTGTC  AAGCTTTCAG  GTAGACTGTT  TTCTTTGGCA  TGTCCGTAAA 
 61  CGATTCGCAG  ACCAAGAACT  GGGTGATGCC  CCATTCCTTG  ACCGGCTTCG  CCGAGACCAG 
 121  AAGTCCCTAA  GAAGAAGAGG  TATCACTCTT  GGTCTGGACA  TCGAAACAGC  CACTCATGCA 
 181  GGAAAGCAGA  TAGTGGAGCA  GATTCTGGAA  AAGGAATCAG  ATGAGGCACT  TAAAATGACC 
 241  ATTGCCTCTA  TTCCTACTTC  ACGTTACTTA  ACTGACATGA  CTCTTGATGA  GATGTCAAGA 
 301  GACTGGTTCA  TGCTCATGCC  CAAGCAAAAA  GTAACAGGCT  CCCTATGTAT  AAGAATGGAC 
 361  CAGGCAATTA  TGGATAAGAA  CATCATACTT  AAAGCAAACT  TTAGTGTGAT  TTTCGAAAGG 
 421  CTGGAAACAC  TAATACTACT  TAGAGCCTTC  ACCGAAGAAG  GAGCAGTCGT  TGGCGAAATT 
 481  TCACCATTAC  CTTCTCTTCC  AGGACATACT  AATGAGGATG  TCAAAAATGC  AATTGGGGTC 
 541  CTCATCGGAG  GACTTAAATG  GAATGATAAT  ACGGTTAGAA  TCTCTGAAAC  TCTACAGAGA 
 601  TTCGCTTGGA  GAAGCAGTCA  TGAGAATGGG  AGACCTTCAT  TCCCTTCAAA  GCAGAAATGA 
 
 
NS1 amino acid sequence (unassigned): 219 aa 
 
 1  MDSNTVSSFQ  VDCFLWHVRK  RFADQELGDA  PFLDRLRRDQ  KSLRRRGITL  GLDIETATHA 
 61  GKQIVEQILE  KESDEALKMT  IASIPTSRYL  TDMTLDEMSR  DWFMLMPKQK  VTGSLCIRMD 
 121  QAIMDKNIIL  KANFSVIFER  LETLILLRAF  TEEGAVVGEI  SPLPSLPGHT  NEDVKNAIGV 
 181  LIGGLKWNDN  TVRISETLQR  FAWRSSHENG  RPSFPSKQK 
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APPENDIX 20: Ambisense plasmid stocks of U/63 and O/03 viruses. 
 
Two sets of 8 ambisense expression plasmids encoding for the viral segments of U/63 and O/03, were 
grown as described in the method section. A specific PCR was done for each segment and the PCR 
products were run on a 1% agarose gel to check for their respective size. The number of base pairs 
(total bp) found in each segment is indicated below the gel, under the corresponding band. 
 
 
   
850 bp
1 kb
5000 bp
U/63
PB1PB2 NAHAPA M NSNP 1 kb
1000 bp
1650 bp
2000 bp
1 kb
850 bp
5000 bp
1000 bp
1650 bp
2000 bp
O/03
PB1PB2 NAHAPA M NSNP
1762 1762890 8901027 10271461 14611565 15652233 22332341 23412341 2341Total bp:
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APPENDIX 21: Sequencing of U/63 & O/03 PB2 segments – Part 1 
 
Nucleotide sequence alignment 
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APPENDIX 22: Sequencing of U/63 & O/03 PB2 segments – Part 2 
 
Amino acid sequence alignment  
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APPENDIX 23: Sequencing of U/63 & O/03 PB1 segments – Part 1 
 
Nucleotide sequence alignment 
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APPENDIX 24: Sequencing of U/63 & O/03 PB1 segments – Part 2 
 
Amino acid sequence alignment 
 
Ø PB1 
 
 
Ø PB1-F2 
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APPENDIX 25: Sequencing of U/63 & O/03 PA segments – Part 1 
 
Nucleotide sequence alignment 
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APPENDIX 26: Sequencing of U/63 & O/03 PA segments – Part 2 
 
Amino acid sequence alignment 
 
Ø PA 
 
 
Ø PA-X 
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APPENDIX 27: Sequencing of U/63 & O/03 HA segments 
 
Nucleotide sequence alignment 
 
 
Amino acid sequence alignment 
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APPENDIX 28: Sequencing of U/63 & O/03 NP segments 
 
Nucleotide sequence alignment 
 
 
 
Amino acid sequence alignment 
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APPENDIX 29: Sequencing of U/63 & O/03 NA segments 
 
Nucleotide sequence alignment 
 
 
 
Amino acid sequence alignment 
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APPENDIX 30: Sequencing of U/63 & O/03 M segments 
 
Nucleotide sequence alignment 
 
 
Amino acid sequence alignment 
 
Ø M1 
 
 
Ø M2 
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APPENDIX 31: Alignment of U/63 and O/03 NS segment 
 
Nucleotide sequence alignment 
 
 
 
Amino acid sequence alignment 
 
Ø NS1 
 
 
Ø NS2 
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APPENDIX 32: Alignment of U/63 NS WT and mutant inserts in ambisense plasmid 
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APPENDIX 33: Alignment of O/03 NS WT and mutant inserts in ambisense plasmid 
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APPENDIX 34: Mutation of codon 186 and 220 in NS ambisense plasmid 
 
 
NEP A(n)L(TTA/G)
N
(AAT/C)
NS1	O/03	K186E	230 A(n)E(GAA)
R
(CGA)
NS1	O/03	230 A(n)K(AAA)
R
(CGA)
NS1	O/03	K186E A(n)E(GAA)
*
(TGA)
NS1	O/03 A(n)K(AAA)
*
(TGA)
NS	segment
1 890	nt582-584nt 684-686nt
NS	segment
WTDouble	mutant
NEP
NS1
U/63 O/03
WT Double	mutant
K186E
E186K
219
230
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APPENDIX 35: List of DEGs INO/03-infected samples – Part 1 
 
 
  
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000010153 IFIT3 Up15 2.8169 Up2 5.21902 Up3 3.73116 Up3 4.28147
ENSECAG00000027377 5_8S_rRNA Up39 1.31487 Up12 2.86602 Up14 1.38835 Up15 1.73267
ENSECAG00000023135 LYRM7 Up53 1.06639 Up57 0.740132 Up43 0.941237 Up34 1.03292
ENSECAG00000004574 ENSECAG00000004574 Up41 1.23114 Up37 1.14136 Up53 0.879453 Up37 0.941438
ENSECAG00000004433 IFIT1 Up104 0.771454 Up7 4.13469 Up5 2.51653 Up9 3.1852
ENSECAG00000008899 LSS Down137 -0.624569 Down31 -0.820577 Down11 -0.962401 Down5 -1.00929
ENSECAG00000009202 TYSND1 Down27 -0.907853 Down18 -0.942333 Down32 -0.740013 Down48 -0.615778
ENSECAG00000004572 CH25H Down12 -1.13537 Down10 -1.04437 Down9 -1.01427 Down8 -0.977711
ENSECAG00000025867 U3 Up17 2.40357 Up15 2.44815 	 	 Up5 3.37152
ENSECAG00000019095 ENSECAG00000019095 Up46 1.16439 Up49 0.866737 	 	 Up56 0.704857
ENSECAG00000027676 ENSECAG00000027676 Up57 1.02918 Up35 1.1478 	 	 Up27 1.16402
ENSECAG00000016730 ENSECAG00000016730 Up85 0.84377 Up43 0.966973 	 	 Up39 0.893828
ENSECAG00000003015 SERPINB2 Up151 0.676015 Up58 0.684345 	 	 Up83 0.61405
ENSECAG00000019165 CENPK Up177 0.649676 Up65 0.581247 	 	 Up45 0.823367
ENSECAG00000016459 ENSECAG00000016459 Up190 0.642261 Up64 0.594166 	 	 Up89 0.609109
ENSECAG00000004107 DDIT4 Down175 -0.586586 Down103 -0.608796 	 	 Down25 -0.716045
ENSECAG00000000429 POLRMT Down157 -0.604098 Down82 -0.650021 	 	 Down47 -0.61954
ENSECAG00000019125 FASN Down155 -0.605124 Down32 -0.819688 	 	 Down27 -0.713131
ENSECAG00000012635 BRAT1 Down146 -0.611826 Down86 -0.641948 	 	 Down29 -0.692893
ENSECAG00000004005 MESDC1 Down134 -0.627071 Down37 -0.785754 	 	 Down49 -0.608919
ENSECAG00000018860 ZFP36L1 Down113 -0.653149 Down84 -0.64632 	 	 Down51 -0.60197
ENSECAG00000001989 SESN2 Down88 -0.698381 Down94 -0.62295 	 	 Down32 -0.682113
ENSECAG00000000607 TRIB3 Down50 -0.800805 Down38 -0.781903 	 	 Down11 -0.833385
ENSECAG00000013176 MEGF6 Down39 -0.842357 Down80 -0.665181 	 	 Down37 -0.664524
ENSECAG00000009989 CHAC1 Down29 -0.901175 Down27 -0.849656 	 	 Down23 -0.72979
ENSECAG00000011234 COL7A1 Down26 -0.926848 Down89 -0.636524 	 	 Down33 -0.675143
ENSECAG00000011475 ENSECAG00000011475 Down17 -1.05965 Down9 -1.08052 	 	 Down9 -0.924415
ENSECAG00000009190 TMSB4X Up58 1.02308 	 	 Up15 1.3809 Up68 0.658129
ENSECAG00000021345 POLR2K Up51 1.08059 	 	 Up22 1.25657 Up72 0.646725
ENSECAG00000009383 TBCA Up77 0.919505 	 	 Up13 1.39272 Up79 0.62422
ENSECAG00000013756 C8orf59 Up82 0.869592 	 	 Up87 0.730823 Up50 0.734264
ENSECAG00000020689 SPA17 Up197 0.633619 	 	 Up135 0.642672 Up94 0.600385
ENSECAG00000014624 SPX Up243 0.586334 	 	 Up119 0.671073 Up87 0.61023
ENSECAG00000008688 ENSECAG00000008688 Down100 -0.673453 Down101 -0.611868 Down2 -1.23933 	 	
ENSECAG00000019576 ENSECAG00000019576 Up3 inf 	 	 	 	 Up1 inf
ENSECAG00000020819 AGER Up26 1.65782 	 	 	 	 Up18 1.53619
ENSECAG00000005401 ENSECAG00000005401 Up32 1.48633 	 	 	 	 Up22 1.29573
ENSECAG00000012348 EFNB2 Up33 1.45556 	 	 	 	 Up30 1.08431
ENSECAG00000014338 EGR1 Up35 1.38557 	 	 	 	 Up23 1.27712
ENSECAG00000015342 CXCL8 Up40 1.30399 	 	 	 	 Up31 1.08159
ENSECAG00000007744 RSRP1 Up44 1.1724 	 	 	 	 Up36 0.979854
ENSECAG00000017181 PTGS2 Up67 0.954572 	 	 	 	 Up41 0.868289
ENSECAG00000001334 C3orf14 Up75 0.922307 	 	 	 	 Up64 0.671459
ENSECAG00000005903 ENSECAG00000005903 Up80 0.899233 	 	 	 	 Up44 0.825845
ENSECAG00000003755 PIGW Up87 0.833383 	 	 	 	 Up92 0.600669
ENSECAG00000007070 TPRKB Up101 0.80597 	 	 	 	 Up69 0.657097
ENSECAG00000025162 ATP5EP2 Up115 0.752403 	 	 	 	 Up78 0.631377
ENSECAG00000024911 ITGB3BP Up118 0.746261 	 	 	 	 Up82 0.61876
ENSECAG00000010468 CHCHD7 Up120 0.743429 	 	 	 	 Up98 0.597031
ENSECAG00000027699 ENSECAG00000027699 Up129 0.714441 	 	 	 	 Up42 0.82849
ENSECAG00000018495 SSB Up130 0.71181 	 	 	 	 Up93 0.60062
ENSECAG00000019053 FAM175A Up136 0.7075 	 	 	 	 Up62 0.681148
ENSECAG00000026862 GCSH Up145 0.69445 	 	 	 	 Up91 0.606816
ENSECAG00000011843 ENSECAG00000011843 Up153 0.673509 	 	 	 	 Up66 0.664985
ENSECAG00000018894 RPL22L1 Up161 0.665869 	 	 	 	 Up67 0.664411
ENSECAG00000027675 ND4 Up170 0.653594 	 	 	 	 Up52 0.726651
ENSECAG00000011465 ISCA1 Up184 0.645685 	 	 	 	 Up84 0.613693
ENSECAG00000020965 CMC1 Up191 0.641895 	 	 	 	 Up99 0.594351
ENSECAG00000027684 ND1 Up200 0.626917 	 	 	 	 Up49 0.735849
ENSECAG00000020387 MRPS18C Up204 0.625188 	 	 	 	 Up59 0.6987
ENSECAG00000016939 RPS24 Up212 0.619026 	 	 	 	 Up81 0.621074
ENSECAG00000017538 LY96 Up215 0.614693 	 	 	 	 Up75 0.634798
ENSECAG00000020416 ARPC3 Up225 0.604788 	 	 	 	 Up96 0.598332
ENSECAG00000020144 UBXN2A Up237 0.590855 	 	 	 	 Up100 0.594333
ENSECAG00000023484 SKA1 Up244 0.585847 	 	 	 	 Up76 0.633546
ENSECAG00000009792 UNC5B Down160 -0.598728 	 	 	 	 Down22 -0.734704
ENSECAG00000023637 ADAM33 Down135 -0.626909 	 	 	 	 Down36 -0.666905
ENSECAG00000007338 SCARF2 Down106 -0.66066 	 	 	 	 Down54 -0.593362
ENSECAG00000018651 GTPBP3 Down96 -0.682899 	 	 	 	 Down30 -0.684212
ENSECAG00000003436 APBB3 Down65 -0.736995 	 	 	 	 Down42 -0.640553
ENSECAG00000007112 ENSECAG00000007112 Down41 -0.831601 	 	 	 	 Down40 -0.652355
ENSECAG00000012059 OPLAH Down40 -0.838903 	 	 	 	 Down35 -0.670492
ENSECAG00000023782 SLC16A13 Down10 -1.20782 	 	 	 	 Down2 -1.18221
O/03-WT O/03-K186E O/03-230 O/03-K186E-230
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ENSECAG00000023782 SLC16A13 Down10 -1.20782 	 	 	 	 Down2 -1.18221
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000019932 ENSECAG00000019932 	 	 Up17 2.33603 Up9 1.62176 	 	
ENSECAG00000009543 EPSTI1 	 	 Up31 1.21872 Up23 1.25582 	 	
ENSECAG00000014295 PI3 	 	 Up40 1.08421 Up44 0.920787 	 	
ENSECAG00000012662 SEMA3A 	 	 Down113 -0.596351 Down30 -0.741631 	 	
ENSECAG00000014601 GADD45A 	 	 Down111 -0.597874 Down42 -0.678195 	 	
ENSECAG00000010554 MSMO1 	 	 Down79 -0.666701 Down3 -1.18586 	 	
ENSECAG00000011271 IGFBP4 	 	 Down74 -0.670052 Down43 -0.673379 	 	
ENSECAG00000020860 LSMEM1 Up13 3.19098 Up14 2.51879 	 	 	 	
ENSECAG00000022299 LRRC66 Up28 1.59154 Up33 1.20033 	 	 	 	
ENSECAG00000004180 HSPA6 Up31 1.50962 Down5 -1.31121 	 	 	 	
ENSECAG00000026824 LYRM4 Up96 0.817396 Up53 0.764381 	 	 	 	
ENSECAG00000026993 CEBPZOS Up116 0.749826 Up56 0.740731 	 	 	 	
ENSECAG00000013685 TNXB Down170 -0.588493 Down115 -0.594876 	 	 	 	
ENSECAG00000006963 NACC2 Down156 -0.604823 Down97 -0.620019 	 	 	 	
ENSECAG00000021411 TM7SF2 Down147 -0.611736 Down47 -0.73979 	 	 	 	
ENSECAG00000024890 CCDC120 Down141 -0.616803 Down56 -0.72215 	 	 	 	
ENSECAG00000012684 SWSAP1 Down138 -0.623099 Down98 -0.615043 	 	 	 	
ENSECAG00000010395 RIN1 Down130 -0.636608 Down99 -0.614772 	 	 	 	
ENSECAG00000010506 PLEKHH3 Down124 -0.643436 Down125 -0.58471 	 	 	 	
ENSECAG00000018552 CDKN2A Down120 -0.646724 Down95 -0.621609 	 	 	 	
ENSECAG00000001181 CBX4 Down119 -0.647958 Down119 -0.591799 	 	 	 	
ENSECAG00000006501 FJX1 Down118 -0.649401 Down121 -0.590583 	 	 	 	
ENSECAG00000013443 AKNA Down117 -0.649643 Down118 -0.592903 	 	 	 	
ENSECAG00000016720 OBSCN Down111 -0.654409 Down120 -0.59137 	 	 	 	
ENSECAG00000012169 ATP5D Down110 -0.656075 Down93 -0.623178 	 	 	 	
ENSECAG00000020898 RELB Down104 -0.663394 Down104 -0.606461 	 	 	 	
ENSECAG00000011704 TNFAIP2 Down103 -0.667399 Down29 -0.834622 	 	 	 	
ENSECAG00000015306 ATG4D Down97 -0.682022 Down81 -0.658705 	 	 	 	
ENSECAG00000006302 SLC25A29 Down93 -0.688544 Down53 -0.729061 	 	 	 	
ENSECAG00000013820 KMT5C Down86 -0.702321 Down39 -0.779386 	 	 	 	
ENSECAG00000021748 ENSECAG00000021748 Down80 -0.705971 Down23 -0.864304 	 	 	 	
ENSECAG00000003315 IRS2 Down79 -0.707088 Down85 -0.64472 	 	 	 	
ENSECAG00000021641 SNX21 Down75 -0.718118 Down46 -0.744673 	 	 	 	
ENSECAG00000016064 SYDE1 Down74 -0.720635 Down54 -0.725743 	 	 	 	
ENSECAG00000017274 KRT13 Down72 -0.722815 Down100 -0.613584 	 	 	 	
ENSECAG00000019910 PDLIM2 Down69 -0.728577 Down61 -0.710742 	 	 	 	
ENSECAG00000023023 OSGIN1 Down57 -0.762054 Down43 -0.765127 	 	 	 	
ENSECAG00000013201 MMP17 Down51 -0.794045 Down30 -0.821235 	 	 	 	
ENSECAG00000013281 IRGQ Down47 -0.804184 Down19 -0.928778 	 	 	 	
ENSECAG00000014596 GYLTL1B Down44 -0.815025 Down15 -0.974631 	 	 	 	
ENSECAG00000003075 BORCS6 Down43 -0.818891 Down11 -1.03005 	 	 	 	
ENSECAG00000019726 ENSECAG00000019726 Down42 -0.819503 Down12 -1.01958 	 	 	 	
ENSECAG00000003591 TPGS1 Down38 -0.84294 Down67 -0.694915 	 	 	 	
ENSECAG00000020219 ENSECAG00000020219 Down36 -0.852069 Down20 -0.920106 	 	 	 	
ENSECAG00000006082 ENSECAG00000006082 Down34 -0.863856 Down22 -0.866239 	 	 	 	
ENSECAG00000010241 SPSB4 Down33 -0.867167 Down70 -0.691728 	 	 	 	
ENSECAG00000021543 CDKN1A Down25 -0.933939 Down17 -0.954175 	 	 	 	
ENSECAG00000004462 HIC1 Down21 -0.989624 Down63 -0.701717 	 	 	 	
ENSECAG00000005956 TPBGL Down20 -1.00602 Down13 -1.01796 	 	 	 	
ENSECAG00000019043 SSC5D Down15 -1.07302 Down21 -0.888949 	 	 	 	
ENSECAG00000000154 SDHAF1 Down14 -1.07843 Down3 -1.38192 	 	 	 	
ENSECAG00000011185 BTBD19 Down8 -1.22584 Down14 -1.00361 	 	 	 	
ENSECAG00000006098 ANKRD9 Down2 -1.95687 Down1 -1.94064 	 	 	 	
ENSECAG00000015180 NEXN 	 	 	 	 Up21 1.26305 Up58 0.702545
ENSECAG00000016232 IL22RA1 	 	 	 	 Up91 0.728298 Up48 0.774814
ENSECAG00000008852 ABCA1 	 	 	 	 Up160 0.603089 Up53 0.717703
ENSECAG00000010720 ELOVL6 	 	 	 	 Down28 -0.752294 Down17 -0.747894
ENSECAG00000014658 SCD 	 	 	 	 Down17 -0.898684 Down55 -0.590867
ENSECAG00000005106 FIBIN 	 	 	 	 Down15 -0.917468 Down18 -0.740236
ENSECAG00000008637 HMGCS1 	 	 	 	 Down14 -0.935547 Down24 -0.72822
ENSECAG00000015140 LIPG 	 	 	 	 Down12 -0.942586 Down7 -0.989717
ENSECAG00000010664 GNRH1 Up2 inf 	 	 Up1 inf 	 	
ENSECAG00000025973 U1 Up8 inf 	 	 Up2 inf 	 	
ENSECAG00000016983 ANKRD1 Up47 1.14911 	 	 Up29 1.1145 	 	
ENSECAG00000011446 ENSECAG00000011446 Up72 0.932911 	 	 Up19 1.26822 	 	
ENSECAG00000025120 SBSN Up86 0.843737 	 	 Up34 1.06734 	 	
ENSECAG00000018861 ENSECAG00000018861 Up91 0.827969 	 	 Up100 0.713307 	 	
ENSECAG00000020428 ENSECAG00000020428 Up110 0.760672 	 	 Up37 0.989556 	 	
ENSECAG00000013843 TUBE1 Up114 0.752447 	 	 Up62 0.828848 	 	
ENSECAG00000021551 UTP11L Up119 0.74427 	 	 Up88 0.730403 	 	
ENSECAG00000018544 SPDL1 Up121 0.740986 	 	 Up164 0.599705 	 	
ENSECAG00000000651 SPINK5 Up133 0.709617 	 	 Up47 0.910982 	 	
ENSECAG00000000708 SARNP Up134 0.709311 	 	 Up150 0.627748 	 	
O/03-WT O/03-K186E O/03-230 O/03-K186E-230
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ENSECAG00000000708 SARNP Up134 0.709311 	 	 Up150 0.627748 	 	
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000002607 WBP5 Up144 0.695514 	 	 Up27 1.14543 	 	
ENSECAG00000010777 FAM107B Up154 0.672125 	 	 Up38 0.989344 	 	
ENSECAG00000007912 HMGN4 Up156 0.670885 	 	 Up56 0.869776 	 	
ENSECAG00000015007 SKA2 Up162 0.665233 	 	 Up90 0.729377 	 	
ENSECAG00000020945 MNS1 Up193 0.639925 	 	 Up33 1.07119 	 	
ENSECAG00000019024 FAM204A Up196 0.636851 	 	 Up157 0.604718 	 	
ENSECAG00000003783 ENSECAG00000003783 Up199 0.630491 	 	 Up138 0.639737 	 	
ENSECAG00000026937 SNRNP48 Up202 0.626273 	 	 Up147 0.629964 	 	
ENSECAG00000006773 CIR1 Up221 0.609636 	 	 Up45 0.914679 	 	
ENSECAG00000024519 SPC25 Up232 0.598761 	 	 Up179 0.585074 	 	
ENSECAG00000026920 HSBP1 Up236 0.59354 	 	 Up111 0.6827 	 	
ENSECAG00000011948 FIGF Down81 -0.704733 	 	 Down19 -0.841851 	 	
ENSECAG00000024260 TMEM160 Down52 -0.793587 	 	 Down13 -0.937601 	 	
ENSECAG00000001022 UCN2 Down13 -1.08918 	 	 Up61 0.835742 	 	
ENSECAG00000024167 DDX60 	 	 Up3 4.63181 	 	 Up6 3.31012
ENSECAG00000007881 IFIH1 	 	 Up6 4.40685 	 	 Up4 3.5855
ENSECAG00000010185 ENSECAG00000010185 	 	 Up16 2.33874 	 	 Up14 1.90592
ENSECAG00000025328 ENSECAG00000025328 	 	 Up18 2.28563 	 	 Up13 1.90771
ENSECAG00000000968 ENSECAG00000000968 	 	 Up21 2.10439 	 	 Up33 1.0504
ENSECAG00000027056 ENSECAG00000027056 	 	 Up22 1.95999 	 	 Up19 1.51838
ENSECAG00000001481 SAMD9L 	 	 Up27 1.48532 	 	 Up40 0.876975
ENSECAG00000021220 ENSECAG00000021220 	 	 Up29 1.34581 	 	 Up46 0.789085
ENSECAG00000012331 PARP9 	 	 Up38 1.12343 	 	 Up60 0.692215
ENSECAG00000011726 EIF2AK2 	 	 Up41 1.04597 	 	 Up47 0.781161
ENSECAG00000001399 SAMD9 	 	 Up51 0.816776 	 	 Up95 0.600358
ENSECAG00000010055 RSAD2 	 	 Up52 0.780623 	 	 Up51 0.730225
ENSECAG00000002264 ISL1 	 	 Down117 -0.593754 	 	 Down38 -0.664083
ENSECAG00000010566 ENSECAG00000010566 	 	 Down65 -0.699738 	 	 Down50 -0.608559
ENSECAG00000019557 LDLR 	 	 Down58 -0.712427 	 	 Down26 -0.715306
ENSECAG00000011206 MVD 	 	 Down40 -0.779099 	 	 Down20 -0.736368
ENSECAG00000011439 DHX58 	 	 Up4 4.61608 Up4 3.09973 Up8 3.19554
ENSECAG00000009020 IFI44 	 	 Up5 4.44821 Up6 2.17917 Up7 3.27331
ENSECAG00000009618 IFI44L 	 	 Up8 3.82991 Up7 1.77632 Up10 2.80855
ENSECAG00000001324 ISG15 	 	 Up9 3.01778 Up8 1.74358 Up11 2.04705
ENSECAG00000000284 ENSECAG00000000284 	 	 Up10 2.99697 Up11 1.43109 Up16 1.72675
ENSECAG00000011776 MX1 	 	 Up11 2.92668 Up12 1.40675 Up12 2.01323
ENSECAG00000012132 ENSECAG00000012132 	 	 Up19 2.21372 Up20 1.26429 Up24 1.23645
ENSECAG00000014422 OAS2 	 	 Up20 2.11659 Up50 0.897975 Up25 1.21193
ENSECAG00000024429 IRF9 	 	 Up23 1.95478 Up10 1.533 Up21 1.36893
ENSECAG00000001598 IFI35 	 	 Up25 1.56816 Up70 0.806505 Up29 1.12405
ENSECAG00000014226 ENSECAG00000014226 	 	 Up28 1.40464 Up30 1.10198 Up28 1.13741
ENSECAG00000025265 7SK 	 	 Up30 1.23285 Up16 1.32949 Up17 1.63899
ENSECAG00000021133 FDFT1 	 	 Down108 -0.603939 Down29 -0.745322 Down31 -0.68223
ENSECAG00000023067 MVK 	 	 Down57 -0.717767 Down26 -0.753929 Down28 -0.697242
ENSECAG00000016389 ACSS2 	 	 Down52 -0.729119 Down23 -0.791528 Down43 -0.636744
ENSECAG00000000714 FAM26D Up1 inf 	 	 	 	 	 	
ENSECAG00000022734 SGPP2 Up4 inf 	 	 	 	 	 	
ENSECAG00000026877 C17orf98 Up5 inf 	 	 	 	 	 	
ENSECAG00000009955 TEX43 Up6 inf 	 	 	 	 	 	
ENSECAG00000027680 ENSECAG00000027680 Up7 inf 	 	 	 	 	 	
ENSECAG00000007414 SV2A Up9 4.7725 	 	 	 	 	 	
ENSECAG00000000207 ACTA1 Up10 4.27728 	 	 	 	 	 	
ENSECAG00000009535 FCER1G Up11 3.62833 	 	 	 	 	 	
ENSECAG00000024000 PYGM Up12 3.57668 	 	 	 	 	 	
ENSECAG00000009793 TAGLN3 Up14 3.0704 	 	 	 	 	 	
ENSECAG00000004408 GPR1 Up16 2.79532 	 	 	 	 	 	
ENSECAG00000008107 FERMT3 Up18 2.34706 	 	 	 	 	 	
ENSECAG00000009256 CPE Up19 2.33724 	 	 	 	 	 	
ENSECAG00000019367 ENSECAG00000019367 Up20 2.03985 	 	 	 	 	 	
ENSECAG00000016226 ANKRD35 Up21 1.93647 	 	 	 	 	 	
ENSECAG00000012826 CDO1 Up22 1.93113 	 	 	 	 	 	
ENSECAG00000006922 ENSECAG00000006922 Up23 1.86167 	 	 	 	 	 	
ENSECAG00000015232 ZNF619 Up24 1.82611 	 	 	 	 	 	
ENSECAG00000008044 PPP1R27 Up25 1.76342 	 	 	 	 	 	
ENSECAG00000018052 ZNF514 Up27 1.59839 	 	 	 	 	 	
ENSECAG00000015717 TSSK3 Up29 1.54859 	 	 	 	 	 	
ENSECAG00000018029 THSD1 Up30 1.51379 	 	 	 	 	 	
ENSECAG00000012898 PNLDC1 Up34 1.39412 	 	 	 	 	 	
ENSECAG00000007194 CHRNE Up36 1.3793 	 	 	 	 	 	
ENSECAG00000009142 ENSECAG00000009142 Up37 1.37497 	 	 	 	 	 	
ENSECAG00000020764 ENSECAG00000020764 Up38 1.34451 	 	 	 	 	 	
ENSECAG00000005115 ZNF454 Up42 1.2287 	 	 	 	 	 	
ENSECAG00000010656 HBEGF Up43 1.22256 	 	 	 	 	 	
O/03-WT O/03-K186E O/03-230 O/03-K186E-230
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ENSECAG00000010656 HBEGF Up43 1.22256 	 	 	 	 	 	
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000012746 STAR Up45 1.16959 	 	 	 	 	 	
ENSECAG00000020952 ENSECAG00000020952 Up48 1.13517 	 	 	 	 	 	
ENSECAG00000008668 CSF3 Up49 1.11637 	 	 	 	 	 	
ENSECAG00000012179 RGS2 Up50 1.1118 	 	 	 	 	 	
ENSECAG00000024298 PTPN22 Up52 1.06985 	 	 	 	 	 	
ENSECAG00000021582 ENSECAG00000021582 Up54 1.06426 	 	 	 	 	 	
ENSECAG00000016648 IL5 Up55 1.05992 	 	 	 	 	 	
ENSECAG00000008723 CASP12 Up56 1.04135 	 	 	 	 	 	
ENSECAG00000013528 AVIL Up59 1.01567 	 	 	 	 	 	
ENSECAG00000018966 FBXO48 Up60 1.01195 	 	 	 	 	 	
ENSECAG00000014572 ENSECAG00000014572 Up61 0.989668 	 	 	 	 	 	
ENSECAG00000003681 ENSECAG00000003681 Up62 0.980483 	 	 	 	 	 	
ENSECAG00000020923 LEAP2 Up63 0.980251 	 	 	 	 	 	
ENSECAG00000016085 SYCP2 Up64 0.967566 	 	 	 	 	 	
ENSECAG00000012653 DYRK4 Up65 0.965215 	 	 	 	 	 	
ENSECAG00000012680 N4BP2L1 Up66 0.961023 	 	 	 	 	 	
ENSECAG00000008533 ITGA10 Up68 0.951696 	 	 	 	 	 	
ENSECAG00000024279 FAM200B Up69 0.945443 	 	 	 	 	 	
ENSECAG00000013527 ENSECAG00000013527 Up70 0.939975 	 	 	 	 	 	
ENSECAG00000006567 SLITRK4 Up71 0.939637 	 	 	 	 	 	
ENSECAG00000010606 CCDC169 Up73 0.930152 	 	 	 	 	 	
ENSECAG00000023507 GPR19 Up74 0.925208 	 	 	 	 	 	
ENSECAG00000013748 KRT25 Up76 0.921815 	 	 	 	 	 	
ENSECAG00000003669 HLA-DMA Up78 0.909888 	 	 	 	 	 	
ENSECAG00000026852 ZCCHC10 Up79 0.905548 	 	 	 	 	 	
ENSECAG00000005249 IQUB Up81 0.883674 	 	 	 	 	 	
ENSECAG00000012801 KBTBD3 Up83 0.868281 	 	 	 	 	 	
ENSECAG00000010700 CREG2 Up84 0.844446 	 	 	 	 	 	
ENSECAG00000021939 FAM122C Up88 0.832568 	 	 	 	 	 	
ENSECAG00000018428 HSPH1 Up89 0.831423 	 	 	 	 	 	
ENSECAG00000002021 ENSECAG00000002021 Up90 0.829023 	 	 	 	 	 	
ENSECAG00000011618 EDN1 Up92 0.824924 	 	 	 	 	 	
ENSECAG00000001667 DEPDC7 Up93 0.823128 	 	 	 	 	 	
ENSECAG00000002452 CCDC121 Up94 0.820488 	 	 	 	 	 	
ENSECAG00000013653 TPMT Up95 0.81773 	 	 	 	 	 	
ENSECAG00000004698 PTGR1 Up97 0.816365 	 	 	 	 	 	
ENSECAG00000011003 PDE4B Up98 0.814737 	 	 	 	 	 	
ENSECAG00000022568 TMEM154 Up99 0.809303 	 	 	 	 	 	
ENSECAG00000019742 CCDC126 Up100 0.807428 	 	 	 	 	 	
ENSECAG00000024185 GNG11 Up102 0.778049 	 	 	 	 	 	
ENSECAG00000002759 MTRF1L Up103 0.776082 	 	 	 	 	 	
ENSECAG00000020892 TLR10 Up105 0.770745 	 	 	 	 	 	
ENSECAG00000013766 E2F5 Up106 0.766488 	 	 	 	 	 	
ENSECAG00000016965 SUV39H2 Up107 0.764009 	 	 	 	 	 	
ENSECAG00000020223 HACD1 Up108 0.763083 	 	 	 	 	 	
ENSECAG00000020380 COMMD8 Up109 0.761872 	 	 	 	 	 	
ENSECAG00000004590 TIPIN Up111 0.758445 	 	 	 	 	 	
ENSECAG00000001407 CHSY3 Up112 0.756332 	 	 	 	 	 	
ENSECAG00000013255 ENSECAG00000013255 Up113 0.755364 	 	 	 	 	 	
ENSECAG00000006869 MAP9 Up117 0.748459 	 	 	 	 	 	
ENSECAG00000013661 FAM184B Up122 0.740297 	 	 	 	 	 	
ENSECAG00000017348 BCAP29 Up123 0.736949 	 	 	 	 	 	
ENSECAG00000011592 HNMT Up124 0.734835 	 	 	 	 	 	
ENSECAG00000012354 LMLN Up125 0.725545 	 	 	 	 	 	
ENSECAG00000015510 FGF7 Up126 0.723648 	 	 	 	 	 	
ENSECAG00000014615 STX2 Up127 0.719371 	 	 	 	 	 	
ENSECAG00000010953 TNIP3 Up128 0.717209 	 	 	 	 	 	
ENSECAG00000019097 TANK Up131 0.710888 	 	 	 	 	 	
ENSECAG00000016351 ENSECAG00000016351 Up132 0.71022 	 	 	 	 	 	
ENSECAG00000022765 ZC3H8 Up135 0.709287 	 	 	 	 	 	
ENSECAG00000022541 ZNF25 Up137 0.706972 	 	 	 	 	 	
ENSECAG00000007540 CYP7B1 Up138 0.706454 	 	 	 	 	 	
ENSECAG00000010696 ENSECAG00000010696 Up139 0.705146 	 	 	 	 	 	
ENSECAG00000016586 NUCB2 Up140 0.704499 	 	 	 	 	 	
ENSECAG00000010433 CHMP2B Up141 0.700278 	 	 	 	 	 	
ENSECAG00000010663 SKIL Up142 0.698517 	 	 	 	 	 	
ENSECAG00000016844 MEIOC Up143 0.696118 	 	 	 	 	 	
ENSECAG00000009108 C1orf189 Up146 0.693171 	 	 	 	 	 	
ENSECAG00000006803 SYTL2 Up147 0.69218 	 	 	 	 	 	
ENSECAG00000024373 ZBTB11 Up148 0.686358 	 	 	 	 	 	
ENSECAG00000016487 ATP6V1E1 Up149 0.68053 	 	 	 	 	 	
ENSECAG00000010450 CCDC59 Up150 0.677447 	 	 	 	 	 	
ENSECAG00000014597 MCTS1 Up152 0.675524 	 	 	 	 	 	
O/03-WT O/03-K186E O/03-230 O/03-K186E-230
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ENSECAG00000014597 MCTS1 Up152 0.675524 	 	 	 	 	 	
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000019989 SNRPG Up155 0.671256 	 	 	 	 	 	
ENSECAG00000011295 THAP2 Up157 0.668933 	 	 	 	 	 	
ENSECAG00000017572 ZNF280C Up158 0.667444 	 	 	 	 	 	
ENSECAG00000024614 FAM161A Up159 0.66698 	 	 	 	 	 	
ENSECAG00000003510 TXNDC9 Up160 0.666237 	 	 	 	 	 	
ENSECAG00000024815 RFESD Up163 0.663531 	 	 	 	 	 	
ENSECAG00000008493 SERPINB10 Up164 0.662478 	 	 	 	 	 	
ENSECAG00000004919 CACYBP Up165 0.659535 	 	 	 	 	 	
ENSECAG00000026897 MRPS36 Up166 0.655053 	 	 	 	 	 	
ENSECAG00000008428 CEP83 Up167 0.654762 	 	 	 	 	 	
ENSECAG00000023743 CCDC58 Up168 0.654648 	 	 	 	 	 	
ENSECAG00000002943 ENSECAG00000002943 Up169 0.654099 	 	 	 	 	 	
ENSECAG00000024870 CWH43 Up171 0.653246 	 	 	 	 	 	
ENSECAG00000024704 CETN3 Up172 0.653123 	 	 	 	 	 	
ENSECAG00000000880 SPATA33 Up173 0.652458 	 	 	 	 	 	
ENSECAG00000008390 FOXN2 Up174 0.651412 	 	 	 	 	 	
ENSECAG00000010323 ENSECAG00000010323 Up175 0.651347 	 	 	 	 	 	
ENSECAG00000016530 LYPLA1 Up176 0.64999 	 	 	 	 	 	
ENSECAG00000009675 N4BP2 Up178 0.649494 	 	 	 	 	 	
ENSECAG00000009898 UEVLD Up179 0.649393 	 	 	 	 	 	
ENSECAG00000015185 AK6 Up180 0.649205 	 	 	 	 	 	
ENSECAG00000000546 CCDC62 Up181 0.648597 	 	 	 	 	 	
ENSECAG00000009776 CEP57L1 Up182 0.646206 	 	 	 	 	 	
ENSECAG00000024399 FGF12 Up183 0.645883 	 	 	 	 	 	
ENSECAG00000021026 BCAS2 Up185 0.645444 	 	 	 	 	 	
ENSECAG00000002513 ERCC6L Up186 0.642977 	 	 	 	 	 	
ENSECAG00000013569 LAMTOR3 Up187 0.642613 	 	 	 	 	 	
ENSECAG00000015459 ENSECAG00000015459 Up188 0.642552 	 	 	 	 	 	
ENSECAG00000015237 PIBF1 Up189 0.642502 	 	 	 	 	 	
ENSECAG00000015355 CLK1 Up192 0.640763 	 	 	 	 	 	
ENSECAG00000018554 ENSECAG00000018554 Up194 0.639487 	 	 	 	 	 	
ENSECAG00000011862 C11orf1 Up195 0.638822 	 	 	 	 	 	
ENSECAG00000015376 GLRX2 Up198 0.631247 	 	 	 	 	 	
ENSECAG00000015464 RPL36AL Up201 0.626847 	 	 	 	 	 	
ENSECAG00000005764 ENSECAG00000005764 Up203 0.625927 	 	 	 	 	 	
ENSECAG00000005178 CCSAP Up205 0.624865 	 	 	 	 	 	
ENSECAG00000023869 CRLS1 Up206 0.624073 	 	 	 	 	 	
ENSECAG00000015765 THAP6 Up207 0.621924 	 	 	 	 	 	
ENSECAG00000004316 HRSP12 Up208 0.621403 	 	 	 	 	 	
ENSECAG00000019506 ARRDC3 Up209 0.620906 	 	 	 	 	 	
ENSECAG00000019146 NDUFAF6 Up210 0.620436 	 	 	 	 	 	
ENSECAG00000006587 RWDD1 Up211 0.620345 	 	 	 	 	 	
ENSECAG00000008716 EIF3J Up213 0.61719 	 	 	 	 	 	
ENSECAG00000015757 RPL26 Up214 0.616644 	 	 	 	 	 	
ENSECAG00000018478 NIFK Up216 0.614659 	 	 	 	 	 	
ENSECAG00000011393 GKAP1 Up217 0.614196 	 	 	 	 	 	
ENSECAG00000018693 ENSECAG00000018693 Up218 0.612525 	 	 	 	 	 	
ENSECAG00000011218 HAT1 Up219 0.610503 	 	 	 	 	 	
ENSECAG00000017063 TIMM9 Up220 0.610056 	 	 	 	 	 	
ENSECAG00000014668 ZNF614 Up222 0.608307 	 	 	 	 	 	
ENSECAG00000009780 UQCRB Up223 0.607478 	 	 	 	 	 	
ENSECAG00000012316 DTWD1 Up224 0.605808 	 	 	 	 	 	
ENSECAG00000007803 LSM3 Up226 0.602689 	 	 	 	 	 	
ENSECAG00000018635 ZNF674 Up227 0.601725 	 	 	 	 	 	
ENSECAG00000010661 RPL21 Up228 0.601547 	 	 	 	 	 	
ENSECAG00000017850 TAF1D Up229 0.601284 	 	 	 	 	 	
ENSECAG00000016758 ENSECAG00000016758 Up230 0.601139 	 	 	 	 	 	
ENSECAG00000019035 LIPT1 Up231 0.60087 	 	 	 	 	 	
ENSECAG00000008524 SSBIP1 Up233 0.598617 	 	 	 	 	 	
ENSECAG00000015468 MGAT4A Up234 0.598338 	 	 	 	 	 	
ENSECAG00000015373 ENSECAG00000015373 Up235 0.593591 	 	 	 	 	 	
ENSECAG00000020566 DYNC2LI1 Up238 0.589788 	 	 	 	 	 	
ENSECAG00000011795 OSGEPL1 Up239 0.589122 	 	 	 	 	 	
ENSECAG00000024976 OCIAD1 Up240 0.588753 	 	 	 	 	 	
ENSECAG00000017059 FAM105A Up241 0.587727 	 	 	 	 	 	
ENSECAG00000014972 PHF11 Up242 0.587703 	 	 	 	 	 	
ENSECAG00000009760 GMNN Up245 0.585393 	 	 	 	 	 	
ENSECAG00000012399 SUB1 Up246 0.583617 	 	 	 	 	 	
ENSECAG00000014530 Sep-10 Up247 0.581098 	 	 	 	 	 	
ENSECAG00000013324 TXN Up248 0.58067 	 	 	 	 	 	
ENSECAG00000023217 KLHL17 Down181 -0.580187 	 	 	 	 	 	
ENSECAG00000011637 SLC1A5 Down180 -0.580647 	 	 	 	 	 	
ENSECAG00000017955 SLC12A9 Down179 -0.580741 	 	 	 	 	 	
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ENSECAG00000017955 SLC12A9 Down179 -0.580741 	 	 	 	 	 	
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000000402 NDUFS7 Down178 -0.580877 	 	 	 	 	 	
ENSECAG00000022744 RHBDD3 Down177 -0.582825 	 	 	 	 	 	
ENSECAG00000014263 ENSECAG00000014263 Down176 -0.585909 	 	 	 	 	 	
ENSECAG00000002668 RHOB Down174 -0.586719 	 	 	 	 	 	
ENSECAG00000011565 GMPPA Down173 -0.587266 	 	 	 	 	 	
ENSECAG00000008220 ENSECAG00000008220 Down172 -0.587499 	 	 	 	 	 	
ENSECAG00000012351 FUK Down171 -0.588028 	 	 	 	 	 	
ENSECAG00000009148 LPAR2 Down169 -0.589867 	 	 	 	 	 	
ENSECAG00000022309 DGKQ Down168 -0.590556 	 	 	 	 	 	
ENSECAG00000023189 DDAH2 Down167 -0.593593 	 	 	 	 	 	
ENSECAG00000003398 MARCKS Down166 -0.593864 	 	 	 	 	 	
ENSECAG00000024775 PRKD2 Down165 -0.594245 	 	 	 	 	 	
ENSECAG00000008659 SHISA5 Down164 -0.594512 	 	 	 	 	 	
ENSECAG00000016677 MFSD3 Down163 -0.597456 	 	 	 	 	 	
ENSECAG00000019788 WDR83 Down162 -0.598005 	 	 	 	 	 	
ENSECAG00000026863 EFS Down161 -0.59856 	 	 	 	 	 	
ENSECAG00000012961 HSPG2 Down159 -0.600732 	 	 	 	 	 	
ENSECAG00000014491 NLRC5 Down158 -0.602386 	 	 	 	 	 	
ENSECAG00000008298 WNT10B Down154 -0.605397 	 	 	 	 	 	
ENSECAG00000023401 ZNF414 Down153 -0.60616 	 	 	 	 	 	
ENSECAG00000021488 DYRK1B Down152 -0.606423 	 	 	 	 	 	
ENSECAG00000018474 DDR1 Down151 -0.607061 	 	 	 	 	 	
ENSECAG00000021964 ASB9 Down150 -0.607786 	 	 	 	 	 	
ENSECAG00000012006 BCL9L Down149 -0.608293 	 	 	 	 	 	
ENSECAG00000023274 LAMA5 Down148 -0.60959 	 	 	 	 	 	
ENSECAG00000021765 TSPO Down145 -0.614029 	 	 	 	 	 	
ENSECAG00000017916 ENSECAG00000017916 Down144 -0.614305 	 	 	 	 	 	
ENSECAG00000017838 IGFLR1 Down143 -0.615358 	 	 	 	 	 	
ENSECAG00000015936 ENSECAG00000015936 Down142 -0.615914 	 	 	 	 	 	
ENSECAG00000012571 ENSECAG00000012571 Down140 -0.618863 	 	 	 	 	 	
ENSECAG00000020484 TBCC Down139 -0.621186 	 	 	 	 	 	
ENSECAG00000021290 MBD6 Down136 -0.625814 	 	 	 	 	 	
ENSECAG00000002876 FAAP100 Down133 -0.629622 	 	 	 	 	 	
ENSECAG00000018245 EPHX3 Down132 -0.629753 	 	 	 	 	 	
ENSECAG00000017322 METTL12 Down131 -0.63042 	 	 	 	 	 	
ENSECAG00000012500 AP5Z1 Down129 -0.637977 	 	 	 	 	 	
ENSECAG00000017084 DPYSL4 Down128 -0.638735 	 	 	 	 	 	
ENSECAG00000016798 MIEF2 Down127 -0.64028 	 	 	 	 	 	
ENSECAG00000008910 KLRG2 Down126 -0.640342 	 	 	 	 	 	
ENSECAG00000011354 DHX34 Down125 -0.642514 	 	 	 	 	 	
ENSECAG00000026952 ENSECAG00000026952 Down123 -0.64348 	 	 	 	 	 	
ENSECAG00000009314 TMEM132A Down122 -0.643783 	 	 	 	 	 	
ENSECAG00000010992 NFATC4 Down121 -0.644947 	 	 	 	 	 	
ENSECAG00000008387 TSC22D4 Down116 -0.650186 	 	 	 	 	 	
ENSECAG00000009361 COL5A1 Down115 -0.650422 	 	 	 	 	 	
ENSECAG00000005577 GPR39 Down114 -0.651523 	 	 	 	 	 	
ENSECAG00000015448 TAPBP Down112 -0.653639 	 	 	 	 	 	
ENSECAG00000001072 TYMP Down109 -0.657227 	 	 	 	 	 	
ENSECAG00000021314 COL4A2 Down108 -0.659806 	 	 	 	 	 	
ENSECAG00000004662 SPTSSA Down107 -0.660094 	 	 	 	 	 	
ENSECAG00000017905 LTBP4 Down105 -0.661668 	 	 	 	 	 	
ENSECAG00000002142 TRIP6 Down102 -0.66844 	 	 	 	 	 	
ENSECAG00000022526 CDH15 Down101 -0.669839 	 	 	 	 	 	
ENSECAG00000016695 SLC27A5 Down99 -0.678787 	 	 	 	 	 	
ENSECAG00000020085 RELL2 Down98 -0.681381 	 	 	 	 	 	
ENSECAG00000007615 PTRH1 Down95 -0.683101 	 	 	 	 	 	
ENSECAG00000012759 PLPPR2 Down94 -0.686553 	 	 	 	 	 	
ENSECAG00000020780 PELP1 Down92 -0.69176 	 	 	 	 	 	
ENSECAG00000018161 C1QTNF5 Down91 -0.692114 	 	 	 	 	 	
ENSECAG00000024412 ARHGAP39 Down90 -0.696513 	 	 	 	 	 	
ENSECAG00000021280 SHISA4 Down89 -0.697033 	 	 	 	 	 	
ENSECAG00000015814 LRRC73 Down87 -0.698787 	 	 	 	 	 	
ENSECAG00000015240 PROM2 Down85 -0.702809 	 	 	 	 	 	
ENSECAG00000006999 PLEKHG4 Down84 -0.702886 	 	 	 	 	 	
ENSECAG00000009891 ARMC5 Down83 -0.703847 	 	 	 	 	 	
ENSECAG00000018111 NAPRT Down82 -0.704411 	 	 	 	 	 	
ENSECAG00000021034 YDJC Down78 -0.708416 	 	 	 	 	 	
ENSECAG00000019381 MEGF8 Down77 -0.713517 	 	 	 	 	 	
ENSECAG00000013608 KAZALD1 Down76 -0.714613 	 	 	 	 	 	
ENSECAG00000013419 MNT Down73 -0.721419 	 	 	 	 	 	
ENSECAG00000014566 WISP2 Down71 -0.723337 	 	 	 	 	 	
ENSECAG00000023946 SDC3 Down70 -0.72685 	 	 	 	 	 	
ENSECAG00000011353 MFSD7 Down68 -0.730068 	 	 	 	 	 	
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ENSECAG00000011353 MFSD7 Down68 -0.730068 	 	 	 	 	 	
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000006116 PPP1R35 Down67 -0.73076 	 	 	 	 	 	
ENSECAG00000014470 EEPD1 Down66 -0.731131 	 	 	 	 	 	
ENSECAG00000004551 FOXG1 Down64 -0.741996 	 	 	 	 	 	
ENSECAG00000011160 TP53INP2 Down63 -0.747131 	 	 	 	 	 	
ENSECAG00000017501 TOR4A Down62 -0.747398 	 	 	 	 	 	
ENSECAG00000006619 ZNF688 Down61 -0.751039 	 	 	 	 	 	
ENSECAG00000013524 ZNF219 Down60 -0.751192 	 	 	 	 	 	
ENSECAG00000011907 C19orf54 Down59 -0.751823 	 	 	 	 	 	
ENSECAG00000002911 KCTD11 Down58 -0.75277 	 	 	 	 	 	
ENSECAG00000017451 FAM110A Down56 -0.770603 	 	 	 	 	 	
ENSECAG00000015612 FAM212A Down55 -0.785398 	 	 	 	 	 	
ENSECAG00000007474 SPHK2 Down54 -0.791489 	 	 	 	 	 	
ENSECAG00000002061 NEURL2 Down53 -0.792894 	 	 	 	 	 	
ENSECAG00000006058 FUT1 Down49 -0.803043 	 	 	 	 	 	
ENSECAG00000000440 TMEM8B Down48 -0.803244 	 	 	 	 	 	
ENSECAG00000024202 XKR8 Down46 -0.804649 	 	 	 	 	 	
ENSECAG00000018426 ERF Down45 -0.812761 	 	 	 	 	 	
ENSECAG00000023399 GADD45G Down37 -0.848082 	 	 	 	 	 	
ENSECAG00000022258 SDSL Down35 -0.85835 	 	 	 	 	 	
ENSECAG00000006591 ATG9B Down32 -0.873 	 	 	 	 	 	
ENSECAG00000002570 HS3ST1 Down31 -0.884388 	 	 	 	 	 	
ENSECAG00000007647 COL5A3 Down30 -0.89889 	 	 	 	 	 	
ENSECAG00000006133 NXPH4 Down28 -0.90606 	 	 	 	 	 	
ENSECAG00000013867 ENSECAG00000013867 Down24 -0.96001 	 	 	 	 	 	
ENSECAG00000006208 MBLAC1 Down23 -0.976957 	 	 	 	 	 	
ENSECAG00000012116 CARNS1 Down22 -0.97915 	 	 	 	 	 	
ENSECAG00000015692 SERTAD4 Down19 -1.02147 	 	 	 	 	 	
ENSECAG00000024458 KCTD7 Down18 -1.04533 	 	 	 	 	 	
ENSECAG00000011161 ENSECAG00000011161 Down16 -1.06533 	 	 	 	 	 	
ENSECAG00000026812 FANCF Down11 -1.18548 	 	 	 	 	 	
ENSECAG00000007684 SLC2A4 Down9 -1.22492 	 	 	 	 	 	
ENSECAG00000009912 PCSK1N Down7 -1.32892 	 	 	 	 	 	
ENSECAG00000018591 CTU1 Down6 -1.35574 	 	 	 	 	 	
ENSECAG00000025020 FHL1 Down5 -1.35746 	 	 	 	 	 	
ENSECAG00000009027 WBSCR27 Down4 -1.4755 	 	 	 	 	 	
ENSECAG00000014282 NPPB Down3 -1.81488 	 	 	 	 	 	
ENSECAG00000003656 NANOS1 Down1 -inf 	 	 	 	 	 	
ENSECAG00000015034 PLAC8 	 	 Up1 inf 	 	 	 	
ENSECAG00000019309 GBP2 	 	 Up13 2.77326 	 	 	 	
ENSECAG00000004306 ENSECAG00000004306 	 	 Up24 1.70432 	 	 	 	
ENSECAG00000008809 OAS3 	 	 Up26 1.56128 	 	 	 	
ENSECAG00000010036 SLC15A3 	 	 Up32 1.21219 	 	 	 	
ENSECAG00000016217 RNF213 	 	 Up34 1.18669 	 	 	 	
ENSECAG00000009686 DTX3L 	 	 Up36 1.1458 	 	 	 	
ENSECAG00000019411 HERC6 	 	 Up39 1.0866 	 	 	 	
ENSECAG00000002176 ENSECAG00000002176 	 	 Up42 0.996487 	 	 	 	
ENSECAG00000017394 ZC3HAV1 	 	 Up44 0.95748 	 	 	 	
ENSECAG00000020562 AXDND1 	 	 Up45 0.929863 	 	 	 	
ENSECAG00000013435 OAS1 	 	 Up46 0.908969 	 	 	 	
ENSECAG00000021989 DDX58 	 	 Up47 0.896421 	 	 	 	
ENSECAG00000015395 HERC5 	 	 Up48 0.889434 	 	 	 	
ENSECAG00000012773 CMPK2 	 	 Up50 0.862742 	 	 	 	
ENSECAG00000009937 UBE2N 	 	 Up54 0.754702 	 	 	 	
ENSECAG00000001514 ENSECAG00000001514 	 	 Up55 0.750024 	 	 	 	
ENSECAG00000022601 PARP12 	 	 Up59 0.679275 	 	 	 	
ENSECAG00000020384 ENSECAG00000020384 	 	 Up60 0.638286 	 	 	 	
ENSECAG00000006930 ENSECAG00000006930 	 	 Up61 0.637825 	 	 	 	
ENSECAG00000023195 ENSECAG00000023195 	 	 Up62 0.631552 	 	 	 	
ENSECAG00000004349 IFIT5 	 	 Up63 0.621803 	 	 	 	
ENSECAG00000001560 SCO2 	 	 Down128 -0.580853 	 	 	 	
ENSECAG00000016361 COL18A1 	 	 Down127 -0.58119 	 	 	 	
ENSECAG00000013728 MFSD2A 	 	 Down126 -0.583615 	 	 	 	
ENSECAG00000010237 FBXL6 	 	 Down124 -0.586447 	 	 	 	
ENSECAG00000001342 SCAND1 	 	 Down123 -0.588235 	 	 	 	
ENSECAG00000005017 FBXW9 	 	 Down122 -0.590475 	 	 	 	
ENSECAG00000022018 TRIM47 	 	 Down116 -0.593891 	 	 	 	
ENSECAG00000017795 ENSECAG00000017795 	 	 Down114 -0.595276 	 	 	 	
ENSECAG00000010553 NGF 	 	 Down112 -0.596973 	 	 	 	
ENSECAG00000018835 FAM46B 	 	 Down110 -0.601717 	 	 	 	
ENSECAG00000008333 MSC 	 	 Down109 -0.601983 	 	 	 	
ENSECAG00000003816 JUNB 	 	 Down107 -0.6043 	 	 	 	
ENSECAG00000002992 MID1IP1 	 	 Down106 -0.604792 	 	 	 	
ENSECAG00000001265 TMEM223 	 	 Down105 -0.60591 	 	 	 	
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ENSECAG00000001265 TMEM223 	 	 Down105 -0.60591 	 	 	 	
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000004050 ENSECAG00000004050 	 	 Down102 -0.610559 	 	 	 	
ENSECAG00000000138 ACVR2A 	 	 Down96 -0.620891 	 	 	 	
ENSECAG00000024319 ENSECAG00000024319 	 	 Down92 -0.634334 	 	 	 	
ENSECAG00000019789 STOML1 	 	 Down91 -0.635372 	 	 	 	
ENSECAG00000006931 ATF4 	 	 Down90 -0.636222 	 	 	 	
ENSECAG00000004791 TICAM1 	 	 Down88 -0.638507 	 	 	 	
ENSECAG00000011779 ARID3A 	 	 Down87 -0.639476 	 	 	 	
ENSECAG00000013794 MRPS12 	 	 Down83 -0.649639 	 	 	 	
ENSECAG00000014783 ENSECAG00000014783 	 	 Down78 -0.668662 	 	 	 	
ENSECAG00000021308 APBA3 	 	 Down77 -0.669118 	 	 	 	
ENSECAG00000016405 REPIN1 	 	 Down76 -0.669615 	 	 	 	
ENSECAG00000011011 SNAPC2 	 	 Down75 -0.669702 	 	 	 	
ENSECAG00000024720 ENTHD2 	 	 Down73 -0.68113 	 	 	 	
ENSECAG00000016486 ARRDC2 	 	 Down72 -0.682995 	 	 	 	
ENSECAG00000017157 IER3 	 	 Down71 -0.685588 	 	 	 	
ENSECAG00000020178 WNT9A 	 	 Down69 -0.691772 	 	 	 	
ENSECAG00000012599 TRMT61A 	 	 Down68 -0.694494 	 	 	 	
ENSECAG00000024986 ENSECAG00000024986 	 	 Down66 -0.697917 	 	 	 	
ENSECAG00000004492 RRS1 	 	 Down64 -0.701231 	 	 	 	
ENSECAG00000000529 MAP1S 	 	 Down62 -0.709554 	 	 	 	
ENSECAG00000022294 ENSECAG00000022294 	 	 Down60 -0.711121 	 	 	 	
ENSECAG00000016441 DOHH 	 	 Down59 -0.711948 	 	 	 	
ENSECAG00000008194 MIDN 	 	 Down55 -0.724055 	 	 	 	
ENSECAG00000014794 MIIP 	 	 Down51 -0.729532 	 	 	 	
ENSECAG00000015758 IRX2 	 	 Down50 -0.730415 	 	 	 	
ENSECAG00000013124 BCL3 	 	 Down49 -0.730821 	 	 	 	
ENSECAG00000016942 NUDT14 	 	 Down48 -0.731937 	 	 	 	
ENSECAG00000013787 HMX3 	 	 Down45 -0.747514 	 	 	 	
ENSECAG00000021909 C14orf80 	 	 Down44 -0.751221 	 	 	 	
ENSECAG00000019359 DUS3L 	 	 Down42 -0.768069 	 	 	 	
ENSECAG00000010803 ENSECAG00000010803 	 	 Down41 -0.778312 	 	 	 	
ENSECAG00000026965 SOCS1 	 	 Down36 -0.789464 	 	 	 	
ENSECAG00000021887 TRIM62 	 	 Down35 -0.803212 	 	 	 	
ENSECAG00000022195 ENSECAG00000022195 	 	 Down34 -0.804666 	 	 	 	
ENSECAG00000004504 C19orf52 	 	 Down33 -0.810494 	 	 	 	
ENSECAG00000022697 TRABD2B 	 	 Down28 -0.843641 	 	 	 	
ENSECAG00000013721 SH2D5 	 	 Down26 -0.854379 	 	 	 	
ENSECAG00000024586 ENSECAG00000024586 	 	 Down25 -0.85534 	 	 	 	
ENSECAG00000015715 ADAMTS15 	 	 Down24 -0.861468 	 	 	 	
ENSECAG00000014511 IL11 	 	 Down16 -0.96058 	 	 	 	
ENSECAG00000012197 SPATA2L 	 	 Down8 -1.10335 	 	 	 	
ENSECAG00000018561 CDKN2B 	 	 Down7 -1.22934 	 	 	 	
ENSECAG00000022402 GFOD1 	 	 Down6 -1.23897 	 	 	 	
ENSECAG00000014921 GPRC5A 	 	 Down4 -1.33756 	 	 	 	
ENSECAG00000003025 HLX 	 	 Down2 -1.63124 	 	 	 	
ENSECAG00000003585 RPL19 	 	 	 	 Up17 1.32346 	 	
ENSECAG00000024426 PDAP1 	 	 	 	 Up18 1.29205 	 	
ENSECAG00000002024 ENSECAG00000002024 	 	 	 	 Up24 1.24544 	 	
ENSECAG00000006844 CALD1 	 	 	 	 Up25 1.19409 	 	
ENSECAG00000006493 PTMA 	 	 	 	 Up26 1.15249 	 	
ENSECAG00000019300 CARD9 	 	 	 	 Up28 1.12444 	 	
ENSECAG00000008785 ENSECAG00000008785 	 	 	 	 Up31 1.09935 	 	
ENSECAG00000016025 SNRNP27 	 	 	 	 Up32 1.07142 	 	
ENSECAG00000008257 RBMX2 	 	 	 	 Up35 1.00488 	 	
ENSECAG00000011155 ATP6V1G1 	 	 	 	 Up36 0.995159 	 	
ENSECAG00000005090 BASP1 	 	 	 	 Up39 0.962889 	 	
ENSECAG00000009472 CLSPN 	 	 	 	 Up40 0.955786 	 	
ENSECAG00000014983 HIRIP3 	 	 	 	 Up41 0.951502 	 	
ENSECAG00000008992 HYPK 	 	 	 	 Up42 0.944431 	 	
ENSECAG00000021583 LMOD1 	 	 	 	 Up46 0.911345 	 	
ENSECAG00000008506 HMMR 	 	 	 	 Up48 0.903499 	 	
ENSECAG00000010638 SREK1IP1 	 	 	 	 Up49 0.900818 	 	
ENSECAG00000014412 ZMAT2 	 	 	 	 Up51 0.897111 	 	
ENSECAG00000009621 INCENP 	 	 	 	 Up52 0.887348 	 	
ENSECAG00000009886 TRAF3IP1 	 	 	 	 Up54 0.874669 	 	
ENSECAG00000010132 HMGB2 	 	 	 	 Up55 0.874481 	 	
ENSECAG00000022843 ZC3H13 	 	 	 	 Up57 0.851282 	 	
ENSECAG00000012666 PSIP1 	 	 	 	 Up58 0.842963 	 	
ENSECAG00000019845 SPAG7 	 	 	 	 Up59 0.838775 	 	
ENSECAG00000022972 TCHP 	 	 	 	 Up60 0.838251 	 	
ENSECAG00000008385 ENSECAG00000008385 	 	 	 	 Up63 0.828334 	 	
ENSECAG00000015871 CDCA8 	 	 	 	 Up64 0.821569 	 	
ENSECAG00000008649 CCDC12 	 	 	 	 Up65 0.821442 	 	
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ENSECAG00000008649 CCDC12 	 	 	 	 Up65 0.821442 	 	
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000000734 HMGA1 	 	 	 	 Up66 0.812707 	 	
ENSECAG00000012708 DNAJC8 	 	 	 	 Up67 0.809498 	 	
ENSECAG00000012364 MYEOV2 	 	 	 	 Up68 0.808633 	 	
ENSECAG00000026810 FAM133B 	 	 	 	 Up69 0.806944 	 	
ENSECAG00000009987 PCNP 	 	 	 	 Up71 0.797147 	 	
ENSECAG00000017165 ENSA 	 	 	 	 Up72 0.797126 	 	
ENSECAG00000012760 LUC7L3 	 	 	 	 Up73 0.792121 	 	
ENSECAG00000010635 GPS2 	 	 	 	 Up74 0.784306 	 	
ENSECAG00000021311 NUDC 	 	 	 	 Up75 0.777538 	 	
ENSECAG00000026980 ENSECAG00000026980 	 	 	 	 Up76 0.774947 	 	
ENSECAG00000008928 ENSECAG00000008928 	 	 	 	 Up77 0.769984 	 	
ENSECAG00000024127 CENPF 	 	 	 	 Up78 0.767092 	 	
ENSECAG00000003089 ENSECAG00000003089 	 	 	 	 Up79 0.764132 	 	
ENSECAG00000023366 SUDS3 	 	 	 	 Up80 0.761729 	 	
ENSECAG00000014880 CFAP45 	 	 	 	 Up81 0.752188 	 	
ENSECAG00000003072 C8orf4 	 	 	 	 Up82 0.746632 	 	
ENSECAG00000023594 FAM50A 	 	 	 	 Up83 0.737634 	 	
ENSECAG00000026981 SRRM1 	 	 	 	 Up84 0.735645 	 	
ENSECAG00000000593 PTN 	 	 	 	 Up85 0.733931 	 	
ENSECAG00000013485 MFAP1 	 	 	 	 Up86 0.731433 	 	
ENSECAG00000016693 GOLIM4 	 	 	 	 Up89 0.729457 	 	
ENSECAG00000003766 GADD45GIP1 	 	 	 	 Up92 0.727814 	 	
ENSECAG00000013395 RBM25 	 	 	 	 Up93 0.72709 	 	
ENSECAG00000014949 TPM1 	 	 	 	 Up94 0.726056 	 	
ENSECAG00000003616 ENSECAG00000003616 	 	 	 	 Up95 0.725223 	 	
ENSECAG00000017015 MYH11 	 	 	 	 Up96 0.723533 	 	
ENSECAG00000024809 C1orf131 	 	 	 	 Up97 0.718484 	 	
ENSECAG00000023288 RNPS1 	 	 	 	 Up98 0.717031 	 	
ENSECAG00000010941 CCDC150 	 	 	 	 Up99 0.713529 	 	
ENSECAG00000006666 MURC 	 	 	 	 Up101 0.712238 	 	
ENSECAG00000026989 PDCD7 	 	 	 	 Up102 0.711159 	 	
ENSECAG00000008098 TCF7 	 	 	 	 Up103 0.707057 	 	
ENSECAG00000019569 ENSECAG00000019569 	 	 	 	 Up104 0.707021 	 	
ENSECAG00000014847 NUPR1 	 	 	 	 Up105 0.706403 	 	
ENSECAG00000012794 LYAR 	 	 	 	 Up106 0.705285 	 	
ENSECAG00000014812 KRT23 	 	 	 	 Up107 0.697669 	 	
ENSECAG00000013815 ENSECAG00000013815 	 	 	 	 Up108 0.694679 	 	
ENSECAG00000007123 ENSECAG00000007123 	 	 	 	 Up109 0.68695 	 	
ENSECAG00000019621 ENSECAG00000019621 	 	 	 	 Up110 0.686873 	 	
ENSECAG00000016947 UPF3B 	 	 	 	 Up112 0.680315 	 	
ENSECAG00000014069 GOLM1 	 	 	 	 Up113 0.679488 	 	
ENSECAG00000022323 PSMC3IP 	 	 	 	 Up114 0.679355 	 	
ENSECAG00000021350 SRSF4 	 	 	 	 Up115 0.676075 	 	
ENSECAG00000017963 E2F7 	 	 	 	 Up116 0.675926 	 	
ENSECAG00000021271 ENSECAG00000021271 	 	 	 	 Up117 0.67362 	 	
ENSECAG00000021276 BRD3 	 	 	 	 Up118 0.672743 	 	
ENSECAG00000018958 C9orf78 	 	 	 	 Up120 0.669381 	 	
ENSECAG00000010862 TNIP1 	 	 	 	 Up121 0.668438 	 	
ENSECAG00000005865 HAUS8 	 	 	 	 Up122 0.666204 	 	
ENSECAG00000011826 ATPIF1 	 	 	 	 Up123 0.666041 	 	
ENSECAG00000010367 RAD51AP1 	 	 	 	 Up124 0.665138 	 	
ENSECAG00000012231 DEK 	 	 	 	 Up125 0.663819 	 	
ENSECAG00000021097 ACIN1 	 	 	 	 Up126 0.660863 	 	
ENSECAG00000011870 PYM1 	 	 	 	 Up127 0.656765 	 	
ENSECAG00000013512 ENSECAG00000013512 	 	 	 	 Up128 0.655647 	 	
ENSECAG00000014953 KIF15 	 	 	 	 Up129 0.653919 	 	
ENSECAG00000011337 ODF2 	 	 	 	 Up130 0.652646 	 	
ENSECAG00000017141 UPF3A 	 	 	 	 Up131 0.646773 	 	
ENSECAG00000014242 MAD1L1 	 	 	 	 Up132 0.646476 	 	
ENSECAG00000016495 NUSAP1 	 	 	 	 Up133 0.646448 	 	
ENSECAG00000026853 CEP152 	 	 	 	 Up134 0.644139 	 	
ENSECAG00000018476 TPX2 	 	 	 	 Up136 0.642373 	 	
ENSECAG00000022315 BIN3 	 	 	 	 Up137 0.641456 	 	
ENSECAG00000002115 ENSECAG00000002115 	 	 	 	 Up139 0.639271 	 	
ENSECAG00000008466 ENSECAG00000008466 	 	 	 	 Up140 0.638539 	 	
ENSECAG00000026905 RPL37 	 	 	 	 Up141 0.637897 	 	
ENSECAG00000018538 PPIG 	 	 	 	 Up142 0.637641 	 	
ENSECAG00000003357 ING1 	 	 	 	 Up143 0.635161 	 	
ENSECAG00000012624 POLD3 	 	 	 	 Up144 0.634971 	 	
ENSECAG00000024902 ENSECAG00000024902 	 	 	 	 Up145 0.634489 	 	
ENSECAG00000013696 SLU7 	 	 	 	 Up146 0.633604 	 	
ENSECAG00000001897 SUMO2 	 	 	 	 Up148 0.628834 	 	
ENSECAG00000015060 PRR11 	 	 	 	 Up149 0.627963 	 	
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ENSECAG00000015060 PRR11 	 	 	 	 Up149 0.627963 	 	
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000020610 NDUFB10 	 	 	 	 Up151 0.61959 	 	
ENSECAG00000015496 ENSECAG00000015496 	 	 	 	 Up152 0.616784 	 	
ENSECAG00000007487 ENSECAG00000007487 	 	 	 	 Up153 0.61607 	 	
ENSECAG00000021538 CKAP2L 	 	 	 	 Up154 0.613215 	 	
ENSECAG00000017105 SEC62 	 	 	 	 Up155 0.610318 	 	
ENSECAG00000004534 CCDC136 	 	 	 	 Up156 0.605553 	 	
ENSECAG00000017076 NSRP1 	 	 	 	 Up158 0.603928 	 	
ENSECAG00000012779 IK 	 	 	 	 Up159 0.603291 	 	
ENSECAG00000000633 ZWINT 	 	 	 	 Up161 0.600546 	 	
ENSECAG00000000644 MAP7D3 	 	 	 	 Up161 0.600546 	 	
ENSECAG00000013640 CEP85 	 	 	 	 Up162 0.60029 	 	
ENSECAG00000022449 MEAF6 	 	 	 	 Up163 0.599962 	 	
ENSECAG00000012637 LENG1 	 	 	 	 Up165 0.598714 	 	
ENSECAG00000018394 MESDC2 	 	 	 	 Up166 0.597826 	 	
ENSECAG00000022285 ENSECAG00000022285 	 	 	 	 Up167 0.597506 	 	
ENSECAG00000018438 CEP55 	 	 	 	 Up168 0.596321 	 	
ENSECAG00000006129 NUP62 	 	 	 	 Up169 0.595882 	 	
ENSECAG00000014320 PPL 	 	 	 	 Up170 0.595836 	 	
ENSECAG00000008538 SPECC1 	 	 	 	 Up171 0.593915 	 	
ENSECAG00000019321 TXLNA 	 	 	 	 Up172 0.590412 	 	
ENSECAG00000012023 ENSECAG00000012023 	 	 	 	 Up173 0.590344 	 	
ENSECAG00000017006 CHMP4A 	 	 	 	 Up174 0.588888 	 	
ENSECAG00000014009 TPM2 	 	 	 	 Up175 0.587612 	 	
ENSECAG00000005815 LLPH 	 	 	 	 Up176 0.58692 	 	
ENSECAG00000011537 C14orf119 	 	 	 	 Up177 0.586732 	 	
ENSECAG00000011778 C11orf58 	 	 	 	 Up178 0.585521 	 	
ENSECAG00000015878 AMOT 	 	 	 	 Down62 -0.583045 	 	
ENSECAG00000008577 PPP3CB 	 	 	 	 Down61 -0.58889 	 	
ENSECAG00000022342 PKIA 	 	 	 	 Down60 -0.590756 	 	
ENSECAG00000024974 RNF11 	 	 	 	 Down59 -0.592537 	 	
ENSECAG00000017012 PTEN 	 	 	 	 Down58 -0.601453 	 	
ENSECAG00000010628 PPP1R14B 	 	 	 	 Down57 -0.602554 	 	
ENSECAG00000016862 SLC25A33 	 	 	 	 Down56 -0.608907 	 	
ENSECAG00000023284 ENSECAG00000023284 	 	 	 	 Down55 -0.619739 	 	
ENSECAG00000003002 CD9 	 	 	 	 Down54 -0.624481 	 	
ENSECAG00000014232 NR4A2 	 	 	 	 Down53 -0.625517 	 	
ENSECAG00000011223 HGF 	 	 	 	 Down52 -0.6264 	 	
ENSECAG00000010571 AGL 	 	 	 	 Down51 -0.636853 	 	
ENSECAG00000014113 CCNG2 	 	 	 	 Down50 -0.64024 	 	
ENSECAG00000021307 TGDS 	 	 	 	 Down49 -0.650154 	 	
ENSECAG00000001318 UBL3 	 	 	 	 Down48 -0.652025 	 	
ENSECAG00000002481 ENSECAG00000002481 	 	 	 	 Down47 -0.655159 	 	
ENSECAG00000012577 HOXA10 	 	 	 	 Down46 -0.658534 	 	
ENSECAG00000008215 TSC22D3 	 	 	 	 Down45 -0.666727 	 	
ENSECAG00000010827 ENSECAG00000010827 	 	 	 	 Down44 -0.667793 	 	
ENSECAG00000015783 PTBP2 	 	 	 	 Down41 -0.686615 	 	
ENSECAG00000005757 ENSECAG00000005757 	 	 	 	 Down40 -0.690087 	 	
ENSECAG00000019834 CYP39A1 	 	 	 	 Down39 -0.695967 	 	
ENSECAG00000021330 HMGCR 	 	 	 	 Down38 -0.700786 	 	
ENSECAG00000012062 EFNA5 	 	 	 	 Down37 -0.708252 	 	
ENSECAG00000005163 SLC38A6 	 	 	 	 Down36 -0.712477 	 	
ENSECAG00000011841 FAM174A 	 	 	 	 Down35 -0.717274 	 	
ENSECAG00000009515 ATRNL1 	 	 	 	 Down34 -0.729997 	 	
ENSECAG00000016183 STARD4 	 	 	 	 Down33 -0.739402 	 	
ENSECAG00000008425 LURAP1L 	 	 	 	 Down31 -0.740235 	 	
ENSECAG00000017787 FLVCR1 	 	 	 	 Down27 -0.752844 	 	
ENSECAG00000020317 RAP2C 	 	 	 	 Down25 -0.76238 	 	
ENSECAG00000024992 HSD17B7 	 	 	 	 Down24 -0.772415 	 	
ENSECAG00000006455 CYP51A1 	 	 	 	 Down22 -0.803576 	 	
ENSECAG00000000046 FAM13C 	 	 	 	 Down21 -0.819509 	 	
ENSECAG00000008926 RNF139 	 	 	 	 Down20 -0.827204 	 	
ENSECAG00000013998 SQLE 	 	 	 	 Down18 -0.853104 	 	
ENSECAG00000018059 SC5D 	 	 	 	 Down16 -0.913739 	 	
ENSECAG00000002626 GPR12 	 	 	 	 Down10 -0.983593 	 	
ENSECAG00000007020 C14orf28 	 	 	 	 Down8 -1.07536 	 	
ENSECAG00000011527 CASD1 	 	 	 	 Down7 -1.1038 	 	
ENSECAG00000021607 TXNDC8 	 	 	 	 Down6 -1.12117 	 	
ENSECAG00000024444 CTNNA2 	 	 	 	 Down5 -1.1567 	 	
ENSECAG00000003658 ENSECAG00000003658 	 	 	 	 Down4 -1.16691 	 	
ENSECAG00000006174 ENSECAG00000006174 	 	 	 	 Down1 -1.46428 	 	
ENSECAG00000027451 ENSECAG00000027451 	 	 	 	 	 	 Up2 inf
ENSECAG00000016985 IL36G 	 	 	 	 	 	 Up20 1.39083
ENSECAG00000027624 ENSECAG00000027624 	 	 	 	 	 	 Up26 1.18142
O/03-WT O/03-K186E O/03-230 O/03-K186E-230
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ENSECAG00000027624 ENSECAG00000027624 	 	 	 	 	 	 Up26 1.18142
Gene	ID Gene	name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000015449 IRF8 	 	 	 	 	 	 Up32 1.07107
ENSECAG00000014398 ENSECAG00000014398 	 	 	 	 	 	 Up35 1.01109
ENSECAG00000015389 SV2B 	 	 	 	 	 	 Up38 0.908518
ENSECAG00000022387 RUNDC3B 	 	 	 	 	 	 Up43 0.82593
ENSECAG00000024909 FBXL2 	 	 	 	 	 	 Up54 0.713893
ENSECAG00000015959 MYBL1 	 	 	 	 	 	 Up55 0.705196
ENSECAG00000009742 S100A12 	 	 	 	 	 	 Up57 0.704123
ENSECAG00000024016 IL13RA2 	 	 	 	 	 	 Up61 0.68763
ENSECAG00000011226 CENPQ 	 	 	 	 	 	 Up63 0.6774
ENSECAG00000024391 CD58 	 	 	 	 	 	 Up65 0.667648
ENSECAG00000011292 MSR1 	 	 	 	 	 	 Up70 0.653605
ENSECAG00000009925 ARNTL2 	 	 	 	 	 	 Up71 0.648288
ENSECAG00000023416 F3 	 	 	 	 	 	 Up73 0.64621
ENSECAG00000019890 VRK1 	 	 	 	 	 	 Up74 0.635457
ENSECAG00000020270 CCNE2 	 	 	 	 	 	 Up77 0.631894
ENSECAG00000010871 TMEM126B 	 	 	 	 	 	 Up80 0.623039
ENSECAG00000027692 COX2 	 	 	 	 	 	 Up85 0.611617
ENSECAG00000022189 PFDN4 	 	 	 	 	 	 Up86 0.611601
ENSECAG00000019398 TFPI2 	 	 	 	 	 	 Up88 0.60962
ENSECAG00000019817 SNRPF 	 	 	 	 	 	 Up90 0.608546
ENSECAG00000027681 ND2 	 	 	 	 	 	 Up97 0.597166
ENSECAG00000020878 ENSECAG00000020878 	 	 	 	 	 	 Up101 0.581476
ENSECAG00000017926 TROAP 	 	 	 	 	 	 Down57 -0.582251
ENSECAG00000002482 PQLC1 	 	 	 	 	 	 Down56 -0.58856
ENSECAG00000011939 CLIP2 	 	 	 	 	 	 Down53 -0.595107
ENSECAG00000008012 CHST3 	 	 	 	 	 	 Down52 -0.598346
ENSECAG00000007907 ENSECAG00000007907 	 	 	 	 	 	 Down46 -0.619994
ENSECAG00000009352 OBSL1 	 	 	 	 	 	 Down45 -0.621182
ENSECAG00000017294 SNTB1 	 	 	 	 	 	 Down44 -0.624512
ENSECAG00000021037 FEZF2 	 	 	 	 	 	 Down41 -0.64712
ENSECAG00000017142 SEZ6 	 	 	 	 	 	 Down39 -0.663987
ENSECAG00000000744 TBC1D2 	 	 	 	 	 	 Down34 -0.673914
ENSECAG00000026973 BCL11B 	 	 	 	 	 	 Down21 -0.736266
ENSECAG00000014357 DLL1 	 	 	 	 	 	 Down19 -0.739284
ENSECAG00000008871 ALDH1A3 	 	 	 	 	 	 Down16 -0.75701
ENSECAG00000009779 SORCS2 	 	 	 	 	 	 Down15 -0.772107
ENSECAG00000013825 NOD1 	 	 	 	 	 	 Down14 -0.79745
ENSECAG00000017019 ARHGAP33 	 	 	 	 	 	 Down13 -0.810786
ENSECAG00000011401 CATSPERD 	 	 	 	 	 	 Down12 -0.814234
ENSECAG00000014632 CPLX2 	 	 	 	 	 	 Down10 -0.904945
ENSECAG00000023032 AZIN2 	 	 	 	 	 	 Down6 -1.00068
ENSECAG00000017175 REM1 	 	 	 	 	 	 Down4 -1.09741
ENSECAG00000013783 ENSECAG00000013783 	 	 	 	 	 	 Down3 -1.14067
ENSECAG00000026054 U6 	 	 	 	 	 	 Down1 -inf
O/03-WT O/03-K186E O/03-230 O/03-K186E-
230
Up-regulated	genes 248 65 179 101
Down-regulated	genes 181 128 62 57
Total	DEGs 429 193 241 158
O/03-WT O/03-K186E O/03-230 O/03-K186E-230
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Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000010153 IFIT3 Up6 5.33721 Up9 3.44747 Up4 5.80104 Up4 3.81311
ENSECAG00000011439 DHX58 Up9 4.3019 Up11 2.68535 Up5 5.21961 Up7 3.38991
ENSECAG00000009020 IFI44 Up10 4.22229 Up12 2.65132 Up9 4.58574 Up8 3.38161
ENSECAG00000004433 IFIT1 Up11 4.11074 Up14 2.06929 Up7 4.81752 Up10 2.91267
ENSECAG00000009618 IFI44L Up12 3.63587 Up15 2.05809 Up10 3.90641 Up11 2.72257
ENSECAG00000011776 MX1 Up14 3.14878 Up33 1.28711 Up11 3.69529 Up17 1.89618
ENSECAG00000001324 ISG15 Up18 2.77236 Up24 1.51271 Up12 3.63029 Up18 1.8953
ENSECAG00000012132 ENSECAG00000012132 Up22 2.14977 Up73 0.827483 Up17 2.7074 Up33 1.40367
ENSECAG00000014422 OAS2 Up27 1.82461 Up57 0.941087 Up20 2.34113 Up53 1.2398
ENSECAG00000024429 IRF9 Up28 1.79513 Up44 1.06099 Up19 2.59713 Up43 1.30893
ENSECAG00000001481 SAMD9L Up32 1.49784 Up123 0.645397 Up24 1.70405 Up52 1.259
ENSECAG00000001598 IFI35 Up48 1.05837 Up70 0.850989 Up26 1.62154 Up106 1.00694
ENSECAG00000023135 LYRM7 Up64 0.928043 Up85 0.74354 Up76 0.718885 Up114 0.995131
ENSECAG00000012179 RGS2 Up89 0.751255 Up36 1.19713 Up85 0.665814 Up57 1.2091
ENSECAG00000015959 MYBL1 Up133 0.595256 Up99 0.710276 Up108 0.604595 Up140 0.966431
ENSECAG00000015814 LRRC73 Down39 -0.90033 Down37 -0.675876 Down81 -0.63939 Down53 -0.618326
ENSECAG00000009202 TYSND1 Down23 -0.959203 Down55 -0.597133 Down88 -0.621765 Down46 -0.664262
ENSECAG00000008899 LSS Down22 -0.963068 Down28 -0.745571 Down65 -0.726256 Down20 -0.80581
ENSECAG00000010664 GNRH1 Up4 inf Up2 inf Up2 inf
ENSECAG00000020860 LSMEM1 Up15 3.00232 Up7 3.52154 Up14 2.54166
ENSECAG00000009793 TAGLN3 Up20 2.54268 Up8 3.49492 Up9 2.98379
ENSECAG00000019367 ENSECAG00000019367 Up25 1.88129 Up16 1.96328 Up16 1.97533
ENSECAG00000022299 LRRC66 Up26 1.82795 Up13 2.21072 Up19 1.8297
ENSECAG00000022605 FAM179A Up29 1.74385 Up20 1.62461 Up129 0.978574
ENSECAG00000012898 PNLDC1 Up31 1.56451 Up23 1.55336 Up92 1.05295
ENSECAG00000020923 LEAP2 Up37 1.29596 Up27 1.42569 Up44 1.30241
ENSECAG00000012348 EFNB2 Up39 1.27502 Up35 1.21889 Up34 1.3969
ENSECAG00000023507 GPR19 Up42 1.15431 Up40 1.10944 Up237 0.849092
ENSECAG00000016648 IL5 Up44 1.13772 Up39 1.11771 Up99 1.03268
ENSECAG00000010656 HBEGF Up52 1.01248 Up22 1.58423 Up21 1.78032
ENSECAG00000015342 CXCL8 Up61 0.956865 Up58 0.935643 Up25 1.59604
ENSECAG00000023566 DHRS9 Up75 0.853005 Up56 0.944545 Up26 1.57134
ENSECAG00000005903 ENSECAG00000005903 Up76 0.849148 Up77 0.806524 Up153 0.949382
ENSECAG00000024298 PTPN22 Up78 0.824954 Up52 1.00397 Up155 0.93912
ENSECAG00000013756 C8orf59 Up84 0.783365 Up120 0.650365 Up310 0.80989
ENSECAG00000020270 CCNE2 Up88 0.758335 Up48 1.01197 Up84 1.06706
ENSECAG00000022874 SCG5 Up93 0.737912 Up63 0.891699 Up567 0.705102
ENSECAG00000016965 SUV39H2 Up94 0.736519 Up64 0.886631 Up90 1.05648
ENSECAG00000013843 TUBE1 Up97 0.730053 Up69 0.853153 Up45 1.29863
ENSECAG00000023484 SKA1 Up101 0.706982 Up107 0.691046 Up277 0.829442
ENSECAG00000007803 LSM3 Up102 0.704097 Up109 0.677778 Up108 1.00363
ENSECAG00000009925 ARNTL2 Up103 0.703787 Up67 0.862834 Up79 1.08686
ENSECAG00000015496 ENSECAG00000015496 Up104 0.702803 Up75 0.819189 Up294 0.818364
ENSECAG00000003755 PIGW Up105 0.701986 Up80 0.788466 Up228 0.8568
ENSECAG00000015510 FGF7 Up106 0.695944 Up45 1.02384 Up31 1.48791
ENSECAG00000004590 TIPIN Up109 0.676348 Up74 0.821189 Up274 0.830524
ENSECAG00000014615 STX2 Up110 0.672309 Up134 0.611084 Up145 0.959706
ENSECAG00000017194 FANCB Up111 0.670598 Up118 0.656224 Up136 0.969754
ENSECAG00000020201 GCNT1 Up114 0.661875 Up110 0.672867 Up967 0.600993
ENSECAG00000013298 POLE2 Up118 0.648491 Up121 0.647938 Up102 1.02063
ENSECAG00000024391 CD58 Up122 0.639183 Up88 0.735449 Up50 1.26502
ENSECAG00000011449 ANKS1B Up123 0.638934 Up55 0.965427 Up477 0.736421
ENSECAG00000007070 TPRKB Up126 0.625957 Up92 0.730267 Up113 0.996073
ENSECAG00000002238 MIS12 Up130 0.60541 Up82 0.780604 Up292 0.81948
ENSECAG00000009754 NETO2 Up134 0.594759 Up144 0.589724 Up376 0.775708
ENSECAG00000006472 EIF4E Up135 0.590533 Up145 0.589428 Up96 1.04404
ENSECAG00000023637 ADAM33 Down235 -0.593988 Down29 -0.742143 Down27 -0.733496
ENSECAG00000005577 GPR39 Down114 -0.697544 Down27 -0.76466 Down47 -0.662203
ENSECAG00000001989 SESN2 Down46 -0.879919 Down21 -0.833335 Down64 -0.585299
ENSECAG00000009989 CHAC1 Down18 -0.993054 Down16 -0.905742 Down37 -0.691439
ENSECAG00000021543 CDKN1A Down10 -1.09995 Down54 -0.597673 Down58 -0.60167
ENSECAG00000007881 IFIH1 Up7 4.55421 Up6 5.13002 Up5 3.65116
ENSECAG00000024167 DDX60 Up8 4.43945 Up8 4.69968 Up6 3.4278
ENSECAG00000000284 ENSECAG00000000284 Up19 2.72162 Up14 3.36723 Up28 1.54525
ENSECAG00000010185 ENSECAG00000010185 Up21 2.3283 Up16 3.03826 Up29 1.53936
ENSECAG00000019932 ENSECAG00000019932 Up23 1.9909 Up18 2.64499 Up27 1.56487
ENSECAG00000000968 ENSECAG00000000968 Up30 1.613 Up23 1.83489 Up116 0.992858
ENSECAG00000021220 ENSECAG00000021220 Up38 1.29564 Up21 2.04664 Up373 0.776238
ENSECAG00000008809 OAS3 Up40 1.2671 Up22 1.93784 Up473 0.740666
ENSECAG00000011726 EIF2AK2 Up49 1.04951 Up50 0.944299 Up120 0.988205
ENSECAG00000021989 DDX58 Up50 1.03753 Up35 1.34299 Up563 0.705945
ENSECAG00000007744 RSRP1 Up53 1.01076 Up47 1.00543 Up35 1.38565
ENSECAG00000009686 DTX3L Up55 1.00164 Up28 1.46786 Up437 0.755732
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000009686 DTX3L Up55 1.00164 Up28 1.46786 Up437 0.755732
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000012331 PARP9 Up56 0.998805 Up34 1.34397 Up296 0.816214
ENSECAG00000016217 RNF213 Up65 0.923765 Up27 1.49935 Up705 0.663515
ENSECAG00000001399 SAMD9 Up66 0.912912 Up52 0.942535 Up211 0.870057
ENSECAG00000017394 ZC3HAV1 Up68 0.903109 Up37 1.30002 Up959 0.602414
ENSECAG00000004349 IFIT5 Up71 0.885287 Up48 0.985357 Up845 0.625025
ENSECAG00000009543 EPSTI1 Up77 0.83257 Up29 1.4297 Up279 0.828657
ENSECAG00000014295 PI3 Up83 0.785474 Up32 1.37746 Up217 0.86702
ENSECAG00000016983 ANKRD1 Up85 0.780023 Up40 1.09562 Up259 0.838183
ENSECAG00000020428 ENSECAG00000020428 Up116 0.657532 Up64 0.793587 Up223 0.861115
ENSECAG00000010667 ERG Up128 0.610224 Up71 0.747632 Up551 0.709218
ENSECAG00000008688 ENSECAG00000008688 Down189 -0.625213 Down3 -1.77432 Down59 -0.599041
ENSECAG00000024650 FADS2 Down181 -0.63414 Down52 -0.799129 Down41 -0.670507
ENSECAG00000013009 KIF26B Down138 -0.677023 Down77 -0.649226 Down24 -0.737876
ENSECAG00000013608 KAZALD1 Down123 -0.687527 Down54 -0.783873 Down54 -0.614904
ENSECAG00000021964 ASB9 Down117 -0.695657 Down33 -0.916693 Down32 -0.71169
ENSECAG00000023067 MVK Down96 -0.717135 Down84 -0.627694 Down38 -0.687078
ENSECAG00000018552 CDKN2A Down64 -0.800677 Down71 -0.692934 Down45 -0.665138
ENSECAG00000016389 ACSS2 Down50 -0.860334 Down56 -0.770018 Down19 -0.824737
ENSECAG00000017229 ENSECAG00000017229 Down34 -0.907961 Down13 -1.16944 Down49 -0.637804
ENSECAG00000006999 PLEKHG4 Down33 -0.909293 Down72 -0.686726 Down18 -0.838619
ENSECAG00000013176 MEGF6 Down26 -0.939986 Down39 -0.877218 Down52 -0.63014
ENSECAG00000005316 PIF1 Down25 -0.940866 Down37 -0.906174 Down13 -0.901346
ENSECAG00000013300 CXCL10 Up13 3.61765 Up12 2.59049
ENSECAG00000003681 ENSECAG00000003681 Up41 1.19309 Up152 0.952266
ENSECAG00000005249 IQUB Up45 1.12424 Up55 1.21895
ENSECAG00000020285 NMUR2 Up59 0.964004 Up314 0.808767
ENSECAG00000015389 SV2B Up72 0.880344 Up225 0.858517
ENSECAG00000012680 N4BP2L1 Up73 0.877394 Up172 0.908449
ENSECAG00000019165 CENPK Up90 0.748959 Up75 1.11258
ENSECAG00000022568 TMEM154 Up95 0.732243 Up770 0.648252
ENSECAG00000008723 CASP12 Up96 0.73034 Up268 0.832213
ENSECAG00000016844 MEIOC Up98 0.720769 Up412 0.762811
ENSECAG00000023416 F3 Up99 0.716922 Up171 0.913206
ENSECAG00000016730 ENSECAG00000016730 Up100 0.713195 Up163 0.926146
ENSECAG00000018861 ENSECAG00000018861 Up112 0.670498 Up267 0.832327
ENSECAG00000005331 ISOC1 Up113 0.662094 Up288 0.822006
ENSECAG00000024519 SPC25 Up115 0.658804 Up744 0.654211
ENSECAG00000024911 ITGB3BP Up119 0.647272 Up135 0.970525
ENSECAG00000014972 PHF11 Up120 0.641586 Up443 0.752192
ENSECAG00000023743 CCDC58 Up124 0.637457 Up585 0.696651
ENSECAG00000018693 ENSECAG00000018693 Up127 0.621964 Up989 0.595197
ENSECAG00000003015 SERPINB2 Up131 0.604312 Up530 0.717132
ENSECAG00000018544 SPDL1 Up136 0.589304 Up198 0.884021
ENSECAG00000019024 FAM204A Up137 0.58901 Up713 0.661039
ENSECAG00000009006 USP46 Up138 0.58693 Up272 0.830979
ENSECAG00000019053 FAM175A Up140 0.581694 Up74 1.12084
ENSECAG00000010225 GRID2IP Down165 -0.647613 Down25 -0.735195
ENSECAG00000021280 SHISA4 Down164 -0.647663 Down60 -0.595579
ENSECAG00000022901 PKMYT1 Down152 -0.658362 Down57 -0.601905
ENSECAG00000003075 BORCS6 Down98 -0.712612 Down23 -0.751196
ENSECAG00000011160 TP53INP2 Down82 -0.741446 Down31 -0.715738
ENSECAG00000010118 SRGAP3 Down80 -0.747885 Down43 -0.667821
ENSECAG00000000931 TMEM119 Down79 -0.748376 Down30 -0.718741
ENSECAG00000021186 FHOD3 Down71 -0.771865 Down61 -0.590052
ENSECAG00000021155 MXD3 Down69 -0.773135 Down10 -1.01078
ENSECAG00000004462 HIC1 Down66 -0.794084 Down63 -0.586445
ENSECAG00000008443 TMEM259 Down54 -0.835336 Down51 -0.637604
ENSECAG00000014632 CPLX2 Down52 -0.838319 Down33 -0.710916
ENSECAG00000011206 MVD Down51 -0.859346 Down56 -0.611066
ENSECAG00000019910 PDLIM2 Down40 -0.899907 Down28 -0.73035
ENSECAG00000012197 SPATA2L Down38 -0.900881 Down35 -0.701257
ENSECAG00000001022 UCN2 Down36 -0.905955 Down34 -0.704328
ENSECAG00000021411 TM7SF2 Down32 -0.913836 Down22 -0.752184
ENSECAG00000011185 BTBD19 Down15 -1.0045 Down21 -0.786424
ENSECAG00000023782 SLC16A13 Down12 -1.0319 Down9 -1.01198
ENSECAG00000014282 NPPB Down4 -1.37353 Down7 -1.06006
ENSECAG00000010322 LDHD Down3 -1.39661 Down4 -1.20231
ENSECAG00000006098 ANKRD9 Down1 -1.99072 Down1 -2.86832
ENSECAG00000025973 U1 Up6 inf Up3 inf
ENSECAG00000008637 HMGCS1 Down56 -0.594789 Down68 -0.710506
ENSECAG00000008871 ALDH1A3 Down4 -1.13855 Up90 0.652271
ENSECAG00000018139 ENSECAG00000018139 Up1 inf Up3 inf
ENSECAG00000019576 ENSECAG00000019576 Up2 inf Up4 inf
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000019576 ENSECAG00000019576 Up2 inf Up4 inf
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000022734 SGPP2 Up3 inf Up5 inf
ENSECAG00000021468 POPDC2 Up34 1.34092 Up21 1.59069
ENSECAG00000016080 KCNB1 Up35 1.33649 Up30 1.32885
ENSECAG00000012746 STAR Up36 1.31773 Up28 1.39059
ENSECAG00000012826 CDO1 Up43 1.14266 Up26 1.45509
ENSECAG00000018029 THSD1 Up54 1.00861 Up19 1.69768
ENSECAG00000013528 AVIL Up57 0.972598 Up83 0.754989
ENSECAG00000020562 AXDND1 Up69 0.890887 Up38 1.13744
ENSECAG00000003669 HLA-DMA Up70 0.888328 Up32 1.29289
ENSECAG00000026993 CEBPZOS Up80 0.81461 Up96 0.722319
ENSECAG00000023052 POLG2 Up81 0.813714 Up105 0.696331
ENSECAG00000009937 UBE2N Up82 0.805787 Up116 0.659094
ENSECAG00000001215 C12orf73 Up86 0.768625 Up129 0.618742
ENSECAG00000010871 TMEM126B Up129 0.607189 Up124 0.63787
ENSECAG00000011939 CLIP2 Down214 -0.60504 Down34 -0.71819
ENSECAG00000011401 CATSPERD Down209 -0.606865 Down9 -1.00675
ENSECAG00000014566 WISP2 Down206 -0.608505 Down41 -0.66546
ENSECAG00000014470 EEPD1 Down194 -0.618182 Down22 -0.819937
ENSECAG00000009779 SORCS2 Down190 -0.624447 Down11 -0.97256
ENSECAG00000008298 WNT10B Down173 -0.640325 Down53 -0.59968
ENSECAG00000013825 NOD1 Down166 -0.646151 Down30 -0.739632
ENSECAG00000009792 UNC5B Down143 -0.668636 Down7 -1.05305
ENSECAG00000005067 KRT16 Down118 -0.693857 Down3 -1.14763
ENSECAG00000012059 OPLAH Down106 -0.707164 Down20 -0.840835
ENSECAG00000012961 HSPG2 Down103 -0.708486 Down58 -0.585461
ENSECAG00000007907 ENSECAG00000007907 Down83 -0.74087 Down36 -0.682479
ENSECAG00000005017 FBXW9 Down74 -0.762503 Down23 -0.804287
ENSECAG00000013443 AKNA Down56 -0.823496 Down44 -0.633176
ENSECAG00000000607 TRIB3 Down29 -0.923731 Down24 -0.793802
ENSECAG00000013817 CYP1A1 Down28 -0.928951 Down1 -2.00177
ENSECAG00000011234 COL7A1 Down27 -0.933107 Down45 -0.621001
ENSECAG00000011475 ENSECAG00000011475 Down9 -1.10002 Down42 -0.661868
ENSECAG00000010953 TNIP3 Up54 0.932075 Up890 0.616436
ENSECAG00000019809 MB21D1 Up72 0.745114 Up442 0.752859
ENSECAG00000017105 SEC62 Up83 0.671821 Up954 0.603615
ENSECAG00000008426 PAPSS2 Up87 0.66224 Up538 0.714752
ENSECAG00000009472 CLSPN Up95 0.629392 Up1020 0.589565
ENSECAG00000019817 SNRPF Up96 0.629116 Up769 0.648327
ENSECAG00000022166 AKAP12 Up98 0.626063 Up493 0.730739
ENSECAG00000003783 ENSECAG00000003783 Up102 0.613639 Up965 0.601284
ENSECAG00000013778 PINX1 Up113 0.592925 Up859 0.622534
ENSECAG00000015715 ADAMTS15 Down24 -1.01545 Down39 -0.682253
ENSECAG00000024260 TMEM160 Down21 -1.04154 Down29 -0.7263
ENSECAG00000020157 KRT5 Down11 -1.23713 Down15 -0.893729
ENSECAG00000003332 H1FX Down8 -1.30571 Down11 -0.947437
ENSECAG00000027624 ENSECAG00000027624 Down2 -2.0526 Down3 -1.21182
ENSECAG00000024888 CCL5 Up16 2.79473 Up13 3.37828
ENSECAG00000019309 GBP2 Up17 2.78832 Up15 3.33191
ENSECAG00000019411 HERC6 Up46 1.12094 Up38 1.29109
ENSECAG00000002176 ENSECAG00000002176 Up51 1.01873 Up25 1.62778
ENSECAG00000003585 RPL19 Up67 0.907307 Up31 1.41658
ENSECAG00000010055 RSAD2 Up74 0.856092 Up36 1.31333
ENSECAG00000004574 ENSECAG00000004574 Up87 0.760706 Up49 0.967775
ENSECAG00000012773 CMPK2 Up91 0.74871 Up46 1.02271
ENSECAG00000009190 TMSB4X Up108 0.678294 Up61 0.829304
ENSECAG00000013435 OAS1 Up117 0.655917 Up41 1.08034
ENSECAG00000024399 FGF12 Up139 0.583093 Up88 0.6566
ENSECAG00000010262 PERP Down247 -0.586801 Down87 -0.623274
ENSECAG00000012818 TUBB3 Down215 -0.6047 Down86 -0.624004
ENSECAG00000013744 HSPB6 Down204 -0.610737 Down85 -0.626631
ENSECAG00000005956 TPBGL Down183 -0.630657 Down64 -0.728843
ENSECAG00000006734 ENSECAG00000006734 Down146 -0.66453 Down63 -0.734948
ENSECAG00000021748 ENSECAG00000021748 Down130 -0.683528 Down58 -0.7599
ENSECAG00000021308 APBA3 Down105 -0.707515 Down42 -0.865827
ENSECAG00000015240 PROM2 Down101 -0.709566 Down99 -0.58243
ENSECAG00000020198 NOTUM Down91 -0.728727 Down23 -1.02528
ENSECAG00000016441 DOHH Down87 -0.734432 Down80 -0.640043
ENSECAG00000010652 ENSECAG00000010652 Down73 -0.762938 Down35 -0.91315
ENSECAG00000024586 ENSECAG00000024586 Down31 -0.913975 Down40 -0.873208
ENSECAG00000025020 FHL1 Down21 -0.981485 Down15 -1.12762
ENSECAG00000018561 CDKN2B Down14 -1.01255 Down30 -0.940305
ENSECAG00000024000 PYGM Up10 3.2163 Up13 2.58043
ENSECAG00000023733 MMP1 Up17 1.7786 Up15 2.11539
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000023733 MMP1 Up17 1.7786 Up15 2.11539
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000010700 CREG2 Up29 1.36946 Up207 0.876578
ENSECAG00000011626 S1PR1 Up31 1.30539 Up58 1.19872
ENSECAG00000012553 HSF2 Up37 1.18814 Up809 0.635701
ENSECAG00000006567 SLITRK4 Up41 1.10058 Up54 1.22945
ENSECAG00000007918 TNS4 Up43 1.06618 Up740 0.655654
ENSECAG00000023729 SHC3 Up47 1.01967 Up587 0.695941
ENSECAG00000020145 FBXO43 Up51 1.00485 Up93 1.05037
ENSECAG00000008533 ITGA10 Up54 0.976869 Up453 0.750406
ENSECAG00000019438 OSMR Up59 0.932801 Up440 0.753755
ENSECAG00000013106 ESM1 Up61 0.908903 Up146 0.959285
ENSECAG00000000152 KITLG Up62 0.905236 Up65 1.14341
ENSECAG00000021206 HAS2 Up68 0.85518 Up97 1.03863
ENSECAG00000020380 COMMD8 Up71 0.845789 Up72 1.12474
ENSECAG00000011003 PDE4B Up72 0.841612 Up688 0.666768
ENSECAG00000013514 DUSP5 Up78 0.799917 Up142 0.963009
ENSECAG00000011978 LRR1 Up79 0.79051 Up158 0.934407
ENSECAG00000016457 E2F8 Up86 0.741605 Up807 0.636158
ENSECAG00000016339 ADAMTS1 Up87 0.737078 Up372 0.776367
ENSECAG00000011630 FBXO5 Up90 0.734096 Up89 1.05982
ENSECAG00000018894 RPL22L1 Up91 0.730381 Up105 1.01037
ENSECAG00000014572 ENSECAG00000014572 Up93 0.725896 Up233 0.851117
ENSECAG00000011186 ENSECAG00000011186 Up94 0.72516 Up982 0.597596
ENSECAG00000019989 SNRPG Up95 0.724849 Up182 0.896792
ENSECAG00000002414 SGTB Up97 0.717154 Up69 1.13378
ENSECAG00000020295 GEN1 Up98 0.714695 Up188 0.889261
ENSECAG00000012899 ESCO2 Up100 0.707083 Up115 0.993846
ENSECAG00000002250 SPRY2 Up101 0.705795 Up245 0.843575
ENSECAG00000011364 RNF219 Up102 0.702664 Up124 0.985682
ENSECAG00000004120 ABHD18 Up104 0.700428 Up164 0.925574
ENSECAG00000011226 CENPQ Up108 0.683434 Up250 0.84234
ENSECAG00000021234 NET1 Up111 0.671168 Up457 0.749431
ENSECAG00000017783 FST Up112 0.665451 Up759 0.650341
ENSECAG00000026862 GCSH Up113 0.664199 Up149 0.955276
ENSECAG00000018634 UBASH3B Up114 0.6607 Up494 0.729732
ENSECAG00000015790 SLF1 Up115 0.660057 Up68 1.1352
ENSECAG00000007885 ORC5 Up117 0.657888 Up271 0.83168
ENSECAG00000022189 PFDN4 Up119 0.650603 Up47 1.28856
ENSECAG00000015003 PLGRKT Up122 0.646453 Up111 0.997463
ENSECAG00000022137 DNA2 Up125 0.635694 Up239 0.848146
ENSECAG00000022964 CDC7 Up126 0.634887 Up224 0.860216
ENSECAG00000024016 IL13RA2 Up127 0.630485 Up71 1.12539
ENSECAG00000002211 CD80 Up128 0.623285 Up232 0.852307
ENSECAG00000026888 MRPL42 Up130 0.616 Up1031 0.58653
ENSECAG00000018443 ATAD5 Up131 0.614103 Up213 0.869753
ENSECAG00000009576 MMS22L Up132 0.612656 Up179 0.901609
ENSECAG00000002513 ERCC6L Up133 0.611934 Up367 0.777908
ENSECAG00000018810 HELLS Up135 0.610723 Up327 0.804216
ENSECAG00000009270 ORC2 Up136 0.603078 Up201 0.883252
ENSECAG00000009716 CDK1 Up137 0.602965 Up218 0.866389
ENSECAG00000015376 GLRX2 Up138 0.596 Up821 0.632132
ENSECAG00000022495 NKRF Up139 0.593306 Up407 0.766519
ENSECAG00000017572 ZNF280C Up141 0.592528 Up94 1.0462
ENSECAG00000008852 ABCA1 Up142 0.592405 Up561 0.706499
ENSECAG00000022190 GALNT1 Up143 0.591049 Up125 0.983941
ENSECAG00000016959 B3GNT2 Up146 0.588384 Up752 0.652061
ENSECAG00000003773 MICALCL Up53 1.00184 Up43 1.05852 Up64 1.14546
ENSECAG00000026524 U2 Up5 inf
ENSECAG00000003230 AKAP5 Up24 1.88967
ENSECAG00000015717 TSSK3 Up33 1.48859
ENSECAG00000023835 KLHL32 Up47 1.06422
ENSECAG00000014398 ENSECAG00000014398 Up58 0.967904
ENSECAG00000012653 DYRK4 Up60 0.963909
ENSECAG00000012801 KBTBD3 Up62 0.940261
ENSECAG00000015383 ITGB1BP2 Up63 0.935973
ENSECAG00000026834 TMEM167A Up79 0.8229
ENSECAG00000026955 SELK Up92 0.741346
ENSECAG00000023753 OGFRL1 Up107 0.694384
ENSECAG00000001334 C3orf14 Up121 0.640623
ENSECAG00000021036 LSM6 Up125 0.627901
ENSECAG00000026824 LYRM4 Up132 0.595951
ENSECAG00000008435 LMF2 Down258 -0.582244
ENSECAG00000012006 BCL9L Down257 -0.582536
ENSECAG00000009361 COL5A1 Down256 -0.583028
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000009361 COL5A1 Down256 -0.583028
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000019381 MEGF8 Down255 -0.583606
ENSECAG00000015071 PTRF Down254 -0.584623
ENSECAG00000019242 PLXNB2 Down253 -0.584943
ENSECAG00000019803 GALK1 Down252 -0.585071
ENSECAG00000010237 FBXL6 Down251 -0.58569
ENSECAG00000013823 SCRIB Down250 -0.586134
ENSECAG00000022794 ENSECAG00000022794 Down249 -0.586204
ENSECAG00000025129 NDRG1 Down248 -0.58647
ENSECAG00000024665 GHDC Down246 -0.587181
ENSECAG00000019465 PLTP Down245 -0.587261
ENSECAG00000000369 CERS4 Down244 -0.58816
ENSECAG00000004871 SERPINH1 Down243 -0.588866
ENSECAG00000007152 ENSECAG00000007152 Down242 -0.590067
ENSECAG00000009826 SCRN2 Down241 -0.590353
ENSECAG00000014242 MAD1L1 Down240 -0.591694
ENSECAG00000014699 NUAK2 Down239 -0.5923
ENSECAG00000024119 COL16A1 Down238 -0.592302
ENSECAG00000010619 F12 Down237 -0.592422
ENSECAG00000005169 ABCC10 Down236 -0.592478
ENSECAG00000007647 COL5A3 Down234 -0.595539
ENSECAG00000007338 SCARF2 Down233 -0.597139
ENSECAG00000024863 ENSECAG00000024863 Down232 -0.597405
ENSECAG00000002876 FAAP100 Down231 -0.597518
ENSECAG00000019788 WDR83 Down230 -0.597677
ENSECAG00000018063 D2HGDH Down229 -0.598239
ENSECAG00000024966 RAVER1 Down228 -0.598494
ENSECAG00000021805 LAMB2 Down227 -0.599262
ENSECAG00000007334 SMG9 Down226 -0.599316
ENSECAG00000005228 PHGDH Down225 -0.600207
ENSECAG00000019299 TBL3 Down224 -0.600235
ENSECAG00000000797 SUN2 Down223 -0.600716
ENSECAG00000000402 NDUFS7 Down222 -0.601934
ENSECAG00000012599 TRMT61A Down221 -0.602192
ENSECAG00000026879 TXNRD2 Down220 -0.60288
ENSECAG00000020780 PELP1 Down219 -0.603108
ENSECAG00000007474 SPHK2 Down218 -0.603315
ENSECAG00000016486 ARRDC2 Down217 -0.603381
ENSECAG00000021290 MBD6 Down216 -0.603718
ENSECAG00000015054 XXYLT1 Down213 -0.605379
ENSECAG00000025091 MVP Down212 -0.606154
ENSECAG00000015206 SYNE3 Down211 -0.606585
ENSECAG00000016933 FZR1 Down210 -0.606742
ENSECAG00000007611 INF2 Down208 -0.607694
ENSECAG00000012180 NAGPA Down207 -0.607697
ENSECAG00000013037 ALDOC Down205 -0.609886
ENSECAG00000015488 KCNN4 Down203 -0.612627
ENSECAG00000002668 RHOB Down202 -0.614745
ENSECAG00000003436 APBB3 Down201 -0.615551
ENSECAG00000000744 TBC1D2 Down200 -0.616395
ENSECAG00000010992 NFATC4 Down199 -0.616504
ENSECAG00000017794 IRF1 Down198 -0.616974
ENSECAG00000011852 ALDH4A1 Down197 -0.617007
ENSECAG00000007272 NCOR2 Down196 -0.617372
ENSECAG00000022228 KLC4 Down195 -0.617479
ENSECAG00000009550 FLNA Down193 -0.619276
ENSECAG00000011133 HSD3B7 Down192 -0.62008
ENSECAG00000017863 PFKL Down191 -0.623694
ENSECAG00000020716 MYH9 Down188 -0.625961
ENSECAG00000024224 WDR34 Down187 -0.626388
ENSECAG00000023595 ENSECAG00000023595 Down186 -0.628599
ENSECAG00000024038 YPEL3 Down185 -0.629591
ENSECAG00000006063 JRK Down184 -0.630245
ENSECAG00000021765 TSPO Down182 -0.632928
ENSECAG00000006963 NACC2 Down180 -0.634188
ENSECAG00000017371 SMTN Down179 -0.636204
ENSECAG00000016064 SYDE1 Down178 -0.636416
ENSECAG00000021059 MED16 Down177 -0.637326
ENSECAG00000021785 MHCB3 Down176 -0.637447
ENSECAG00000021774 DNAAF5 Down175 -0.637672
ENSECAG00000023341 DHCR7 Down174 -0.638126
ENSECAG00000018860 ZFP36L1 Down172 -0.640812
ENSECAG00000004107 DDIT4 Down171 -0.641177
ENSECAG00000014491 NLRC5 Down170 -0.641394
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000014491 NLRC5 Down170 -0.641394
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000017998 DHCR24 Down169 -0.644519
ENSECAG00000015944 TKFC Down168 -0.644629
ENSECAG00000021659 CCDC157 Down167 -0.645226
ENSECAG00000009314 TMEM132A Down163 -0.647746
ENSECAG00000015936 ENSECAG00000015936 Down162 -0.648071
ENSECAG00000012654 EMC10 Down161 -0.649023
ENSECAG00000006501 FJX1 Down160 -0.650037
ENSECAG00000012635 BRAT1 Down159 -0.651806
ENSECAG00000010792 INTS1 Down158 -0.653575
ENSECAG00000018273 TFPT Down157 -0.65384
ENSECAG00000022294 PITX3 Down156 -0.654148
ENSECAG00000021606 WDR81 Down155 -0.654419
ENSECAG00000013515 SEMA3B Down154 -0.657088
ENSECAG00000011354 DHX34 Down153 -0.657335
ENSECAG00000012169 ATP5D Down151 -0.658918
ENSECAG00000003772 DEDD2 Down150 -0.658949
ENSECAG00000024481 AHNAK2 Down149 -0.659233
ENSECAG00000011779 ARID3A Down148 -0.662581
ENSECAG00000009818 AMOTL2 Down147 -0.66367
ENSECAG00000012166 LRP1 Down145 -0.666203
ENSECAG00000012712 PNPLA6 Down144 -0.668635
ENSECAG00000024608 SREBF2 Down142 -0.669327
ENSECAG00000003570 PICK1 Down141 -0.671165
ENSECAG00000010395 RIN1 Down140 -0.671403
ENSECAG00000022578 HSPBP1 Down139 -0.673144
ENSECAG00000018111 NAPRT Down137 -0.677179
ENSECAG00000018924 PTK2B Down136 -0.677781
ENSECAG00000019633 IGFBP6 Down135 -0.678353
ENSECAG00000014761 LONP1 Down134 -0.679579
ENSECAG00000021979 CARD10 Down133 -0.680155
ENSECAG00000006931 ATF4 Down132 -0.681204
ENSECAG00000007115 FRMD8 Down131 -0.683335
ENSECAG00000006908 CD248 Down129 -0.683685
ENSECAG00000008993 HIP1R Down128 -0.685781
ENSECAG00000020178 WNT9A Down127 -0.685894
ENSECAG00000016374 ENSECAG00000016374 Down126 -0.686582
ENSECAG00000011353 MFSD7 Down125 -0.686602
ENSECAG00000022526 CDH15 Down124 -0.687095
ENSECAG00000019236 LDLRAD3 Down122 -0.688462
ENSECAG00000009562 ZC3H12A Down121 -0.68927
ENSECAG00000019238 ENSECAG00000019238 Down120 -0.691056
ENSECAG00000016798 MIEF2 Down119 -0.691551
ENSECAG00000005097 IFI27 Down116 -0.696728
ENSECAG00000020730 RNH1 Down115 -0.697501
ENSECAG00000003836 LRRC75A Down113 -0.698118
ENSECAG00000017789 SIX2 Down112 -0.700091
ENSECAG00000022697 TRABD2B Down111 -0.700461
ENSECAG00000019882 CALHM3 Down110 -0.702522
ENSECAG00000003591 TPGS1 Down109 -0.703566
ENSECAG00000021641 SNX21 Down108 -0.704026
ENSECAG00000011011 SNAPC2 Down107 -0.705215
ENSECAG00000009170 PINK1 Down104 -0.707591
ENSECAG00000019969 CCDC142 Down102 -0.70912
ENSECAG00000022949 WFDC3 Down100 -0.709883
ENSECAG00000006619 ZNF688 Down99 -0.710044
ENSECAG00000019359 DUS3L Down97 -0.716211
ENSECAG00000014320 PPL Down95 -0.717457
ENSECAG00000002911 KCTD11 Down94 -0.727666
ENSECAG00000000706 MEGF11 Down93 -0.727672
ENSECAG00000002928 FAM212B Down92 -0.727917
ENSECAG00000010566 ENSECAG00000010566 Down90 -0.729019
ENSECAG00000005302 GJB5 Down89 -0.729846
ENSECAG00000011246 GLI1 Down88 -0.730742
ENSECAG00000001181 CBX4 Down86 -0.735125
ENSECAG00000013685 TNXB Down85 -0.735295
ENSECAG00000019557 LDLR Down84 -0.739951
ENSECAG00000024412 ARHGAP39 Down81 -0.74398
ENSECAG00000023023 OSGIN1 Down78 -0.755167
ENSECAG00000015448 TAPBP Down77 -0.759283
ENSECAG00000008194 MIDN Down76 -0.759865
ENSECAG00000012500 AP5Z1 Down75 -0.761725
ENSECAG00000011704 TNFAIP2 Down72 -0.769714
ENSECAG00000007112 ENSECAG00000007112 Down70 -0.772325
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000007112 ENSECAG00000007112 Down70 -0.772325
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000023969 ENSECAG00000023969 Down68 -0.774057
ENSECAG00000020219 ENSECAG00000020219 Down67 -0.780144
ENSECAG00000012116 CARNS1 Down65 -0.798911
ENSECAG00000020592 JUP Down63 -0.80294
ENSECAG00000011097 LMNA Down62 -0.80346
ENSECAG00000026973 BCL11B Down61 -0.804756
ENSECAG00000015514 PLEC Down60 -0.809049
ENSECAG00000023274 LAMA5 Down59 -0.813921
ENSECAG00000024458 KCTD7 Down58 -0.814027
ENSECAG00000017961 ENSECAG00000017961 Down57 -0.814127
ENSECAG00000002061 NEURL2 Down55 -0.834217
ENSECAG00000021487 TRIM66 Down53 -0.835356
ENSECAG00000014794 MIIP Down49 -0.861415
ENSECAG00000008566 CTSE Down48 -0.866538
ENSECAG00000014899 ENSECAG00000014899 Down47 -0.877504
ENSECAG00000009375 FAM198A Down45 -0.890646
ENSECAG00000019125 FASN Down44 -0.892033
ENSECAG00000004572 CH25H Down43 -0.895983
ENSECAG00000016720 OBSCN Down42 -0.897825
ENSECAG00000022258 SDSL Down41 -0.899809
ENSECAG00000020167 RGMA Down37 -0.905854
ENSECAG00000024574 GATA3 Down35 -0.907896
ENSECAG00000017274 KRT13 Down30 -0.915744
ENSECAG00000016829 ABTB2 Down24 -0.95072
ENSECAG00000004091 SNN Down20 -0.984933
ENSECAG00000019043 SSC5D Down19 -0.986903
ENSECAG00000019677 EPHX1 Down17 -0.997667
ENSECAG00000013281 IRGQ Down16 -0.998544
ENSECAG00000015822 VDR Down13 -1.02021
ENSECAG00000013201 MMP17 Down11 -1.0566
ENSECAG00000006082 ENSECAG00000006082 Down8 -1.12489
ENSECAG00000014911 APC2 Down7 -1.12532
ENSECAG00000023427 HES2 Down6 -1.18056
ENSECAG00000013662 DNAI2 Down5 -1.28415
ENSECAG00000003025 HLX Down2 -1.50756
ENSECAG00000009955 TEX43 Up1 inf
ENSECAG00000020819 AGER Up18 1.77703
ENSECAG00000012470 PLA2G4F Up25 1.4647
ENSECAG00000024712 CASR Up34 1.27409
ENSECAG00000020764 ENSECAG00000020764 Up42 1.07186
ENSECAG00000019045 FGF18 Up46 1.02334
ENSECAG00000014921 GPRC5A Up49 1.01123
ENSECAG00000013893 SCARA5 Up50 1.00702
ENSECAG00000021165 STAC Up60 0.909029
ENSECAG00000005651 SLC35G2 Up65 0.879381
ENSECAG00000027377 5_8S_rRNA Up66 0.876109
ENSECAG00000011929 NR4A3 Up76 0.819122
ENSECAG00000016228 CA2 Up81 0.787795
ENSECAG00000002759 MTRF1L Up84 0.750066
ENSECAG00000015611 ETV4 Up89 0.73455
ENSECAG00000008811 KCNJ15 Up103 0.70262
ENSECAG00000001815 PYURF Up106 0.691616
ENSECAG00000023134 KCNK5 Up140 0.592647
ENSECAG00000011672 TMEM63C Down59 -0.582332
ENSECAG00000011229 SLC1A4 Down57 -0.594733
ENSECAG00000006553 CHST4 Down52 -0.600533
ENSECAG00000014601 GADD45A Down51 -0.601335
ENSECAG00000023217 KLHL17 Down50 -0.603489
ENSECAG00000018603 SLC46A2 Down49 -0.604993
ENSECAG00000000178 RUNX1T1 Down48 -0.609126
ENSECAG00000023946 SDC3 Down47 -0.610372
ENSECAG00000006847 PIK3CD Down46 -0.613399
ENSECAG00000000828 ENSECAG00000000828 Down43 -0.645836
ENSECAG00000000046 FAM13C Down40 -0.668659
ENSECAG00000024309 LRRC24 Down39 -0.671771
ENSECAG00000005000 PPM1K Down38 -0.67219
ENSECAG00000006249 ENSECAG00000006249 Down35 -0.687782
ENSECAG00000012946 CYP7A1 Down33 -0.724282
ENSECAG00000016753 LIMS2 Down32 -0.727509
ENSECAG00000014767 PLXNB1 Down31 -0.727954
ENSECAG00000008485 ITGAL Down26 -0.766866
ENSECAG00000020162 PRR5L Down25 -0.79314
ENSECAG00000023458 OLFM2 Down19 -0.876702
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000023458 OLFM2 Down19 -0.876702
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000024139 LONRF3 Down18 -0.886645
ENSECAG00000017015 MYH11 Down17 -0.894766
ENSECAG00000011583 KRT14 Down15 -0.945321
ENSECAG00000011524 CAP2 Down14 -0.948603
ENSECAG00000006058 FUT1 Down13 -0.950377
ENSECAG00000021037 FEZF2 Down12 -0.970215
ENSECAG00000007020 C14orf28 Down10 -0.973021
ENSECAG00000011427 TRPM8 Down8 -1.04342
ENSECAG00000023032 AZIN2 Down6 -1.10437
ENSECAG00000017175 REM1 Down5 -1.11577
ENSECAG00000012161 ZNF711 Down2 -1.14786
ENSECAG00000012253 CXCL11 Up1 inf
ENSECAG00000025480 SNORA71 Up2 inf
ENSECAG00000010206 SMTNL1 Up30 1.42041
ENSECAG00000010036 SLC15A3 Up33 1.35719
ENSECAG00000023195 ENSECAG00000023195 Up39 1.18057
ENSECAG00000024430 ENSECAG00000024430 Up42 1.07985
ENSECAG00000025120 SBSN Up44 1.05685
ENSECAG00000006493 PTMA Up45 1.03333
ENSECAG00000015395 HERC5 Up51 0.944138
ENSECAG00000019621 ENSECAG00000019621 Up53 0.936982
ENSECAG00000008257 RBMX2 Up55 0.915059
ENSECAG00000009273 SLC45A3 Up56 0.914838
ENSECAG00000019590 NINL Up57 0.906708
ENSECAG00000010638 SREK1IP1 Up58 0.892027
ENSECAG00000006211 TRIM21 Up59 0.876248
ENSECAG00000022601 PARP12 Up60 0.833009
ENSECAG00000024957 C19orf66 Up62 0.817361
ENSECAG00000006666 MURC Up63 0.814026
ENSECAG00000012843 PAG1 Up65 0.776355
ENSECAG00000018264 TRANK1 Up66 0.771467
ENSECAG00000014880 CFAP45 Up67 0.768676
ENSECAG00000001514 ENSECAG00000001514 Up68 0.765041
ENSECAG00000012660 HLA-DRA Up69 0.763677
ENSECAG00000009586 C16orf89 Up70 0.761276
ENSECAG00000014480 AIM2 Up73 0.725967
ENSECAG00000004617 PML Up74 0.719505
ENSECAG00000006844 CALD1 Up75 0.718923
ENSECAG00000004534 CCDC136 Up77 0.705269
ENSECAG00000012794 LYAR Up78 0.701695
ENSECAG00000009383 TBCA Up79 0.701142
ENSECAG00000021345 POLR2K Up80 0.684892
ENSECAG00000002607 WBP5 Up81 0.680495
ENSECAG00000018205 OTUD6B Up82 0.67276
ENSECAG00000006454 ENSECAG00000006454 Up84 0.668792
ENSECAG00000022765 ZC3H8 Up86 0.663995
ENSECAG00000012760 LUC7L3 Up89 0.656039
ENSECAG00000009432 PDRG1 Up91 0.643733
ENSECAG00000002619 GREM1 Up92 0.638078
ENSECAG00000026989 PDCD7 Up93 0.637717
ENSECAG00000014812 KRT23 Up94 0.636528
ENSECAG00000002251 TLL1 Up97 0.627479
ENSECAG00000015180 NEXN Up99 0.620353
ENSECAG00000011155 ATP6V1G1 Up100 0.617714
ENSECAG00000008210 ZNFX1 Up101 0.614708
ENSECAG00000014051 MED19 Up103 0.613226
ENSECAG00000007848 ITGA9 Up104 0.612344
ENSECAG00000026874 ENSECAG00000026874 Up105 0.611339
ENSECAG00000016947 UPF3B Up106 0.610805
ENSECAG00000011899 PNN Up107 0.607343
ENSECAG00000003698 ENSECAG00000003698 Up109 0.603593
ENSECAG00000000974 ADAR Up110 0.602139
ENSECAG00000009258 DAAM1 Up111 0.600076
ENSECAG00000004232 AMER1 Up112 0.594351
ENSECAG00000013395 RBM25 Up114 0.585833
ENSECAG00000009310 ENSECAG00000009310 Up115 0.584806
ENSECAG00000016025 SNRNP27 Up116 0.584254
ENSECAG00000022972 TCHP Up117 0.581557
ENSECAG00000009013 CCDC107 Down98 -0.589534
ENSECAG00000012066 FBLN5 Down97 -0.597537
ENSECAG00000021133 FDFT1 Down96 -0.602278
ENSECAG00000014017 PRKG1 Down95 -0.602867
ENSECAG00000021576 SGCG Down94 -0.603469
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000021576 SGCG Down94 -0.603469
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000000857 PRKCDBP Down93 -0.609082
ENSECAG00000004817 CDKN2C Down92 -0.610564
ENSECAG00000006455 CYP51A1 Down91 -0.613223
ENSECAG00000024992 HSD17B7 Down90 -0.616537
ENSECAG00000011479 PLAC9 Down89 -0.620718
ENSECAG00000008926 RNF139 Down83 -0.63596
ENSECAG00000014658 SCD Down82 -0.638683
ENSECAG00000024852 FABP3 Down79 -0.641854
ENSECAG00000022769 RAB30 Down78 -0.649176
ENSECAG00000018059 SC5D Down76 -0.658513
ENSECAG00000012893 ENSECAG00000012893 Down75 -0.665706
ENSECAG00000013998 SQLE Down74 -0.674203
ENSECAG00000018012 SELENBP1 Down73 -0.683824
ENSECAG00000016942 NUDT14 Down70 -0.699527
ENSECAG00000000668 COL4A5 Down69 -0.704672
ENSECAG00000014263 ENSECAG00000014263 Down67 -0.711492
ENSECAG00000011271 IGFBP4 Down66 -0.717586
ENSECAG00000026960 UBE2S Down62 -0.735956
ENSECAG00000005600 ZNF48 Down61 -0.750375
ENSECAG00000004504 C19orf52 Down60 -0.756271
ENSECAG00000009515 ATRNL1 Down59 -0.757059
ENSECAG00000016271 CENPA Down57 -0.761043
ENSECAG00000023354 ENSECAG00000023354 Down55 -0.778611
ENSECAG00000003398 MARCKS Down53 -0.784416
ENSECAG00000014113 CCNG2 Down51 -0.799668
ENSECAG00000008259 ENSECAG00000008259 Down50 -0.804779
ENSECAG00000011663 NPTX1 Down49 -0.814449
ENSECAG00000017914 L3HYPDH Down48 -0.8174
ENSECAG00000015351 LRRN3 Down47 -0.82161
ENSECAG00000023284 ENSECAG00000023284 Down46 -0.82698
ENSECAG00000012662 SEMA3A Down45 -0.828823
ENSECAG00000019765 ENSECAG00000019765 Down44 -0.836411
ENSECAG00000017407 MOXD1 Down43 -0.86484
ENSECAG00000010554 MSMO1 Down41 -0.873197
ENSECAG00000000795 ADHFE1 Down38 -0.894171
ENSECAG00000022251 MAP3K15 Down36 -0.910299
ENSECAG00000000374 PLEKHG7 Down34 -0.913772
ENSECAG00000000154 SDHAF1 Down32 -0.919585
ENSECAG00000021607 TXNDC8 Down31 -0.921575
ENSECAG00000015644 SLC1A2 Down29 -0.95657
ENSECAG00000009248 IL1RL1 Down28 -0.962654
ENSECAG00000001140 ANAPC11 Down27 -0.967842
ENSECAG00000018831 ENSECAG00000018831 Down26 -0.975751
ENSECAG00000011356 ENSECAG00000011356 Down25 -0.978965
ENSECAG00000006880 WNT16 Down22 -1.03741
ENSECAG00000021431 ENSECAG00000021431 Down20 -1.04623
ENSECAG00000011948 FIGF Down19 -1.04654
ENSECAG00000026965 SOCS1 Down18 -1.06771
ENSECAG00000014525 ENSECAG00000014525 Down17 -1.09085
ENSECAG00000021076 MBNL3 Down16 -1.10087
ENSECAG00000015692 SERTAD4 Down14 -1.16276
ENSECAG00000024192 FAM180A Down12 -1.22548
ENSECAG00000011313 SLC35F1 Down10 -1.24767
ENSECAG00000007071 ENSECAG00000007071 Down9 -1.28301
ENSECAG00000011090 PTPN18 Down7 -1.33035
ENSECAG00000006174 ENSECAG00000006174 Down6 -1.33559
ENSECAG00000018591 CTU1 Down5 -1.56674
ENSECAG00000013137 ENSECAG00000013137 Down4 -1.68257
ENSECAG00000027702 ENSECAG00000027702 Down1 -inf
ENSECAG00000021420 PSORS1C2 Up1 inf
ENSECAG00000027406 SNORA31 Up3 inf
ENSECAG00000018077 ENSECAG00000018077 Up20 1.78161
ENSECAG00000003848 ENSECAG00000003848 Up22 1.74835
ENSECAG00000015232 ZNF619 Up23 1.61786
ENSECAG00000001216 ENSECAG00000001216 Up24 1.60188
ENSECAG00000023287 ENSECAG00000023287 Up30 1.51745
ENSECAG00000015950 CCDC68 Up32 1.46019
ENSECAG00000003073 ENSECAG00000003073 Up36 1.36806
ENSECAG00000020282 FAM71F2 Up37 1.36036
ENSECAG00000020088 NOSTRIN Up38 1.35307
ENSECAG00000012949 ENSECAG00000012949 Up39 1.34644
ENSECAG00000020053 SLC4A4 Up40 1.32211
ENSECAG00000010739 ITGA2 Up41 1.31901
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ENSECAG00000010739 ITGA2 Up41 1.31901
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000005115 ZNF454 Up42 1.31614
ENSECAG00000006323 LEKR1 Up46 1.29041
ENSECAG00000010696 ENSECAG00000010696 Up48 1.27549
ENSECAG00000016295 EED Up49 1.27278
ENSECAG00000013869 CFI Up51 1.26099
ENSECAG00000021404 ENSECAG00000021404 Up56 1.21353
ENSECAG00000014092 ENSECAG00000014092 Up59 1.19261
ENSECAG00000007757 DNAJC15 Up60 1.16908
ENSECAG00000003510 TXNDC9 Up61 1.16618
ENSECAG00000020127 THEM4 Up62 1.16257
ENSECAG00000015237 PIBF1 Up63 1.15827
ENSECAG00000005951 TMEM81 Up66 1.13633
ENSECAG00000016771 ENSECAG00000016771 Up67 1.1355
ENSECAG00000021582 ENSECAG00000021582 Up70 1.12995
ENSECAG00000017181 PTGS2 Up73 1.12235
ENSECAG00000012316 DTWD1 Up76 1.09488
ENSECAG00000021942 TEX30 Up77 1.09118
ENSECAG00000013268 AP1S3 Up78 1.08918
ENSECAG00000014388 ZNF432 Up80 1.08198
ENSECAG00000001069 CCRL2 Up81 1.07963
ENSECAG00000001696 ENSECAG00000001696 Up82 1.07929
ENSECAG00000011685 ENSECAG00000011685 Up83 1.06848
ENSECAG00000024704 CETN3 Up85 1.06309
ENSECAG00000023859 BTG3 Up86 1.06205
ENSECAG00000000785 ENSECAG00000000785 Up87 1.06037
ENSECAG00000000546 CCDC62 Up88 1.06035
ENSECAG00000018128 ENSECAG00000018128 Up91 1.05572
ENSECAG00000017138 ENSECAG00000017138 Up95 1.04454
ENSECAG00000018881 ENSECAG00000018881 Up98 1.03269
ENSECAG00000023471 ZNF879 Up100 1.02874
ENSECAG00000009776 CEP57L1 Up101 1.02754
ENSECAG00000008540 C5orf28 Up103 1.01649
ENSECAG00000000629 ENSECAG00000000629 Up104 1.01507
ENSECAG00000026852 ZCCHC10 Up107 1.00462
ENSECAG00000019742 CCDC126 Up109 1.00252
ENSECAG00000010663 SKIL Up110 0.999293
ENSECAG00000002936 WDR89 Up112 0.997324
ENSECAG00000014054 CDKL4 Up117 0.990473
ENSECAG00000014144 ENSECAG00000014144 Up118 0.989901
ENSECAG00000018495 SSB Up119 0.98935
ENSECAG00000019188 ESF1 Up121 0.987375
ENSECAG00000010084 DNAJC10 Up122 0.986149
ENSECAG00000016480 SPCS3 Up123 0.985784
ENSECAG00000000750 MMP3 Up126 0.981314
ENSECAG00000000473 ATAD1 Up127 0.980964
ENSECAG00000023644 PPAT Up128 0.978733
ENSECAG00000019554 LRRC40 Up130 0.97854
ENSECAG00000017606 SNAPC1 Up131 0.978287
ENSECAG00000012601 CEP85L Up132 0.974621
ENSECAG00000010744 ADSS Up133 0.974107
ENSECAG00000020144 UBXN2A Up134 0.972839
ENSECAG00000010608 ENSECAG00000010608 Up137 0.968727
ENSECAG00000006518 SLC39A10 Up138 0.96839
ENSECAG00000005272 ENSECAG00000005272 Up139 0.966818
ENSECAG00000011946 CHEK1 Up141 0.965269
ENSECAG00000013569 LAMTOR3 Up143 0.961549
ENSECAG00000011218 HAT1 Up144 0.960955
ENSECAG00000021075 FGD6 Up147 0.955674
ENSECAG00000024815 RFESD Up148 0.955448
ENSECAG00000018428 HSPH1 Up150 0.954381
ENSECAG00000022011 AKAP7 Up151 0.954176
ENSECAG00000000733 C18orf21 Up154 0.947336
ENSECAG00000000794 EMB Up156 0.936423
ENSECAG00000015765 THAP6 Up157 0.935283
ENSECAG00000009502 AASDH Up159 0.933024
ENSECAG00000024018 TWF1 Up160 0.92771
ENSECAG00000004023 SSBP1 Up161 0.926606
ENSECAG00000026810 FAM133B Up162 0.926265
ENSECAG00000014393 CEP135 Up165 0.923896
ENSECAG00000014702 MEDAG Up166 0.923659
ENSECAG00000009859 PAPOLG Up167 0.920183
ENSECAG00000014665 ASF1A Up168 0.915956
ENSECAG00000011381 TRIM13 Up169 0.915786
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
  248 
APPENDIX 56: List of DEGs IN U/63-infected samples – Part 11 
 
  
ENSECAG00000011381 TRIM13 Up169 0.915786
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000014890 BRCA2 Up170 0.914551
ENSECAG00000011465 ISCA1 Up173 0.908385
ENSECAG00000011151 USP1 Up174 0.907819
ENSECAG00000013901 ANKRD12 Up175 0.907316
ENSECAG00000011563 GXYLT1 Up176 0.906656
ENSECAG00000021329 CHRNA5 Up177 0.905666
ENSECAG00000008226 NPAT Up178 0.905321
ENSECAG00000018407 SNRPB2 Up180 0.90142
ENSECAG00000002222 ZBTB6 Up181 0.898987
ENSECAG00000017788 TRMT11 Up183 0.894171
ENSECAG00000000971 SUCO Up184 0.893548
ENSECAG00000013226 ZDHHC6 Up185 0.892831
ENSECAG00000021782 DCK Up186 0.892166
ENSECAG00000008096 FAM111B Up187 0.890394
ENSECAG00000022016 NAPB Up189 0.889208
ENSECAG00000009554 SLC25A40 Up190 0.886986
ENSECAG00000020387 MRPS18C Up191 0.886957
ENSECAG00000008461 DEPDC1 Up192 0.886739
ENSECAG00000024416 ANAPC10 Up193 0.885864
ENSECAG00000016106 AGPAT5 Up194 0.885861
ENSECAG00000022164 SMC4 Up195 0.884991
ENSECAG00000010606 CCDC169 Up196 0.884799
ENSECAG00000016676 SEMA6D Up197 0.884087
ENSECAG00000018454 RBBP8 Up199 0.883905
ENSECAG00000009303 GFPT2 Up200 0.883629
ENSECAG00000008428 CEP83 Up202 0.882909
ENSECAG00000010845 RASA2 Up203 0.881371
ENSECAG00000004370 ENSECAG00000004370 Up204 0.87915
ENSECAG00000008716 EIF3J Up205 0.878892
ENSECAG00000018870 IVNS1ABP Up206 0.877243
ENSECAG00000021185 ZFP82 Up208 0.87433
ENSECAG00000018478 NIFK Up209 0.873967
ENSECAG00000000609 BIRC2 Up210 0.873165
ENSECAG00000024267 TFRC Up212 0.869865
ENSECAG00000019388 MPHOSPH6 Up214 0.868697
ENSECAG00000026943 ZFAND1 Up215 0.868481
ENSECAG00000004919 CACYBP Up216 0.867527
ENSECAG00000008261 FCF1 Up219 0.864592
ENSECAG00000010746 RAD18 Up220 0.864507
ENSECAG00000018267 CENPC Up221 0.864364
ENSECAG00000020337 DOCK11 Up222 0.86312
ENSECAG00000011889 USPL1 Up226 0.857688
ENSECAG00000019146 NDUFAF6 Up227 0.856812
ENSECAG00000023133 ENSECAG00000023133 Up229 0.856381
ENSECAG00000021440 TBC1D8B Up230 0.853147
ENSECAG00000006038 SGOL2 Up231 0.852325
ENSECAG00000016705 UGP2 Up234 0.851063
ENSECAG00000022387 RUNDC3B Up235 0.850115
ENSECAG00000022541 ZNF25 Up236 0.849159
ENSECAG00000024999 SMC5 Up238 0.848589
ENSECAG00000013725 NEDD1 Up240 0.84797
ENSECAG00000016586 NUCB2 Up241 0.8477
ENSECAG00000021200 ENSECAG00000021200 Up242 0.846875
ENSECAG00000007436 FAM210A Up243 0.845835
ENSECAG00000010070 ZNF484 Up244 0.844603
ENSECAG00000024762 RECQL Up246 0.843354
ENSECAG00000009447 KIAA1586 Up247 0.843326
ENSECAG00000017190 ENSECAG00000017190 Up248 0.843295
ENSECAG00000016109 RCHY1 Up249 0.842404
ENSECAG00000023808 ATAD2 Up251 0.842176
ENSECAG00000013631 SPOPL Up252 0.841639
ENSECAG00000013523 ZUFSP Up253 0.841258
ENSECAG00000005234 ENSECAG00000005234 Up254 0.840729
ENSECAG00000024810 PLA2G4A Up255 0.840594
ENSECAG00000007411 RPAP2 Up256 0.839565
ENSECAG00000009638 MPP6 Up257 0.839056
ENSECAG00000019829 FNTA Up258 0.838624
ENSECAG00000021949 RAD54B Up260 0.837896
ENSECAG00000016351 ENSECAG00000016351 Up261 0.837601
ENSECAG00000019865 ZNF277 Up262 0.836582
ENSECAG00000016479 ENSECAG00000016479 Up263 0.835472
ENSECAG00000015597 HIF1A Up264 0.833704
ENSECAG00000003122 FRG1 Up265 0.833678
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ENSECAG00000003122 FRG1 Up265 0.833678
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000018650 SMC2 Up266 0.832745
ENSECAG00000017007 FANCL Up269 0.831852
ENSECAG00000027684 ND1 Up270 0.831689
ENSECAG00000008390 FOXN2 Up273 0.830815
ENSECAG00000012475 SGOL1 Up275 0.830233
ENSECAG00000015468 MGAT4A Up276 0.830121
ENSECAG00000012780 CBX3 Up278 0.828811
ENSECAG00000015297 PRIM1 Up280 0.82814
ENSECAG00000013255 ENSECAG00000013255 Up281 0.826572
ENSECAG00000023208 NAA50 Up282 0.82613
ENSECAG00000013326 POC1B Up283 0.825179
ENSECAG00000021679 CDK17 Up284 0.824436
ENSECAG00000011928 LRRC8C Up285 0.824414
ENSECAG00000023941 PIK3CB Up286 0.823712
ENSECAG00000005550 SFN Up287 0.822724
ENSECAG00000024396 LMBR1 Up289 0.821743
ENSECAG00000019455 NIPAL1 Up290 0.820077
ENSECAG00000007814 ENSECAG00000007814 Up291 0.819874
ENSECAG00000014613 DBF4 Up293 0.81887
ENSECAG00000018792 ZNF782 Up295 0.817939
ENSECAG00000024709 COPS2 Up297 0.816191
ENSECAG00000005178 CCSAP Up298 0.816035
ENSECAG00000018274 FAM172A Up299 0.815964
ENSECAG00000005384 SPRY4 Up300 0.813706
ENSECAG00000012685 SLC10A6 Up301 0.813273
ENSECAG00000010304 ZNF644 Up302 0.813061
ENSECAG00000024588 ENSECAG00000024588 Up303 0.8124
ENSECAG00000008892 ENSECAG00000008892 Up304 0.812272
ENSECAG00000015330 SRFBP1 Up305 0.811695
ENSECAG00000022748 ZNF850 Up306 0.811598
ENSECAG00000019890 VRK1 Up307 0.811203
ENSECAG00000015993 ENSECAG00000015993 Up308 0.81055
ENSECAG00000021912 C5orf34 Up309 0.81055
ENSECAG00000021009 GUCY1B3 Up311 0.809782
ENSECAG00000013562 ZNF706 Up312 0.809778
ENSECAG00000016028 N4BP2L2 Up313 0.808837
ENSECAG00000021480 ZNF573 Up315 0.808623
ENSECAG00000017104 ERRFI1 Up316 0.808531
ENSECAG00000006526 CENPJ Up317 0.807766
ENSECAG00000010929 MRPS35 Up318 0.807129
ENSECAG00000014888 NEK5 Up319 0.806471
ENSECAG00000009568 CENPI Up320 0.806382
ENSECAG00000003722 ZFP62 Up321 0.806048
ENSECAG00000022278 CASC5 Up322 0.805769
ENSECAG00000008456 SLC39A6 Up323 0.805328
ENSECAG00000017041 ACTR6 Up324 0.804921
ENSECAG00000022169 PDSS1 Up325 0.804535
ENSECAG00000007552 HYKK Up326 0.804533
ENSECAG00000020404 DENND1B Up328 0.803833
ENSECAG00000021030 IFT74 Up329 0.802744
ENSECAG00000013653 TPMT Up330 0.802692
ENSECAG00000016302 ENSECAG00000016302 Up331 0.799943
ENSECAG00000018635 ZNF674 Up332 0.799163
ENSECAG00000000543 CYBRD1 Up333 0.798916
ENSECAG00000023709 SRSF10 Up334 0.795492
ENSECAG00000012133 VEGFC Up335 0.795275
ENSECAG00000018299 FKBP3 Up336 0.795122
ENSECAG00000000194 ZMYM5 Up337 0.794542
ENSECAG00000020631 CISD2 Up338 0.794491
ENSECAG00000027675 ND4 Up339 0.79389
ENSECAG00000016313 PTPN4 Up340 0.793514
ENSECAG00000017951 GTF2E2 Up341 0.793424
ENSECAG00000015910 KTN1 Up342 0.791806
ENSECAG00000017121 RPF2 Up343 0.791251
ENSECAG00000009654 DCAF13 Up344 0.789531
ENSECAG00000020873 GIN1 Up345 0.789478
ENSECAG00000010922 RAD50 Up346 0.789154
ENSECAG00000013909 SIRT1 Up347 0.788563
ENSECAG00000013041 ETF1 Up348 0.787588
ENSECAG00000007351 PLAU Up349 0.787434
ENSECAG00000013757 ERO1A Up350 0.787069
ENSECAG00000016530 LYPLA1 Up351 0.78654
ENSECAG00000013770 INTS6 Up352 0.786222
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ENSECAG00000013770 INTS6 Up352 0.786222
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000021776 ENSECAG00000021776 Up353 0.786217
ENSECAG00000013889 NBN Up354 0.786073
ENSECAG00000005243 MOCS2 Up355 0.785907
ENSECAG00000008211 ENSECAG00000008211 Up356 0.784995
ENSECAG00000014325 LIN9 Up357 0.784569
ENSECAG00000023994 DIS3 Up358 0.784169
ENSECAG00000008568 SLC35A3 Up359 0.783492
ENSECAG00000001407 CHSY3 Up360 0.782537
ENSECAG00000020958 ARL6 Up361 0.78164
ENSECAG00000019325 CNOT6 Up362 0.780968
ENSECAG00000019228 UBLCP1 Up363 0.780914
ENSECAG00000024277 HLTF Up364 0.780794
ENSECAG00000008642 PRKD3 Up365 0.780113
ENSECAG00000014173 ZRANB2 Up366 0.778485
ENSECAG00000018207 RMND1 Up368 0.777712
ENSECAG00000012085 SWT1 Up369 0.777512
ENSECAG00000023113 SASS6 Up370 0.776898
ENSECAG00000000767 SLC4A7 Up371 0.776671
ENSECAG00000000823 ATG4C Up374 0.776204
ENSECAG00000023747 CCBL2 Up375 0.776063
ENSECAG00000000188 NMD3 Up377 0.77561
ENSECAG00000018129 PSMC6 Up378 0.77556
ENSECAG00000004339 ENSECAG00000004339 Up379 0.774834
ENSECAG00000027699 ENSECAG00000027699 Up380 0.774814
ENSECAG00000018042 SRP54 Up381 0.774776
ENSECAG00000008289 C1orf27 Up382 0.774672
ENSECAG00000024373 ZBTB11 Up383 0.774646
ENSECAG00000005653 PTP4A2 Up384 0.774479
ENSECAG00000010986 MTDH Up385 0.774228
ENSECAG00000014894 FASTKD3 Up386 0.772111
ENSECAG00000013441 APOO Up387 0.772022
ENSECAG00000013223 PBK Up388 0.77197
ENSECAG00000009163 NUF2 Up389 0.771462
ENSECAG00000021732 GOSR1 Up390 0.771193
ENSECAG00000006638 CASP8AP2 Up391 0.771134
ENSECAG00000019097 TANK Up392 0.770936
ENSECAG00000013090 POLA1 Up393 0.770924
ENSECAG00000009697 ENSECAG00000009697 Up394 0.770849
ENSECAG00000013053 TOP2A Up395 0.770577
ENSECAG00000014475 STK39 Up396 0.770064
ENSECAG00000019782 PNISR Up397 0.77001
ENSECAG00000017978 CCNYL1 Up398 0.769857
ENSECAG00000008222 ENSECAG00000008222 Up399 0.769832
ENSECAG00000015355 CLK1 Up400 0.769787
ENSECAG00000013845 HUS1 Up401 0.769061
ENSECAG00000020240 ARPP19 Up402 0.768674
ENSECAG00000011527 CASD1 Up403 0.76783
ENSECAG00000024764 ARHGAP18 Up404 0.767817
ENSECAG00000017193 PUM3 Up405 0.767812
ENSECAG00000010800 PPID Up406 0.767061
ENSECAG00000010736 KIAA1551 Up408 0.764425
ENSECAG00000019984 ZCWPW2 Up409 0.763664
ENSECAG00000002021 ENSECAG00000002021 Up410 0.763293
ENSECAG00000022265 SMC6 Up411 0.763122
ENSECAG00000009632 PSMA4 Up413 0.762404
ENSECAG00000011545 RNF149 Up414 0.762032
ENSECAG00000014668 ZNF614 Up415 0.761629
ENSECAG00000016651 NSMCE4A Up416 0.761559
ENSECAG00000013040 MANEA Up417 0.761007
ENSECAG00000012903 WDR76 Up418 0.760876
ENSECAG00000009760 GMNN Up419 0.759888
ENSECAG00000008106 FAM111A Up420 0.759822
ENSECAG00000008396 CALM2 Up421 0.759687
ENSECAG00000013138 RAB27B Up422 0.759409
ENSECAG00000008088 NIPSNAP3B Up423 0.759158
ENSECAG00000013691 MALT1 Up424 0.758805
ENSECAG00000018335 ERCC8 Up425 0.758771
ENSECAG00000000237 DGKH Up426 0.758484
ENSECAG00000022599 RFC4 Up427 0.758483
ENSECAG00000024978 ZNHIT6 Up428 0.758462
ENSECAG00000005765 ADI1 Up429 0.758343
ENSECAG00000023790 MNAT1 Up430 0.758137
ENSECAG00000020788 MECOM Up431 0.757715
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ENSECAG00000020788 MECOM Up431 0.757715
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000022617 PRKAA1 Up432 0.75737
ENSECAG00000011592 HNMT Up433 0.756717
ENSECAG00000011108 PARP8 Up434 0.756694
ENSECAG00000019257 RBPJ Up435 0.756265
ENSECAG00000013766 E2F5 Up436 0.756186
ENSECAG00000007770 ERCC6L2 Up438 0.755168
ENSECAG00000000558 KIF5B Up439 0.754153
ENSECAG00000015412 WDHD1 Up441 0.753124
ENSECAG00000015098 MORC3 Up444 0.751967
ENSECAG00000002866 UGCG Up445 0.751774
ENSECAG00000004756 METTL5 Up446 0.751608
ENSECAG00000018130 ZFAND6 Up447 0.751001
ENSECAG00000009676 SAP30 Up448 0.750959
ENSECAG00000010978 ENSECAG00000010978 Up449 0.75092
ENSECAG00000012777 MPHOSPH8 Up450 0.750868
ENSECAG00000022460 U2SURP Up451 0.750583
ENSECAG00000018885 ENSECAG00000018885 Up452 0.750449
ENSECAG00000014852 DUS4L Up454 0.75017
ENSECAG00000009898 UEVLD Up455 0.750152
ENSECAG00000000308 RICTOR Up456 0.749504
ENSECAG00000010191 PYGO1 Up458 0.749213
ENSECAG00000010482 CCDC186 Up459 0.748646
ENSECAG00000000648 LCORL Up460 0.748418
ENSECAG00000011878 DTL Up461 0.747845
ENSECAG00000024976 OCIAD1 Up462 0.746897
ENSECAG00000010433 CHMP2B Up463 0.746774
ENSECAG00000022396 SMC3 Up464 0.746237
ENSECAG00000010054 NOX4 Up465 0.745877
ENSECAG00000001533 TRMT10C Up466 0.744993
ENSECAG00000024558 ENSECAG00000024558 Up467 0.744984
ENSECAG00000023959 GTF2H3 Up468 0.74478
ENSECAG00000022582 FBXW7 Up469 0.744552
ENSECAG00000021058 RMDN2 Up470 0.743931
ENSECAG00000011139 ENSECAG00000011139 Up471 0.743769
ENSECAG00000013324 TXN Up472 0.743567
ENSECAG00000022045 DNTTIP2 Up474 0.73877
ENSECAG00000023445 NUDCD1 Up475 0.738599
ENSECAG00000016383 USP53 Up476 0.736881
ENSECAG00000020276 HOOK3 Up478 0.735647
ENSECAG00000024279 FAM200B Up479 0.735024
ENSECAG00000004389 MFF Up480 0.734382
ENSECAG00000024495 LYSMD3 Up481 0.734222
ENSECAG00000002556 ZNF770 Up482 0.734039
ENSECAG00000027676 ENSECAG00000027676 Up483 0.733823
ENSECAG00000002402 ENSECAG00000002402 Up484 0.733424
ENSECAG00000017714 FDX1 Up485 0.733198
ENSECAG00000017271 ARHGAP5 Up486 0.732418
ENSECAG00000022168 ENSECAG00000022168 Up487 0.732399
ENSECAG00000017588 MMD Up488 0.732394
ENSECAG00000024964 ATP6V1C1 Up489 0.732385
ENSECAG00000015920 PHTF2 Up490 0.732208
ENSECAG00000019398 TFPI2 Up491 0.730831
ENSECAG00000020674 NDUFB3 Up492 0.730739
ENSECAG00000013644 TRDMT1 Up495 0.729582
ENSECAG00000004651 RAP1B Up496 0.728989
ENSECAG00000006779 USP12 Up497 0.728922
ENSECAG00000015560 MOB4 Up498 0.728632
ENSECAG00000018064 CCDC82 Up499 0.728617
ENSECAG00000011935 SMURF2 Up500 0.727753
ENSECAG00000019335 ENSECAG00000019335 Up501 0.727541
ENSECAG00000000306 GLRX3 Up502 0.727311
ENSECAG00000002063 C2orf76 Up503 0.727143
ENSECAG00000021355 STAM2 Up504 0.726268
ENSECAG00000015019 PIK3CA Up505 0.725859
ENSECAG00000016922 AZIN1 Up506 0.725054
ENSECAG00000014227 ENSECAG00000014227 Up507 0.724213
ENSECAG00000002691 RSBN1L Up508 0.723845
ENSECAG00000014420 TRNT1 Up509 0.723566
ENSECAG00000020878 ENSECAG00000020878 Up510 0.723345
ENSECAG00000024392 BRIP1 Up511 0.72263
ENSECAG00000011295 THAP2 Up512 0.722421
ENSECAG00000002452 CCDC121 Up513 0.722386
ENSECAG00000002675 ENSECAG00000002675 Up514 0.722304
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ENSECAG00000002675 ENSECAG00000002675 Up514 0.722304
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000010367 RAD51AP1 Up515 0.722242
ENSECAG00000021408 VRK2 Up516 0.722188
ENSECAG00000018694 FANCM Up517 0.722029
ENSECAG00000018114 ENSECAG00000018114 Up518 0.720715
ENSECAG00000023331 KIF20B Up519 0.720676
ENSECAG00000007966 NCK1 Up520 0.720543
ENSECAG00000015497 NAA16 Up521 0.720495
ENSECAG00000016974 BRCA1 Up522 0.719901
ENSECAG00000006911 ENSECAG00000006911 Up523 0.719855
ENSECAG00000009794 ENSECAG00000009794 Up524 0.719602
ENSECAG00000006497 SETD9 Up525 0.719387
ENSECAG00000024180 BTF3L4 Up526 0.718872
ENSECAG00000024327 FBXL5 Up527 0.718589
ENSECAG00000019841 CYB5R4 Up528 0.718263
ENSECAG00000014112 SLC20A1 Up529 0.717378
ENSECAG00000017169 ZNF283 Up531 0.717014
ENSECAG00000019810 KIF2A Up532 0.716804
ENSECAG00000017911 PDCD10 Up533 0.716619
ENSECAG00000019791 RAB11FIP2 Up534 0.716448
ENSECAG00000014686 HAUS6 Up535 0.715297
ENSECAG00000007207 SLC35A1 Up536 0.715123
ENSECAG00000021538 CKAP2L Up537 0.715088
ENSECAG00000023723 SKIV2L2 Up539 0.714449
ENSECAG00000010564 GLMN Up540 0.714396
ENSECAG00000003883 CDC26 Up541 0.714359
ENSECAG00000013285 ATR Up542 0.714123
ENSECAG00000008693 PTPN12 Up543 0.714063
ENSECAG00000022920 VPS54 Up544 0.713625
ENSECAG00000013488 TMEM38B Up545 0.713571
ENSECAG00000012634 CEP78 Up546 0.713163
ENSECAG00000022376 ENSECAG00000022376 Up547 0.711951
ENSECAG00000014937 ENSECAG00000014937 Up548 0.710822
ENSECAG00000015796 LIAS Up549 0.710226
ENSECAG00000013436 TCEA1 Up550 0.709893
ENSECAG00000022494 USP15 Up552 0.708881
ENSECAG00000016556 LRP12 Up553 0.708484
ENSECAG00000022698 CEP162 Up554 0.708482
ENSECAG00000017727 ORC3 Up555 0.708037
ENSECAG00000011322 RPS6KA3 Up556 0.707851
ENSECAG00000005798 CNOT7 Up557 0.707494
ENSECAG00000018523 RNMT Up558 0.707067
ENSECAG00000017971 DDX43 Up559 0.706771
ENSECAG00000008524 SSBIP1 Up560 0.706739
ENSECAG00000001545 TSPAN12 Up562 0.706078
ENSECAG00000000477 ENSECAG00000000477 Up564 0.705457
ENSECAG00000021154 ZNF699 Up565 0.705208
ENSECAG00000024383 RARS Up566 0.705148
ENSECAG00000026906 COX16 Up568 0.705042
ENSECAG00000019205 PPP2R2A Up569 0.704791
ENSECAG00000004180 HSPA6 Up570 0.704738
ENSECAG00000018438 CEP55 Up571 0.703252
ENSECAG00000018686 PPA1 Up572 0.703212
ENSECAG00000009967 PHAX Up573 0.702434
ENSECAG00000021700 FLT1 Up574 0.70149
ENSECAG00000012624 POLD3 Up575 0.701158
ENSECAG00000023263 RNF13 Up576 0.701055
ENSECAG00000022108 BORA Up577 0.700225
ENSECAG00000017215 ZFP30 Up578 0.699635
ENSECAG00000024648 EPC1 Up579 0.699336
ENSECAG00000004011 ENSECAG00000004011 Up580 0.698884
ENSECAG00000023186 ZCCHC9 Up581 0.697818
ENSECAG00000026853 CEP152 Up582 0.696754
ENSECAG00000000102 EIF5B Up583 0.696744
ENSECAG00000016168 CLIC4 Up584 0.696715
ENSECAG00000023076 GPCPD1 Up586 0.696244
ENSECAG00000022536 REST Up588 0.695712
ENSECAG00000023697 FNDC3A Up589 0.695461
ENSECAG00000001496 ZNF407 Up590 0.695444
ENSECAG00000020412 LDAH Up591 0.693903
ENSECAG00000014326 SNX25 Up592 0.693711
ENSECAG00000024525 ENSECAG00000024525 Up593 0.693372
ENSECAG00000009283 ZNF114 Up594 0.693359
ENSECAG00000017115 ENSECAG00000017115 Up595 0.693052
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000017115 ENSECAG00000017115 Up595 0.693052
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000021693 CAPZA2 Up596 0.692931
ENSECAG00000013427 RAB23 Up597 0.692732
ENSECAG00000015025 GCH1 Up598 0.692339
ENSECAG00000017850 TAF1D Up599 0.691947
ENSECAG00000027671 ATP6 Up600 0.691656
ENSECAG00000015326 RFC5 Up601 0.691608
ENSECAG00000024811 TSC22D2 Up602 0.691029
ENSECAG00000023244 TAF1B Up603 0.6906
ENSECAG00000009655 FAM60A Up604 0.690235
ENSECAG00000009119 JAK2 Up605 0.690057
ENSECAG00000012157 YAF2 Up606 0.689951
ENSECAG00000015589 MTM1 Up608 0.689677
ENSECAG00000022933 ELL2 Up607 0.689677
ENSECAG00000016494 MICU2 Up609 0.68907
ENSECAG00000007680 RPA3 Up610 0.688894
ENSECAG00000026939 GINS1 Up611 0.688713
ENSECAG00000016387 NDC1 Up612 0.6886
ENSECAG00000000090 MAP3K8 Up613 0.68833
ENSECAG00000021027 PAPOLA Up614 0.688188
ENSECAG00000012409 SAR1B Up615 0.687703
ENSECAG00000000426 CENPL Up616 0.687685
ENSECAG00000012484 NAMPT Up617 0.687526
ENSECAG00000011326 TAPT1 Up618 0.687366
ENSECAG00000014323 SKA3 Up619 0.687278
ENSECAG00000019428 UTP15 Up620 0.685909
ENSECAG00000017368 MTF2 Up621 0.6856
ENSECAG00000021001 SENP6 Up622 0.685515
ENSECAG00000015041 CEP76 Up623 0.685249
ENSECAG00000021033 WBP4 Up624 0.684971
ENSECAG00000022573 USP25 Up625 0.684307
ENSECAG00000014865 ADGRA3 Up626 0.684286
ENSECAG00000023648 ABCE1 Up627 0.684255
ENSECAG00000006626 ZDHHC17 Up628 0.684243
ENSECAG00000006103 NIPSNAP3A Up629 0.6838
ENSECAG00000009108 C1orf189 Up630 0.683627
ENSECAG00000012597 EIF5 Up631 0.683592
ENSECAG00000000110 WRN Up632 0.683582
ENSECAG00000008999 CHORDC1 Up633 0.68321
ENSECAG00000016131 FRMD4B Up634 0.682452
ENSECAG00000017704 ZBTB1 Up635 0.681805
ENSECAG00000009162 ENSECAG00000009162 Up636 0.680927
ENSECAG00000015739 TOPBP1 Up637 0.680471
ENSECAG00000012168 RCOR1 Up638 0.67923
ENSECAG00000020566 DYNC2LI1 Up639 0.679029
ENSECAG00000000889 ZNF322 Up640 0.678948
ENSECAG00000019842 NAA15 Up641 0.67894
ENSECAG00000023625 FCHO2 Up642 0.678939
ENSECAG00000020208 LIFR Up643 0.67888
ENSECAG00000005678 TMEM200A Up644 0.678736
ENSECAG00000021484 TMEM2 Up645 0.678515
ENSECAG00000021834 MIOS Up646 0.678383
ENSECAG00000023851 SCAF11 Up647 0.678322
ENSECAG00000017348 BCAP29 Up648 0.678143
ENSECAG00000023456 NDUFAF4 Up649 0.677993
ENSECAG00000014530 SEPT10 Up650 0.67784
ENSECAG00000008584 AKAP10 Up651 0.677457
ENSECAG00000016850 KRIT1 Up652 0.677206
ENSECAG00000013476 PHF6 Up653 0.676845
ENSECAG00000009507 ENSECAG00000009507 Up654 0.676558
ENSECAG00000002569 FLRT3 Up655 0.676513
ENSECAG00000008493 SERPINB10 Up656 0.676204
ENSECAG00000026976 ENSECAG00000026976 Up657 0.67612
ENSECAG00000009872 ROCK2 Up658 0.675653
ENSECAG00000007487 ENSECAG00000007487 Up659 0.675001
ENSECAG00000011706 DENND6A Up660 0.67485
ENSECAG00000013772 MDFIC Up661 0.674618
ENSECAG00000014496 PPP2R3A Up662 0.674427
ENSECAG00000024369 NIP7 Up663 0.674205
ENSECAG00000020392 AZI2 Up664 0.674063
ENSECAG00000015902 ZNF615 Up665 0.673927
ENSECAG00000014841 ENSECAG00000014841 Up666 0.673717
ENSECAG00000008458 ENSECAG00000008458 Up667 0.673458
ENSECAG00000010560 CXCL2 Up668 0.673179
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000010560 CXCL2 Up668 0.673179
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000009214 SACM1L Up669 0.672708
ENSECAG00000024696 NOP58 Up670 0.671405
ENSECAG00000005916 CEP44 Up671 0.671225
ENSECAG00000004043 SOCS4 Up672 0.671163
ENSECAG00000000757 ENSECAG00000000757 Up673 0.671138
ENSECAG00000015185 AK6 Up674 0.670738
ENSECAG00000011712 C5orf22 Up675 0.670561
ENSECAG00000015373 ENSECAG00000015373 Up676 0.670422
ENSECAG00000017560 USP33 Up677 0.670337
ENSECAG00000006749 ATP13A3 Up678 0.670198
ENSECAG00000015452 MCM8 Up679 0.670004
ENSECAG00000017376 NEMF Up680 0.669359
ENSECAG00000006890 MAP3K1 Up681 0.668971
ENSECAG00000017534 HPRT1 Up682 0.668674
ENSECAG00000024909 FBXL2 Up683 0.668606
ENSECAG00000019135 SRSF12 Up684 0.668479
ENSECAG00000008011 MLH3 Up685 0.668224
ENSECAG00000020148 SGCB Up686 0.667324
ENSECAG00000002798 KIFAP3 Up687 0.667251
ENSECAG00000022066 SCYL2 Up689 0.666742
ENSECAG00000007007 STT3B Up690 0.666268
ENSECAG00000015352 PPP2R3C Up691 0.666247
ENSECAG00000019624 OSTF1 Up692 0.666028
ENSECAG00000024244 CASP10 Up693 0.665918
ENSECAG00000016769 TAF4B Up694 0.665667
ENSECAG00000000313 ECI2 Up695 0.665365
ENSECAG00000018413 NUP43 Up696 0.664509
ENSECAG00000018209 CAAP1 Up697 0.664173
ENSECAG00000018367 ZWILCH Up698 0.663954
ENSECAG00000014764 FAM206A Up699 0.663847
ENSECAG00000004124 MMGT1 Up700 0.663807
ENSECAG00000006587 RWDD1 Up701 0.663734
ENSECAG00000011198 ENSECAG00000011198 Up702 0.663689
ENSECAG00000014344 ZNF568 Up703 0.663684
ENSECAG00000010824 LTN1 Up704 0.663631
ENSECAG00000015791 PRIM2 Up706 0.662496
ENSECAG00000013918 ZFYVE16 Up707 0.662468
ENSECAG00000014712 DDHD1 Up708 0.661886
ENSECAG00000024185 GNG11 Up709 0.661846
ENSECAG00000021950 NPM1 Up710 0.661721
ENSECAG00000009877 HSPA4L Up711 0.661616
ENSECAG00000017076 NSRP1 Up712 0.661435
ENSECAG00000005377 PREPL Up714 0.66086
ENSECAG00000019340 ZNF800 Up715 0.660293
ENSECAG00000027692 COX2 Up716 0.660201
ENSECAG00000002113 BARD1 Up717 0.660082
ENSECAG00000006243 RANBP6 Up718 0.659932
ENSECAG00000020917 STAG2 Up719 0.659907
ENSECAG00000018322 EXO1 Up720 0.659594
ENSECAG00000008574 RNF138 Up721 0.659301
ENSECAG00000019522 ENSECAG00000019522 Up722 0.658949
ENSECAG00000020774 WEE1 Up723 0.658521
ENSECAG00000020044 IMPAD1 Up724 0.65851
ENSECAG00000008412 ICE2 Up725 0.658203
ENSECAG00000019898 TTC21B Up726 0.658141
ENSECAG00000019399 TGS1 Up727 0.658129
ENSECAG00000014866 IRAK4 Up728 0.658051
ENSECAG00000014262 RNASEH2B Up729 0.657926
ENSECAG00000017806 GGPS1 Up730 0.657738
ENSECAG00000012988 UCHL5 Up731 0.656946
ENSECAG00000005171 ENSECAG00000005171 Up732 0.656825
ENSECAG00000010468 CHCHD7 Up733 0.656635
ENSECAG00000012479 LARP4 Up734 0.656518
ENSECAG00000001911 TAX1BP1 Up735 0.656394
ENSECAG00000013304 RFWD2 Up736 0.65623
ENSECAG00000016930 ZNF713 Up737 0.656069
ENSECAG00000004675 PLEKHF2 Up738 0.656047
ENSECAG00000007540 CYP7B1 Up739 0.655746
ENSECAG00000018247 ZNF404 Up741 0.655043
ENSECAG00000005156 ZFP2 Up742 0.654878
ENSECAG00000022659 CCL26 Up743 0.654738
ENSECAG00000013200 PEX3 Up745 0.653527
ENSECAG00000009573 RPS3A Up746 0.653215
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ENSECAG00000009573 RPS3A Up746 0.653215
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000020668 ENSECAG00000020668 Up747 0.652882
ENSECAG00000018957 CEBPZ Up748 0.652833
ENSECAG00000014401 ING5 Up749 0.652805
ENSECAG00000009478 RHOT1 Up750 0.652313
ENSECAG00000017599 ZNF567 Up751 0.652185
ENSECAG00000018921 MTMR2 Up753 0.652013
ENSECAG00000016110 EXTL2 Up754 0.65193
ENSECAG00000010517 PRRG1 Up755 0.651351
ENSECAG00000013971 ATG5 Up756 0.65129
ENSECAG00000000568 TMEM68 Up757 0.650895
ENSECAG00000005128 ZNF30 Up758 0.650494
ENSECAG00000006925 WDR53 Up760 0.650061
ENSECAG00000016657 ZNF211 Up761 0.650016
ENSECAG00000017444 TAB3 Up762 0.649727
ENSECAG00000006127 SBNO1 Up763 0.649371
ENSECAG00000003569 ST6GAL1 Up764 0.649183
ENSECAG00000006287 PARP11 Up765 0.648618
ENSECAG00000022028 C9orf72 Up766 0.648482
ENSECAG00000001445 CHD7 Up767 0.648407
ENSECAG00000027681 ND2 Up768 0.6484
ENSECAG00000011405 BLM Up771 0.648162
ENSECAG00000025074 C9orf64 Up772 0.647274
ENSECAG00000015542 OSBPL8 Up773 0.647227
ENSECAG00000011182 PUS7L Up774 0.646034
ENSECAG00000010941 CCDC150 Up775 0.645983
ENSECAG00000009970 TIAL1 Up776 0.645357
ENSECAG00000010199 EMC2 Up777 0.645357
ENSECAG00000006803 SYTL2 Up778 0.645301
ENSECAG00000024511 MRPL1 Up779 0.645211
ENSECAG00000004770 FAM217B Up780 0.64501
ENSECAG00000015380 EIF2B3 Up781 0.644955
ENSECAG00000004461 TIGD7 Up782 0.644872
ENSECAG00000020867 ACTR3 Up783 0.644559
ENSECAG00000014213 SRPK1 Up784 0.644481
ENSECAG00000005248 ZNF146 Up785 0.644297
ENSECAG00000014236 ENSECAG00000014236 Up786 0.644281
ENSECAG00000023777 WDR43 Up787 0.644272
ENSECAG00000011902 RAB8B Up788 0.644066
ENSECAG00000016552 PAXBP1 Up789 0.643204
ENSECAG00000023235 KPNA4 Up790 0.642234
ENSECAG00000019161 DIAPH3 Up791 0.641917
ENSECAG00000016031 AGGF1 Up792 0.641314
ENSECAG00000000329 C6orf62 Up793 0.641242
ENSECAG00000008769 VAPA Up794 0.641054
ENSECAG00000023450 KATNBL1 Up795 0.641049
ENSECAG00000009131 OMA1 Up796 0.640742
ENSECAG00000020320 CD302 Up797 0.64046
ENSECAG00000015379 FGD4 Up798 0.640379
ENSECAG00000000276 DNAL1 Up799 0.639485
ENSECAG00000005949 MSH6 Up800 0.638933
ENSECAG00000024208 GRSF1 Up801 0.638033
ENSECAG00000023010 USP45 Up802 0.637898
ENSECAG00000020263 ACOT13 Up803 0.636966
ENSECAG00000024919 CDKAL1 Up804 0.636863
ENSECAG00000026878 MAGOHB Up805 0.63661
ENSECAG00000004372 SLC22A3 Up806 0.63636
ENSECAG00000000595 SLC30A9 Up808 0.635839
ENSECAG00000019885 ATP1B3 Up810 0.635221
ENSECAG00000004167 ZBED8 Up811 0.635148
ENSECAG00000019406 PDCD5 Up812 0.635069
ENSECAG00000010243 GALNT7 Up813 0.634973
ENSECAG00000002187 C1D Up814 0.634934
ENSECAG00000010431 THOC2 Up815 0.634399
ENSECAG00000000004 RNF170 Up816 0.633852
ENSECAG00000020692 C2CD5 Up817 0.633805
ENSECAG00000014948 KIAA1524 Up818 0.633697
ENSECAG00000010253 PROKR2 Up819 0.633046
ENSECAG00000016758 ENSECAG00000016758 Up820 0.6323
ENSECAG00000007826 DONSON Up822 0.631923
ENSECAG00000000007 TMEM70 Up823 0.631686
ENSECAG00000016155 KIF18A Up824 0.631676
ENSECAG00000005718 MAP4K5 Up825 0.631569
ENSECAG00000010450 CCDC59 Up826 0.631421
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ENSECAG00000010450 CCDC59 Up826 0.631421
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000018424 EIF2S1 Up827 0.631056
ENSECAG00000013355 APOPT1 Up828 0.630967
ENSECAG00000017176 EYA3 Up829 0.630855
ENSECAG00000020050 RPAP3 Up830 0.630823
ENSECAG00000016099 BMP2K Up831 0.630087
ENSECAG00000007375 ENSECAG00000007375 Up832 0.629973
ENSECAG00000021072 KNTC1 Up833 0.629324
ENSECAG00000003237 GCC2 Up834 0.62894
ENSECAG00000014059 ECT2 Up835 0.628538
ENSECAG00000015182 OSBPL1A Up836 0.628381
ENSECAG00000021929 DNM1L Up837 0.627679
ENSECAG00000004593 HAUS3 Up838 0.627444
ENSECAG00000009229 APOOL Up839 0.627375
ENSECAG00000012941 JMJD1C Up840 0.627194
ENSECAG00000014803 GTF3A Up841 0.626432
ENSECAG00000009060 C3orf58 Up842 0.626395
ENSECAG00000020058 PNPT1 Up843 0.626058
ENSECAG00000013328 TMOD2 Up844 0.625688
ENSECAG00000003367 RAD51C Up846 0.624968
ENSECAG00000013284 ENSECAG00000013284 Up847 0.624319
ENSECAG00000016722 CENPU Up848 0.624072
ENSECAG00000014597 MCTS1 Up849 0.624
ENSECAG00000014963 PIK3C2A Up850 0.623946
ENSECAG00000019722 AKT3 Up851 0.623908
ENSECAG00000025094 TMEM161B Up852 0.623654
ENSECAG00000019778 CFAP97 Up853 0.623572
ENSECAG00000023836 HCFC2 Up854 0.623472
ENSECAG00000021610 GPBP1 Up855 0.623467
ENSECAG00000026949 MTHFD2L Up856 0.62339
ENSECAG00000013560 OSGIN2 Up857 0.623357
ENSECAG00000012944 UBXN8 Up858 0.622873
ENSECAG00000020143 ENSECAG00000020143 Up860 0.622502
ENSECAG00000008626 KLHL28 Up861 0.622129
ENSECAG00000011172 PPP4R3A Up862 0.621925
ENSECAG00000000010 LRRC58 Up863 0.621897
ENSECAG00000011242 DRAM2 Up864 0.621656
ENSECAG00000021923 GTF2F2 Up865 0.621473
ENSECAG00000009675 N4BP2 Up866 0.621405
ENSECAG00000005393 ATP11C Up867 0.621373
ENSECAG00000006861 R3HCC1L Up868 0.620645
ENSECAG00000021921 SCAMP1 Up869 0.620496
ENSECAG00000019938 GFPT1 Up870 0.620092
ENSECAG00000006588 CHUK Up871 0.619812
ENSECAG00000010914 CHSY1 Up872 0.619619
ENSECAG00000010426 RECK Up873 0.619571
ENSECAG00000010332 RRP15 Up874 0.61948
ENSECAG00000018037 CD2AP Up875 0.619333
ENSECAG00000013688 ENSECAG00000013688 Up876 0.619272
ENSECAG00000018517 MCPH1 Up877 0.619116
ENSECAG00000027694 ND5 Up878 0.618683
ENSECAG00000016939 RPS24 Up879 0.618245
ENSECAG00000011491 FAM91A1 Up880 0.618218
ENSECAG00000009435 FIGNL1 Up881 0.617947
ENSECAG00000010684 PHIP Up882 0.617723
ENSECAG00000019980 PGAP1 Up883 0.616933
ENSECAG00000014575 RB1 Up884 0.616896
ENSECAG00000006239 NUP155 Up885 0.616852
ENSECAG00000024193 ITGB1BP1 Up886 0.616735
ENSECAG00000011526 SLC35B3 Up887 0.616675
ENSECAG00000013521 MAD2L1 Up888 0.616634
ENSECAG00000019646 AHI1 Up889 0.616496
ENSECAG00000020833 ZNF234 Up891 0.61598
ENSECAG00000014265 ARMC8 Up892 0.615515
ENSECAG00000008550 WBP11 Up893 0.615118
ENSECAG00000023517 FAM49B Up894 0.614997
ENSECAG00000010069 XRCC2 Up895 0.614995
ENSECAG00000014503 MMADHC Up896 0.614628
ENSECAG00000020309 RABGGTB Up897 0.614615
ENSECAG00000021626 DBT Up898 0.614552
ENSECAG00000017202 SNX5 Up899 0.614475
ENSECAG00000025004 NUP54 Up900 0.614233
ENSECAG00000023828 GPAT3 Up901 0.614101
ENSECAG00000023301 GPX8 Up902 0.613921
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ENSECAG00000023301 GPX8 Up902 0.613921
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000021005 ENSECAG00000021005 Up903 0.613895
ENSECAG00000020987 LCA5 Up904 0.613778
ENSECAG00000023731 ABCD3 Up905 0.613573
ENSECAG00000000497 THOC7 Up906 0.613469
ENSECAG00000022483 PTP4A1 Up907 0.613004
ENSECAG00000014982 CCDC112 Up908 0.61285
ENSECAG00000020406 PPP1R12A Up909 0.612613
ENSECAG00000021849 TFPI Up910 0.612557
ENSECAG00000018257 ENSECAG00000018257 Up911 0.612482
ENSECAG00000007715 ZNF638 Up912 0.612245
ENSECAG00000007382 FAM92A1 Up913 0.612207
ENSECAG00000019687 ENSECAG00000019687 Up914 0.611972
ENSECAG00000007737 PLEKHA8 Up915 0.611969
ENSECAG00000011795 OSGEPL1 Up916 0.611905
ENSECAG00000014704 LRRCC1 Up917 0.611726
ENSECAG00000020597 ENSECAG00000020597 Up918 0.61133
ENSECAG00000003621 PTRH2 Up919 0.611244
ENSECAG00000015601 XPR1 Up920 0.610509
ENSECAG00000019812 AGTPBP1 Up921 0.610393
ENSECAG00000024333 TAF2 Up922 0.610148
ENSECAG00000016890 FGFR1OP2 Up923 0.609807
ENSECAG00000006857 DCAF10 Up924 0.609517
ENSECAG00000015865 GLUL Up925 0.609329
ENSECAG00000006476 LRRC8D Up926 0.60914
ENSECAG00000013814 HECTD2 Up927 0.609073
ENSECAG00000016487 ATP6V1E1 Up928 0.608788
ENSECAG00000006869 MAP9 Up929 0.608491
ENSECAG00000012526 DNAJB9 Up930 0.608325
ENSECAG00000015965 IPO7 Up931 0.608282
ENSECAG00000000423 USP16 Up932 0.608197
ENSECAG00000016394 IL1R1 Up933 0.607954
ENSECAG00000011689 SLBP Up934 0.607928
ENSECAG00000017780 TRPM7 Up935 0.607613
ENSECAG00000023470 ATL2 Up936 0.607602
ENSECAG00000012679 RIF1 Up937 0.607193
ENSECAG00000014912 CCDC91 Up938 0.607192
ENSECAG00000018695 ENSECAG00000018695 Up939 0.607027
ENSECAG00000021751 ZFP14 Up940 0.607022
ENSECAG00000026902 MAP4K3 Up941 0.606687
ENSECAG00000012298 ENSECAG00000012298 Up942 0.606104
ENSECAG00000021067 ENSECAG00000021067 Up943 0.606021
ENSECAG00000018145 NT5DC3 Up944 0.605246
ENSECAG00000013853 CCDC90B Up945 0.605135
ENSECAG00000017131 ENSECAG00000017131 Up946 0.604861
ENSECAG00000010204 ERI2 Up947 0.604669
ENSECAG00000024473 MCM10 Up948 0.604605
ENSECAG00000021804 PELI1 Up949 0.604562
ENSECAG00000022755 EIF5A2 Up950 0.603978
ENSECAG00000010712 AP3S1 Up951 0.603814
ENSECAG00000010545 TTC39C Up952 0.603787
ENSECAG00000002701 UHRF1BP1L Up953 0.603673
ENSECAG00000022985 USP14 Up955 0.603344
ENSECAG00000012286 DDX52 Up956 0.603277
ENSECAG00000004792 UBE3A Up957 0.603149
ENSECAG00000000259 RTKN2 Up958 0.602764
ENSECAG00000012255 MTFMT Up961 0.602221
ENSECAG00000014564 UFM1 Up960 0.602221
ENSECAG00000010212 SLK Up962 0.60161
ENSECAG00000011393 GKAP1 Up963 0.601583
ENSECAG00000015913 ENSECAG00000015913 Up964 0.601426
ENSECAG00000014922 EPS8 Up966 0.601129
ENSECAG00000005271 FASTKD5 Up968 0.600919
ENSECAG00000012742 CXCL6 Up969 0.600719
ENSECAG00000021752 FBXO33 Up970 0.600492
ENSECAG00000024758 TMX3 Up971 0.600366
ENSECAG00000007182 ORC6 Up972 0.600128
ENSECAG00000020698 MELK Up973 0.600067
ENSECAG00000010710 WDR75 Up974 0.600004
ENSECAG00000010756 PPME1 Up975 0.599442
ENSECAG00000024870 CWH43 Up976 0.598294
ENSECAG00000011778 C11orf58 Up977 0.598282
ENSECAG00000024188 ANKRD49 Up978 0.598259
ENSECAG00000021389 NCKAP1 Up979 0.598013
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ENSECAG00000021389 NCKAP1 Up979 0.598013
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000000513 PRELID3B Up980 0.597944
ENSECAG00000014838 TSC22D1 Up981 0.597818
ENSECAG00000023656 DCAF17 Up983 0.597369
ENSECAG00000019466 ARIH1 Up984 0.597355
ENSECAG00000020790 ABHD17B Up985 0.597056
ENSECAG00000010493 ENTPD4 Up986 0.59561
ENSECAG00000020166 YEATS4 Up987 0.595543
ENSECAG00000025100 DHX36 Up988 0.59525
ENSECAG00000019292 TCAIM Up990 0.594953
ENSECAG00000011846 RTN4 Up991 0.594947
ENSECAG00000010089 DUSP6 Up992 0.594925
ENSECAG00000011292 MSR1 Up993 0.594791
ENSECAG00000008462 RYK Up994 0.594177
ENSECAG00000008481 ENSECAG00000008481 Up995 0.593958
ENSECAG00000018362 ENSECAG00000018362 Up996 0.593942
ENSECAG00000002193 ENSECAG00000002193 Up997 0.593905
ENSECAG00000022063 ABHD5 Up998 0.593789
ENSECAG00000017558 MLKL Up999 0.593332
ENSECAG00000014592 WDR45B Up1000 0.593062
ENSECAG00000009788 TBC1D31 Up1001 0.59305
ENSECAG00000021819 PPIL4 Up1002 0.592949
ENSECAG00000021498 SNX13 Up1003 0.592929
ENSECAG00000019035 LIPT1 Up1004 0.592871
ENSECAG00000013610 POLR2B Up1005 0.592659
ENSECAG00000020223 HACD1 Up1006 0.592448
ENSECAG00000008861 RRN3 Up1007 0.592393
ENSECAG00000008450 ATP2B1 Up1008 0.591835
ENSECAG00000018048 TRPC1 Up1009 0.591816
ENSECAG00000016522 SCG3 Up1010 0.591498
ENSECAG00000009904 NDUFV2 Up1011 0.591493
ENSECAG00000007655 QSER1 Up1012 0.59143
ENSECAG00000005083 IL1RAP Up1013 0.591414
ENSECAG00000000048 UBA2 Up1014 0.591173
ENSECAG00000012273 UBA6 Up1015 0.591047
ENSECAG00000017880 SEH1L Up1016 0.590664
ENSECAG00000009920 POLR3F Up1017 0.590595
ENSECAG00000008506 HMMR Up1018 0.590134
ENSECAG00000010292 NKIRAS1 Up1019 0.589681
ENSECAG00000009947 TTC33 Up1021 0.589129
ENSECAG00000014071 SLC30A7 Up1022 0.589024
ENSECAG00000014116 SLC38A9 Up1023 0.588865
ENSECAG00000000689 PPP4R2 Up1024 0.588642
ENSECAG00000026842 ACER3 Up1025 0.588102
ENSECAG00000000236 EIF3E Up1026 0.588082
ENSECAG00000009913 CDC6 Up1027 0.587068
ENSECAG00000013019 CCDC34 Up1028 0.586869
ENSECAG00000008167 SPPL2A Up1029 0.586726
ENSECAG00000018948 HSP90AA1 Up1030 0.586602
ENSECAG00000012605 RNGTT Up1032 0.586522
ENSECAG00000019312 PDS5B Up1033 0.586472
ENSECAG00000008062 DDHD2 Up1034 0.586289
ENSECAG00000009297 PLOD2 Up1035 0.585998
ENSECAG00000025163 MAP2K4 Up1036 0.585967
ENSECAG00000013510 HSPA8 Up1037 0.584972
ENSECAG00000018653 TROVE2 Up1038 0.584686
ENSECAG00000005033 WDR5B Up1039 0.58465
ENSECAG00000009463 CCDC15 Up1040 0.584646
ENSECAG00000020103 DSTN Up1041 0.584595
ENSECAG00000024547 ASNSD1 Up1042 0.584521
ENSECAG00000011505 CHD9 Up1043 0.584445
ENSECAG00000021993 GCLM Up1044 0.584316
ENSECAG00000019120 ENSECAG00000019120 Up1045 0.584161
ENSECAG00000016982 CCT4 Up1046 0.583786
ENSECAG00000020616 TMTC3 Up1047 0.583738
ENSECAG00000003331 PLEKHH2 Up1048 0.583324
ENSECAG00000010790 COG6 Up1049 0.583296
ENSECAG00000005374 WAC Up1050 0.58319
ENSECAG00000000511 CFL2 Up1051 0.583148
ENSECAG00000020362 MND1 Up1052 0.583124
ENSECAG00000007763 ALMS1 Up1053 0.582852
ENSECAG00000020945 MNS1 Up1054 0.582136
ENSECAG00000000018 KANSL1L Up1055 0.581878
ENSECAG00000020046 PSMD14 Up1056 0.581702
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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ENSECAG00000020046 PSMD14 Up1056 0.581702
Gene ID Gene name Rank Log2FC Rank Log2FC Rank Log2FC Rank Log2FC
ENSECAG00000021982 PRKRIR Up1057 0.581416
ENSECAG00000024474 SLC30A5 Up1058 0.581388
ENSECAG00000013713 FAM45A Up1059 0.581057
ENSECAG00000004843 MDM4 Up1060 0.580478
ENSECAG00000020786 C1QTNF2 Down66 -0.582546
ENSECAG00000018835 FAM46B Down65 -0.582742
ENSECAG00000021399 FAM98C Down62 -0.588967
ENSECAG00000024890 CCDC120 Down55 -0.613613
ENSECAG00000011219 CDKN2D Down50 -0.637784
ENSECAG00000018161 C1QTNF5 Down48 -0.647381
ENSECAG00000024202 XKR8 Down44 -0.666767
ENSECAG00000012364 MYEOV2 Down42 -0.668985
ENSECAG00000013721 SH2D5 Down40 -0.681721
ENSECAG00000006208 MBLAC1 Down36 -0.695815
ENSECAG00000014275 DBP Down26 -0.733667
ENSECAG00000004743 PPP1R3D Down17 -0.882141
ENSECAG00000017304 MAPK8IP2 Down16 -0.889524
ENSECAG00000006591 ATG9B Down14 -0.895217
ENSECAG00000018855 EP400NL Down12 -0.947197
ENSECAG00000007520 BBS5 Down8 -1.05334
ENSECAG00000002197 ENSECAG00000002197 Down6 -1.09455
ENSECAG00000013952 CADM4 Down5 -1.14208
ENSECAG00000016293 NANOS3 Down2 -1.51865
U/63-WT U/63-E186K U/63-219 U/63-E186K-
219
Up-regulated genes 140 146 117 1060
Down-regulated genes 258 59 99 66
Total DEGs 398 205 216 1126
U/63-WT U/63-E186K U/63-219 U/63-E186K-219
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